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1ABSTRACT
Breast cancer is the greatest health care challenge facing Australian women. While the 
prognosis for women diagnosed with early breast cancer (EBC) is excellent, many will 
experience significant deleterious effects on physical and psychological wellbeing 
during and following treatment to eradicate the disease. Of particular concern is 
adjuvant chemotherapy treatment. Patients report great variations in physical side 
effects and psychological distress during and following chemotherapy treatment, the 
reasons for which are little understood. Past research suggests that the variations may be 
accounted for by monitoring and blunting coping styles. Monitoring refers to the 
persistent efforts to seek out information about the stressful situation while blunting 
refers to the efforts to avoid or escape from information about the situation. Monitoring 
coping has been implicated in decreased physical and psychological wellbeing via 
increases in intrusive and avoidant ideation, greater chance and powerful others locus of 
control beliefs and higher risk perception of cancer recurrence. Conversely, blunting 
coping has been implicated in increased physical and psychological wellbeing, greater 
internal locus of control beliefs and lower risk perception of cancer recurrence.
The present study involved fifty-three women diagnosed with EBC who completed 
questionnaires at five time-points: prior to chemotherapy treatment, after the first, 
middle and final treatments, and six month following treatment completion. Monitoring 
and blunting coping styles were assessed at prior to chemotherapy, perceived risk of 
recurrence at six month follow-up, and levels of side effects, anxiety and depression, 
intrusive and avoidant ideation and health locus of control beliefs at each time-point. 
Analyses accounted for demographic, health, disease and treatment characteristics as 
well as bone marrow, hepatic and renal functioning. The results showed that the use of 
blunting coping directly increased anxiety levels while the use of both monitoring and 
blunting coping directly increased side effects. The use of blunting coping and the use 
of both monitoring and blunting coping indirectly increased anxiety and side effects, via 
intrusive and avoidant ideation. In contrast, the use of blunting coping and the use of 
both monitoring and blunting coping indirectly increased and decreased depression, via 
intrusive and avoidant ideation. It was also found that monitoring coping was associated 
with greater internal, chance and powerful others locus of control beliefs while blunting 
coping was associated with greater chance locus of control beliefs. Participants using
2both monitoring and blunting coping reported more chance locus of control beliefs. 
Lastly, it was found that blunting coping was associated with lower levels of personal 
perceived risk of recurrence.
These results indicate that monitoring and blunting coping styles significantly affect 
patients’ psychological and physical wellbeing, locus of control beliefs and risk 
perception of recurrence during and following chemotherapy treatment. Theoretically, 
the study emphasises the need to accurately and appropriately conceptualise and 
measure monitoring and blunting coping. Clinically, the study highlights the need to 
identify patients at risk of poor wellbeing during and following treatment due to their 
chosen coping style. The possibility of tailoring medical care to patients’ coping styles 
and implementing psychological interventions to alter coping styles are discussed.
3CHAPTER ONE 
Breast Cancer in Australia
Cancer is one of the major health challenges facing Australians. It is the second major 
cause of death for Australians, after cardiovascular disease (Australian Institute of 
Health and Welfare & Australasian Association of Cancer Registries: AIHW & AACR, 
2004). To understand the significant burden cancer presents for the health care system 
and the community, the following chapter will outline the current and projected 
incidence and mortality rates of cancer in Australia and the broad factors affecting these 
rates. There will be a special focus on the rates of breast cancer as a disease of particular 
concern to many Australian women.
1.1 Definition of Cancer
Cancer is a term that can be used generally to describe a diverse set of diseases. Usually, 
the cells that make up the human body grow and multiply in a controlled and orderly 
manner. However, after being affected by a carcinogen or developing a random genetic 
mutation, cells sometimes grow and multiply in an uncontrolled manner. These 
abnormal cells form a mass called a tumour or neoplasm. Tumours can be benign or 
malignant. Benign tumours are innocuous and grow slowly. They do not invade other 
tissues or spread to other parts of the body. They can, however, grow to interfere with 
the body’s existing structures. This interference can cause serious complications and in 
some cases even death. In 2001, there were 126 registered deaths from benign tumours 
(AIHW & AACR, 2004; Lenhard, Osteen, & Gansler, 2001).
Malignant tumours are cancers that can invade locally and spread to other parts of the 
body. Cancer cells from a malignant tumour can travel through the circulatory and 
lymphatic systems and establish themselves in other parts of the body. The original 
tumour is known as the primary tumour and the tumours that develop in other parts of 
the body as a result of the spreading of cells are known as secondary tumours or 
metastases. People who are diagnosed with primary tumours are said to have early stage 
cancer while those who are diagnosed with secondary tumours have advanced stage 
cancer. The damage caused by malignant tumours varies as a result of the pattern of 
growth and spread of the cancer and the surrounding cells and structures. Malignant
4tumours have their own pattern of growth and spread depending on the part of the body 
in which it occurs. Unfortunately, knowledge of the nature, causes and optimal 
treatment of the different forms of cancer varies considerably (AIHW & AACR, 2004; 
Lenhard et ah, 2001).
1.2 Cancer Incidence
According to the Australian Institute of Health and Welfare (AIHW), there were 88,398 
new cancer cases in 2001 compared with 65,966 new cases in 1991, excluding non­
melanoma skin cancers. Colorectal cancer was the most common cancer in 2001 
(12,844), followed by breast cancer (11,886), prostate cancer (11,191), melanoma (8, 
885), and lung cancer (8, 275). Together these accounted for 60% of all cancers in 2001 
(AIHW & AACR, 2004).
1.2.1 Cancer Incidence and Age
The risk of cancer increases with age, with four times as many cancers diagnosed in 
those over the age of 60 years compared with those under the age of 60. In 2001 for all 
cancers combined, the age-standardised incidence rates were 15.2 cases per 100,000 
population for people aged less than 15 years, 95.6 for 15-44 year olds, 100.5 for 45-64 
years olds, and 2,190.2 for people aged 65 years and over. In other words, of the people 
diagnosed with cancer, 0.7% of all cancers occur in those aged less than 15 years, 9.4% 
in the 15-44 years age group, 32.6% in the 45-64 year age group, and 57.2% in those 
aged 65 years and over. Age-standardised rates are rates that are adjusted for age to 
enable comparisons to be made between populations that differ in age (AIHW & 
AACR, 2004).
The most common cancers in each age range vary. Melanoma and breast cancer are 
most frequently diagnosed in people aged 15-44 years while breast, colorectal, 
melanoma, prostate, and lung cancers are most frequent in those over 45 years. Some 
cancers attain their highest rates in early or middle life and these remain constant in 
older age groups (for example, breast and cervical cancer) or decline (for example, 
testicular cancer) (AIHW & AACR, 2004).
51.2.2 Cancer Incidence and Gender
In 2001, overall incidence rates revealed that cancer was more common in males than 
females. The age-standardised incidence rate in 2001 for all cancers combined was 
541.4 new cases per 100,000 for males and 393.3 for females. That is, it is expected that 
one in three men and one in four women will be diagnosed with a cancer in the first 75 
years of life. The average age of the first diagnosis for males was 66 years compared 
with 64 years for females (AIHW & AACR, 2004).
Between 1991 and 2001, age-standardised incidence rates for all cancers combined 
increased for males by an average of 4.4% per annum until 1995 and then declined by 
an average of 1.3% per annum until 2001. Males had a higher incidence rate for every 
cancer site, except for breast, thyroid and anus. In males, prostate cancer was the most 
common cancer (11,191 new cases diagnosed in 2001), followed by colorectal cancer 
(6,961), lung cancer (5,384), and melanoma (5,024). These four cancers accounted for 
60% of all cancers in males (AIHW & AACR, 2004).
The incidence rates for males have been strongly influenced by the rise and fall of 
prostate cancer incidence during this period. Rates for prostate cancer were stable until 
1989. Between 1990 and 1994 there was a dramatic rise in the number of new cases 
registered due to the introduction of Prostate-Specific Antigen (PSA) testing in some 
regions of Australia. PSA testing aims to identify cancers before the onset of clinical 
symptoms. From 1994 to 1997 the rate fell by 30% indicating a return to the underlying 
rate and there has been little change since. Given the frequency of prostate cancer 
diagnosis, small increases in incidence can mean a substantial shift in the number of 
new cases (AIHW & AACR, 2004).
For females, age standardised rates increased by an average of 1.5% per annum until 
1995 and remained constant until 2001. In females, breast cancer (11,791) was the most 
common cancer, followed by colorectal (5,883), melanoma (3,861) and lung cancer 
(2,891). These four cancers accounted for 60% of all cancers in females. Similar to the 
incidence rates for males, the rates for females have been influenced by the introduction 
of routine mammography screening in women at highest risk of breast cancer, that is, 
those over the age of 50 years. The increase indicates the detection of existing breast
cancer in women and the levelling off is a return to the underlying rate (AIHW & 
AACR, 2004).
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1.2.3 Cancer Incidence and Residence
Incidence rates for individual state and territories are based on cancer registration in the 
patients’ state and territory of residence at the time of diagnosis. Differences in state and 
territory cancer incidence rates may be explained by normal incidence rate fluctuations, 
variations in underlying cancer risk, the availability and utilisation of diagnostic 
procedures, and reporting and coding inconsistencies. To reduce the problems of 
statistical variation due to a small number of cases, the numbers and rates presented for 
the states and territories are annual averages of the five-year period of 1997-2001 
(AIHW & AACR, 2004).
South Australia (SA) reported the highest incidence rates for males (509.3 cases per
100.000 population), followed by Victoria (Vic: 500.5), Queensland (Qld: 498.2), the 
Australian Capital Territory (ACT: 496.0), Tasmania (Tas: 480.8), New South Wales 
(NSW: 482.0), Western Australia (WA: 456.0), and the Northern Territory (NT: 452.4). 
For females, the ACT reported the highest rate (382.1 cases per 100,000 population), 
followed by NSW (381.6), Qld (365.6), Vic (359.1), SA (358.2), Tas (354.3), the NT 
(330.2), and WA (330.2) (AIHW & AACR, 2004).
1.2.4 Projected Cancer Incidence
The cancer incidence rates are projected to remain fairly stable on the whole, with an 
increase of 2% in age-standardised incidence rates for females from 393.3 per 100,000 
in 2001 to 402.9 per 100,000 in 2011 and a decrease of 1% for males from 541.4 per
100.000 in 2001 to 538.3 per 100,000 in 2011. When considering the overall incidence 
rates, it is expected that there will be a considerable increase in the numbers of new 
cases diagnosed. The expected increase in incidence is due to the projected increase in 
the Australian population in the older age groups where the incidence rates of cancer are 
highest (AIHW, 2005).
Current estimates indicate that the total population is expected to increase by 12% from 
19,413,240 in 2001 to 21,765,911 in 2011 but the increase in the age group 65 and over 
is expected to increase by 30% from 2,435,534 to 3,169,188. Indeed, evidence of this
7already exists with the increase in cancer incidence in the past ten years far greater than 
the growth of population during this time, roughly 36% compared to 12%. This means 
that the number of Australians diagnosed and living with cancer will continue to rise in 
the coming years (AIHW, 2005; AIHW & AACR, 2004; Senate Community Affairs 
References Committee, 2005).
The number of new cases is projected to increase by 32% for men from 47,820 in 2001 
to 63,087 in 2011 and by 29% for women from 40,578 in 2001 to 52,356 in 2011. For 
men, the most common cancers are expected to change slightly with a projected 
increase in the rates of prostate cancer (24%), colorectal (15%), melanoma (11%) and 
lung (10%). For women, the most common cancer are expected to be the same as those 
in 2001, breast cancer (28% of new cases), colorectal (15%), melanoma (9%), and lung 
(8%) (AIHW, 2005).
1.3 Cancer Mortality
In 1991, there were 30,928 deaths due to cancer (or 26% of all deaths), which rose by 
17.4% to 36,750 deaths (or 29% of all deaths) in 2001. These rates are those in which 
cancer was the underlying cause of death as coded on the death certificates. There were 
an additional 4,519 deaths where cancer was an associated cause reported on the death 
certificate in 2001. Among the 4,519 cases, the most common underlying causes of 
death were ischemic heart disease, chronic obstructive pulmonary disease and stroke 
(AIHW & AACR, 2004).
Person-years of life lost (PYLL) describes the number of years of life lost due to an 
early death from cancer, that is, before the expected age of 75 years. In 2001, there were 
an estimated 257,458 PYLL as a result of people dying of cancer before the age of 75. 
The PYLL estimates are typically dominated by the most common cancers as they 
represent the large number of cases diagnosed. The cancer responsible for the highest 
number of PYLL were lung cancer (44,978), followed by colorectal cancer (29,768) and 
breast cancer (28,733) (AIHW & AACR, 2004).
1.3.1 Cancer Mortality and Age
While the pattern of deaths across age groups is similar to that of incidence, a larger 
proportion (72.5%) of cancer deaths occurs in those aged 65 years and over. The age-
specific incidence rate for all cancers combined was 15.2 per 100,000 population for 
people less than 15 years, 95.6 for 15-44 year olds, 700.5 for 45-64 year olds, and
2,190.2 for those 65 years and over (AIHW & AACR, 2004).
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1.3.2 Cancer Mortality and Gender
In 2001, cancer accounted for 31% of male deaths and 26% of female deaths. The 
cancers most commonly causing death were lung (4,657), prostate (2,718) and 
colorectal cancer (2,601) in males and breast (2,612), lung (2,382) and colorectal cancer 
(2,153) in females. Between 1991 and 2001, the age-standardised cancer mortality rate 
for males was 270 cases per 100,000 population until 1995 and then declined by 1.8% 
until 2001. For females, the rate was 160 cases per 100,000 population until 1997 and 
then declined by 1.4% until 2001. Declines are thought to be due to improvements in 
screening, accuracy of diagnosis and the introduction of increasingly effective 
treatments (AIHW & AACR, 2004).
1.3.3 Cancer Mortality and Residence
The 1997-2001 cancer mortality rates reported for males were highest in Tas (262.7 
cases per 100,000 population), Qld (251.7), Vic (249.9), SA (247.7), WA (247.5), the 
NT (246.5), NSW (246.4), and lowest in the ACT (219.6). For females, the rates were 
highest in the NT (187.9 cases per 100,000), Tas (169.8), ACT (159.0), Vic (155.0), SA 
(149.5), WA (149.3), Qld (147.0), and lowest in NSW (146.7) (AIHW & AACR, 2004).
Similar to state and territory incidence rates, mortality rates refer to the state and 
territory of usual residence. However, it is not uncommon for people diagnosed with 
cancer to travel interstate for treatment and palliative care, so state of usual residence at 
diagnosis may differ from the state of residence at time of death. This is particularly the 
case for the ACT. During the period 1997-2001, 16.3% of those dying of cancer in the 
ACT usually resided in another state or territory, the majority (15.1%) coming from 
NSW (AIHW & AACR, 2004).
1.4 Cancer Survival
1.4.1 Cancer Survival and Age
Cancer survival has continued to improve in the past two decades in Australia. Relative 
survival rates compare the crude survival rate (the time between diagnosis and death)
9and the expected survival time in the general population. The highest five-year survival 
proportions were reported in the 20-29 year age group at 82.9% for males and 87.2% for 
females. Survival proportions then declined in the later year groups to 30.2% for males 
and 32.7% for females in the 90-99 year group (AIHW & AACR, 2001a).
1.4.2 Cancer Survival and Gender
On average, females have higher survival rates than males. For the period 1992-1997, 
females had a five-year relative survival rate of 63.4% compared to 56.8% for males. 
There were significant improvements in one, five, and ten-year survival rates for both 
males and females across the periods 1982-1986 and 1992-1997. One-year survival 
rates increased from 64.5% to 73.6% for males and 73.5 to 77.5% for females. Five- 
year survival rates increased from 43.8% to 56.8% for males and 55.3% to 63.4% for 
females. Ten-year survival rates increased from 38.9% to 43.2% for males and 50.8% to 
55.0% for females (AIHW & AACR, 2001a).
Cancer sites with the highest five-year survival rates in males were cancers of the testis 
(95.4%), thyroid (87.9%), and prostate cancer (82.7%). Those cancer sites with the 
lowest survival rates were cancers of the pancreas (5.4%), lung (11.0%), unknown 
primary site (13.4%), stomach (22.6%), and brain (23.8%). For women, the highest 
five-year survival rates were cancers of the thyroid (95.6%) and breast (84.0%). Those 
with the lowest survival rates were cancers of the pancreas (5.2%), unknown primary 
tumour (11.5%), lung (14.0%), brain (23.8%) and stomach (24.8%) (AIHW & AACR, 
2001a).
1.5 International Comparisons of Cancer Incidence, Mortality and Survival 
In comparison with other developed countries, Australia has comparatively high 
incidence but low mortality rates, suggesting that Australians experience relatively good 
cancer survival. This is most likely due to early detection and effective treatment. The 
AIHW reported the international incidence, mortality and survival rates. These rates are 
expressed in an age-standardised rate based on World population figures (ASR(W)) and 
are estimates for the year 2000. These estimates were based on the most recent data 
available, generally three to five years earlier. Incidence and mortality rates were 
available for a range of countries while survival rates were available for a selection of 
developed countries (AIHW & AACR, 2004).
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The male World incidence rate of cancer was 201.9 cases per 100,000 population, with 
rates for developed countries significant higher (301.0) and for underdeveloped 
countries lower (153.8). When comparing a range of world regions, Australia’s 
incidence rate for males was third (355.3) behind New Zealand (375.3) and the United 
States (361.4). Australia’s rates were followed by Canada (323.4), Western Europe
(318.7) , Eastern Europe (290.0), Southern Europe (275.4), Northern Europe (263.4), the 
United Kingdom (260.3), and South-East Asia (131.1) (AIHW & AACR, 2004).
For females, the World incidence rate of cancer was 157.8 cases per 100,000 
population. Again, the incidence rate for developed countries was higher (218.3) and for 
underdeveloped countries was lower (127.9). Australia’s incidence rate for females was 
also third (279.3) compared to New Zealand (303.2) and the United States (283.2). 
Australia’s rates were followed by Canada (266.0), Northern Europe (235.1), the United 
Kingdom (234.3), Western Europe (230.7), Eastern Europe (197.2), Southern Europe 
(194.3), and South-East Asia (120.1) (AIHW & AACR, 2004).
The male World incidence rate was 134.4 cases per 100,000 population, with a higher 
rate for developed countries (173.9) and a lower rate for underdeveloped countries 
(112.9). The mortality rate for males in Australia (150.9) was lower than almost all 
other regions except South-Eastern Asia (101.3). The highest mortality rates were 
reported in Eastern Europe (199.9), followed closely by Western Europe (185.2), 
Southern Europe (172.1), and the United Kingdom (171.0), Northern Europe (168.2), 
New Zealand (167.3), and Canada (160.5) (AIHW & AACR, 2004).
The female World incidence rate was 88.3 cases per 100,000 population. Similarly, a 
higher rate was reported for developed countries (103.1) and a lower rate for 
underdeveloped countries (77.5). The mortality rate for females in Australia was one of 
the lowest of the regions (103.2), ahead of South-Eastern Asia (74.1), Southern Europe
(92.7) , and Eastern Europe (101.4). The highest rates were reported for New Zealand 
(131.1), the United Kingdom (128.1) and Northern Europe (121.7), Canada (116.7), the 
United States (116.4), and Western Europe (110.4) (AIHW & AACR, 2004).
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Consideration of the international survival rates shows that the five-year survival rate 
overall and for individual cancer sites in Australia is one of the best of those examined. 
For males, the Australian five-year survival rate was second (48%) behind the United 
States (58%). Australia was followed closely by Iceland (47%), Finland (38%), Europe 
(35%), Italy (34%), Denmark (32%), England/Wales (31%) and Scotland (29%). For 
females, the five-year survival rate in Australia also second (59) to the United States 
(61%) and followed by Iceland (56%), Finland (54%), Italy (52%), Europe (50%), 
Denmark (47%), England/Wales (43%) and Scotland (41%). It should be noted, 
however, that differences in definitions and coding as well as the presence of lead-time 
bias can make some direct comparisons difficult. Lead-time bias is when the period 
between diagnosis and death is extended due to the implementation of screening 
(AIHW& AACR, 2001a).
1.6. Cancer Expenditure
Undoubtedly, cancer represents a significant threat to the wellbeing of all Australians. 
The severity of this threat is reflected in the large amount of money spent on cancer 
services and research in Australia. It is estimated that in 2000-2001, cancer expenditure 
was $2.7 billion, representing 5.7% of Australia’s total health expenditure. The majority 
of the expenditure was in hospital care ($ 1,988m), followed by out-of-hospital medical 
expenses ($343m) and pharmaceuticals ($183m). Total expenditure on cancer services 
was 9% of total hospital expenditure. Cancer research was funded at a cost of $215m in 
2000-2001, representing 18% of all health research expenditure in Australia (AIHW & 
AACR, 2004).
The average cancer expenditure per person has been estimated at $146 for males and 
$135 for females in 2000-2001, although estimates were higher in older age groups. In 
the 65-74 year age group, average expenditure per person in 2000-2001 was $641 for 
males and $389 for females, while in the 75 years and over groups, the averages were 
$984 for males and $480 for females. The considerable cost of cancer services and 
research in Australia has risen by 31% from 1993-1994 to 2000-2001 and is expected to 
continue growing in the future (AIHW & AACR, 2004).
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7.7. Breast Cancer
1.7.1 Breast Cancer Incidence
For Australian women, the risk of breast cancer is of great concern. Breast cancer is the 
most frequently diagnosed and fatal cancer in women. As such, it affects many women 
and their families and friends in Australia every year. In 2001, there were 11,791 
women diagnosed with breast cancer (or 117.2 cases per 100,000 population). This 
represents 29.1% of all cancers diagnosed in women. This is up from 7,992 (100.4 cases 
per 100,000) in 1991, with an average increase of 1.4% per annum between 1991 and 
2001. As outlined, there was an inflection in the incidence rate around the 
implementation of routine screening program called BreastScreen Australia in 1995, 
indicating the detection of previously undiagnosed cases. In other words, around one in 
11 Australian women will develop breast cancer in their lifetime (Australian Institute of 
Health and Welfare & National Breast Cancer Centre: AIHW & NBCC, 2006).
Although figures are not currently available, the number of women diagnosed with early 
(EBC), as opposed to advanced or late stage (ABC) breast cancer, is increasing (AIHW 
& AACR, 2004). This is undoubtedly due to the increased awareness of breast cancer 
and the improvements and access to screening across Australia.
In 2001, there were no cases of breast cancer in females under 15 years, 123.1 cases per 
100,000 population for 15-44 year olds, 352.7 for 44-65 year olds, and 304.9 for 65 year 
olds and over. The ACT reported the highest incidence rates for breast cancer (122.1 
cases per 100,000 population) and the NT the lowest (97.9) (AIHW & AACR, 2004). 
Residents of the ACT have the highest level of socio-economic status. High 
socioeconomic status has long been associated with an increased risk of breast cancer as 
it is an indicator of a range of high-risk factors for breast cancer. These include an 
earlier onset of menstruation, a greater likelihood of nulliparity, an older average age at 
birth of first child and later age at menopause. Unfortunately, these risk factors are not 
easily modifiable through public education or other interventions (Population Health 
Research Centre, 2003a, 2003b).
7.7.2 Projected Breast Cancer Incidence
The age-standardised incidence rate of breast cancer is expected to remain stable from 
2002-2011, at 117.2 per 100,000 population in 2001 and 117.3 per 100,000 in 2011. 
Given the increasing numbers of women in the older age groups and the propensity for
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breast cancer to affect older women, the number of new cases is expected to increase 
significantly during this time. The number of new cases is expected to increase by 26% 
from 11,791 in 2001 to 14,818 in 2011 (AIHW, 2005).
1.7.3 Breast Cancer Mortality
Fortunately, while breast cancer is the most common cancer in women, the survival 
rates have improved significantly in the past two decades and are relatively high. In the 
period 1982-1986, one-year survival was estimated at 94.0% and five-year survival at 
72.3%. In 1992-1997, one-year survival had risen to 96.4% and five-year survival to 
84.0%. There is no relationship between age and survival rates, although survival has 
significantly increased for women between 30-39 years and 70-79 years by 7.7% and 
15.0%, respectively during this time (AIHW & AACR, 2001a).
Nonetheless, breast cancer is still the most common cause of cancer-related death for 
females. In 2001,2,612 people died with breast cancer and a further 609 had breast 
cancer listed as an additional cause of death, meaning breast cancer deaths accounted 
for 28,540 PYLL. Fortunately, the overall breast mortality rate declined on average 
2.2% per year between 1991 and 2001. There were no deaths due to breast cancer in 15 
year olds and under, 17.1 deaths per 100,000 population for 15-44 year olds, 56.1 for 
44-65 year olds, and 178.9 for those over 65. The ACT reported the highest mortality 
rates for breast cancer (122.1 deaths per 100,000), followed by SA (117.4), Qld (117.2), 
Vic (114.9), WA (112.9), NSW (112.3), Tas (104.1), and the NT (97.9) (AIHW & 
AACR, 2004).
A recalculation of the rates of breast cancer in the ACT was conducted in order to 
account for the proportion of women from other states travelling to the ACT for 
treatment and palliative care. The adjusted rates indicate that the breast cancer mortality 
rates in the ACT are still considerably higher than those of other states and territory.
The mortality rate was 31.8 deaths per 100,000 population between 1995 and 1999, 
which was significantly greater than the national average of 22.0 deaths. The increased 
rate is probably due to the increased incidence rates previously reported. Investigation 
of factors that might affect mortality, including screening participation, treatment 
quality, and high risk lifestyle factors (for example, alcohol consumption), did not
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reveal any differences between women residing in and outside the ACT (AIHW & 
AACR, 2004; Population Health Research Centre, 2003a).
1.7.4 International Comparisons of Breast Cancer Incidence, Mortality and 
Survival
Overall, breast cancer incidence and mortality is particularly high in most developed 
countries (for example, Western Europe, the Americas, Australia) but low in less 
developed countries (Central and Eastern Europe, Asia, Africa) and Japan (although the 
rate in Japan is rising). Incidence rates in most developed countries have steadily 
increased since the 1950s, with characteristic inflections in rates in 1990s when routine 
screening programs were introduced (AIHW & AACR, 2004; Key, Verkasalo, &
Banks, 2001; Veronesi, Boyle, Goldhirsch, Orecchia, & Viale, 2005).
The World incidence rate for breast cancer was 35.7 ASR(W), with a higher rate for 
developed countries (63.2) and lower for underdeveloped countries (23.1). Australia’s 
incidence rate of female breast cancer (82.7) was second behind the United States 
(91.4). Australia’s rate was followed by New Zealand (82.6), Canada (81.8), Western 
Europe (78.2), the United Kingdom (74.9), Northern Europe (73.2), South-East Asia 
(56.2), Southern Europe (56.2), and Eastern Europe (49.4) (AIHW & AACR, 2004).
In comparison, mortality rates rose from 1951 to 1990 and declined during the 1990s. 
Variations in incidence, survival, and mortality rates worldwide is probably due to 
different levels of exposure to risk factors for the disease and differences in available 
screening, diagnosis and treatment. The World mortality rate for breast cancer was 12.5 
ASR(W), with a higher rate for developed countries (18.6) and lower for 
underdeveloped countries (9.1) (AIHW & AACR, 2004; Key et al., 2001; Veronesi et 
al., 2005).
Australia’s mortality rate for breast cancer was comparatively low (19.7), ahead of 
South-East Asia (11.5) and Southern Europe (19.1). The highest rates were reported for 
the United Kingdom (26.8), New Zealand (25.9), Northern Europe (24.6), Western 
Europe (23.5), Canada (22.8), the United States (21.2) and Eastern Europe (17.2) 
(AIHW & AACR, 2004). The five-year survival rate for breast cancer in Australia was 
placed second with Iceland and Finland (79%) behind the United States (85%). Those
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reporting the lowest survival rates included Italy (77%), Europe (73%), Denmark 
(71%), England/Scotland (66%) and Wales (64%). These estimates were taken from the 
period from approximately 1987-1991 (AIHW & AACR, 2001a, 2001b).
1.8 Conclusions
Cancer is one of the greatest health challenges facing Australians and will continue to 
be so in the coming years. Current efforts at screening, diagnosis, and treatment of 
cancer appear to be effective in slowing the rise in incidence rates and prolonging 
survival. Of particular interest is breast cancer. Improvements in the screening, 
treatment, and awareness of breast cancer have meant many women are receiving a 
diagnosis of EBC and are surviving longer. Nonetheless, it still remains a disease many 
Australian women will experience. As there is no cure for cancer in the immediate 
future, it will be vitally important to continue these efforts to improve outcomes. 
Increasingly important, though, is gaining an understanding of the experience of breast 
cancer so that those receiving a diagnosis of breast cancer can receive the best possible 
medical and psychosocial care.
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CHAPTER TWO
The Clinical Experience of Breast Cancer
The research conducted on women diagnosed with breast cancer has shown that the 
clinical experience of the disease is complex. Fortunately, the proliferation of research 
in the area has gone some way to delineating the nature of the experience. The ‘cancer 
journey’ describes the stages people may experience as part of the development, 
diagnosis and treatment of cancer. For those with EBC, the journey includes the 
experience of risk factors, screening and detection, diagnosis, treatment (surgery, and 
adjuvant chemotherapy, radiation therapy and/or adjuvant endocrine therapy), and 
survival, all of which pose unique challenges for women and their family and friends 
(National Health and Medical Research Council & National Breast Cancer Centre: 
NHMRC & NBCC, 2001). This chapter will outline women’s typical experience of 
these stages.
2.1 Risk Factors
The first stage of the cancer journey is the experience of risk factors. In the absence of 
any known cure, risk factors for the disease have become the focus of research 
internationally (NHMRC & NBCC, 2001). To date, there exist numerous well- 
established risk factors for the disease and many more are currently under investigation. 
These factors are genetic, biological, and environmental.
2.1.1 Genetic Factors
When considering genetic factors, a family history of breast cancer has been shown to 
strongly increase the risk of developing the disease. Women at a high risk have: 1) three 
or more first or second degree relatives on the same side of the family with breast or 
ovarian cancer, or 2) two or more first or second degree relatives on the same side of the 
family with breast or ovarian cancer including any of the following high risk features: 
bilateral disease, breast and ovarian cancer in one individual, breast cancer in a male, 
diagnosis at age 40 or younger, or Jewish people of Ashkenazi origin. Less than 1% of 
women will be categorised as high risk. The lifetime risk on average of women in this 
category is usually between 25% and 50% but may be as high as 80% (NHMRC &
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NBCC, 2001). This is in comparison with the usual lifetime risk of 9% for Australian 
women (AIHW & NBCC, 2006).
Women fall into the moderately increased risk category if: 1) one or two first degree 
relatives were diagnosed with breast cancer before the age of 50, or 2) two first or 
second degree relatives on the same side of the family were diagnosed with breast or 
ovarian cancer (without the additional features of the women at potentially high risk 
described below). Fewer than 4% of women are in the moderately increased risk 
category and their lifetime risk of developing breast cancer is 12-25% (NHMRC & 
NBCC, 2001).
Those women who fall into the moderate and high risk categories typically have 
damage to genes (referred to as a genetic mutation) that suppress the multiplication of 
cancer cells. Damage to these genes means that cancer cells are able to multiply 
untempered. The most important and best-established genes involved in this process are 
the BRCA1 and BRCA2 genes although a range of other genes are currently under 
investigations (de Jong et al., 2002a). Damage may occur by mutation, amplification or 
rearrangement, and loss or deletion (Chap, Barsky, Bassett, & Haskell, 2001b). In the 
general population, about 1 in 1000 women have inherited a mutation in one or other of 
these genes which increases their risk of breast cancer at least 8-9 fold. BRCA1 and 
BRCA2 mutations explain only 1-2% of all breast cancer. These mutations can be 
transmitted through either the maternal or paternal lines (NHMRC & NBCC, 2001). In 
several ethnic groups, mutations to one or both of these genes are more prevalent. For 
example, 1 in 44 Ashkenazi Jews carry a mutation, leading to considerably higher 
incidence of the disease (Chap et ah, 2001b).
The discovery of the genetic heritability of breast cancer has led to the development of 
genetic testing and counselling. Genetic testing and counselling involves screening for 
BRAC1 and BRAC2 mutations and communicating the results in terms of potential risk 
of developing breast cancer. At present, genetic testing and counselling is not widely 
available to women in Australia or overseas due to uncertainty about the extent to which 
carrier status places a person at risk of breast cancer and concern about the potential and 
as yet unknown psychological impact of learning one’s carrier status. While prospective 
studies investigating the former issue continue, a number of cross-sectional and short-
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term prospective studies have been conducted to address the latter (Daly, 2001; Meiser 
et al., 2002).
Research has indicated that the period immediately prior to genetic testing and 
counselling is accompanied by increased general and breast cancer-specific distress but 
that distress declines after counselling and is accompanied by a more accurate perceived 
risk. This has been confirmed in a recent meta-analysis (Meiser et ah, 2002). Despite the 
general trend, there appears to be a proportion of people who remain distressed. Recent 
research has attempted to determine the factors responsible for the increased distress in 
some people. The potential factors identified to date include gender, family history of 
breast cancer, whether siblings have received genetic counselling, and the results of 
siblings’ genetic counselling (Smith, West, Croyle, & Botkin, 1999). Unfortunately, 
most studies have offered genetic testing and counselling to people accompanying a 
relative to out-patient cancer appointments, making it difficult to distinguish between 
distress resulting from having a relative with cancer and that resulting from genetic 
testing and counselling (Meiser et al., 2002; Moyer & Salovey, 1996).
2.7.2 Biological Factors
A number of biological factors has shown an association with breast cancer risk. The 
most significant of these is age (NHMRC & NBCC, 2001). The increasing incidence of 
breast cancer with age likely reflects, as for many other cancers, the accumulation of 
somatic mutations over time (Adami, Signorello, & Trichopoulos, 1998; Chap et al., 
2001b). A smaller yet equally consistent risk factor is height, with greater height 
providing greater risk. Why this is the case is unknown but it is thought that height 
reflects, to a certain extent, nutritional adequacy in childhood and adolescence which in 
turn affect levels of oestrogen in the body (Adami et al., 1998; van den Brandt et al., 
2000).
Reproductive factors strongly influence a woman’s risk of breast cancer, particularly 
those characteristics of menstrual and childbirth history (NHMRC & NBCC, 2001). 
While these factors are closely related and therefore the individual effects of each are 
difficult to delineate, extensive research has been able to do so fairly conclusively 
(CGHFBC, 2002). These factors are mainly associated with increased lifetime exposure
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to oestrogen, an integral risk factor for breast cancer as oestrogen is important in the 
initiation and progression of breast cancer (Carmichael & Bates, 2004).
An earlier age at menarche and a later age at menopause are associated with increased 
risk. Earlier age at menarche appears to be associated with a more rapid establishment 
of regular ovulatory cycles and therefore greater exposure to estrogens throughout the 
reproductive life of the woman. Menopause involves the cessation of ovarian 
functioning and the resultant decreased exposure to oestrogen. A later age at menopause 
means there is a longer period of exposure to oestrogen (Adami et al., 1998).
In general, pregnancy is associated with a reduced risk of breast cancer albeit in a 
complex manner, while nulliparity is associated with an increased risk. An earlier age at 
first full-term pregnancy lowers risk but after the age of around 30, a first full-term 
pregnancy increases breast cancer risk. Subsequent pregnancies have similar but weaker 
effects on risk. Prolonged lactation provides weak protection, but the effect is small and 
may be limited to pre-menopausal women with breast cancer. Again, this is due to 
exposure to oestrogens whereby pregnancy and lactation produce a large increase in 
endogenous hormones, including oestrogen. Interestingly, there is a transient increase in 
risk following a pregnancy but this is as yet not understood (Collaborative Group on 
Hormonal Factors in Breast Cancer: Adami et al., 1998; CGHFBC, 2002).
The use of exogenous hormones, either oral contraceptives (OC) or hormone 
replacement therapy (HRT) also increases lifetime exposure to oestrogen and as such is 
associated with a slight increased risk (Adami et al., 1998; Carmichael & Bates, 2004). 
For the OC, the risk is increased during use but the effect on lifetime risk of breast 
cancer is small because risk of the disease is low at ages when women commonly take 
the OC. The excess risk disappears within several years of stopping use. HRT after 
menopause also appears to elevate risk with increasing duration of use but the excess 
risk disappears within two years of stopping (Chap et al., 2001b).
2.1.3 Environmental Factors
Environmental factors consistently shown to be associated with increased risk are 
exposure to ionising radiation, excess weight, and alcohol consumption. Exposure to 
ionising radiation is strongly associated with an increased risk of breast cancer, even at
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low levels of exposure and particularly during adolescence (Veronesi et al., 2005). 
Evidence for this comes from longitudinal research on populations exposed to ionising 
radiation to treat medical conditions in childhood and adolescence and to the World 
War II atomic bomb in Japan (Marcus et al., 2000; Tokunaga et ah, 1987).
Excess weight or weight gain is associated with an increased risk in postmenopausal 
women while the reverse is true for pre-menopausal women. These findings are 
independent of confounding factors such as breast size, breast density, weight 
distribution and socio-economic status (Adami et al., 1998; Barnett, 2003). The 
mechanism for the increased risk in postmenopausal women is not well understood but 
there are several hypotheses. Overweight women exhibit greater deposits of adipose 
tissue, lower levels of sex hormone binding globulins, and a higher risk of insulin 
resistance, all of which confer to increase the levels of oestrogens in the body and 
therefore increase risk of breast cancer. Alternatively, the protective effect of excess 
weight in pre-menopausal women may reflect a residual protective effect of greater 
weight in the early pre-menopausal years, which is a predictor of longer anovular cycles 
and lower levels of oestrogen. Interestingly, overall and disease-free survivals appear to 
be lower in obese pre- and postmenopausal women with breast cancer, even after 
accounting for stage at diagnosis and treatment. Reasons for this are unknown but may 
be partly due to delayed detection and more rapid growth of metastatic tissue observed 
in obese women (Carmichael & Bates, 2004; Harvie, Hooper, & Howell, 2003).
Of the many diet-related factors investigated, only alcohol consumption is shown to be 
modestly associated with increased risk. The nature of the association indicates a dose- 
response relationship that levels off at higher doses of up to 60g/day or six standard 
drinks/day and is independent of type of alcohol consumed, intensity of consumption 
across the lifespan, and other known risk factors. However, a number of limitations in 
the literature need to be overcome to further confirm the nature of the relationship 
(Adami et al., 1998; CGHFBC, 2002; Chap et al., 2001b; Singletary & Gapstur, 2001; 
Smith-Warner et al., 2001).
Fortunately, these environmental factors consist of potentially modifiable behaviours. 
This means that interventions may be developed and implemented to reduce these 
behaviours and thereby help to reduce the risk of breast cancer. However, further
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research is needed to determine the extent of the risk afforded by these factors and 
weigh the results with the cost of developing interventions to modify behaviour (Smith- 
Warner et al., 1998).
2.2 Screening For Breast Cancer
There are three pathways through which women discover they may have EBC: self 
examination (either by accident or as a result of breast self examination, BSE), clinical 
examination by a medical professional, and routine mammography screening. Women 
whose cancer is detected via self and clinical examinations are more likely to have 
symptoms while those whose cancer is detected via screening mammography are more 
likely to be asymptomatic (AIHW & AACR, 2004).
2.2.7. Breast Self-Examination and Clinical Examination 
Breast self-examination (BSE) and clinical examination by a medical professional both 
consist of a manual search for changes in breast tissue and are thought to be appealing 
screening options due to their patient-centred, non-invasive nature (Elmore, Armstrong, 
Lehman, & Fletcher, 2005). BSE has been widely promoted in the community as an 
integral technique for identifying breast cancer. Clinical examinations are performed as 
part of routine care by many medical professionals, particularly general practitioners. 
Nonetheless, BSE and to a lesser extent clinical examination, have been criticised as 
effective screening techniques for several reasons.
The overall findings of the empirical literature do not appear to show a clear benefit of 
BSE in reducing breast cancer mortality (Baxter & Canadian Task Force on Preventive 
Health, 2001). Some believe BSE and clinical examinations result in unacceptably high 
rates of false positive findings. Indeed, there are claims that the ineffectiveness of BSE 
does not warrant the cost of widespread promotion, especially given that rates of BSE 
are thought to be low. It is also speculated that few medical professionals are as 
proficient in performing clinical examinations as those participating in clinical trials of 
their effectiveness (Elmore et al., 2005; Pfeffer, 2004).
For those whose disease is detected via self or clinical examination, the most commonly 
experienced symptoms reported are lumps in the breast, skin oedema, peau d’orange, 
and discharge or bleeding (Arndt et al., 2002). The average length of delay between
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onset of symptoms and presentation for medical care is 14-16 days, with around two- 
thirds (64-69%) of women presenting within one month. Of concern is the significant 
number (14-18%) who delay presentation for one and a half months or more (Arndt et 
ah, 2002; Meechan, Collins, & Petrie, 2003), as patient delay is associated with 
increased mortality (Coates, 1999; Ramirez et al., 1999; Richards, Smith, Ramirez, 
Fentiman, & Rubens, 1999). Fortunately, the number of women who delay presentation 
for medical care has declined over recent years, most likely due to increasing public 
awareness and openness about breast cancer (Bish, Ramirez, Burgess, & Hunter, 2005).
Limited research has investigated the reasons for delay but so far those reported include 
the consideration of symptoms as harmless or temporary, and time constraints. Risk 
factors for extended delay are many and varied and include older age, obesity, having 
breast symptom other than lump, history of benign breast biopsy, non-participation in 
routine screening, negative attitudes to GP, not disclosing the symptom to someone else, 
fears about cancer treatment, and low initial distress on discovering symptom(s).
Further replication of findings and extension to other possible risk factors is necessary 
before specific strategies can be developed and implemented to shorten presentation 
delay (Arndt et al., 2002; Bish et al., 2005; Hunter, Grunfeld, & Ramirez, 2003; 
Meechan et al., 2003).
2.2.2 Mammography Screening
In 2002, breast cancer was detected by mammography screening in 2,357 women aged 
40 years and over. In other words, mammography screening is responsible for detecting 
30% of breast cancers each year (AIHW, 2005; AIHW & NBCC, 2006). The national 
screening program, BreastScreen Australia, was implemented in 1995. The program is 
jointly funded by the Australian Commonwealth State and Territory governments and 
consists of cost-free, fixed or mobile, twice yearly screening and assessment services 
throughout metropolitan, rural, and remote areas of Australia. The program is aimed 
specifically at women aged 50-69 years of age without symptoms, although women 
aged 40-49 years and 70 years and older may attend for screening. Evaluation of the 
program indicates that early detection is effective in reducing illness and death from 
breast cancer (AIHW, 2005; AIHW & AACR, 2004).
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Nationally, the proportion of women in the target age group (50-69 years) who attended 
BreastScreen rose from 61% in 1996-1997 to 63% in 1998-1999 and then declined to 
61% in 2000-2001. Reasons for the decline in participation are unknown but may be 
due to improvements in the linking of records to identify women previously screened 
and to lack of media campaigning in most states. Women aged 40 years and over were 
increasingly screened by the BreastScreen program with over 1.24 million in 1996-1997 
to more than 1.61 million in 2001-2002. A meta-analysis of the effectiveness of routine 
mammogram suggest that it can reduce mortality in women aged 50-69 years by 20- 
32% (Taylor, Morrell, Estoesta, & Brassil, 2004). It is difficult to observe the effects of 
BreastScreen Australia. Any reductions in mortality are probably not observable given 
the program is only a decade old, women access mammography screening in the private 
sector, and there are continual changes in treatment efficacy (Giles & Amos, 2003).
The age-standardised program sensitivity for asymptomatic women aged 50-69 years 
who attended for a first-time screen ranges from 88.9-94.7% and for subsequent screens 
from 75.0-83.7% (Giles & Amos, 2003). Mammography screening tends to detect 
breast cancers that are smaller and have more favourable disease characteristics than 
those detected via other methods. The benefits for women under age 50 years are less 
clear, although a recent report stresses the need to regularly review the evidence of the 
effectiveness of mammography screening in women under age 50 years (Senate 
Community Affairs References Committee, 2005). Again, concern exists that the 
community practice of mammography screening differs from that in clinical trials 
(Elmore et al., 2005).
Lower participation rates were evident if women were Indigenous Australians, those of 
a non-English-speaking background and of high socio-economic status (AIHW, 2005; 
AIHW & AACR, 2004; Population Health Research Centre, 2003a). Debate continues 
regarding whether elevated distress facilitates or hinders mammography screening. A 
recent meta-analysis and review concluded that breast cancer worry increases screening 
but perhaps in a curvilinear manner (Hay, McCaul, & Magnan, 2006). This is most 
likely because higher rates of distress have been found to predict over-estimation of 
breast cancer risk, which would in turn facilitate screening behaviour (Bowen et al., 
2003; Lebel et al., 2003). Further research is needed to access those with high levels of
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distress, as little is known about the effects of elevated distress on screening (Hay et al., 
2006).
Despite the clear advances of mammography screening and high levels of consumer 
satisfaction (Ekeberg, Skjauff, & Karesen, 2001), the psychosocial impact of breast 
cancer screening should not be underestimated (Brawley, Prorok, Gohagen, & Kramer, 
2001). Women attending mammography screening consistently report elevated levels of 
anxiety and depression symptoms, although these tend to decline after mammography 
screening (Ekeberg et al., 2001; van Dooren et al., 2005). Those that are more 
susceptible to increased distress both prior to and following mammography are younger, 
over-estimate their risk of breast cancer, conduct frequent BSE, use fewer and/or more 
avoidant coping strategies, have a history of benign breast biopsies, and are involved in 
the care of a relative with breast cancer (Heckman et al., 2004; Lebel et al., 2003; 
McCaui, Branstetter, Schroeder, & Glasgow, 1996; van Dooren et al., 2005).
2.3 Diagnosis of Breast Cancer 
2.3.1 Diagnostic Tests
The diagnosis of breast cancer is established by medical history, clinical examination, 
mammography (with or without ultrasound), and fine needle aspiration or core biopsy.
A selection of additional investigations may be performed when clinically indicated and 
as determined by the medical professionals involved in women’s care. These include 
full blood count and serum biochemistry (including bone marrow, hepatic and renal 
functioning), chest X-ray, bone scan, liver ultrasound, and chest computed tomography 
(NHMRC&NBCC, 2001).
Apart from the diagnostic information they provide, these investigations also offer 
prognostic information. Factors generally associated with a high risk of recurrence 
and/or death are larger tumour size, higher histological grade, and the presence and 
number of lymph node metastases. Higher histological grade refers to the extent to 
which the tumour is differentiated, that is the extent to which it can be distinguished 
from surrounding normal tissue. Lower grade reflects a well differentiated tumour and 
higher grades a poorly differentiated tumour. Lymph node metastases refer to the early 
spread of cancer cells to the nearby lymphoid tissue located under the armpits (NHMRC 
&NBCC, 2001).
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Other potential factors for high risk include early age-at-onset, and negative oestrogen 
receptor (ER) and progesterone receptor (PR) expression, and high HER2 receptor 
expression. ER is a receptor protein binds oestrogens and anti-oestrogens and as a result 
mediates the effects of oestrogens and alters the expression of specific genes. PR is a 
receptor that binds progestins and anti-progestins. As an oestrogen-induced protein, it 
can be used as an indicator of ER status. Positive ER and PR statuses also reflect 
responsiveness to certain therapies (that is, endocrine or hormonal therapies). HER2 is a 
cell receptor which, when activated, results in the process of cell division. That is, 
activation of HER2 affects the rate at which tumour cells replicate (Anderson, Jatoi, & 
Devesa, 2005).
Patients often report that the experience of diagnostic tests can be overwhelming, 
confusing and occur in a very short space of time (Senate Community Affairs 
References Committee, 2005). As a result, they have considerable information needs 
including when they will receive the results of tests, the risks of a diagnosis of breast 
cancer, and the treatment options for breast cancer (Deane & Degner, 1998).
2.3.2 Receiving the Diagnosis
Once the diagnosis of EBC has been established, this is communicated to the woman 
and her family. The diagnosis of EBC presents a threat to the woman’s life, which often 
elicits feelings of helplessness and powerlessness and a sense of uncertainty about the 
future. These feelings may present a significant challenge to women’s sense of identity, 
femininity, body image, self-esteem, psychological wellbeing, sense of independence, 
relationships with family and friends, and future plans in all areas of life (Turner, Kelly, 
Swanson, Allison, & Wetzig, 2005).
Indeed, cancer and/or its treatment may disrupt all areas of life. Women report concerns 
regarding physical and psychological wellbeing, relationships with friends and family, 
and the ability to continue normal daily activities. Some of the more commonly reported 
include fear of being stigmatised and rejected once the diagnosis is known, making 
decisions about medical care, ability to cope with treatment, the effect of the diagnosis 
and treatment on the rest of the family, disruptions to family, work and social life, and
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changes in financial situation due to time off paid work and/or the cost of medical 
expenses (NHMRC & NBCC, 2001).
When receiving a diagnosis of cancer, patients have reported considerable informational 
needs. Most patients desire extensive information regarding their diagnosis, prognosis 
and treatment options (Jenkins, Fallowfield, & Saul, 2001). This is clearly evident in 
patients’ use of a variety of information sources in the period following diagnosis, 
particularly the internet and popular books (Satterlund, McCaul, & Sandgren, 2003). 
Patients also have preferences regarding the way in which this information is 
communicated. They favour a supportive setting and a patient-centred, compassionate, 
caring, and truthful manner using simple, unambiguous terms (Dowsett et ah, 2000; 
Girgis, Sanson-Fisher, & Schofield, 1999; Parker & Withers, 2001; Senate Community 
Affairs References Committee, 2005).
Unfortunately, the information needs tend to be at odds with the general quality of 
doctor-patient communication. Research has revealed that doctor-patient 
communication is often characterised by terms and euphemisms not well understood by 
the general public, closed questions, few opportunities for discussion, few questions 
regarding psychological wellbeing and quality of life, but voluminous information about 
medical wellbeing (Chapman, Abraham, Jenkins, & Fallowfield, 2003; Fallowfield, 
2001; Ford, Fallowfield, & Lewis, 1996).
Not surprisingly, patients have reported low levels of satisfaction with the way in which 
their diagnosis was communicated (Turner et al., 2005). Such dissatisfaction has the 
potential to affect their quality of life and satisfaction with subsequent treatment up to 
three months post-consultation (Gerits & Ce Brabander, 1999; Ong, Visser, Lammes, & 
de Flaes, 2000). Recent attempts to design and implement communication skills training 
for doctors in the oncology setting has been met with limited success (Fallowfield, 
Jenkins, Farewell, & Solis-Trapala, 2003; Shilling, Jenkins, & Fallowfield, 2003).
Once a patient receives the diagnosis, they are encouraged to participate in the decision­
making process regarding their treatment (Butow et ah, 2005). Although most patients 
desire a lot of information, not all want to use this information as part of an active role 
in decision-making. In fact, a significant number of patients report that although they
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desire much information they would prefer to leave decisions, particularly those 
regarding treatment, up to the doctor (Fallowfield, 2001; Jansen, Otten, van de Velde, 
Nortier, & Stiggelbout, 2004; Jenkins et al., 2001). In a study of Australian cancer 
patients attending their first consultation with their oncologist, 37% reported that they 
preferred the doctor to take the primary role, 49% preferred an equal role in decision­
making, and 14% preferred to take the primary role (Butow, Maclean, Dunn, Tattersall, 
& Boyer, 1997).
The preference for a passive role in decision-making is understandable. The diagnosis 
of EBC is a stressful process during which patients often need to gather and understand 
new medical terms and concepts not previously encountered and consult with several 
medical specialists. Moreover, this information needs to be mastered in a short period of 
time, a time in which many patients are still coming to terms with their diagnosis 
(Moyer & Salovey, 1996; Senate Community Affairs References Committee, 2005). 
Encouraging an active role in such circumstances may cause undue stress, although it is 
also possible that patients who prefer a passive role may change their preference when 
provided with appropriate information and support. Further research is needed to 
confirm the decision-making preferences of patients and investigate their effects on 
adjustment to diagnosis and treatment (Butow et al., 1997; Jansen et al., 2004).
2.4 Treatment o f Breast Cancer
Unlike women diagnosed with ABC, women with EBC are treated with curative intent. 
In line with this objective, the treatment of EBC has two aims: to remove as many 
cancer cells as possible and to destroy any undetected cancer cells in the body to ensure 
the cancer does not recur. The first aim is achieved via surgery and the second aim 
through adjuvant treatments such as the administration of cancer-destroying drugs 
(adjuvant chemotherapy and adjuvant endocrine therapy) and/or X-ray treatment 
(adjuvant radiation therapy). Surgery and radiation therapy are described as local 
treatments because they focus on cells at the site of the primary tumour and regional 
lymph nodes. Chemotherapy and endocrine therapy are systemic treatments because 
they targets cells throughout the entire body (NHMRC & NBCC, 2001).
To ensure comprehensive and effective treatment, patients with EBC usually undergo 
several treatment modalities. Treatment often follows a rigid schedule that can last
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many months and all modalities have the potential to elicit numerous debilitating side 
effects which can continue for the duration of treatment and for many months 
following. The demands of treatment and the side effects of each modality can have a 
significant impact on body image, levels of psychiatric morbidity, and quality of life. As 
such, guidelines for medical professionals practicing in Australia (NHMRC & NBCC, 
2001) stipulate that women should be fully informed of the short- and long-term effects 
of all treatments. These effects should be weighed up against the potential benefits of 
treatment in prolonging survival when doctors and patients are collaboratively deciding 
on appropriate treatment (Senate Community Affairs References Committee, 2005).
The preparation and receipt of multi-modal treatment often presents patients with what 
Alder and Bitzer (2003) describe as a “completely ‘new world’ of investigative 
procedures and treatments... and a multitude of different staff members” (p. 96). While 
the aim is to provide patients with the best care possible, women often report feeling 
overwhelmed by the change in their circumstances and feeling out of control in their 
new role as patient. This can lead to feelings of being lost and lonely in an intimidating 
and confusing schedule of treatment (Alder & Bitzer, 2003; Senate Community Affairs 
References Committee, 2005). Indeed, recent awareness of this experience has led to the 
identification of the need for patient-centred continuity of care throughout all stages of 
the cancer journey as a priority in cancer care. This is currently being addressed by 
several government organizations (Cancer Strategies Group, 2001; Senate Community 
Affairs References Committee, 2005).
2.4.1 Surgical Interventions
Surgical treatment occurs after the necessary diagnostic investigations are completed. 
Although this can delay surgery by one to two weeks, the information gained provides 
knowledge integral to the selection of the appropriate surgical procedure. EBC surgery 
consists of two basic procedures; breast conserving surgery (BCS) and unilateral or 
bilateral total mastectomy (TM). BCS involves removing the primary tumour including 
a rim of normal breast tissue around the periphery to ensure all cancer cells of the 
tumour are removed. When there is a well-defined rim of normal tissue around the 
tumour this is referred to as a clear margin (NHMRC & NBCC, 2001).
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TM involves completely removing the breast tissue while preserving the underlying 
pectoral muscles. A unilateral TM is when this procedure is conducted on one breast 
and a bilateral TM is when it is conducted on both breasts. TM is appropriate for 
women whose tumours extend widely within the breast, have poorly-defined margins 
which prohibit complete local excision, directly involve the nipple or skin, or for those 
who do not choose BCS. Many women who receive a TM have the option of 
undergoing a breast reconstruction at a later date (NHMRC & NBCC, 2001).
In some cases, cancer cells have spread to the lymph nodes in the armpits. Surgical 
intervention can be extended to include axillary dissection. Axillary dissection is the 
removal of cells in the armpits. The presence and number of affected axillary lymph 
nodes are the most powerful indicators of prognosis for primary breast cancer. Axillary 
dissection carries the risk of lymphedema in the arm, a condition in which excess fluid 
collected in the lymph nodes and causes swelling (IDG Books Worldwide, 2000). To 
reduce this risk, a sentinel node biopsy is increasingly carried out to determine whether 
the lymph nodes are affected (that is, whether they contain cancer cells) and therefore 
whether axillary dissection is necessary. A sentinel node biopsy consists of sampling the 
lymph nodes that first receive drainage from the tumour cells. If these nodes are found 
to be affected, then axillary dissection is performed (NHMRC & NBCC, 2001).
Some women may not only have a primary breast tumour, but also breast diseases that 
increase the risk of developing a breast tumour. The two most common breast diseases 
are ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). DCIS 
describes the abnormal proliferation of epithelial cells in the mammary ducts while 
LCIS is the abnormal proliferation of these cells in the lobules and terminal ducts of the 
breast. Typically, these breast diseases are also surgically removed along with the 
primary breast tumour (NHMRC & NBCC, 2001).
The socio-cultural value placed on the breast as a symbol of femininity, sexuality and 
attractiveness mean that surgical intervention can threaten a woman’s sense of body 
image, self-esteem, sexuality, sexual relationships, and psychological wellbeing. 
Women may be concerned about their new appearance, friends and family’s response to 
their appearance, partners’ or potential partners’ acceptance of their appearance,
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initiation of first sexual experience following surgery, and the ability to experience 
sensation in the altered breast (Alder & Bitzer, 2003; Moyer & Salovey, 1996).
To date, research has repeatedly indicated that decrements in these areas are felt more 
severely by those women undergoing TM compared to TM plus reconstruction and 
BCS. BCS is associated with less impact on body image and sexuality, higher levels of 
self-esteem and quality of life, and lower levels of distress from one month and up to 
five years post-surgery than TM plus reconstruction and TM (Al-Ghazal, Sully, 
Fallowfield, & Blarney, 2000; Arora et al., 2001; Curran et al., 1998; Ganz et al., 2004; 
Hartl et al., 2003; Hopwood, Fletcher, Lee, & AI Ghazal, 2001; Meyerowitz, Desmond, 
Rowland, Wyatt, & Ganz, 1999; Moyer & Salovey, 1996).
Prospective studies have shown that some of the decrements in body image and quality 
of life decline over time (Arora et al., 2001; Hopwood et al., 2001). Despite this general 
trend, women vulnerable to decrements in these areas tend to be younger, less 
optimistic, report little agreement in their relationship, and have lower levels of 
perceived social support (Abend & Williamson, 2002; Hopwood et al., 2001), although 
it must not be assumed that physical appearance and sexual functioning are irrelevant 
for older women.
The majority of women undergoing breast surgery report satisfaction with the resulting 
cosmetic outcome, but satisfaction is greatest for those undergoing BCS (91%) due to 
preservation of the breast shape, a better fit of clothing, and avoidance of a prosthesis or 
reconstructive surgery. Satisfaction is also high following TM plus reconstruction 
(80%) and less so following TM (73%). Dissatisfaction with the cosmetic outcome can 
be extremely distressing for patients and has been associated with higher levels of 
distress, poorer body image and self-esteem, and younger age (Al-Ghazal, Fallowfield, 
& Blarney, 1999; Al-Ghazal et al., 2000; Hartl et al., 2003; Moyer & Salovey, 1996). 
Given the significance of these benefits, it is recommended that these issues are 
discussed with patients when making the choice between BCS, TM, and TM plus 
reconstruction (NHMRC & NBCC, 2001).
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2.4.2 Adjuvant Chemotherapy
After surgery, the appropriate adjuvant treatments are undertaken. Most patients with 
EBC will receive one or more adjuvant treatments consisting of chemotherapy, 
radiation therapy and/or endocrine therapy. Overall, the data from clinical trials 
indicates that using several adjuvant therapies is beneficial because the effects of these 
therapies on recurrence-free and overall survival are independent. These benefits are 
evident in all patients aged under 69 years (NHMRC & NBCC, 2001).
Chemotherapy treatment for patients with EBC involves the administration of cytotoxic 
drugs on an outpatient basis, either in oral form or intravenously, followed by a rest 
period of one to three weeks. This pattern of administration and rest is known as a cycle 
and, depending on the regimen prescribed, most patients will undergo between four and 
eight cycles. Up to the age of 70 years, combination (or multi-agent), moderately 
prolonged (approximately four to six months) chemotherapy is most effective in 
extending recurrence-free and overall survival for patients with EBC. Combination 
chemotherapy lasting several months is more effective than single agent chemotherapy 
or combined chemotherapy lasting less than one month but no more effective than 
combined chemotherapy lasting longer. Dose intensity of chemotherapy appears 
important and should follow standard dosing, as lower doses have poorer outcomes and 
the evidence for the effectiveness of high-dose chemotherapy is as yet unknown 
(NHMRC & NBCC, 2001).
The most recent overview data demonstrated a significant improvement in recurrence- 
free survival with absolute differences in 10-year recurrence-free survival ranging from 
35% for women aged less than 50 years and 20% for women aged 50-69 years receiving 
several months of combination chemotherapy versus those receiving no chemotherapy. 
The main divergence was observed during the first five years, with curves remaining 
roughly parallel thereafter. A significant improvement in overall survival was also 
evident with absolute differences in 10-year overall survival ranging from 27% for those 
under 50 years or 11% for those aged 50-69 years. Improvements in overall survival 
were significant in the first five years and continued to improve between five and ten 
years. The benefits in recurrence-free and overall survival existed regardless of 
oestrogen and progesterone receptor expression statuses, menopausal status, and receipt
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of adjuvant radiation therapy or endocrine therapy (Early Breast Cancer Trialists' 
Collaborative Group: EBCTCG, 1998; EBCTCG, 2005; NHMRC & NBCC, 2001).
CMF (cyclophosphamide, methotrexate and 5-fluorouracil) was one of the initial 
combination regimens and has been the standard chemotherapy treatment for many 
years. Generally CMF has been replaced by AC-based (Anthracycline-containing) 
regimens as these appear superior in improving recurrence-free and overall survival. 
Ten-year recurrence-free and overall survival for AC regimens yielded a further 12% 
proportional reduction in recurrence and 11 % in mortality than CMF regimens. 
However, AC regimes are associated with increased toxicity, including alopecia (hair 
loss), febrile neutropenia, and increased risk of cardiac toxicity. Febrile neutropenia 
describes a condition in which bone marrow functioning is compromised, leaving the 
patient at risk of infection (EBCTCG, 1998, 2005; NHMRC & NBCC, 2001).
Adjuvant chemotherapy for EBC can cause a number of side effects, all of which may 
impact on quality of life, particularly physical, cognitive, emotional and social domains. 
Almost half of patients report severe disruption to their lives (Given et al., 2004; Lee, 
Dibble, Pickett, & Luce, 2005; Osoba et al., 1997). The most frequently reported are 
nausea and vomiting (NHMRC & NBCC, 2001). Acute nausea and vomiting refers to 
that occurring during the 24 hours after chemotherapy and delayed nausea and vomiting 
occurs after this period. Despite the use of anti-emetics, acute nausea is experienced by 
at least 45% and delayed nausea by 31 %. Acute vomiting is experienced by at least 15% 
of patients and delayed vomiting by 28% (Lee et al., 2005). The worst vomiting usually 
occurs in the first three days following chemotherapy infusion (Dibble, Casey, Nussey, 
Israel, & Luce, 2004; Kris, Roila, De Mulder, & Marty, 1998).
Effective early control of chemotherapy induced nausea and vomiting is vital as it can 
worsen if not dealt with immediately, in some cases leading to the development of 
anticipatory nausea and vomiting. This is when patients begin to experience nausea and 
vomiting prior to receiving a chemotherapy infusion. The mechanisms for anticipatory 
nausea and vomiting are not yet well understood (Carey & Burish, 1988). In the worst 
instance, uncontrolled nausea and vomiting may contribute to the decision to delay or 
even withdraw from treatment.
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The most effective medications are 5 HT3 receptor antagonists and corticosteroids, either 
via oral or intravenous administration prior to initiation of treatment. The ‘gold 
standards’ for anti-emetic treatment include a corticosteroid for mildly emetogenic 
regimens, and both a 5HT3 receptor antagonist and a corticosteroid in moderately to 
highly emetogenic regimens. The addition of an apprepitant or an anxiolytic six to 
twelve hours prior to chemotherapy infusion is recommended when anticipatory nausea 
and/or vomiting are experienced or when the use of both a 5 HT3 antagonist and 
corticosteroid is ineffective (Bartlett & Koczwara, 2002; Dibble et al., 2004; Gandara et 
al., 1998; Kris et al., 1998; Oettle & Riess, 2001). Given that the emetogenic potential 
of regimens is largely based on expert consensus (Bartlett & Koczwara, 2002), and a 
range of other non-medical factors are implicated in the development of nausea and 
vomiting (Montgomery & Bovbjerg, 2001), anti-emetic treatment should also be based 
on patients’ medical history and individual requirements (Oettle & Riess, 2001).
Fatigue is also commonly experienced and in some cases, fatigue may become a chronic 
problem. Patients report experiencing fatigue across cycles and a decline after treatment 
but difficulties in the measurement of fatigue and the tendency to measure it across a 
selection of cycles makes it difficult to draw firm conclusions about patients’ experience 
of it (Bower et al., 2000; de Jong, Courtens, Abu-Saad, & Schouten, 2002b; Sadler & 
Jacobsen, 2001). In a similar vein, patients may also report experiencing impaired 
cognitive abilities during chemotherapy treatment, including poor concentration and 
memory, but this usually resolves upon completion. Investigations are underway to 
determine whether these impairments are subjective or objective, and whether they can 
be attributed to the chemotherapeutic drugs or co-morbid fatigue and/or psychological 
distress (Castellon, Silverman, & Ganz, 2005; Failed, Sanfilippo, Maruff, Weih, & 
Phillips, 2005; Jansen, Miaskowski, Dodd, & Dowling, 2005; Schagen et al., 1999).
Temporary but significant alopecia requiring a wig is common following anthracyclines 
although less common in women having CMF. Alopecia may be very distressing for the 
woman and her family as it is a highly visible reminder of the cancer and can negatively 
impact on body image and identity. Although hair usually grows back within three 
months of completing treatment, it may have a different texture and be curlier than 
before (Ferrell, Grant, Funk, Otis-Green, & Garcia, 1997).
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Chemotherapy has been associated with impairment in sexual functioning during and 
following treatment (Arora et al., 2001; Dow, Ferrell, Leigh, Ly, & Gulasekaram, 1996; 
Meyerowitz et al., 1999). The most common aspects affected include fatigue, breast 
sensitivity, vaginal atrophy, decreased vaginal lubrication, decreased libido, and body 
image problems (Ganz et al., 2004; Meyerowitz et al., 1999; Takahashi & Kai, 2005). 
Some of these symptoms may occur as a result of menopause, a common consequence 
of chemotherapy (McPhail, 1999; Meyerowitz et al., 1999; Young-McCaughan, 1996). 
Despite these difficulties, more than 80% of patients reported that they were never 
asked by health professionals about sexual functioning and most were reluctant to raise 
it (Young-McCaughan, 1996).
Less common side effects experienced during chemotherapy include mouth ulcers, 
diarrhoea, conjunctivitis, and chemical cystitis. Rare side effects include febrile 
neutropenia, infection, and venous thromboembolism. In some cases, patients who have 
previously experienced febrile neutropenia in response to chemotherapy treatment are 
provided with medication to boost their bone marrow functioning and therefore avoid 
the future development of febrile neutropenia. This medication is known as 
Granulocyte-colony stimulating factors (GCSF) support. The risk of death from 
adjuvant chemotherapy is very low. Cardiac failure is associated with higher cumulative 
doses of AC regimens. In the longer term, therapy-induced leukaemia can occur, 
especially after AC regimens, but is rare (NHMRC & NBCC, 2001).
2.4.3 Radiation Therapy
Radiation therapy involves the direction of a moderate dose of ionising radiations at the 
breast and/or chest wall, often followed by a higher dose (or boost) to the site of 
excision. The boost allows the delivery of a higher dose to a small volume within which 
the risk of residual cancer cells is greatest. Radiation therapy can destroy sizeable 
masses of tumour cells while preserving the structure, function and cosmesis of normal 
tissues. Radiation therapy is most effective when the number of cancer cells is limited 
and the tumour has not destroyed the adjacent tissues so that only modest doses of 
radiation are required and tissue can be preserved. The disadvantage is that it requires 
daily administration for ten to twenty minutes on an outpatient basis for five to six 
weeks (Parker & Withers, 2001).
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Radiation therapy significantly increases recurrence-free and overall survival, 
independent of other treatment received. The majority of recurrences occur in the first 
five years with an absolute risk of recurrence of 7% for those receiving radiotherapy 
versus 26%'for those who did not receive radiotherapy. The 5-year risk of mortality is 
less extreme than the risk of recurrence but is not significant. However, the 15-year risk 
of mortality is significant with 30.5% for those receiving radiotherapy compared to 
35.9% for those not receiving radiotherapy. Greatest benefit in 5-year risk of recurrence 
was evident in women who were younger (under 50 years), had larger tumours 
(>50mm), poorly differentiated tumours and tumours that involved the skin or chest 
wall (Clarke et ah, 2005; Veronesi et ah, 2005).
The side effects of radiotherapy are a function of the anatomical extent of the radiation 
fields, the field arrangement, the fraction size, and the total dose. Patients most 
commonly report redness, soreness, alopecia, tight skin, discomfort or pain to the 
treated breast, and sometimes lymphedema (if the axillary lymph nodes are irradiated). 
Redness, soreness and alopecia may last up to one to two weeks post-treatment but tight 
skin, discomfort, pain and lymphedema may occur for many months or years (NHMRC 
&NBCC, 2001).
A number of rare side effects have been reported and include osteitis (inflammation or 
brittleness), radiation pneumonitis (inflammation of the lungs), and in the longer term, 
brachial plexopathy (decreased movement or sensation in the arm). A risk of cardiac 
damage exists but is unlikely given recent trends to irradiate only the chest wall and to 
avoid high doses. Other causes of mortality, particularly resulting from vascular 
problems, may occur in patients who are older or have a low risk of recurrence 
(NHMRC &NBCC, 2001).
2.4.4 Endocrine Therapy
Endocrine therapy for EBC involves taking an oral dose of a medication that opposes 
the effect of oestrogen in the body. The medications used in endocrine therapy work to 
oppose oestrogen in different ways. At present, Tamoxifen (20mg daily) is the most 
widely studied and commonly prescribed form of endocrine therapy for EBC patients. 
For those with oestrogen receptor-positive tumours, five years of Tamoxifen 
significantly increases recurrence-free and overall survival. The 15-year absolute risk of
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recurrence for those receiving Tamoxifen is 33.2% compared to 45.0% for those not 
receiving Tamoxifen, and the 15-year absolute risk of mortality is 25.6% compared to 
34.8%. The annual increase in recurrence-free and overall survival are similar during 
years 0-4 and 5-14 so the cumulative reduction in mortality is more than twice as big at 
year fifteen as at five years post-diagnosis. These benefits are independent of age, 
progesterone receptor status, other tumour characteristics and other treatments received. 
Trials show that five years of Tamoxifen is more effective than one or two years. 
Mortality from other causes is not significantly increased (Cuzick et al., 2002;
EBCTCG, 1998, 2005; NHMRC & NBCC, 2001).
The potential side effects of Tamoxifen include hot flushes, dyspareunia, 
vasocongestion, and decreased vaginal lubrication. Ocular toxicity and ocular changes 
have been reported but are usually asymptomatic (NHMRC & NBCC, 2001). The risk 
of osteoporosis is elevated for pre-menopausal women and can lead to bone fractures 
(Mrozek & Shapiro, 2005). Increased rates of pulmonary embolism, stroke and DVT 
were elevated in women aged 50 years and over following treatment with tamoxifen 
(NHMRC & NBCC, 2001). Therefore, endocrine therapy is contraindicated in women 
at high risk of thromboembolic disease (Cuzick et al., 2002). A more significant 
problem is the increased incidence of endometrial cancer in post-menopausal women. 
The exact risk in the Australian context is uncertain, but overseas reports show the 
incidence of endometrial cancer was increased about 2.5-fold. For most women, the 
protective effects of Tamoxifen against the recurrence of breast cancer will vastly 
outweigh the increased risk of side effects (NHMRC & NBCC, 2001).
More recently, alternative endocrine therapies have been investigated, the most common 
being Anastrazole (lmg daily). Recent findings suggest that Anastrazole alone is 
significantly more effective in improving recurrence-free and overall survival after four 
years than either Tamoxifen or a combination of Anastrazole and Tamoxifen. 
Anastrazole demonstrated significantly lower rates of contralateral breast cancer and 
was better tolerated with respect to endometrial cancer, vaginal bleeding and discharge, 
cerebrovascular events, venous thromboembolic events and hot flushes than Tamoxifen. 
However, Tamoxifen showed significantly lower rates of musculoskeletal disorders and 
fractures. Longer follow-up is required before a final benefit and risk assessment can be
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made (Arimidex, Tamoxifen Alone or In Combination Trialists' Group: ATACTG,
2002, 2003).
2.5. Survivorship
The high incidence and survival rates of EBC makes women with a history of breast 
cancer one of the largest group of cancer survivors. Indeed, the number of women 
surviving a diagnosis of breast cancer is increasing, from 72% for the period of 1982- 
1986 to 84% for 1992-1997 for the five years following diagnosis (AIHW & AACR, 
2001a). Until recently, little was known about the experience of surviving a diagnosis of 
EBC with medical professionals relying on anecdotal evidence to inform women of the 
experience of survivorship (Ganz et al., 2004). However, increasing improvements in 
EBC survival rates, improved access to screening, increasing public awareness and 
consumer activities, and widespread media attention have led to increased attention to 
survivorship (Dow et al., 1996) and its identification as a priority for community 
services and research (Vivar & McQueen, 2005).
The potential benefit of a comprehensive understanding of the experience of 
survivorship in women with a history of EBC is significant. It will enable health 
professionals to have an accurate understanding of the impact of and adjustment to 
diagnosis and treatment, will help them provide future patients with more specific 
information about what to expect from their diagnosis and treatment, and to identify and 
develop or maintain necessary psychosocial interventions (Ganz et al., 2004; Holzner et 
al., 2001; Mosconi, Colozza, De Laurentiis, De Placido, & Maltoni, 2001).
While adjustment to survivorship is widely considered a process (Breaden, 1997), there 
are many consistencies in the issues reported by women with a history of EBC in the 
literature. Overall, women report good quality of life and some benefits of their 
experience with EBC, all of which continue with time (Dow et al., 1996). Nonetheless, 
issues are evident in the domains of physical and psychological wellbeing, spirituality, 
relationship with health care providers, and social and role functioning.
Women report a range of residual side effects from treatment including fatigue, nausea, 
pain, weight gain, forgetfulness, fertility problems, and menopausal symptoms (Ferrell 
et al., 1996; Ferrell et al., 1997; Ferrell, Grant, Funk, Otis-Green, & Garcia, 1998; Ganz
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et al., 2004; Thomas-MacLean, 2005; Vivar & McQueen, 2005). While some of these 
symptoms decline with time, they still have a significant negative impact on quality of 
life, sometimes up to five years post-diagnosis (Bower et al., 2000; Ganz et al., 2004; 
Helgeson & Tomich, 2005). The symptoms may also cause concern in women who 
believe they indicate a recurrence of the disease. Some women reported that their 
attempts to obtain treatment for these side effects and clarify this concern were 
dismissed by health professionals (Ferrell et al., 1997; Vivar & McQueen, 2005).
Changes to the body following treatment may have a number of effects including 
eliciting feelings of loss and grief, concern about management of new appearance (e.g. 
use of prosthesis) (Thomas-MacLean, 2005), and a decline in sexuality and sexual 
functioning. The negative impact in sexual functioning is attributed to concern about 
appearance as well as the development of menopausal symptoms known to affect ability 
to engage in sexual activities (Ferrell et al., 1997; McPhaii, 1999). This is particularly 
the case for women undergoing chemotherapy who may experience a change in 
menopausal status. This change may be considered a permanent and potentially 
devastating side effect, especially for those women who wish to have children (Dow et 
al., 1996; Ferrell et al., 1997; Ganz et al., 2002; Knobf, 2002; Meyerowitz et al., 1999; 
Wimberly, Carver, Laurenceau, Harris, & Antoni, 2005); Senate Community Affairs 
References Committee, 2005). Women may feel embarrassed and guilty to be 
concerned about their physical appearance and sexual functioning when they should be 
grateful for being alive (Ferrell et al., 1997, 1998).
Although there may be a tendency for health care professionals to focus on physical 
wellbeing, it is evident that psychological wellbeing during survivorship are equally 
important (Ferrell et al., 1996). Women may describe intense fears of recurrence and 
dying, a sense of uncertainty about the future, and the feelings of loss of control over 
their health and lives as the most distressing and consuming aspects of survivorship 
(Curran et al., 1998; Dow et al., 1996; Tomich & Helgeson, 2002). These concerns are 
particularly evident in young women who perhaps have different expectations of disease 
and disability and therefore feel a greater sense of deprivation in their life compared 
with older women (Wenzel et al., 1999). Unfortunately, these concerns are triggered by 
being around others with cancer, hearing about cancer, and physical reminders of 
cancer, all of which occur during the course of routine follow-up (Johnson Vickberg,
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2001). In some cases, intense fears of recurrence can lead to preoccupation with 
physical wellbeing (Kissane et ah, 1997).
However, women report tempering these concerns with a renewed sense of purpose and 
satisfaction with life as a result of a dramatic shift in their life priorities and life 
meaning (Dow et al., 1996; Ferrell et al., 1997; Tomich & Helgeson, 2002; Wyatt,
Kurtz, & Liken, 1993). Spirituality was raised by some women as an important support, 
either through formal religious practices or informal existential faith or beliefs, and was 
an important predictor of overall quality of life (Brady, Peterman, Fitchett, Mo, & Celia, 
1999; Dow et al., 1996; Ferrell et al., 1996; Ferrell et al., 1997, 1998; Tomich & 
Helgeson, 2002).
Some women continue to report symptoms of anxiety and depression after completion 
of treatment but these symptoms typically decline with time (Ganz et al., 2002). Given 
the ongoing presence of physical side effects, the importance of distinguishing 
depressive symptoms is still pertinent in survivorship (Dow et al., 1996). The few 
women who develop anxiety and depressive symptoms for the first time in survivorship 
often report surprise, particularly if they feel they coped well during their diagnosis and 
treatment (Ganz et al., 2004).
An area of great concern is the impact of EBC on the family (Dow et al., 1996; Ferrell 
et al., 1997). Women may be concerned that the needs of family members are not met, 
feel guilty about the possibility of ‘passing it on’ to daughters or having survived when 
many family and friends have not (Ferrell et al., 1997, 1998; Ganz et al., 2004), feel 
hurt by the their rejection by certain friends, and have a decreased tolerance for the 
minor complaints of others (Wyatt et al., 1993). Nonetheless, women reported the 
significance of support and acceptance from family and friends in their improvement 
(Dow et al., 1996).
This sense of support extended to relationships with health professionals. Women 
reported having confidence in their health professionals and found their continued 
access to them provided significant reassurance regarding their ongoing health status 
(Breaden, 1997; Ganz et al., 2004; Vivar & McQueen, 2005; Wyatt et al., 1993).
Indeed, patients report that one of the most difficult stages in the cancer journey is when
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they complete treatment and are no longer in close contact with health professionals. 
They believe it was not until this point in their experience that they fully considered the 
meaning of their diagnosis, treatment, and future plans (Lethborg & Kissane, 2003).
The majority of women feel that their levels of functioning in normal daily life return to 
those before diagnosis within around two years of diagnosis (Dow et al., 1996; Ferrell et 
al., 1997, 1998; Ganz et al., 2002) and that their future plans for education, employment 
and leisure were unaffected by the breast cancer experience (Ganz et al., 2002). Most 
concerns about role functioning centred on the ability to return to the workplace, 
particularly whether they would be accepted and physically able to cope. This may be of 
particular concern for those women who experienced significant out-of-pocket expenses 
as a result of diagnosis and treatment (Butler & Howarth, 1999; Lauzier et al., 2005). 
These expenses can be felt by the whole family for a considerable period of time after 
completing treatment. On the other hand, returning to work eased concerns about the 
financial impact of illness and helped return a sense of normalcy (Breaden, 1997; Dow 
et al., 1996; Ferrell et al., 1997, 1998; Rendle, 1997).
It should be noted that research into survivorship is plagued by shortcomings, all of 
which must be overcome to better understand the challenges and benefits experienced in 
survivorship by women with a history of EBC. Theoretical issues include variation in 
the definition of quality of life (QOL) and the tendency to focus on a narrow selection 
of QOL domains (for example, physical and psychological wellbeing) to the exclusion 
of others (for example, sexual functioning, role functioning) (Gotay & Muraoka, 1998; 
Mosconi et al., 2001; Tomich & Helgeson, 2002; Vivar & McQueen, 2005).
Methodological issues include small sample sizes, large variation in time since 
diagnosis, the description of survival according to time since diagnosis rather than end 
of treatment, failure to account for those patients receiving daily Tamoxifen, use of ad 
hoc QOL instruments developed for a specific study instead of well-known standardised 
and validated questionnaires, and the failure to use control groups to determine the 
extent to which declines are due to the normal process of ageing (Gotay & Muraoka, 
1998; Mosconi et al., 2001; Tomich & Helgeson, 2002; Vivar & McQueen, 2005). 
Clearly, research will need to overcome these theoretical and methodological issues to
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clarify our understanding of survivorship and to extend this knowledge to efforts at 
rehabilitation (Lethborg & Kissane, 2003).
2.6 Psychological Distress
It is apparent that the diagnosis and treatment of EBC is challenging on many fronts. 
Treatment is lengthy, consists of several modalities with their own rigid procedures and 
side effects, requires significant commitment from patients, and may affect several 
aspects of quality of life. Thus, it is not surprising that many women report feelings of 
distress at one or more stages of their treatment. Distress commonly occurs at the time 
of diagnosis, awaiting biopsy results, after diagnosis while waiting for treatment, during 
any prolonged wait for treatment, following discharge from hospital, and following 
completion of treatment. Women may be more vulnerable to elevated levels of distress 
if they are younger, single, of lower socio-economic status, have poor romantic 
relationships and social support, a past history of psychiatric illness, cumulative 
stressful life events or poorer physical health (Alder & Bitzer, 2003; Compas & 
Luecken, 2002; Dausch et al., 2004; Osborne, Elsworth, & Hopper, 2003; Pasacreta, 
1997).
Although the majority of women will adjust to their diagnosis and treatment, a 
significant proportion will go on to develop a psychiatric disorder which may require 
pharmacological and/or psychological interventions (NHMRC & NBCC, 2001). It is 
well established that much of this psychological morbidity goes undetected (Badger, 
Braden, Mishel, & Longman, 2004; Berard, Boermeester, & Viljoen, 1998; Nordin, 
Berglund, Glimelius, & Sjoden, 2001; Payne, Hoffman, Theodoulou, Dosik, & Massie, 
1999). In a recent large-scale study of clinicians’ ability to detect patients with 
psychiatric morbidity, results indicated that clinicians’ had a sensitivity of 29%, 
specificity of 85%, and misclassification of 35% (Fallowfield, 2001).
Health care professionals may fail to detect distress due to time constraints during 
outpatient visits, concern about the treatment of the disease and any immediate medical 
issues, concern about the cost and reimbursement of services, and access to appropriate 
mental health referral services. Furthermore, patients may be reluctant to report distress 
due to a lack of symptom awareness, fear of the stigma associated with mental illness, 
lack of support from family and friends, reactions of stoicism or hopelessness, and fears
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of appearing weak and losing their health care professionals’ support (Croyle & 
Rowland, 2003).
Undetected and untreated patient distress can have a deleterious impact on medical 
outcomes due to lack of compliance with treatment plans, greater side effect burden, 
slower recovery, decreased patient satisfaction, and reduced quality of life, all of which 
serve to inflate health care costs (Badger et al., 2004; Dausch et al., 2004; Girgis & 
Boyes, 2005; Pasacreta, 1997). Consequently, most psychosocial care is offered 
reactively, that is, when the patient is in a state of crisis (Girgis & Boyes, 2005). In an 
effort to reverse this trend, the guidelines for medical professionals in Australia 
recommend that doctors enquire about patients’ mood and adjustment (NHMRC & 
NBCC, 2001).
To determine the prevalence of psychiatric disorders, the clinical interview is 
considered the ‘gold standard’. Current estimates of the prevalence of anxiety and 
depressive disorders in women with breast cancer vary but it has been estimated that 11- 
50% of women meet criteria for a diagnosis of major depression and 9-37% for anxiety 
disorder at three to four months following diagnosis (Hall, A'Hern, & Fallowfield, 1999; 
Love, Kissane, Bloch, & Clarke, 2002; Pasacreta, 1997). Typically, the prevalence of 
anxiety and depressive disorders declines over the ensuing months with estimates one to 
two years following diagnosis of 4-18% for depression and 3-14% for anxiety (Dausch 
et al., 2004; Grassi, Malacarne, Maestri, & Ramelli, 1997; Morasso et al., 2001). These 
rates are similar to those experienced by the general population (Compas & Luecken, 
2002; Dausch et al., 2004; Pasacreta, 1997; Payne et al., 1999; Waller, Compas, Hollon, 
& Beckjord, 2005).
More commonly, investigators have considered the prevalence of anxiety and 
depressive symptoms in women with breast cancer by employing self-report measures. 
The estimates indicate that while a number of women develop an anxiety or depressive 
disorder, many more will experience levels of anxiety and depressive symptoms 
significantly higher than the general population (Compas & Luecken, 2002; Dausch et 
al., 2004). According to widely accepted measures, levels of anxiety and depressive 
symptoms indicative of anxiety and depression cases are estimated at 14-48% and 3- 
34% respectively, within three months of diagnosis (Dausch et al., 2004; Groenvold et
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al., 1999; Hall et al., 1999; Love et al., 2002; Montazeri et al., 2000; Nosarti, Roberts, 
Crayford, McKenzie, & David, 2002), and 22-28% and 3-19% respectively, at one year 
or more (Nosarti et al., 2002; Osborne et al., 2003; Rodgers, Martin, Morse, Kendell, & 
Verrill, 2005; Schou, Ekeberg, Ruland, Sandvik, & Karesen, 2004), respectively.
In spite of the importance of accurately assessing the prevalence of anxiety and 
depression in patients with breast cancer, theoretical and methodological challenges 
have hampered efforts to do so and are reflected in the varying rates reported (Dausch et 
al., 2004). The symptoms of anxiety and depression that often accompany bad news 
may be assumed to be appropriate but this may not be the case when these symptoms 
persist or worsen over time (Croyle & Rowland, 2003). Thus, the boundary between 
normal response and clinical symptoms remains undefined (Pasacreta, 1997). It is 
widely acknowledged that the characteristic symptoms of psychiatric disorders and 
those experienced as a result of the disease and its treatment overlap significantly. 
Therefore it can be difficult to distinguish between the two (Bower et al., 2000; Croyle 
& Rowland, 2003; Nordin et al., 2001; Pasacreta, 1997).
Investigation into the accuracy of reliance on alternative criteria for psychiatric 
disorders in patients may be useful. For example, fatigue and disruptions in sleep and 
appetite are depressive symptoms that may be considered consequences of the disease 
and treatment. Alternative depressive symptoms to be considered include 
indecisiveness, guilt, helplessness, worthlessness and suicidality . These are all 
symptoms included in the diagnostic criteria of depression in the widely accepted and 
used diagnostic manuals of the latest Diagnostic and Statistical Manual (American 
Psychiatric Association, 1994) and International Classification of Diseases (World 
Health Organization, 1992).
Moreover, the association between the diagnosis and treatment of breast cancer and the 
depression symptoms may vary according to time since diagnosis, type and stage of 
EBC, concurrent treatment, and medical co-morbidities. Thus, the assessment of 
seemingly homogenous samples of women with EBC may contain confounding 
variables that affect the prevalence rates of disorders reported (Compas & Luecken, 
2002; Croyle & Rowland, 2003; Dausch et al., 2004; Nordin et al., 2001; Pasacreta, 
1997). The error in prevalence estimates may be exaggerated by a reliance on a single
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assessment of psychiatric morbidity (Dausch et al., 2004). Lastly, a variety of structured 
clinical interviews have been utilised and may account for the broad range in estimates 
(Dausch et al., 2004; Grassi et al., 1997; Hall et ah, 1999; Morasso et al., 2001; 
Pasacreta, 1997).
While the focus on the psychiatric disorders of anxiety and depression are important, it 
has come at the cost of investigation of other equally distressing, debilitating, and 
potentially elevated disorders such as adjustment disorder, post-traumatic stress disorder 
(PTSD) and acute stress disorder (ASD). Recent research has attempted to estimate the 
prevalence of these disorders. Rates of around 2-24% for adjustment disorder, 3-5% for 
PTSD and 2% ASD have been reported in women at least six months after diagnosis 
(Dausch et al., 2004; Grassi et al., 1997; Morasso et al., 2001). Again, consideration of 
the prevalence of the symptoms of PTSD and ASD reveal much higher rates (Green et 
al., 1998; Turner et al., 2005). More research is needed to determine the prevalence of 
these disorders in patients with EBC in order to gain a comprehensive understanding of 
the nature of distress in women dealing with the disease and the ways in which they 
might be best supported (Dausch et al., 2004; Love et al., 2002; Payne et al., 1999).
Not only can the diagnosis and treatment of breast cancer affect a woman’s 
psychological wellbeing, it can also affect that of her partner. Research investigating 
symptoms of anxiety and depression in partners of women diagnosed with breast cancer 
reveal that they also experience elevated levels of symptoms (Ben-Zur, Gilbar, & Lev, 
2001). This is probably due to offering much needed informational, instrumental, and 
emotional support to partners, perhaps to the neglect of their own support needs (Moyer 
& Salovey, 1996). Women’s and partners’ levels of symptoms have been found to affect 
the quality of the relationship. Lack of perceived support, closeness, and agreement as 
well as discrepancies in the way in which diagnosis and treatment challenges are coped 
with, all lead to increased symptoms (Barnoy, Bar-Tal, & Zisser, 2006; Ben-Zur et al., 
2001). These findings have led to the development and implementation of couple- 
focused interventions, so far with limited success (Cochrane & Lewis, 2005).
Little research has been conducted to determine the effect on the children or family of 
women with breast cancer, although speculation and suggestion are common. It is 
thought that the impact of breast cancer on children depends largely on their
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developmental stage, signalling a need to provide information and support appropriate 
to the level of understanding. It is considered that the promotion and maintenance of 
open communication and expression of thoughts and feelings in the home setting is 
helpful for all members of the family, including women diagnosed with breast cancer 
(Wimberly et al., 2005).
To combat the levels of psychological distress encountered by women diagnosed with 
and treated for breast cancer, there is a plethora of support organizations. At recent 
count, there were more than 100 government and non-government organizations 
involved in cancer policy, treatment and support in Australia (Cancer Strategies Group, 
2001; Senate Community Affairs References Committee, 2005). This, together with the 
large volume of information available on breast cancer, signals an understanding and 
openness about the significant distress and challenges engendered in the diagnosis and 
treatment of breast cancer (Moyer & Salovey, 1996). It should be noted, however, that 
difficulties accessing these services are widely acknowledged and are currently being 
addressed by several government organisations (Cancer Strategies Group, 2001; Senate 
Community Affairs References Committee, 2005).
2.7 Conclusions
The clinical experience of breast cancer is complex and challenging. It involves a 
journey in which patients are faced with a series of diagnostic tests, receipt of a 
diagnosis and prognosis, decision-making regarding appropriate treatment, the receipt 
of multi-modal treatments, and the uncertainty of survival. All of these present unique 
challenges that have the potential to result in significant declines in physical and 
psychological wellbeing (Moyer & Salovey, 1996). While the research outlined has 
effectively delineated the many stressful aspects of the cancer journey, it is now 
necessary to understand the way in which women come to experience stress and cope 
with this stress (Butow, Coates, & Dunn, 2000a).
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CHAPTER THREE
The History of Stress and Coping Theory
The experience and ways of coping with stress have long been implicated in physical 
and psychological wellbeing. Understanding how women diagnosed with EBC 
experience stress and cope with this stress may provide invaluable insights into the wide 
range of physical and psychological wellbeing reported during the EBC journey. If this 
is the case, medical and allied health professionals may be able to develop and 
implement supportive medical and psychosocial interventions aimed at enhancing 
wellbeing. First, it is necessary to gain an understanding of the nature of stress and 
coping. The following chapter aims to outline the most widely acknowledged stress and 
coping theories in the psychological literature.
3.1 Approaches to Stress
Stress is a concept that has secured the attention of diverse disciplines. As a result, a 
range of definitions and theories of stress have been proposed. In the area of psychology 
and health, three main theories of stress have shaped our understanding of the concept 
and guided research. In order to understand the way in which stress is thought to 
operate, the following section presents the three main theories of stress; Cannon’s 
(1915, 1929) Fight-or-Flight Response theory, Selye’s (1956, 1976) General Adaptation 
Syndrome theory, and Lazarus and Folkman’s (1984) Cognitive-Transactional theory of 
stress.
3.1.1 Fight-Or-Flight Response Theory
In 1915, Cannon described the human and animal bodies’ experience of stress. He 
outlined many physiological processes of the body that are activated in order to 
maintain physical wellbeing. For example, he outlined the role of hunger and thirst in 
activating processes to ensure the body has sufficient energy to function effectively. It is 
in this context that Cannon coined the term ‘homeostasis’, which refers to the body’s 
attempts to maintain a certain level of wellbeing (Caltabiano, Byrne, Martin, &
Sarafino, 2002; Cannon, 1915; Selye, 1976).
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Cannon also outlined what happened to the body’s physiological processes in a stressful 
situation. When faced with a stressful situation, he explained that the body’s 
sympathetic nervous system was activated to arouse the body, allowing the body to 
attack the threat or flee from it. In this way, the fight-or-flight response consists of both 
benefits and costs to the body. It is an adaptive response in that it allows the avoidance 
of danger but the state of arousal necessary to avoid the threat can damage the body and 
lead to death (Caltabiano et al., 2002; Cannon, 1915; Selye, 1976). In other words, 
Cannon conceptualises stress as a response of the body to objective, external demands 
(Lazarus & Folkman, 1984).
3.1.2 General Adaptation Syndrome Theory 
Several decades later, Selye (1956; 1976) outlined the General Adaptation Syndrome 
(GAS) theory of stress. The GAS theory again views stress as a reaction of the body to 
external demands but describes the response in more detail. The GAS consists of three 
stages in which the body defends itself against threat: the alarm reaction, resistance, and 
exhaustion. The alarm reaction describes the perception of threat and the process of 
initial arousal when the body prepares to defend itself. Resistance consists of the use of 
physiological resources to defend against the threat as it is experienced. If the threat 
continues, exhaustion occurs and involves the depletion of the body’s physiological 
resources. This depletion can be reversible or irreversible. In cases of mild threat, the 
body’s physiological resources are depleted so that the body is weakened. However, 
when the threat ceases, the body is able to restore its resources thereby reversing any 
damage. In cases of prolonged or intense threat, the body’s physiological resources are 
depleted so much that injury or in some cases, death occurs (Selye, 1956, 1976, 1993).
Not all stages are experienced in response to a threat. The GAS theory states that most 
threats are of limited duration and intensity and as such, typically only the first two 
stages are experienced. Hence depletion is reversible. A later revision of the GAS 
proposed the concepts of eustress and distress. Selye (1976) specified that when the 
threat necessitates the first two stages, that is the threat provides a challenge to the body, 
the stress experienced is referred to as eustress. When the threat involves all three stages 
and damages the body, the stress experienced is referred to as distress (Selye, 1956, 
1976).
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Selye’s (1956, 1976) theory signalled an extension of Cannon’s (1929) theory in two 
main ways. First, the GAS specified in more detail the physiological processes that 
enable the body to prepare and defend itself against threat. This detail provided a series 
of objective indices of stress that have been widely utilised in subsequent theory and 
research. Second, the specification of three main stages of the stress response indicated 
the finite capacity of the body to deal with stress (Caltabiano et al., 2002).
Since its inception, the GAS has attracted several criticisms. These criticisms have 
focused on two main omissions: the failure to consider the strength of the response to 
stressful situations and the role of cognitive appraisal processes in the perception of 
situations as stressful. Selye (1956, 1976) states that the body’s response to a stressful 
situation is the same, regardless of the nature of the situation. In fact, it has been 
suggested that some stressful situations elicit stronger emotional responses than others 
(Caltabiano et al., 2002). Selye also states that situations are inherently stressful and 
cause the body to respond. However, it has also been suggested that people differ in the 
extent to which they consider a situation to be stressful. Failure to consider the nature of 
this appraisal may result in all situations to which people have to adapt being considered 
stressful situations (Caltabiano et al., 2002; Lazarus & Folkman, 1984; Mormede,
1990).
3.1.3 Cognitive Transactional Theory
The cognitive transactional theory of stress moves beyond the view that stress is the 
response of a person to an objective, external demands and instead considers the 
psychological processes influencing the experience of stress (Stone, Greenberg, 
Kennedy-Moore, & Newman, 1991). The transactional theory outlines a reciprocal 
relationship between a person and a stressful situation such that stress occurs when a 
situation is perceived to challenge or exceed the resources available to deal with the 
situation and threaten wellbeing. The reciprocal relationship in which a transaction 
between the person and the environment is considered stressful is known as the process 
of cognitive appraisal. Cognitive appraisal consists of primary and secondary appraisal. 
Primary appraisal refers to the process of evaluating the degree of threat the situation 
presents. Primary appraisals typically categorise situations as irrelevant, benign or 
stressful. A situation that is considered irrelevant is one that has no implications for a 
person’s wellbeing. A situation that is benign is thought to have positive implications
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for a person’s wellbeing. A stressful situation is one that consists of threat, challenge or 
harm/loss (Lazarus & Folkman, 1984).
A stressful situation involving threat is one that the person perceives to be highly 
threatening and exceeding his/her personal resources. A challenge is a stressful situation 
that is perceived as threatening but not exceeding personal resources. A loss is a 
situation in which a valued thing (for example, a possession, a personal attribute or 
feeling) or person is lost. These categories are not mutually exclusive or static. Stressful 
situations may involve elements of all of the categories or may change categories 
according to the changes in appraisal as the situation unfolds (Lazarus & Folkman, 
1984).
For example, a woman receiving a diagnosis of EBC may perceive the diagnosis to be 
fatal and therefore consider her situation as highly threatening and exceeding her 
resources. Another woman undergoing adjuvant chemotherapy for EBC may perceive 
the treatment to be taxing but not exceeding her resources and therefore consider her 
situation as a challenge. Another woman undergoing bilateral mastectomy may perceive 
the treatment to be damaging to her self-esteem, body image, and sexuality. Therefore, 
she may consider her situation as a loss.
Secondary appraisal refers to the evaluation of ways in which the situation can be dealt 
with. It involves consideration of the coping options available, the expected success of 
the coping options, and the ability of the person to carry out the coping options 
effectively (Lazarus & Folkman, 1984). For example, consider a woman with EBC who 
is suffering from debilitating nausea and vomiting as a result of chemotherapy 
treatment. Her secondary appraisal might include considering all of the things that she 
could do to reduce the nausea and vomiting (for example, taking anti-emetic 
medication) and then considering the success of these options (whether the anti-emetic 
medication had worked in the past) and her ability to carry out the option (whether she 
has any medication left).
Cognitive-transactional theory of stress also states that the process of appraisal is 
influenced by a range of personal and situational factors. Personal factors include 
commitments (for example values, goals and desires) and beliefs (existing ideas about
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the self and world). Situational factors include the properties of situations that 
contribute to their perception of being stressful (for example, novelty, predictability, 
uncertainty, ambiguity, and the timing of stressful situations). The theory considers 
these factors to be interdependent in their influence on appraisal (Lazarus & Folkman, 
1984).
3.1.4 Summary
The evolution of stress theories has increasingly emphasised the importance of both the 
person and the environment and the appraisal of this relationship in the experience of 
stress. While early theories considered stress to be an objective, external demand placed 
on a person, it is now widely considered to be a situation that is perceived to be 
threatening by the person. This appraisal then results in the experience of a range of 
psychological and physical outcomes indicative of stress. The level of stress 
experienced will vary as a function of this relationship such that any changes in the way 
in which the threat is perceived will alter the stress experienced (Cannon, 1915; Lazarus 
& Folkman, 1984; Selye, 1956, 1976).
3.2 Approaches to Coping
The significant detrimental effects of stress on physiological and psychological 
wellbeing highlight the importance of effectively dealing with that stress. This begs the 
question as to what can be done to mitigate the effects of stress. This question has 
captured the attention of many researchers and resulted in an extensive literature 
devoted to the theory and empirical findings of the concept of coping. At the 
fundamental level, coping may be conceived as any attempt aimed at mitigating the 
effects of a stressful situation (Stone et al., 1991; Stone, Helder, & Schneider, 1988). 
The sheer volume of literature serves to emphasise the critical role of coping in 
mediating the effects of stress on wellbeing (Endler & Parker, 1990).
Despite the attention accorded to coping theory and research, the range of coping 
responses and the way in which these mitigate the effects of stress is still poorly 
understood. Early theories of coping followed on from Cannon (1915, 1929) and 
Selye’s (1956, 1976) theories of stress and focused on the behavioural responses of 
animals to stressful environmental conditions (Koolhaas et al., 1999; Lazarus & 
Folkman, 1984). Although they provided important empirical confirmation of the
51
theories, they were criticised for failing to capture the complexity of both behavioural 
and cognitive coping responses employed by humans (Lazarus & Folkman, 1984). Later 
theories attempted to do so, but from very different perspectives. Few attempts have 
been made to unite the many diverse theories in an effort to gain an overall 
understanding of the nature of coping (Stone et al., 1988). The following section will 
outline the three main approaches to coping: the trait, strategy and disposition 
approaches.
3.3 Trait Approach to Coping
The trait approach originated in Freud’s (Freud, 1938) psychoanalytic theories and 
received much attention in the 1960s to present day. He stated that people sometimes 
experience thoughts, impulses and desires that are considered unacceptable and lead to 
the experience of anxiety. In order to resolve the discrepancy and in turn reduce anxiety, 
a series of defense mechanisms are activated. These defenses ensure the thoughts, 
impulses, and desires are kept out of awareness but that gratification is achieved by 
expressing the desire in some alternative, acceptable manner (referred to as a symptom). 
The defenses are not observable but are instead inferred from the resulting, observable 
symptoms (Cramer, 1991, 1998; Davidson & MacGregor, 1998; Perry & Ianni, 1998).
Defenses are defined as unconscious, unintentional, automatically activated cognitive 
operations in which perception of the stressful event or state is altered in order to reduce 
anxiety. They are distinguishable from defensive behaviour which is the observable 
behaviour that operates consciously to decrease threat. In theory, people can be aware of 
their habitual behaviour but still remain unaware of both the perception of the stressful 
event or state and the activation of the defense mechanism (Cramer, 1991, 1998; 
Davidson & MacGregor, 1998; Krohne, 1993; Weinberger, 1995).
Some commonly discussed examples of defense mechanisms include repression, 
devaluation, idealisation, intellectualisation, denial, and projection. Repression is when 
disturbing thoughts, feelings or desires are barred from awareness. Devaluation is when 
the negative qualities of others are exaggerated while idealisation is when the positive 
qualities of others are exaggerated. Intellectualisation is when a person excessively uses 
abstract, rational thinking to control or minimise painful feelings. Denial is when a
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person refuses to acknowledge painful aspects of reality (American Psychiatric 
Association, 1994).
Several examples of these defenses can be provided when considering the case of a 
woman undergoing chemotherapy for EBC. After undergoing the first chemotherapy 
treatment, the woman experiences nausea and vomiting, alopecia, and fatigue. As a 
result, she is dreading her next treatment. She says that although she cannot engage in 
any of her hobbies, these are not enjoyable anyway (intellectualisation). While she 
knows she may experience alopecia, her hair is not falling out (denial). She reports to 
her husband that she cannot remember her next treatment appointment (repression).
Despite accusations to the contrary, defenses are thought to be part of normal 
personality functioning and only become associated with psychopathology when they 
are used excessively, rigidly, and/or inappropriately according to developmental stage 
(Cramer, 1991; Davidson & MacGregor, 1998). As such, all people display a pattern of 
defenses which are thought to be based on early childhood experiences of anxiety in 
response to stressful external or internal states (Cramer, 1991).
As a part of personality, defenses are considered to be relatively stable, enduring, and 
predictable ways of coping with stressful states (Cramer, 1991; Krohne, 1993; 
Weinberger, 1995). It is thought that each defense is unidimensional and therefore 
people are classified on a continuum of each defense according to the extent to which 
they employ the defense (Lazarus & Folkman, 1984). At present, limited empirical 
research has been conducted to validate the stability of defenses (Cramer, 1998) with 
some maintaining that their employment depends on the situation at hand (Davidson & 
MacGregor, 1998). However, little research has investigated the person and content 
factors that might affect such employment (Miller, 1990; Wilson, 1984).
There is little consistency in the identification and description of the defense 
mechanisms. Freud (1938) did not clearly distinguish between the defenses referring 
instead to one mechanism of repression. It was not until later that efforts were made to 
delineate the various defenses. A lack of consistency and clarity regarding the number 
and nature of defenses remains (Cramer, 1998; Davidson & MacGregor, 1998; Watson, 
Pettingale, & Greer, 1984).
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Within each taxonomy of defenses, there is a hierarchy based on psychological 
maturity. Defenses are thought to reflect the level of personality functioning with higher 
levels considered more mature and complex and lower levels more immature and 
primitive. Typically, denial is considered an immature defense, projection is considered 
of intermediate maturity, and identification is a mature defense. The range of possible 
defenses and their effectiveness are thought to vary as a function of development but 
again, limited empirical research has been conducted to investigate this idea (Cramer, 
1998, 1999).
Just as the type and nature of defenses are disputed, so too are the organization of 
defenses into hierarchies. To date, many hierarchies have been proposed (Cramer, 1991; 
Haan, 1977; Vaillant, 1977), but few have received empirical investigation. Generally, 
the more mature the defense, the more effective method of coping it is considered to be. 
More mature defenses are thought to be better able to reduce anxiety, restore self­
esteem and preserve the integration of the self. That is, the trait approach equates 
effective coping with adaptational success (Lazarus & Folkman, 1984). Although this 
appears to imply that all defenses are adaptive, this is not the intention (Davidson & 
MacGregor, 1998). Some believe that the focus on adaptational success is too limited a 
definition of coping effectiveness for two reasons: not all stressful situations can be 
adapted to and mastered, and it fails to acknowledge other important outcomes of 
coping such as problem-solving (Lazarus & Folkman, 1984). Some ways of coping 
considered immature (for example denial and avoidance) have been shown to be 
effective in terms of psychological outcomes (Auerbach, 1989).
3.3.1 Measurement of Trait Approach
The unconscious nature of defenses and the existence of numerous and diverse 
definitions have seen clinicians and researchers interpret and conceptualise defenses in 
different ways. This has led to the development of several methods of measurement, 
none of which have been universally accepted and utilised by researchers (Cramer, 
1998; Lazarus & Folkman, 1984; Weinberger, 1995). The forms of measurement 
consist of unstructured interviews, projective tests, and self-report inventories.
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Following from Freud’s (1938) work, initial methods of assessing defenses involved 
unstructured interviews by a trained clinician. The information collected is used to 
determine which defenses are routinely employed by the respondent. The identification 
of defenses from the information collected may be determined via clinician intuition or 
through the use of one of the many formal, published coding systems. However, 
concern exists regarding the lack of standardised conditions under which information is 
elicited in unstructured interviews.
In an attempt to overcome this issue, projective tests have been employed. Projective 
tests involve the presentation of a series of cards consisting of pictures of ambiguous 
stimuli that the respondent is instructed to interpret. It is thought that interpretation of 
the stimuli requires respondents to draw on their own drives, emotions, and conflicts, all 
of which reveal their personality. The two most commonly employed tests are the 
Rorschach Test (Rorschach, 1941) and the Thematic Apperception Test (Murray, 1943).
Coding systems typically employed for interviews and projective tests aim to provide a 
list of responses that have been reported by large samples, indicate whether responses 
are commonly reported, and the degree to which they reflect defenses. Coding systems 
typically involve written descriptions of defenses which vary from the provision of a 
simple definition to the provision of a definition as well as descriptions of the functions, 
similarities and differences of defenses, and ways of differentiating between them 
(Perry & Ianni, 1998). Although many systems have been proposed and used, none has 
received wide acknowledgement and acceptance.
Once defenses have been identified via the interview or projective test, the coding 
systems then record defenses in two ways: on a dichotomous scale indicating presence 
or absence, or on a Likert scale indicating the extent to which the defense is used. 
Scores may be summed to give a score of individual defenses or global defensiveness 
which may be compared to population norms, if available, or scores of individual 
defenses may be ranked in order of the extent to which they are used in comparison to 
each other (known as the Q-Sort technique) (Perry & Ianni, 1998).
The use of these tests of trait coping ensures that all respondents are presented with the 
same stimuli and the use of defenses is again determined via a coding system. The
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open-ended response format of unstructured interviews and projective tests allows the 
collection of detailed information. This, together with the fact that the information may, 
in part, be collected and interpreted by clinicians experienced in the theory and use of 
defenses, may contribute to the validity of these forms of assessment. The use of 
objective and standardised coding systems are thought to enhance the reliability of the 
forms of assessments (Perry & Ianni, 1998).
Despite attempts to ensure the reliable and valid assessment of defenses, several 
concerns have been raised regarding the use of clinical interviews and projective tests. 
As mentioned, the lack of standardised stimuli to which responses are elicited in 
unstructured interviews has been criticised. While the use of standardised stimuli in 
projective tests have been suggested to overcome this issue, the extent to which the 
stimuli are interpreted similarly across respondents is still largely unknown (Davidson 
& MacGregor, 1998). Neither forms of assessment necessarily involve the use of 
stimuli that require respondents to comment on their responses to stressful situations, 
which may affect validity of interpretations about the use of defenses (Stone et al.,
1991; Stone et al., 1988).
It appears that few coding systems have been standardised on large samples 
representative of the general population and/or specific populations (Davidson & 
MacGregor, 1998; Perry & Ianni, 1998). As a result, it is unknown whether coding 
systems accurately categorises responses into defenses. Although not a criticism, the 
fact that the delivery and interpretation of interviews and projective tests requires 
significant training on the part of clinicians and/or researchers, making them time- and 
labour-intensive and expensive, makes their use in research, especially with large 
samples, potentially prohibitive.
In response to the increasing emphasis on the importance of quantitative measurement 
from some researchers, self-report measures designed to assess individual defenses 
and/or global defensiveness have been developed. They consist of written stimuli to 
which a person responds by selecting one of several response options. Response options 
reflect the extent to which the individual defenses or overall use of defenses are 
employed. Like interviews and projective tests, some self-report measures do not refer
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to stressful situations (Byrne, Golightly, & Sheffield, 1965; Millon, Green, & Meagher, 
1982; Rohde, 1948).
The most commonly utilised self-report inventories include Byrne’s Repression- 
Sensitization Scale (R-S scale) (Byrne et ah, 1965), the Sentence-Completion Test 
(SCT) (Rohde, 1948) and the Millon Behavioural Health Inventory (MBH1) (Millon et 
al., 1982). The R-S scale measures the defense of repression by asking people to 
indicate the extent to which they avoid information about stressful situations or states. 
The SCT measures repression by asking respondents to indicate their desire to avoid or 
block out sentences describing threatening emotions such as hate, fear, sexual desire and 
so on. The MBHI assesses several personality dimensions thought to be relevant to 
wellbeing and decision-making in the medical setting, including three repressive coping 
styles of introversive, cooperative and respectful.
3.3.2 Advantages and Disadvantages of Trait Coping Measures 
There are several clear advantages to using self-report inventories for measuring 
defenses. Like projective tests, the stimuli are objective and the stimuli and response 
scales are standardised across respondents. Self-report measures require no 
interpretation of responses as response options and scale scores are standardised. Unlike 
interviews and projective tests, self-report measures are comparatively inexpensive, 
easy to administer and score, brief, contain easily understandable instructions, and 
require little training of examiners (Groth-Marnat, 1999).
Despite these advantages, self-report measures have also attracted criticism. They are 
considered to lack construct validity. Theoretically, Cramer (Cramer, 1998) asserts that 
asking respondents to report on their use of defenses means they are reporting on 
conscious, not unconscious, cognitive acts. Stone and colleagues (Stone et al., 1991; 
Stone et al., 1988) believe that existing methodology are not able to adequately assess 
unconscious coping. However, Cramer does concede that respondents may be able to 
report on the conscious symptoms of defenses, despite a lack of awareness of the 
meaning of the behaviours from which defenses may be inferred (Cramer, 1998). Even 
so, reports of this behaviour may be affected by social desirability. Methodologically, 
considerable associations have been shown between self-report scores and scores on
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measures of similar, though theoretically distinct, constructs such as social desirability 
and trait anxiety (Weinberger, 1995).
It is thought that the scores obtained on self-report measures focusing on the lower and 
upper scores on defenses, such as the R-S scale, have been used inappropriately. 
Researchers have routinely ignored middle scores when making claims about the 
linearity or otherwise of defense scores and outcomes, which may be misleading 
(Wilson, 1984). It is also unknown whether scores claiming to measure the extent to 
which defenses are employed are valid, as few comparisons have been made with 
clinical judgments of defense use (Davidson & MacGregor, 1998). All of these 
measurement difficulties, coupled with the lack of theoretical consistency of defenses, 
have meant that the use of the trait approach has stalled in recent years.
3.4 Strategy Approach to Coping
The strategy approach has attracted significant attention from theorists and researchers 
alike. Many models taking the strategy approach have been remarkably consistent in 
their definition and conceptualisation of coping and subsequent operationalisations of 
strategies have been amenable to empirical investigation. The strategy approach grew 
out of the transaction theory of stress to provide a very different perspective on the 
conceptualisation of coping from the trait approach. The approach defines coping as the 
dynamic process in which cognitive and/or behavioural efforts (or strategies) are 
employed in order to deal with the demands of a stressful situation that challenges a 
person’s resources (Lazarus & Folkman, 1984).
This definition makes several specifications about coping that distinguish the strategy 
approach from the trait approach. The definition emphasises that coping is a process in 
which efforts aimed at dealing with the stressful situation change continually in 
response to changes in the way the relationship between the person and the stressful 
situation is appraised. Coping only refers to effortful and conscious acts that deal with a 
situation, rather than automatic or unconscious acts that may be adaptive in stressful 
situations. The approach is only concerned with the actual way in which people cope 
with a given situation, not the way in which most situations are coped (Lazarus & 
Folkman, 1984).
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As indicated by the transactional theory of stress, coping results from an appraisal 
process in which people assess the nature and severity of the stressful situation and their 
ability to effectively deal with the situation. Appraisal of the stressful situation is 
thought to continually change, depending on changes to the situation or to the 
effectiveness of coping strategies employed. As such, as appraisals change, so too do 
the coping strategies employed and their effectiveness. Any consistencies in coping 
strategies used over time are determined empirically by assessing coping across a 
number of stressful situations, unlike the trait approach which views defense use as 
inherently stable (Stone et ah, 1991).
Although the strategy approach does view coping largely as context-dependent, it does 
consider other person-specific factors to have an influence on the strategies employed 
and their effectiveness. As yet, the identification of these specific factors and the way in 
which they affect coping are not widely articulated. It is clear, however, that few 
strategy theorists and researchers consider defenses to be one such person-specific 
factor. Alternatively, several trait theorists and researchers acknowledge and distinguish 
between defenses and coping strategies, and their contributions to managing stressful 
situations (Cramer, 1998).
Attempts have been made to identify all possible coping strategies that may be 
employed in stressful situations and to organise these strategies into broader categories 
of coping. The most commonly employed categories are problem-focused and emotion- 
focused coping. Problem-focused coping refers to efforts aimed at directly managing the 
stressful situation. Problem-focused coping is more likely when the situation is 
appraised as controllable. Examples of these strategies include defining the problem, 
generating possible solutions, assessing the costs and benefits of the solutions, decision 
making regarding the solution to be used and executing the solution (Lazarus & 
Folkman, 1984).
Problem-focused coping may be aimed at the environment or the self. For example, 
problem-focused coping strategies aimed at the environment might include reducing 
barriers to managing the problem and engaging the available material resources. 
Problem-focused coping aimed at the self might include developing new aspirations, 
finding alternative forms of gratification, and learning new skills. In the case of a
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woman diagnosed with EBC, problem-focused coping strategies might include taking 
time off work in order to undergo and recover from treatment, reducing high-risk 
behaviours such as alcohol consumption, and taking medication to relieve the side 
effects of treatment (Lazarus & Folkman, 1984).
Emotion-focused coping refers to efforts to reduce distress, induce positive mental 
states and on some occasions, increase distress. Strategies aimed at increasing distress 
are less common but may be helpful in mobilising the person to employ problem- 
focused coping strategies. In contrast to the use of problem-focused coping, emotion- 
focused coping is more likely when the situation is appraised as uncontrollable. 
Examples of the strategies aimed at reducing distress include avoidance, distraction, 
minimisation, selective attention, making positive comparisons, finding benefits in the 
situation and seeking social support. For a woman diagnosed with EBC, emotion- 
focused coping strategies might include avoiding thinking about the prognosis of the 
diagnosis, comparing oneself favourably to others with more serious cancer diagnoses, 
distracting oneself from thoughts of the disease by engaging in unrelated activities (such 
as going to the movies), and seeking reassurance from family and friends (Lazarus & 
Folkman, 1984).
More recently, arguments have been made for the inclusion of avoidance (Endler & 
Parker, 1990) and social support (Moos & Schaefer, 1993) as broad categories in their 
own right. The use of problem- and emotion-focused coping categories has received 
criticism for prematurely oversimplifying the diversity of coping strategies that may 
exist (Stone et al., 1988). Clearly, empirical confirmation of these theoretical categories 
is needed (Krohne, 1993).
Despite consistency in the use of the few broad categories outlined, the individual 
strategies classified in each have differed slightly, depending on the researchers’ 
interpretation of the intention of the strategies. For example, seeking social support may 
be a way of gaining information about the situation or a way of venting distress and as 
such, may be considered a problem-focused or emotion-focused strategy respectively. 
Seeking social support may be employed for both purposes, signalling that strategies 
can have several simultaneous intentions. The categories of strategies are not mutually 
exclusive and can be employed at the same time. In some cases, different categories of
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strategies may interact by facilitating or impeding each other. Stressful situations may 
have various effects on a person and their circumstances, any of which are effectively 
dealt with using different types of strategies (Stone et al., 1991).
The strategy approach views the effectiveness of coping as independent of actual 
outcomes. Unlike the trait approach, the strategy approach does not consider any coping 
strategy a priori to be inherently effective or ineffective. Rather, effectiveness depends 
on the fit between the strategies employed, the other existing person and situational 
factors, and the person’s desired outcomes (Lazarus & Folkman, 1984). The many 
contradictory findings in the literature investigating the outcomes of coping strategies 
may reflect the idea that the effectiveness of strategies depends on many factors 
(Oakland & Ostell, 1996). While this undoubtedly results in a richness of detail 
regarding the people and situations which demonstrate effective coping, it has not 
provided information about the general patterns of association between coping strategies 
and outcomes. Therefore the approach is useful when considering specific people, 
situation and short-term outcomes but not when considering general outcomes in the 
longer term (Lazarus & Folkman, 1984).
3.4.1 Measurement of Strategy Approach
The strategy approach has consistently involved one form of measurement, that is, 
multidimensional self-report inventories. Measures of coping strategies typically 
instruct respondents to recall a past stressful situation and indicate the extent to which 
they employed the listed cognitive and behavioural strategies on a Likert scale. The first 
of these was the Ways of Coping Checklist (WCC) by Lazarus and Folkman (Folkman 
& Lazarus, 1980). Subsequent inventories appear to be mostly modifications of the 
WCC (Oakland & Ostell, 1996) and include the Ways of Coping Questionnaire (WCQ) 
(Folkman & Lazarus, 1988), the Coping Orientations to Problems Experienced (COPE) 
(Carver, 1989), the Multidimensional Coping Inventory (MCI) (Moos & Schaefer, 
1993), and the Coping Inventory for Stressful Situations (CISS) (Endler & Parker,
1990).
More recently, however, scales originally designed to measure adjustment have been 
employed for the express purpose of assessing coping strategy use. The most common 
example is the use of the Mental Adjustment to Cancer (MAC) scale (Watson, Meyer,
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Thomson, & Osofsky, 1998). Where coping refers to voluntary cognitive and 
behavioural efforts to deal with stressful situations, adjustment refers to both voluntary 
and involuntary responses to situations (Nordin, Berglund, Terje, & Glimelius, 1999).
3.4.2 Advantages and Disadvantages Strategy Coping Measures 
Advantages of these measures are their ease and low cost in administration and scoring, 
and the inclusion of a large number of coping strategies. This means they can be 
administered to a large number of participants and a comprehensive understanding of 
the coping strategies employed is possible (Oakland & Ostell, 1996). As such, these 
measures have been hugely popular in the literature with many studies investigating 
coping via this approach.
Even so, the measures have attracted considerable criticism. The lack of theoretical 
reasoning regarding the number and type of coping strategies that exist mean that 
measures appear to include a random sample of strategies that are grouped into broad 
categories empirically. In some cases, items within one broad category are inversely 
correlated so calculation of an overall score can be misleading. For example, emotion- 
focused items of approach and avoidance are inversely correlated so aggregation may 
lead to a loss of information about the extent to which emotion-focused strategies are 
employed (Stone et al., 1991; Stone et al., 1988). As Folkman (1992) states, “the 
problem of finding the critical number of types of strategies to evaluate and how to 
summarise coping patterns awaits a creative solution” (p. 36).
The reliance on retrospective recall may be subject to bias and therefore the accuracy of 
responses of questionable validity. Participants may recall the coping strategies they 
used most frequently, either first or last, at the most intense period of a situation, 
generally across a range of situations, or that were the most effective (Ptacek, Smith, 
Espe, & Raffety, 1994). Empirical research has indicated that people interpret the 
descriptions of coping strategies in measures differently and are often able to provide 
several interpretations of a strategy. Given that measures only assign each strategy one 
meaning, interpretation differences could lead to low internal consistency of items 
(Stone et al., 1991).
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Differences in the coping strategies employed may not reflect different preferences for 
or mastery of particular strategies but rather a difference in the nature of the stressful 
situation and its appraisal. By instructing respondents to recall a stressful situation 
without detailing the situation makes it impossible to know whether its nature and 
appraisal are equivalent between participants. Few, if any, efforts have been made to 
determine and assess the qualities of the stressful situation and appraisal processes that 
may affect the coping strategies employed (Stone et al., 1991; Stone et al., 1988).
Moreover, determining the strategies used to deal with particular aspects of the stressful 
situation at particular times is rarely investigated, despite the importance of temporality 
as emphasised by the approach. Failure to do so means that the comparison of coping 
and its effectiveness between participants is misleading (Auerbach, 1989; Stone et al., 
1991; Stone et al., 1988). A recent attempt to shed light on this issue consisted of daily 
ratings of coping strategies used (Wasteson, Nordin, Hoffman, Glimelius, & Sjoeden, 
2002), although the choice of daily intervals in ratings was arbitrary and the different 
stages may occur at other intervals so despite significant effort on the part of 
respondents, the method may still fail to capture the complexity of coping.
People have also been shown to interpret the response scale differently as well. These 
differences occur in four main ways: the frequency with which the strategy was used, 
the duration of each strategy, the amount of effort required in executing the strategy, 
and the usefulness of the strategy. The last of which, usefulness, contradicts the strategy 
approach in that it equates coping and success (Stone et al., 1991). Asking respondents 
to indicate the extent to which they employed a particular coping strategy and 
correlating responses with outcome variables has several problems. The response does 
not include provision for the competency with which the strategy is employed, the 
adequacy of resources available to deploy the strategies, and the effect of each 
deployment of a strategy as a function of interaction with other situational and personal 
factors (Oakland & Ostell, 1996).
3.5. Dispositional Approach to Coping
The dispositional approach aims to determine the patterns of strategies a person 
habitually employs across a range of stressful situations. These overall patterns are 
referred to as coping styles or modes (Agre et al., 2003; Krohne, 1989; McCrae, 1992;
63
Miller, 1990). Theorists of the dispositional approach do not consider dispositional 
coping to be mutually exclusive from the trait and strategy approaches to coping (Roth 
& Cohen, 1986). Instead, the approaches are thought to focus on different levels of the 
coping process. Coping traits refer to the rigid coping efforts employed in all situations, 
coping styles are preferred coping efforts that are employed in most situations, and 
coping strategies are employed variably in a range of situations, depending on 
situational and personal factors (Compas, Malcarne, & Banez, 1992; Krohne, 1993).
As stated, the strategy approach considers that some person factors may influence the 
strategies employed in situations and coping styles may be one such factor (Lazarus & 
Folkman, 1984). Some empirical evidence has found there to be a moderate association 
between coping styles and the coping strategies employed in stressful situations (Brown 
& Bedi, 2001) although results have been mixed and debate continues regarding the 
level of expected correspondence between the two (Carver, 1989; Myers & Derakshan, 
2000). It has been suggested that an understanding of dispositional coping styles may 
provide a way of systematising research on coping while preserving some of the 
complexity of the process (Lazarus & Folkman, 1984).
Like the strategy approach, the dispositional approach does not view coping styles as 
inherently effective or ineffective but instead relies on their interaction with personal 
and situational factors. That is, the approach has focused on determining the 
circumstances under which individual coping styles are effective (Krohne, 1993; Miller, 
1990; Miller, 1996). Empirical evidence supports the relationships between coping 
styles and the other theoretically distinct personal and situational factors. For example, 
it has been shown that the situational factors of controllability and stressfulness of the 
situation (Valentiner, Holahan, & Moos, 1994; van Zuuren, de Groot, Mulder, & Muris, 
1996) and the person factors of age and gender (van Zuuren et al., 1996; van Zuuren & 
Wolfs, 1991) influence the coping styles reported.
Coping styles have invariably focused on the separate dimensions of information 
seeking and information avoidance (Ben-Zur, 2002; Krohne, 1993; Miller, 1979a; Roth 
& Cohen, 1986). Information seeking describes the cognitive and behavioural efforts to 
obtain information about the stressful situation whereas information avoidance 
describes efforts to distract or escape this information. Well-known theories are
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Krohne’s (1989) theory of vigilance and avoidance, and Miller’s (1979a) theory of 
monitoring and blunting, with vigilance and monitoring referring to information seeking 
and blunting referring to avoidance. The number of theories and their overlap in the 
conceptualisation of information seeking and avoidance is thought to reflect the 
robustness of these coping constructs (Miller, 1996).
3.5.1 Measurement of Dispositional Approach
Measures of dispositional coping typically consist of the presentation of several 
stressful situations, each of which is followed by possible strategies for coping with the 
situation. Participants are asked to indicate the extent to which they believe they would 
utilise these strategies. The use of several situations that vary on dimensions thought to 
influence coping, such as the degree of controllability, predictability and stressfulness, 
is used to ensure the generalised pattern of coping is revealed. Responses to each 
strategy are aggregated to show the overall coping style (Krohne, 1989). The most 
common measure includes the Miller Behavioral Style Scale (MBSS) (Miller, 1987), 
followed by the Threatening Medical Situations Inventory (TMSI) (van Zuuren et al., 
1996) and the Mainz Coping Inventory (MCI) (Krohne, 1989).
3.5.2 Advantages and Disadvantages of Dispositional Coping Measures 
Originally, response scales were a dichotomous true/false format but recent versions 
consist of Likert scales, which have demonstrated higher internal reliability (Muris, Van 
Zuuren, Merckelbach, Stoffels, & et al., 1994e; van Zuuren & Wolfs, 1991). Scores of 
each coping style were commonly collapsed across styles and median split procedures 
were employed to determine those who utilise the combined coping style to a greater or 
lesser extent. Concerns regarding the loss of information entailed in these procedures 
have resulted in the use of individual scores for each coping style measured and 
investigation of scores as a continuous variable (Bijttebier, Vertommen, & Vander 
Steene, 2001; Miller, 1990; Muris et al., 1994e). At times, researchers have utilised only 
a selection of stressful situations in a measure in order to create a short-form version 
(Miro, 1997). This contradicts the purpose of providing a range of stressful situations 
that differ on important dimensions (van Zuuren, de Jongh, Beekers, & Swinkels, 1999) 
and has received limited empirical support (Miro, 1997).
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The limited research available indicates there is a moderate correspondence between the 
coping styles predicted in response to hypothetical stressful situations and those actually 
used (Miller, 1987; Miro, 1997; van Zuuren, 1994) whilst others have shown little or no 
association (Muris et al., 1994e; van Zuuren & Muris, 1993). Empirical evidence from a 
limited number of studies indicates that the stressful situations described may be 
difficult to imagine (Muris, van Zuuren, De Jong, De Beurs, & et al., 1994c; Steptoe, 
1989). At times, it has been reported that coping styles are poorer predictors of 
outcomes than strategies and therefore, their usefulness has been questioned. However, 
Krohne (Krohne, 1993) believes that poor construct validity of some scales may account 
for such results but that trying to predict outcomes from coping efforts occurring 
immediately preceding an event is of little benefit as the aim of the dispositional 
approach is to determine likely outcomes from habitual coping responses, rather than 
those employed in a specific situation which can be taxing to determine on each 
occasion.
3.6 Summary of the Approaches to Coping
Coping aims to minimise the effects of stress on physical and psychological well-being. 
Broadly speaking, coping can be defined as any attempt to mitigate the stressfulness of 
a situation and restore wellbeing. Coping can be considered from several approaches: 
coping may consist of unconscious, defensive cognitive acts (known as the trait 
approach), conscious behavioural and cognitive efforts (the strategy approach), or 
habitual patterns of behavioural and cognitive efforts (the dispositional approach). On 
the whole, the approaches are not considered to be mutually exclusive but rather 
represent the various levels at which coping can be considered.
Despite the advantages of examining coping from a number of approaches, all have 
varying strengths and weaknesses. The trait approach consists of diverse theories about 
potentially powerful yet unconscious coping mechanisms aimed at blocking the 
experience of stress. The definitions of coping defenses are clear and consistent across 
theories but the conceptualisations of individual defenses vary considerably, are 
difficult to operationalise and measure, and therefore investigate empirically (Davidson 
& MacGregor, 1998; Perry & Ianni, 1998).
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The strategy approach involves numerous consistent theories of the individual coping 
strategies employed in specific stressful situations. Benefits of the approach consist of 
the clear definition of coping, coping strategies are easy to operationalise, measure, and 
empirically investigate. However, the conceptualisations of coping strategies are 
sometimes contradictory, unclear, and incomprehensive and such fine-grained analysis 
of coping has generally failed in its efforts to provide an understanding of complexity of 
coping and its outcomes (Folkman, 1992; Stone et al., 1991; Stone et al., 1988).
The dispositional approach has many of the benefits of the strategy approach; it consist 
of clear though narrow definitions of coping styles, the coping styles are easy to 
operationalise, measure and empirically investigate, and it also acknowledges the role of 
other personal and situational factors in coping. Most importantly, it has the potential to 
provide an overall understanding of the outcomes of coping (Krohne, 1993).
3.7 Conclusions
Consideration of the theories of stress and coping are clearly important in understanding 
the experience of stressful situations. The theories outline the way in which people 
come to experience stress and the many ways in which they may cope with stressful 
situations. This serves to highlight the numerous possible avenues for empirical 
investigation of stressful situations. In so doing, variations in the experience of stressful 
situations in terms of physical and psychological wellbeing may be better understood. 
Efforts may be made to utilise this understanding to develop and implement 
interventions aimed at reducing maladaptive forms of coping and enhancing adaptive 
forms, thereby ensuring improved physical and psychological wellbeing. As illustrated, 
the coping approaches have the potential to identify some of the ways in which women 
cope with the diagnosis and treatment of EBC. Therefore, their application to the 
understanding of the EBC journey is critical.
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CHAPTER FOUR
Coping with the Clinical Experience of Breast Cancer
The application of the coping approaches to the experience of breast cancer is prolific. 
Researchers and clinicians alike are excited by the potential for the coping approaches 
to expose the way in which the breast cancer journey is experienced and identify 
opportunities for intervention. All coping approaches have been utilised in an effort to 
fully understand the range of coping and outcomes possible across the entire breast 
cancer experience. It will become evident that many studies have utilised the coping 
strategies approach and have examined the experience of breast cancer rather than EBC. 
The use of the strategies approach is no doubt because the approach is amenable to 
empirical investigation and samples of breast cancer are easier to recruit than those with 
the more specific diagnosis of EBC. The following section will outline the empirical 
literature in four main areas: the aetiology and progression, diagnosis, and treatment of 
breast cancer. Attempts have been made to include research including all coping 
approaches and those examining women with EBC.
4.1 Coping and the Aetiology of Breast Cancer
Interest in the role of coping in the aetiology and progression of breast cancer 
commenced in the 1960s, a time in which rates of breast cancer were noticeably 
increasing in the Western world (Key et al., 2001; Veronesi et al., 2005). This interest 
has continued in recent years, in part due to the inability to explain the medical reason 
as to why and how cancer develops and progresses. As a result, there is considerable 
empirical literature investigating the topic, much of which varies greatly in terms of the 
quality of research designs (Bleiker & van der Ploeg, 1999; Bryant-Lukosius, 2003; 
Butow et al., 2000a; De Boer, Ryckman, Pruyn, & Van den Borne, 1999; Garssen,
2004; Gerits, 2000; Petticrew, Bell, & Hunter, 2002). It is a topic that has captured the 
attention of researchers and clinicians as well as the general public. The latter is 
illustrated by the plethora of media reports, popular books, patient workshops, and so on 
that discuss the role of coping in the cancer experience (Satterlund et al., 2003).
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4.1.1 Retrospective Studies
Studies investigating the topic can be classified into three categories of research design: 
retrospective, quasi-prospective, and prospective designs. In the retrospective design, 
patients diagnosed with breast cancer are analysed retrospectively on coping and 
compared with control groups consisting of patients with other medical conditions 
(most commonly those with benign breast disease) and/or healthy random samples of 
the general population (Bleiker & van der Ploeg, 1999). Several retrospective studies 
have found significant differences in coping used by cancer patients compared to 
controls.
In one of the first retrospective studies, around 70 breast cancer patients were compared 
to controls consisting of a sample of women with a medical condition (cystic fibrosis) 
and a population-based sample. The results suggested that cancer patients used coping 
strategies that involved less assertiveness and expression of anger than both control 
groups (Jansen & Muenz, 1984). This findings was further confirmed in smaller studies 
by Watson and colleagues (Watson et al., 1984), and Goldstein and Antoni (Goldstein 
& Antoni, 1989) involving around 30 breast cancer patients and population-based 
control groups. Both found cancer patients to have more repressive coping than 
controls. The former also found cancer patients engaged in more coping involving the 
suppression of anger than controls.
While these results appear to be similar, it is difficult to distinguish between the coping 
described as emotional suppression versus repression, as the researchers provided few 
descriptions and examples of the forms of coping measured. Traditionally, however, 
suppression involves the conscious avoidance of emotion while repression involves the 
unconscious avoidance of emotion despite significant physiological arousal. In other 
words, suppressors know they are experiencing intense emotions but make efforts to 
actively inhibit them while repressors are unaware that they are experiencing such 
emotions (Giese-Davis & Spiegel, 2002).
Concerns exist regarding the validity of findings from studies using the retrospective 
design. The appropriateness of the control groups has attracted significant debate. Some 
believe that the use of women with benign breast disease as controls is superior to 
population-based controls because the former have similar levels of concern prior to
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diagnosis as those who are diagnosed with cancer. However, others argue that these 
women are also at an increased risk of the disease. There are several additional concerns 
about retrospective designs. There is the possibility that the disease influences 
personality and therefore affects coping efforts. Patients’ knowledge of their diagnosis 
may affect the way they recall information on coping and other psychosocial variables 
assessed. Lastly, the cross-sectional design makes it difficult to determine causality 
(Bleiker & van der Ploeg, 1999).
4.1.2 Quasi-Prospective Studies
The quasi-prospective design consists of examining the coping efforts of patients with 
suspicious symptoms prior to diagnosis and comparing those who go on to receive a 
diagnosis of breast cancer to those who do not. It is thought that by recruiting 
participants with suspicious symptoms, all have equal levels of distress and fear of 
cancer prior to diagnosis. One study investigated coping in more than 2000 women 
attending out-patient health clinics or breast screening centres, over 75% of whom had 
detected breast symptoms indicative of breast cancer. Over 170 of these women were 
subsequently diagnosed with breast cancer. The results showed that those diagnosed 
with cancer used more coping consisting of denial and suppression of anger than those 
without the disease (Cooper & Faragher, 1993).
Similarly, suppression of anger was also reported in a sample of 160 women, 69 of 
whom were diagnosed with breast cancer and the remaining with benign breast disease 
(Greer & Morris, 1975; Greer & Morris, 1978). Although, subsequent re-analysis that 
accounted for risk factors of menopausal status and age revealed that cancer patients 
were more likely to suppress all emotions, not just anger (Bleiker & van der Ploeg, 
1999). Additional studies with smaller samples of more than 60 women reported more 
suppression of anger (Morris, Greer, Pettingale, & Watson, 1981), and emotions in 
general in those receiving a diagnosis of breast cancer than with benign breast disease 
(Wirsching, Hoffmann, Stierlin, Weber, & Wirsching, 1985).
Similarly, a study examining more than 800 women undergoing mammography 
revealed that the 20 women diagnosed with breast cancer demonstrated more coping 
aimed at emotional control than those with benign breast disease and healthy women 
(Fox, Harper, Hyner, & Lyle, 1994), although a poor response rate may indicate a
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selection bias (Butow et al., 2000b). One study aimed to investigate the role of the 
coping efforts of problem-focused and emotion-focused engagement and 
disengagement. Of almost 200 women recalled following a suspicious mammography 
screening or breast biopsy, more than 100 were diagnosed with breast cancer. The 
results of the study revealed that those diagnosed with breast cancer had comparable 
coping efforts as controls. However, women diagnosed with breast cancer that had 
experienced one or more severe life events in the past five years were more likely to use 
problem-focused engagement coping (Chen et ah, 1995).
On the other hand, some large-scale studies also revealed no difference in coping for 
women receiving a diagnosis of breast cancer and those with benign breast disease or 
healthy controls. Price and colleagues (Price et al., 2001) investigated more than 2000 
women recalled following a routine mammography in a breast-screening program. They 
found equivalent use of defenses and strategies of emotional expression and control in 
the almost 300 women who went on to receive a diagnosis of the disease and those that 
did not.
An earlier study of more than 1000 women undergoing clinical examination and 
mammography assessed the coping efforts of maladaptive, denial/avoidance, seeking 
social support and venting. The results revealed equivalent coping for the almost 80 
women with breast cancer and those without (Edwards, Cooper, Pearl, de Paredes, & et 
al., 1990). A smaller study of almost 40 women with breast cancer and 80 with benign 
breast disease undergoing breast biopsy investigated the coping strategies of cognitive 
avoidance, behavioural avoidance, positive focus, distancing and seeking social support. 
The results revealed those with breast cancer and those with benign breast disease 
reported comparative use of coping (Stanton & Snider, 1993).
A limitation of the quasi-prospective design is the possibility that patients may 
accurately infer their diagnosis from their symptoms or from interactions with medical 
professionals who know patients’ diagnoses (Bleiker & van der Ploeg, 1999). Again, 
there is speculation that the disease may influence personality and consequently, coping 
efforts (Bleiker & van der Ploeg, 1999).
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4.1.3 Prospective Studies
The prospective design involves following healthy populations over a period of time to 
allow the assessment of coping before disease becomes apparent and comparisons are 
made between those who develop breast cancer and those who do not. In a study of 
almost 9, 000 women, results indicated that repression was employed equally among 
those diagnosed with breast cancer and those that were not (Hahn & Petitti, 1988).
Given that this was an earlier study, risk factors and medical variables were not widely 
established and as such, were not adequately accounted for. In a second study, almost 
10, 000 women were followed up for over five years. The over 130 women diagnosed 
with breast cancer were found to use more minimisation of emotions coping than the 
remaining women (Bleiker, van der Ploeg, Hendriks, & Ader, 1996).
Although prospective designs are considered the most appropriate (Bleiker & van der 
Ploeg, 1999), the cost inherent in such a design has meant there are few such studies. 
Concerns also exist regarding the measurement of coping. Coping is often measured at 
study entry only, despite long follow-ups. This means that any changes in coping 
employed over time are not considered. This is particularly problematic when 
examining coping strategies, as they are theoretically expected to fluctuate considerably.
4.2 Coping and the Progression of Breast Cancer 
4.2.1 Prospective Studies
More recent research has investigated the role of coping in the progression of breast 
cancer. Study designs have typically involved the assessment of coping within several 
months of diagnosis and overall and recurrence-free survival over a follow-up period of 
at least five years. Most studies accounted for a range of variables that have been 
implicated in increased survival, including demographic factors (for example, age), 
lifestyle factors (for example, alcohol consumption), disease characteristics (for 
example, disease stage, number of affected axillary nodes), and treatment factors (for 
example, type of surgery, whether received chemotherapy). Problems regarding the 
measurement of coping in prospective designs that were previously outlined are again a 
concern for the following studies.
The earliest studies of this kind were conducted by Greer and colleagues (Greer, Morris, 
& Pettingale, 1979; Greer, Morris, Pettingale, & Haybittle, 1990; Pettingale, 1984;
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Pettingale, Morris, Greer, & Haybittle, 1985). They followed almost 70 EBC patients 
for 15 years. Patients completed measures of fighting spirit, stoic acceptance, 
helplessness/hopelessness, and denial at diagnosis. At 15 years, the results suggested 
that those using more denial and fighting spirit experienced increased overall and 
recurrence-free survival. Given that many of the factors implicated in survival were 
unknown at the time of study, these have not been adequately accounted for in the 
analyses (Gerits, 2000). The study has now been replicated by Giraldi and colleagues 
(Giraldi, Rodani, Cartei, & Grassi, 1997) with the appropriate consideration of these 
factors. Ninety-five patients with EBC were followed up for six years and were assessed 
on the similar coping strategies of fighting spirit, hopelessness, anxious preoccupation, 
and fatalism. The results showed that those using greater fighting spirit and less 
helplessness/hopelessness coping experienced greater overall survival.
Two remaining studies, however, failed to yield similar findings. A larger sample of 
almost 600 EBC patients was followed up for five years. The results suggested that 
increased overall survival was instead experienced by those using more 
helplessness/hopelessness coping (Watson, Haviland, Greer, Davidson, & Bliss, 1999). 
The second study with a smaller sample of more than 120 EBC patients followed 
patients for six to eight years. This time, the results indicated that those experiencing 
increased recurrence-free survival used more denial (Dean & Surtees, 1989).
A large-scale study of almost 850 breast cancer patients reported use of coping 
strategies including expression of emotions, wishful thinking, problem solving, positive 
reappraisal, avoidance, and escapism at diagnosis and were followed for up to nine 
years. The results indicated that greater expression of emotions was associated with 
increased overall survival (Reynolds et al., 2000). Similar results were reported in a 
smaller sample of around 130 EBC patients followed up for a shorter period of four 
years. Patients who reported more engagement in behaviours that expressed emotions 
experienced increased overall and recurrence-free survival (Hislop, Waxier, Coldman, 
Elwood, & Kan, 1987).
Two further studies reported an association between coping strategies and survival. 
Ninety-nine ABC patients were followed for two years after reporting the use of active, 
distractive, and avoidant coping. The results showed that these forms of coping were not
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associated with survival but those who minimised the impact of cancer (referred to as a 
pattern of adjustment to cancer by the researchers) experienced increased overall 
survival (Brown, Butow, Culjak, Coates, & Dunn, 2000). In the second study, 27 
women with a recurrence of breast cancer, 25 women in remission for two years, and 34 
healthy controls were followed for almost two years. Participants reported on defensive 
and helplessness/hopelessness coping. The results showed that both strategies were 
associated with survival (Jensen, 1987).
Two further studies reported no significant association between coping and survival. 
The coping strategies of denial, passive coping, and isolation were assessed in more 
than 300 patients diagnosed with EBC who were then followed for 10 years. There was 
no association with survival and any of the coping strategies (Soler-Vila, Kasl, & Jones, 
2003). In the second study, over 100 EBC patients were again followed-up for 10 years. 
Patients reported on their use of problem-solving, emotional control, self­
encouragement, self-revalorisation, distraction, withdrawal, regression, distrust, 
pessimism, and depressive coping. There was no association between coping and 
survival (Buddeberg, Buddeberg-Fischer, & Schnyder, 1997; Buddeberg et al., 1996).
4.2.2 Meta-Analyses
Two recent meta-analyses have been conducted to determine the effect of coping on 
overall and recurrence-free survival in breast cancer, both of which have reported 
conflicting results. The first conducted by McKenna and colleagues (McKenna, Zevon, 
Corn, & Rounds, 1999) considered the results of 46 studies of participants with breast 
cancer, although some studies investigated constructs related to coping but not coping 
itself. The coping constructs investigated included conflict-avoidant coping, 
denial/repression and expression of anger. The results of the meta-analysis suggested a 
small but significant effect of denial/repression and to a lesser extent, conflict-avoidant 
coping on overall survival (McKenna et ah, 1999).
A later meta-analysis conducted by Petticrew and colleagues (Petticrew et ah, 2002) 
applied a more strict criteria to the studies reviewed, including only those that adjusted 
for potential confounders and that assessment of coping was carried out early on in the 
disease process. They considered 26 studies investigating overall survival and 11 
studies investigating recurrence-free survival in participants with a range of cancers.
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The forms of coping investigated included fighting spirit, helplessness/hopelessness, 
denial/avoidance, stoic acceptance/fatalism, anxious preoccupation, depressive coping, 
problem-solving coping, emotion-focused coping and emotional suppression.
The results of the review suggest that there was no demonstrated role of coping in 
survival and recurrence. The studies that reported a significant association between 
coping and overall survival and/or recurrence were small and/or methodologically weak 
studies and there were no consistent patterns in the forms of coping implicated in the 
significant associations. As Petticrew and colleagues (Petticrew et al., 2002) comment, 
“People with cancer should not feel pressured into adopting particular coping styles to 
improve survival or reduce the risk of recurrence” (p.l).
4.2.3 Intervention Studies
Several interventions have been designed to enhance survival following breast cancer 
diagnosis by encouraging the development and use of certain forms of coping. To date, 
interventions have varied significantly in terms of their intensity, the focus of 
intervention, and the point at which they are offered to patients. The most widely known 
intervention study is that of Spiegel and colleagues (Spiegel, Bloom, Kraemer, & 
Gottheil, 1989). They randomly assigned almost 90 patients with ABC to a supportive- 
expressive therapy aimed at enhancing emotional expression and a no intervention 
control group. Patients in the intervention group reported significantly improved mood 
and psychological adjustment around ten months post-entry compared to controls. 
Follow-up at ten years post-entry revealed a significant increase in overall survival in 
those undergoing the intervention compared to the control group, after controlling for a 
range of medical prognostic factors.
While impressive, these results have been challenged by Fox (1998) for two reasons. 
Fox compared the survival rates of the intervention and control groups to the rates of a 
matched control population. The results found that the intervention and control groups 
survived comparatively to the matched control population group. Fox also suggests that 
the median survival periods of the intervention and control groups are similar and 
therefore the difference between the two may be due to extreme values.
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A replication of the effects of supportive-expressive intervention was conducted by 
Cunningham and colleagues (Cunningham et al., 1998). They delivered a similar 
supportive-expressive intervention that also included coping skills training and 
compared the intervention group to a control group that received written material used 
in the intervention. Sixty-six patients with ABC were randomly assigned to the groups. 
There were no significant effects of intervention on mood and psychological adjustment 
except for hopelessness which was reduced in the intervention group. There was no 
effect on survival after five years.
Edelman and colleagues (Edelman, Lemon, Bell, & Kidman, 1999) randomly assigned 
patients with ABC to a cognitive-behavioural intervention in which patients were taught 
a range of cognitive and behavioural coping strategies and a control group in which 
standard care was provided. Significant improvements in mood, depression and self­
esteem were evident for those completing the intervention but not for those completing 
the control condition. These improvements were not maintained three and six months 
post-intervention. Survival after five years revealed no differences between the two 
groups. Morgenstern and colleagues (Morgenstern, Geliert, Walter, Ostfeld, & Siegel, 
1984) delivered an intervention to breast cancer patients that aimed to enhance 
discussion of cancer-related issues as well as the coping efforts of meditation and 
positive mental imagery and a group of controls matched on prognostic factors that 
chose not to participate. Survival analysis five and fifteen years post-intervention 
revealed no significant effect of intervention on survival.
4.2.4 Meta-Analysis of Intervention Studies 
Although it is clear that some interventions have offered significant and important 
improvements in psychological wellbeing, the effect of coping on survival is unclear. A 
recent meta-analysis conducted by Smedslund and Ringdal (2004) has gone some way 
to clarifying this issue. The meta-analysis considered 14 intervention studies of more 
than 2500 participants. The interventions were diverse but mainly included education, 
support and skills training. A range of variables was accounted for in the analysis and 
included age, gender, type of cancer, extensive of disease, cancer treatment received, 
randomisation, type of control group and format of intervention (group or individual). 
The results revealed no overall effect of intervention and this did not change when 
considering randomised versus non-randomised studies. There was, however, a
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significant effect of format of treatment with individual interventions significantly 
prolonging survival but no effect of group interventions (Smedslund & Ringdal, 2004).
4.2.5 Summary
From the research conducted, it cannot be said with certainty that coping influences the 
development and/or progression of breast cancer. A case may be made for the role of 
emotional suppression in the development of cancer. Numerous studies, reviews and 
meta-analyses have found an association between this construct and the development of 
breast cancer. To date, emotional suppression or similar constructs (such as repression, 
minimisation, or denial) have been defined differently in each study but it can be 
broadly claimed that it is characterised by the denial and/or suppression of emotions 
experienced, avoidance of conflicts, and excessive social desirability and compliance. It 
is suggested that future research delineates the various elements of emotional 
suppression that are thought to diminish survival (Giese-Davis & Spiegel, 2002).
Nonetheless, the lack of methodological integrity of the empirical research means that 
further research is needed to clarify the influence of coping on development and 
progression. Generally, research has been hampered by small sample sizes, use of 
samples with varying diagnoses and prognoses, use of measures with questionable 
reliability and validity, the lack of definitions of coping assessed and their distinction 
from similar constructs, a failure to account for risk factors and medical variables in a 
small number of earlier studies and a biased focus on trait coping as this approach was 
popular at the time of much of the research (Goldstein & Antoni, 1989; Stone et al., 
1988; van Elderen, Maes, & Dusseldorp, 1999).
In intervention studies, further issues are the failures to adequately describe 
interventions, to assess different components of interventions individually, and to assess 
changes in coping post-intervention as a manipulation check as well as the selection 
bias of participants self referring to participation and the inadequacy of control groups 
(de Ridder & Schreurs, 2001). All of these methodological issues have made it difficult 
to interpret the findings and need to be overcome in future research. Until these findings 
are replicated, instructing patients to adopt a manner of coping that is at odds with their 
usual coping responses may cause undue pressure. If the results are spurious, this may
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be considered unnecessary if not unethical (Garssen & Goodkin, 1999; Petticrew et al., 
2002)
4.3 Coping and the Diagnosis of Breast Cancer
Attention has shifted from the role of coping in the development and progression of 
breast cancer to adjustment to diagnosis of the disease. This topic has garnered the focus 
of much research over the past two decades. The research of better quality consists of 
moderate to large samples, the use of reliable and valid coping measures, and statistical 
analyses that account for confounding medical variables. The results of these studies 
appear to indicate that avoidance and/or emotion-focused coping results in poorer 
psychological adjustment at diagnosis and up to one year post-diagnosis, regardless of 
the way in which coping is measured or how adjustment is defined or measured. The 
remaining studies are hampered by numerous shortcomings. The most common include 
the use of cross-sectional designs, relatively short-term follow-ups, small sample sizes, 
samples of cancer patients receiving varying diagnoses, prognoses and treatments, 
inadequate coping and outcome measures, a failure to account for medical variables, 
and differences in the conceptualisation of adjustment (Brennan, 2001).
4.3.1 Avoidance Coping
Two cross-sectional studies investigated coping in patients with breast cancer. Friedman 
and colleagues (Friedman, Baer, Lewy, Lane, & et al., 1988) assessed coping in almost 
70 patients diagnosed with EBC and ABC who were between 2 and 225 months post­
diagnosis. The results revealed that greater use of avoidance was associated with higher 
levels of distress and lower levels of adjustment to domestic life. A second study of 
more than 55 patients with EBC assessed coping between 1 and 26 months post­
diagnosis. Similarly, the results showed greater use of avoidance was associated with 
lower levels of psychological wellbeing.
When considering the patients’ adjustment within three weeks of diagnosis, a sample of 
more than 35 patients with EBC reported use of coping strategies. As previously 
outlined, the coping strategies included cognitive avoidance, behavioural avoidance, 
positive focus, distancing and seeking social support. The results showed that those 
using more cognitive avoidance experienced higher levels of negative mood (Stanton & 
Snider, 1993). Similar results were reported in another study investigating coping and
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adjustment at around six months post-diagnosis. More than 60 women diagnosed with 
EBC reported on coping, psychological distress, and quality of life at diagnosis and 
approximately seven months post-diagnosis. Avoidant coping at diagnosis was 
associated with greater psychological distress and poorer quality of life at follow-up 
(McCaul et al., 1999).
In an investigation with a longer follow-up, 70 women with EBC reported coping 
strategies and psychological adjustment at diagnosis to twelve month follow-up. 
Avoidance predicted greater fear of cancer recurrence while active acceptance at 
diagnosis predicted less distress (Stanton, Danoff-Burg, & Huggins, 2002). A study 
with a larger sample of more than 130 patients diagnosed with EBC and ABC 
investigated coping and distress one week post-surgery, and three, six and twelve 
months post-surgery. The results revealed that the use of more behavioural 
disengagement at three months predicted greater distress at six months (Culver, Arena, 
Antoni, & Carver, 2002).
In a smaller study of less than 60 patients with EBC undergoing surgery, coping 
strategies and distress was assessed one day pre-surgery, ten days post-surgery, and 
three, six, and twelve months post-surgery. In terms of concurrent distress, denial and 
behavioural disengagement were positively related to distress at all time points.
Restraint coping pre- and post-surgery was positively related to distress. When trying to 
predict distress over time, denial and behavioural disengagement at three months 
predicted distress at six months. Interestingly, distress post-surgery was also found to 
predict more use of denial, behavioural disengagement, and distraction at three months 
only (Carver, Pozo, Harris, Noriega, & et al., 1993).
A limited number of studies have investigated the long-term association between coping 
and adjustment. A study of 70 EBC patients reported on use of cognitive and 
behavioural approach and avoidance strategies at three months and three years post­
diagnosis. Again, the use of more behavioural approach and less cognitive avoidance 
and negative emotional expression were associated with lower levels of distress at three 
months. Although these associations were not found at three years, the use of more 
passive resignation at three months did predict distress at three years (Hack & Degner, 
1999, 2004).
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A more fine-grained analysis of the association between coping and adjustment in the 
long-term was performed by Heim and colleagues (Heim, Valach, & Schaffner, 1997). 
They employed both self- and observer-rated measures of coping and adjustment every 
three to six months for three to five years. This enabled the investigation of patterns in 
coping and adjustment across specific treatments well into the period of survivorship. 
Results indicated significant patterns existed between coping and adjustment to 
diagnosis during hospitalisation, chemotherapy and rehabilitation but not convalescence 
or metastasis. When dichotomising patients into those with high and low levels of 
adjustment, those experiencing good adjustment reported more passive cooperation, 
acceptance-stoicism, and self-control, and less resignation, rumination, and denial 
coping. More resignation and rumination, and less self-control coping were related to 
more distress (Heim et al., 1997).
4.3.2 Emotion-Focused Coping
There is also some evidence for the association between emotion-focused coping and 
poorer adjustment at diagnosis and up to 6 months post-diagnosis. Epping-Jordan and 
colleagues (Epping-Jordan et al., 1999) investigated dispositional optimism, coping 
strategies and psychological adjustment to breast cancer in 80 EBC and ABC patients at 
diagnosis, three and six month follow-up. At diagnosis and six month follow-up, the use 
of emotion-focused disengagement coping was associated with higher levels of anxiety 
and depressive symptoms. Also at six month follow-up, problem-focused 
disengagement was associated with higher levels.
Comparative results were also evident in a study of coping strategies, perceived control 
and levels of anxiety and depressive symptoms in 70 women with breast cancer at 
diagnosis and at three and six month follow-ups. After controlling for initial levels of 
symptoms, emotion-focused disengagement coping predicted higher levels of symptoms 
at six months (Osowiecki & Compas, 1999). Lastly, in a study of more than 70 women 
with breast cancer and their partners, Ben-Zur and colleagues (Ben-Zur et al., 2001) 
assessed coping strategies, psychological distress, and psychological and social 
adjustment. Patients’, partners’ and dyads’ use of emotion-focused coping were 
associated with higher levels of distress and lower levels of adjustment in patients.
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In contrast, emotion-focused strategies have been associated with better adjustment 
post-diagnosis. Over 90 women diagnosed with EBC were assessed 20 weeks post­
completion of treatment and after a three month follow-up. Those who reported 
expressing emotions regarding cancer were found to have significantly fewer medical 
appointments for cancer-related morbidities, enhanced physical health and vigour, and 
decreased distress compared to those low in emotional expression. Those reporting 
greater emotional expression and perceived social support also had improved quality of 
life (Stanton et al., 2002).
4.3.3. Summary
As indicated, there are many studies that have investigated the role of coping in the 
adjustment to a breast cancer diagnosis. Much of this research contains methodological 
shortcomings and as a result, only the better quality studies were considered. Of those, 
there appears to be associations between avoidance and emotion-focused coping and 
poor adjustment to the diagnosis of breast cancer. Poor adjustment has been defined as 
elevated levels of general distress, anxiety and depressive symptoms, and reduced levels 
of quality of life and to a lesser extent reduced physical functioning.
Despite these consistencies, there are a number of problems with the research that 
preclude any firm conclusions on the role of coping in adjustment to diagnosis. 
Typically, coping was only assessed at one time point. As stated, the strategy approach 
expects coping strategies to fluctuate significantly over time and in response to different 
stressful situations so one assessment of coping would not be sufficient to link coping 
with outcomes. The length of follow-ups also varied and did not appear to be tied to 
significant milestones in the breast cancer journey. Instead, follow-ups often included 
women undergoing different treatment at different stages of treatment. Lastly, a broad 
range of coping was assessed with little description of the nature or aim of the forms of 
coping. It is difficult to ensure that attempts to compare studies assessing similar forms 
of coping are successful.
4.4 Coping and the Treatment of Breast Cancer
In response to the past literature’s tendency to view the process of coping with breast 
cancer as a unitary stressor, more recent research has viewed it as a more complex 
situation consisting of several stressors, each of which may require particular coping
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efforts (Auerbach, 1989). Research has shifted from examining overall adjustment at 
any point post-diagnosis to the focus on the experience of discrete treatments in the 
breast cancer experience. Indeed, as outlined, Heim and colleagues (Heim et al., 1997) 
intensive study of coping over a five year period emphasised that the strongest 
relationships between coping and outcomes occur during specific phases of the breast 
cancer journey. Few studies have been conducted to date so the following outline 
includes research involving patients with breast and other cancers. The results suggest 
that coping may play a significant role in the experience of specific treatments, in terms 
of both physical and psychological wellbeing.
One of the first treatments experienced, breast surgery, often involves significant pain 
and analgesic use. To determine whether such pain and analgesic use is influenced by 
coping efforts, Jacobsen and Butler (Jacobsen & Butler, 1996) assessed the use of 
catastrophising and cognitive coping strategies and self-reported pain and analgesic use 
in the three days of recovery following surgical intervention in around 60 patients 
diagnosed with EBC. The results indicated that catastrophising was associated with 
increased pain and analgesic use while there was no effect of cognitive coping 
strategies. A more recent study investigated the more broad experience of pain. A 
sample of almost 70 women diagnosed with EBC or ABC experiencing pain, either 
from cancer or cancer-related treatment, reported on the severity of the pain and its 
impact on functioning. Active coping strategies were associated with increased, and 
passive strategies with reduced, physical functioning whereas catastrophising was 
associated with greater distress (Bishop & Warr, 2003).
Coping and the experience of chemotherapy has been investigated in several studies, no 
doubt due to the treatment’s ability to significantly impact on physical and 
psychological wellbeing. A study of 55 patients with EBC reported their use of coping 
strategies, and the levels of side effects and distress experienced on days one, three and 
seven after the first chemotherapy infusion. Participants were divided into those with a 
confrontive, confrontive-avoidant, avoidant-resigned or resigned form of coping. The 
results found that those with a confrontive form of coping reported lower levels of 
distress than those using confrontive-avoidant or avoidant-resigned coping and fewer 
side effects than those using confrontive-avoidant, avoidant-resigned or resigned coping 
(Shapiro, Boggs, Rodrigue, Urry, & et al., 1997).
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The same design was employed in a study conducted by Manne and colleagues (1994). 
More than 40 patients diagnosed with EBC reported their use of coping strategies, and 
levels of side effects and positive and negative affect after the first infusion. Results 
indicated that confrontive and escape-avoidance coping was associated with more 
negative affect and physical side effects while distancing, self-control and positive 
reappraisal was associated with more positive affect. The relationship between escape- 
avoidance coping and negative affect remained significant after accounting for physical 
side effects but this was not the case for confrontive coping. The relationships between 
distancing, self-control and positive reappraisal was still significantly associated with 
more positive affect after accounting for side effects. Physical side effects were 
significantly and positively associated with negative but not positive affect.
In a final study, Lerman and colleagues (Lerman et al., 1990) investigated the use of 
monitoring (information seeking) and blunting (information avoidance) coping styles 
and levels of nausea and distress reported by almost 50 patients with varying cancer 
diagnoses undergoing adjuvant chemotherapy. Patients were assigned to receive either 
relaxation training or standard care before chemotherapy. Overall, the results showed 
that blunting was associated with less anxiety, depression and nausea during and 
following chemotherapy while monitoring was associated with more anxiety and nausea 
before and during chemotherapy. The relaxation training group reported significantly 
less post-treatment nausea compared to control groups and those in the relaxation 
training group that reported a blunting coping style experienced significantly lower pre­
treatment anxiety than those with a monitoring style. This may be because relaxation 
involves distraction, a strategy that is consistent with the blunting but not monitoring 
coping style.
In a related vein, Burish and colleagues (Burish, Snyder, & Jenkins, 1991) delivered 
four interventions aimed at enhancing the experience of 60 cancer patients undergoing 
chemotherapy for varying diagnoses. Patients were randomly assigned to one of the four 
single-session preparatory interventions including; relaxation with guided imagery, 
general coping skills, both relaxation and coping skills, and a routine clinic treatment. 
Details of the coping skills training were not detailed but consisted generally of 
education and suggestions as to how to cope with certain side effects. The outcomes
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included self-, nurse- and family-observations of side effects and distress as well as 
physiological measures of arousal after five consecutive infusions. Compared to 
baseline measures, the coping skills intervention increased knowledge about cancer and 
its treatment, reduced negative affect and anticipatory nausea and vomiting while the 
relaxation intervention reduced negative affect and vomiting (Burish et al., 1991).
4.4.1 Summary
Similar methodological problems are evident in this literature as those already reviewed. 
In addition, though, the outcomes assessed have been determined by researchers and 
may therefore fail to account for the expectations and goals of participants. This makes 
it difficult to determine whether coping was effective (Stone et al., 1988). The use of 
such methodology implies that while certain coping strategies are not considered 
intrinsically good or bad, the outcomes of these strategies are. However, each study 
typically included the use of several outcome measures which may increase the 
likelihood of comprehensively capturing the effects of coping (Auerbach, 1989).
4.5. Mechanisms of Coping and the Experience of Breast Cancer 
While much attention is bestowed on the effect of coping on the experience of breast 
cancer, significantly less has focused on the mechanisms by which coping affects 
experience. The most common idea is that psychological factors bring about hormone 
changes, which influence immunological functioning, which in turn increases or 
decreases the chance for tumours to develop and grow. The way in which coping might 
do this is two-fold. First, coping might involve engagement in healthy habits that serve 
to reduce the risk of breast cancer. For example, coping may include behaviours that 
help maintain a healthy weight, abstaining from alcohol and attending routine 
mammography (Garssen & Goodkin, 1999; Gerits, 2000; Lazarus & Folkman, 1984).
Second, coping might lead to physiological states that in turn increase or decrease the 
opportunity for tumours to develop (Garssen & Goodkin, 1999). For example, it has 
been suggested that states of high physiological arousal may reduce immune-system 
functioning and therefore, allow tumours to develop. Coping efforts may increase 
arousal by failing to prevent or ameliorate the stressful situation. This may be due to the 
intractability of the situation, ineffectiveness of coping efforts, or deficits in coping 
abilities or resources. Coping efforts may fail to regulate emotional distress in the face
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of the stressful situation. Again, this may be due to the ineffectiveness of coping efforts 
or deficits in abilities and resources. Thirdly, coping may involve exacerbation of the 
stressful situation. Lastly, coping efforts may aggravate the existing circumstances, 
result in negative consequences that add to the stressfulness of circumstances or impede 
more effective coping efforts (Gerits, 2000; Lazarus & Folkman, 1984). Further 
research is clearly needed to elucidate these potential mechanisms.
4.6 Conclusions
The empirical literature on coping and the aetiology, progression, diagnosis, and 
treatment of breast cancer has yielded many and varied significant results. Although it 
has been claimed that differences in the theoretical approaches to coping and problems 
in methodology and measurement are considered so fundamental that it is impossible to 
make any definitive statements regarding the efficacy of coping (Stone et al., 1988), 
several conclusions can be made.
Coping does not appear to play an unequivocal role in the development or progression 
of breast cancer. However, there is sufficient research to indicate a possible role of 
emotional expression in enhanced survival that deserves further investigation. When 
doing so, it is suggested that the aspect of emotional expression that is responsible for 
enhancing survival is delineated (Gerits, 2000). The use of avoidance and/or emotion- 
oriented coping has been associated with poorer psychological adjustment to the 
diagnosis of breast cancer. Although the research is hampered by a range of 
methodological shortcomings, there does appear to be a consistent link across samples, 
methods of assessment, and lengths of follow-up.
Of particular interest, however, is the role of coping in specific treatments. Little 
research currently exists and the results to date have been conflicting. Nonetheless, it is 
a direction that needs to be pursued. To ensure a comprehensive understanding of the 
role of coping in specific treatments, it is suggested that future research is prospective in 
design, includes a sample of women with similar diagnoses, focuses on well-defined 
and assessable forms of coping, and assesses a range of outcomes.
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CHAPTER FIVE
Monitoring and Blunting Coping Styles and the Clinical Experience of Breast Cancer
The theoretical and empirical literature on coping and the breast cancer experience 
clearly indicates that dispositional coping styles are an important field of investigation. 
They offer the possibility of considering coping as a dynamic process and at the same 
time, provide an overall picture of the habitual way in which people cope and how this 
might affect a range of outcomes (Miller, 1995). In order to investigate these coping 
styles further, the following chapter will outline the dispositional approach of 
monitoring and blunting coping styles. This will include an outline of the theory guiding 
the monitoring and blunting concepts, definitions of monitoring and blunting, and the 
physical and psychological effects of the use of monitoring and blunting, with 
supporting empirical research. To date, there has been a significant amount of research 
conducted on the impact of monitoring and blunting coping styles and the experience of 
a range of medical issues. Where possible, research investigating the experience of 
breast cancer will be detailed.
5.1. Definitions of Monitoring and Blunting Coping
Monitoring and blunting represent two orthogonal dimensions of coping. Monitoring 
refers to the tendency to seek out and attend to information about stressful situations, 
referred to as threat-related information. Threat-related information may be internal or 
external. In the case of breast cancer, internal information may concern breast 
symptoms (for example, a lump) and external information may concern information 
about breast cancer. Blunting refers to the tendency to turn attention away from and 
inhibit the processing of information about stressful situations. Typically, people with a 
preference for monitoring and blunting are referred to as monitors and blunters 
respectively (Hock, Krohne, & Kaiser, 1996; Miller, Combs, & Kruus, 1993).
5.2 Minimax Hypothesis
Miller proposed the monitoring and blunting coping styles as part of the minimax and 
monitoring and blunting hypotheses (Miller, 1979b, 1989; Miller et al., 1993). In order 
to understand the way in which people cope with stressful situations, Miller proposed 
the minimax hypothesis. The hypothesis states that people are motivated to limit the
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amount of stress they have to endure. To do this, people try to minimise how stressful a 
situation can become.
5.3 Monitoring and Blunting Hypothesis
To understand how people might minimise stressfulness, Miller (1979b; 1989; 1993) 
proposed the monitoring and blunting hypothesis. This hypothesis states that in order to 
minimise the stressfulness of a situation, people may employ the two coping styles of 
monitoring and blunting. The hypothesis also states that the effectiveness of each style 
depends on the controllability of the situation. In a controllable situation, monitoring is 
most effective. A controllable situation enables people to perform actions that will 
mitigate the stressfulness of the situation. Although monitoring may involve an initial 
increase in emotional arousal as the information about the stressful situation is sought 
out, arousal will decline as the actions that will mitigate the stressfulness of the situation 
are performed.
Alternatively, in an uncontrollable situation, blunting is most effective. Monitoring will 
heighten arousal with no offsetting benefits as no actions exist that allow the 
stressfulness of the situation to be alleviated whereas blunting will enable an avoidance 
of the threat-related information and therefore will result in a reduction in arousal. It has 
also been hypothesised that by reducing arousal levels, the more relaxed way in which 
the stressful situation is experienced may serve to mitigate the stressfulness of the 
situation, although there is no empirical evidence to date that confirms this idea (Miller, 
1979b, 1989; Miller et al., 1993).
5.4. The Effects o f Monitoring and Blunting Coping
A significant amount of empirical research illustrates that monitoring and blunting 
coping styles affect the way in which stressful situations are experienced. Miller has 
proposed the Cognitive-Social Health Information Processing (C-SHIP) (Miller & 
Diefenbach, 1998; Miller, Green, & Bales, 1999c) model and the Monitoring Processing 
Model (MPM) (Andrykowski et al., 2002; Miller, Rodoletz, Schroeder, Mangan, & 
Sedlacek, 1996a; Tercyak et al., 2001) in order to outline the broad effects of 
monitoring and blunting coping. The many areas in which the coping styles are thought 
to influence include encoding, expectancies and values, psychological and physical 
wellbeing, self-regulatory strategies and coping strategies. The following section will
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outline the theory and supporting research pertaining to the influence of monitoring and 
blunting coping on these areas. Of note is that the models were developed for research 
regarding the experience of cancer patients so a significant amount of the research 
investigating monitoring and blunting concerns cancer patients.
5.4.1 Encoding
Encoding refers to the way in which the stressful situation is perceived and interpreted 
(Miller et al., 1999c). Monitors’ encoding of information about stressful situations 
appears to differ from blunters’ in two ways. Monitors perceive stressful situations to be 
more threatening and more likely than blunters. The influence of monitoring and 
blunting on encoding has been illustrated by research conducted in the laboratory and in 
the medical setting. In the laboratory setting, a sample of undergraduate students were 
asked to complete measures of monitoring and blunting and trait anxiety before rating 
the perceived threatfulncss of a range of situations varying in stressfulness, 
controllability and predictability. After controlling for trait anxiety, the results reveal 
that monitors perceived all situations as more threatening than blunters (Muris & de 
Jong, 1993). The same results were reported in a second sample of women from the 
general population (Muris, de Jong, & Suvrijn, 1995a).
In the medical setting, a sample of gynaecological patients from a low socio-economic 
and minority background were recruited. They had all received an abnormal Pap smear 
result and were scheduled to undergo a follow-up diagnostic procedure. Patients were 
asked to report their level of concern about the seriousness of their medical condition 
and its future course. The results showed that monitors were more concerned about the 
seriousness of their condition and its future course than blunters (Miller, Roussi,
Altman, Helm, & Steinberg, 1994). Similar results were reported in a sample of patients 
attending a health clinic with acute illness symptoms. The results revealed that monitors 
reported similar levels of concern about the seriousness of their condition and its future 
course as blunters, despite having less self- and doctor-rated dysfunction and discomfort 
than blunters. That is, they attended clinics at an earlier stage of illness but were still 
significantly distressed (Miller, Brody, & Summerton, 1988).
Not only do monitors perceive stressful situations to be more threatening, they also 
consider them more likely. Studies of people at an increased risk of cancer have
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consistently reported greater perceived risk of developing cancer in monitors compared 
to blunters. One study asked women at risk of developing ovarian and/or breast cancer 
to estimate their perceived risk of developing the cancer. The results revealed that 
monitoring was associated with a significantly higher level of perceived risk (Schwartz, 
Lerman, Miller, Daly, & et al., 1995). Further, in a study of women undergoing a 
routine mammogram, monitors reported a higher level of perceived risk than blunters 
regardless of whether they had a family history of cancer (Zakowski et al., 1997).
One study failed to find a relationship between coping styles and perceived risk. A 
sample of women attending an ovarian cancer clinic for genetic counseling reported 
their coping styles, family history, and distress prior to consultation. Participants were 
divided into those who under, over and accurately estimated their levels of perceived 
risk. When comparing the groups, only distress was associated with over estimation of 
perceived risk compared to under or accurate estimation of risk. Future research is 
needed to consider the full range of estimated risk rather than the comparison of groups 
(Cull, Fry, Rush, & Steel, 2001).
Indirect evidence that monitors perceive stressful situations as more threatening and 
more likely may be considered to come from recent research regarding coping styles 
and the performance of health promoting behaviours. In one study participants were 
offered the opportunity to undergo a range of genetic tests. It was found that those high 
in monitoring were more interested in genetic testing than those who were low in 
monitoring (Shiloh, Ben-Sinai, & Keinan, 1999). In a second study, a sample of 
students and the community participated in a study in which they were asked to indicate 
the extent to which they engage in a range of health promotion and disease detection 
behaviours. The results indicated that participants reporting the use of the monitoring 
coping style reported more engagement in both health promotion and disease detection 
behaviours (van Zuuren & Dooper, 1999).
These results are particularly pertinent to women diagnosed with EBC. It has been 
consistently demonstrated that perceived risk of recurrence is one of the major concerns 
of women with EBC (Curran et al., 1998; Dow et al., 1996; Tomich & Helgeson, 2002). 
Risk perceptions are often highest once active treatment has been completed (Lethborg, 
Kissane, Burns, & Snyder, 2000). At this point, many women feel vulnerable to
89
recurrence as they are no longer engaged in treatments that are working to reduce their 
risk. As such, risk perceptions are strongly associated with distress at the beginning of 
survivorship and after many years (Curran et al., 1998; Dow et al., 1996; Johnson 
Vickberg, 2001; Kissane et al., 1997; Tomich & Helgeson, 2002; Wenzel et al., 1999). 
Recent attempts to reduce risk perceptions via education about objective risk of 
recurrence have been of limited success (Kent, Howie, Fletcher, Newbury-Ecob, & 
Hosie, 2000; Weinstein et al., 2004). Indeed, it has been argued that risk perceptions are 
based on psychological factors (Weinstein et al., 2004), perhaps one of which is coping 
style.
5.4.2 Expectancies and Values
The second area in which the coping styles affect the experience of stressful situations 
consists of expectancies and values about one’s ability to deal with the stressful 
situation. Miller (1999c) has claimed that monitors are less confident in their own 
ability to cope with stressful situations and instead are more confident in others’ 
abilities than blunters. In other words, monitors appear to have less internal and more 
externally oriented locus of control beliefs. Locus of control beliefs refer to the extent to 
which the outcomes of stressful situations are controlled by a person’s actions (internal 
locus of control) or by external factors such as luck, fate or chance (chance locus of 
control) and other more competent people (powerful others locus of control). In the case 
of the health setting, these people might consist of family, friends, or health 
professionals such as doctors and nurses (Wallston, Wallston, Kaplan, & Maides, 1976; 
Wallston, 1989; Wallston, Stein, & Smith, 1994).
In a laboratory setting, undergraduate students were asked to report on coping styles, 
locus of control beliefs and coping strategies commonly used in stressful situations. The 
results indicated a positive association between monitoring and internal locus of control 
but no relationship with external locus of control beliefs (van Zuuren & Wolfs, 1991). 
Further support has been reported in studies performed in the medical setting. In a study 
described previously, it was reported that patients attending a health clinic for acute 
illness symptoms reported greater concern about their condition and its future course. 
The results also showed that despite their concern, monitors preferred to take a passive 
role in decision-making regarding the treatment options for the illness compared to 
blunters (Miller, 1988).
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Similarly, indirect support for this idea comes from an intervention study of dental 
patients. Patients undergoing dental treatment were given headphones which instructed 
them to focus on using either monitoring or blunting coping strategies. Although there 
was no effect of coping style on experience of anxiety, pain or distress during treatment, 
the use of monitoring was associated with enhanced self-efficacy (Muris, de Jongh, van 
Zuuren, Ter Horst, & et al., 1995b).
Conversely, some research has suggested that monitoring is associated with more 
external locus of control beliefs while blunting is associated with more internal locus of 
control beliefs. Women who had recently received a diagnosis of EBC reported their 
preferred level of decisional control. Those patients with a coping style consisting of 
low cognitive avoidance and high behavioural approach (which may be considered 
similar to monitoring) reported a significantly more active role in decision-making than 
patients with a moderate to high cognitive avoidance and low to moderate approach 
coping style (Hack & Degner, 1999).
Indirect support for the idea that monitors have chance and powerful others locus of 
control beliefs and blunters have internal locus of control beliefs comes from a study of 
women from the general population. Women reported their locus of control beliefs, 
perceived risk, and breast cancer screening behaviour. The results showed that internal 
locus of control beliefs were associated with low levels of perceived risk. As stated, low 
perceived risk is characterised by blunting and therefore, it may also be the case that 
blunting is also associated with internal locus of control beliefs (Rowe, Montgomery, 
Duberstein, & Bovbjerg, 2005).
Perhaps monitoring is equally associated with both internal and powerful others locus of 
control. In line with the minimax hypothesis, it may be hypothesised that in controlling 
situations monitors’ information seeking enables them to discern actions that will 
mitigate the stressful situation, thus enhancing internal locus of control beliefs. 
Alternatively, in uncontrollable situations monitors’ information seeking makes them 
keenly aware of their limitations in controlling stressful situations, thus enhancing 
powerful others locus of control beliefs (Miller et al., 1988). Future research is needed 
to clarify this point.
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When considering women diagnosed with EBC, it has been clearly shown that locus of 
control beliefs have an important role in the engagement in health care decision-making 
and health promotion and disease prevention behaviours. For example, it has been 
shown that those with more internal locus of control beliefs prefer an active role in 
decision-making with medical professionals while those with more chance and powerful 
others locus of control beliefs prefer medical professionals make decisions regarding 
patients’ health care (Helmes, Bowen, & Bengel, 2002). In addition, it has been shown 
that an internal locus of control is associated with participation in cancer screening 
(Aro, de Koning, Absetz, & Schreck, 1999; Borrayo & Guarnaccia, 2000; Bundek, 
Marks, & Richardson, 1993; Fajardo, Saint-Germain, Meakem, Rose, & Hillman, 1992; 
Franco et al., 2000; Glenn & Moore, 1990; Murray & McMillan, 1993; Patterson et al., 
2003) and healthy lifestyle behaviours (van Zuuren & Dooper, 1999).
5.4.3. Psychological and Physical Wellbeing 
The third area in which monitoring and blunting are thought to affect information 
processing of stressful situations is psychological and physical wellbeing. It is perhaps 
unsuiprising that monitors, with their tendency to encode stressful situations as more 
threatening and likely and less controllable, report poor psychological and physical 
wellbeing in response to stressful situations compared to blunters. Monitors report 
poorer wellbeing in response to the initiation of a stressful situations and this distress is 
maintained over time while blunters report less distress and this distress declines 
gradually throughout the stressful situation (Miller, 1996; Miller et al., 1993; Miller et 
al., 1999c).
In the laboratory studies previously outlined, students were told they might receive an 
electric shock and they could listen to an audio channel that provides information about 
the shock or music. At the start of trials, monitors reported more anxiety and recorded 
greater physiological arousal than blunters. Across the trials, monitors maintained these 
levels of anxiety and arousal but blunters lower levels gradually declined over time 
(Miller, 1979b; Miller, 1987).
In a sample of women diagnosed with breast and/or ovarian cancer and their relatives 
were tested for the presence of two genetic mutations that increase the risk of these
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cancers. Participants were asked to report their monitoring coping style and levels of 
psychological distress pre- and post-test results. The results showed that those scoring 
high on monitoring reported greater distress pre-test but not post-test (Tercyak et al., 
2001). Similar results were reported in a second study previously outlined. Children 
who had undergone invasive dental procedure reported their coping styles, use of 
monitoring and blunting strategies and levels of distress. A preference for monitoring, 
especially those with a preference for both monitoring and blunting, displayed higher 
levels of self- and observer-rated anxiety than those with a preference for blunting or 
neither monitoring nor blunting (Miller, Roussi, Caputo, & Kruus, 1995).
Further studies were conducted in which patients’ levels of distress were assessed 
throughout a more prolonged stressful situation. A study outlined in which patients with 
acute illness symptoms attended a clinic and rated their levels of distress, discomfort, 
and symptom improvement prior to and five days post-medical consultation. Monitors 
showed more distress and discomfort prior to and following the consultation compared 
to blunters (Miller et al., 1988).
Similarly, the experience of and recovery from an invasive diagnostic procedure was 
investigated in a sample of gynaecological patients. Subjective, physiological and 
behavioural measures of distress were measured before, during and following the 
procedure. Monitors continued to report more pain and discomfort in the week 
following the procedure than blunters (Miller & Mangan, 1983). Interestingly, half of 
the participants received voluminous information and the other half received minimal 
information about the procedure. Greater subjective and physiological arousal was 
reported by patients who received the information intervention inconsistent with their 
coping style. That is, monitors and blunters were more distressed when they received 
minimal and voluminous information respectively (Miller & Mangan, 1983).
Patients with a range of cancer diagnoses reported their levels of anxiety, depression, 
nausea and vomiting before, during, and following chemotherapy treatment. The results 
showed that monitoring was associated with more anxiety and nausea before and during 
chemotherapy whereas blunting was significantly and positively associated with less 
anxiety, depression and nausea before, during and following chemotherapy (Lerman et 
al., 1990). A follow-up study examined a sample of women with a family history of
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breast cancer undergoing either an individualised breast cancer risk counselling session 
or a general health education session. Again, the results showed that monitoring was 
associated with heightened psychological distress up to 3 months post-sessions, 
regardless of session type (Lerman et al., 1996).
These results are of great importance as they provide some possible explanation of the 
variation in physical and psychological wellbeing reported by women with EBC 
undergoing treatment, particularly for those who experience poor wellbeing during and 
many months following treatment (Beisecker et al., 1997; Bower et al., 2000; Castellon 
et al., 2005; de Jong et al., 2002b; Failed et al., 2005; Frost et al., 2000; Jansen et al., 
2005; NHMRC & NBCC, 2001; Nordin et al., 2001; Sadler & Jacobsen, 2001; Schagen 
et al., 1999; Schou et al., 2004).
Even studies in which participants were instructed to employ a monitoring or blunting 
coping style, despite their dispositional preferences, found that monitoring was 
associated with greater distress. A sample of undergraduate students was instructed to 
employ monitoring or blunting coping strategies when exposed to a series of aversive 
slides. Dispositional coping styles, subjective ratings of psychological distress and 
objective ratings of physiological arousal were recorded. After controlling for the 
influence of coping style, monitoring was associated with greater subjective distress but 
not objective arousal (Muris, De Jong, Merckelbach, & van Zuuren, 1994a).
A second study was conducted in which patients undergoing invasive dental work were 
instructed to use monitoring and blunting coping. Patients reported on the levels of 
anxiety, pain and distress they experienced during the treatment. The results 
contradicted that of the previous study. There was no effect of imposed coping style on 
anxiety, pain or distress (Muris et al., 1995b). It is possible that there are differences in 
the extent to which patients were able to adhere to the coping strategies dictated which 
may have accounted for the contradictory results.
5.4.4 Self-Regulatory Strategies
Miller (1998; 1999c; 1996a) states that the declines in psychological and physical 
wellbeing reported by monitors are due to the engagement in certain self-regulatory 
strategies. Self-regulatory strategies refer to efforts aimed at dealing with the stressful
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situation and consist of the use of intrusive and avoidant ideation. Monitors’ encoding 
of stressful situations as highly threatening and high likely means that they experience 
greater levels of distress than blunters. This distress is maintained due to the activation 
of intrusive ideation. Intrusive ideation consists of persistent, automatic thoughts, 
feelings and images activated in conscious awareness about a stressful situation.
According to Horowitz and colleagues’ (Horowitz, Field, & Classen, 1993; Horowitz, 
Wilner, & Alvarez, 1979) model of the stress response, intrusive ideation is a necessary 
experience of adjusting to and assimilating information about the stressful situation. 
Intrusive ideation enables people to review the information about the stressful situation 
experienced and incorporate it into existing knowledge about the self and world. 
Sometimes, the nature of the stressful situation means that information about the 
situation is at odds with the existing knowledge about the self and world. In this case, 
intrusive ideation is continually experienced in working memory until the discrepancy is 
resolved and the information assimilated.
In response to this elevated distress, it is further proposed that a second self-regulatory 
strategy is triggered. Avoidant ideation refers to attempts to avoid the review of 
information caused by intrusive ideation in order to reduce distress. Examples of 
avoidant ideation might include strategies to suppress, distract or deny the intrusive 
thoughts. While avoidant ideation may be effective in reducing distress in the short­
term, they cannot prevent the experience of intrusive ideation in the longer term. This is 
because as stated, intrusive ideation will be continually experienced until processing of 
the experience is complete. It is thought that the reduction in distress through avoidance 
strategies means avoidance efforts are relaxed, which in turn results in the recurrence of 
the information into working memory (Diefenbach, Miller, & Daly, 1999; Horowitz et 
al., 1993; Miller, 1996; Miller et ah, 1993; Miller & Diefenbach, 1998).
Therefore, the experience of intrusive and avoidant ideation forms a vicious cycle in 
which arousal is maintained and the stressful situation is not processed. This cycle of 
intrusive and avoidant ideation will continue until the information is processed 
sufficiently to warrant a resolution of the new information into the existing schemas. 
The arousal caused by the cycle will in turn, facilitate the experience of intrusive and
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avoidant ideation (Diefenbach et al., 1999; Horowitz et al., 1993; Miller, 1996; Miller et 
al., 1993; Miller & Diefenbach, 1998).
Empirical evidence shows that monitoring is associated with the use of intrusive and 
avoidant ideation. In a sample of gynecological patients undergoing an invasive 
diagnostic procedure previously described, monitors reported higher levels of intrusive 
thoughts and avoidance compared to low monitors (Miller et al., 1994). Similarly, the 
relationships between monitoring, intrusive and avoidant ideation, and distress were 
examined in women at increased risk of ovarian cancer. All patients had at least one 
first-degree relative that had been diagnosed with the disease. The results showed that 
monitoring predicted increased levels of intrusive ideation, which in turn, predicted 
increased distress (Schwartz et al., 1995).
Miller and colleagues (Miller et al., 1996a) conducted similar research in women with 
human papilomammary virus (HPV), a virus which increases the risk of cervical cancer, 
and men who were HIV positive. The results indicated that monitoring was associated 
with intrusive ideation, both of which in turn predicted distress. The relationships 
between monitoring, intrusive and avoidant ideation and distress were stronger in the 
sample of men than women. This is expected given that the effects of monitoring and 
blunting are thought to be more evident in highly stressful situations and HIV is 
considered a more serious condition than HPV. Further, although they did not 
investigate the role of monitoring and blunting, two studies have confirmed the 
relationships between intrusive and avoidant ideation and distress in samples of women 
undergoing infertility treatment compared to healthy controls (Miller et al., 1998) and 
women with and without a history of breast cancer undergoing a routine mammography 
(Zakowski et al., 1997).
As suggested, adjustment to a stressful situation coincides with a reduction in the levels 
of intrusive and avoidance ideation and distress. Women at high risk of developing 
breast and/or ovarian cancer underwent genetic counseling and received either an 
enhanced genetic counseling information session or a general health information 
session. The results demonstrated that those who underwent the enhanced session 
reported a decline in levels of intrusive, avoidance and distress one-week post­
intervention compared to those who underwent the general session. Thus, it is suggested
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that the provision of enhanced information facilitated the understanding and 
assimilation of information about genetic risk and therefore, a reduction in intrusive and 
avoidant ideation and distress (Miller et al., 2005). Clearly, the cross-sectional nature of 
the assessment of intrusive, avoidance and distress mean that it is impossible to 
determine whether the relationships are causal in these studies.
The results appear to be of particular relevance to women diagnosed with EBC, many of 
whom have reported declines in physical and psychological health over an extended 
period of time. It is possible that it is not only coping styles but the consequent use of 
the self-regulation strategies of intrusive and avoidant ideation that serve to maintain the 
levels of poor wellbeing (Beisecker et al., 1997; Bower et al., 2000; Castellon et al., 
2005; de Jong et al., 2002b; Failed et al., 2005; Frost et al., 2000; Jansen et al., 2005; 
NHMRC & NBCC, 2001; Nordin et al., 2001; Sadler & Jacobsen, 2001; Schagen et al., 
1999; Schou et al., 2004).
5.4.5. Coping Strategies
As indicated, monitoring and blunting coping styles are fairly stable dispositional 
attributes that are thought to influence the actual coping strategies utilized in stressful 
situations. This has been demonstrated in a series of studies confirming that monitoring 
and blunting coping styles are associated with corresponding coping strategies. For 
example, monitoring has been shown to be associated with the corresponding coping 
strategies of control-predictability coping, seeking social support and active coping 
(Ben-Zur, 2002; Shiloh et al., 1999). Blunting has been associated with the 
corresponding coping strategies of avoidance, wishful thinking and escape (Ben-Zur, 
2002; Shiloh et al., 1999; van Zuuren & Wolfs, 1991). Then again, monitoring has also 
been linked to the coping strategies of wishful thinking and escape, strategies indicative 
of blunting coping (van Zuuren & Wolfs, 1991). Some of this research has then 
demonstrated that coping styles affect psychological distress via the coping strategies 
(Ben-Zur, 2002; Shiloh et al., 1999).
5.4.6 Conclusions
There is a significant amount of research investigating the experience of stressful 
situations in regards to monitoring and blunting coping styles. The results of the studies 
have indicated that monitoring and blunting are associated with different ways of
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responding to stressful situations. Monitoring is associated with the perception that 
stressful situations are more threatening and likely, more external locus of control 
regarding stressful situations, elevated levels of psychological and physiological 
distress, intrusive and avoidant ideation, and perhaps certain coping strategies, 
compared to blunters.
While these findings are significant in terms of understanding the variation in 
experience of stressful situations, there are some consistent methodological problems 
with the research. Small samples are common which may have affected the results 
reported (Miller & Mangan, 1983; van Zuuren, 1993, 1994), although the difficulties of 
recruiting a clinical sample are widely acknowledged. Despite claims that monitoring 
and blunting are orthogonal coping styles, much research has simply investigated those 
that report a preference for monitoring (Miller et al., 1996a; Schwartz et al., 1995; 
Tercyak et al., 2001). Therefore, little is known about the outcomes of preferring both or 
neither monitoring and blunting.
This trend is due in part to the initial methods of measuring monitoring and blunting. 
Early research investigated monitoring and blunting as a single dimension with high 
monitoring/low blunting at one end (known as monitors) and low monitoring/high 
blunting at the other (blunters) (Miller, 1987). In an attempt to overcome this, it has 
been suggested that people are categorised into one of four coping styles: high 
monitoring/low blunting, high monitoring/high blunting, low monitoring/high blunting, 
and low monitoring/low blunting (Krohne, 1989; McKinnon, 2001; Miller, 1996; Miller 
et al., 1993). Given the small samples, this method was not widely employed.
Alternatively, cluster analysis has been used to investigate the coping styles that exist in 
a sample and typically, the analysis has demonstrated similar results to the four styles 
described (Hack & Degner, 1999; Shapiro et al., 1997; Voss, Rolling, & Heidenreich, 
2006). More recent research has considered the two styles as separate dimensions, and 
reported on the outcomes of a preference or lack of preference for monitoring and/or 
blunting (Krohne, 1993; Miller et al., 1995).
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5.5 Adaptiveness of Monitoring and Blunting Coping 
5.5.1 Advantages of Monitoring
Reasons for preferring a monitoring coping style are manifold. As stated in the 
monitoring and blunting hypothesis, monitoring in controllable stressful situations may 
enable people to determine and perform actions that will minimise the stressfulness of 
the situation. Empirical evidence exists that monitors’ information seeking may have 
helped them to engage in adaptive actions that reduced the stressfulness of situations 
(Miller et al., 1993; Roth & Cohen, 1986). In one study, women at increased risk of 
ovarian cancer were offered a medical procedure that lowers risk. After the provision of 
information, high monitors appeared to use the information to make an adaptive 
decision about the procedure compared to low monitors. Significantly more high 
monitors chose not to have the procedure, an adaptive decision given that none of the 
women were medically appropriate candidates for the procedure (Fang, Miller, Daly, & 
Hurley, 2002). Also, monitoring has been associated with the tendency to perform 
health promotion behaviour such as getting regular medical check-ups, participating in 
regular exercise, and following a healthy diet (van Zuuren & Dooper, 1999).
Alternatively, monitoring may enable people to identify actions that others can perform 
to reduce the stressfulness of the situation. Indeed, it has been proposed that information 
seeking may allow monitors to instigate and maintain contact with these more 
competent people (Miller, 1996; Miller et al., 1993). This may explain the contradictory 
associations between monitoring and internal and external locus of control beliefs. That 
is, monitoring may provide information regarding what actions need to be performed by 
whom to effectively deal with the stressful situation. However, there is evidence that 
contradicts this idea. People who prefer to monitor have been found to do so even in 
situations that do not allow instrumental actions to be undertaken (Miller, 1979a).
Several additional benefits of monitoring have been proposed, but limited research 
exists to support the idea. It is possible that people engage in monitoring to gain 
information regarding the severity, probability, nature, and duration of the stressful 
situation. This reduces uncertainty and identifies safety signals, both of which serve to 
reduce arousal (Krohne, 1993; Miller et al., 1993; Shiloh et al., 1999). Another benefit 
is that monitoring may allow people to develop a sense of personal meaning about their 
experience in stressful situations. It has been shown that people who have a sense of
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meaning about their experiences report lower levels of distress or greater adjustment 
than those who are not able to (Thompson, 1981). This proposition relates to the idea 
outlined that monitoring allows the activation of intrusive ideation which in turn, 
facilitates the emotional processing of stressful situations, which has received some 
support in the empirical literature (Manne, Glassman, & Du Hamel, 2001; Miller et al., 
2005; Schwartz et al., 1995).
5.5.2 Disadvantages o f Monitoring
Despite the number of potential benefits of monitoring, there are several disadvantages 
to consider. Research involving a range of settings and samples has shown that 
monitoring tends to lead to increased distress (Miller, 1979b; Miller et al., 1996a; Miller 
et al., 1995; Muris & de Jong, 1993; Schwartz et al., 1995; Tercyak et al., 2001; van 
Zuuren, 1993). The association between monitoring and elevated distress has led Miller 
to speculate on two disadvantages of this coping style, although little or no evidence 
exists to support these ideas as yet. First, it has been suggested that this heightened level 
of distress may inhibit monitors from engaging in appropriate coping responses. Miller 
provides an example of this in the medical setting. She explains that a high level of 
distress may encourage monitors to seek help for illness too readily. This may then have 
unintended negative consequences whereby monitors may be considered an annoyance 
by health professionals resulting in them being ignored when their need is real and 
urgent (Miller, 1996).
Second, it has also been hypothesised that monitoring may put people at risk of 
developing anxiety disorders (Miller, 1992). At least one study of children has 
suggested that a monitoring style is associated with more symptoms of anxiety disorders 
(Muris et al., 2000). If a monitoring coping style does increase the risk of anxiety 
disorders, it might be expected that it affects the outcomes of therapy. To date, evidence 
of both short- and long-term therapeutic outcomes in people with a spider phobia has 
been mixed, with studies showing no influence of coping styles (Muris et al., 1993), a 
favourable effect of monitoring (Steketee, Bransfield, Miller, & Foa, 1989) and an 
unfavourable effect of monitoring (Muris, de Jong, Merckelbach, & Van Zuuren, 1993a; 
Muris, Merckelbach, & de Jong, 1995c).
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5.5.3 Advantages o f Blunting
On the other hand, a preference for blunting tends to result in lower levels of distress in 
response to stressful situations. In turn, this may enable blunters to gradually approach 
the situation, rather than becoming highly aroused and overwhelmed by it. This may 
then facilitate other positive experiences such as enabling a sense of hope and mastery 
throughout the situation. At present no research has been conducted to confirm these 
ideas (Roth & Cohen, 1986).
5.5.4 Disadvantages o f Blunting
There are also some possible disadvantages of blunting. A preference for blunting may 
put people at risk of failing to identify stressful situations. In cases where the threat is 
identified, blunting may also interfere with the collection of information regarding the 
execution of coping responses necessary to reduce the stressfulness of the situation. An 
example Miller provides from the medical setting is the presentation of illness at such a 
late stage that the appropriate treatment is not received. Although past research has 
shown that blunters attending a health clinic for acute illness symptoms present at a 
later stage than monitors, it is not known whether this later stage is appropriate to the 
illness experienced, or whether it was too late for effective treatment. Further research is 
needed to clarify this point. There is also concern that blunting may result in emotional 
numbness and disruption to the processing of and adjustment to the stressful situation 
(Roth & Cohen, 1986). The limited research investigating longer term stressful medical 
situations does indicate that blunters adjust better than monitors (Lerman et al., 1996; 
Miller, 1988; Miller & Mangan, 1983).
5.6 Effectiveness o f Monitoring and Blunting Coping
Overall, it is hypothesised that monitoring and blunting coping are most effective when 
individuals are able to flexibly apply them in accordance with the characteristics of 
stressful situations. This would maximise the benefits and minimise the costs of 
employing each coping style. According to the monitoring and blunting hypothesis, this 
refers to the deployment monitoring strategies when the situation is controllable and 
blunting strategies when the situation is uncontrollable. Further, it has been suggested 
that the use of both styles within controllable and uncontrollable situations would be the 
most adaptive. For example, people could use monitoring for long enough to implement 
problem-solving strategies but also distract themselves with blunting periodically in
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order to modulate levels of distress (Krohne, 1993; Miller et al., 1999c; Roth & Cohen, 
1986; Voss et al., 2006). Evidence that people can be taught to use monitoring and 
blunting coping makes it likely that future coping interventions will be designed and 
implemented to enhance outcomes of stressful situations (Muris et al., 1994a; Muris et 
al., 1995b).
However, the extent to which coping styles can be flexibly employed may be 
constrained by dispositional preferences for monitoring and blunting as well as personal 
and situational characteristics. In the first instance, it has been shown that although 
coping styles employed varied slightly according to beliefs about the extent to which 
electric shocks were avoidable, a number of participants still employed their 
dispositional coping style (Miller, 1979b). Situational factors may include the 
controllability, probability and predictability of stressful situations. For example, Miller 
suggests that stressful situations that are highly controllable and probable, highly 
threatening, imminent and of long duration are difficult to blunt as they are so 
confronting when compared to situations that are improbable, relatively unthreatening, 
remote and of short duration (Miller, 1979b, 1990). Person-specific characteristics may 
include the ability to accurately perceive these characteristics in stressful situations 
(Krohne, 1993). Further research is needed to gain an understanding of these factors and 
the extent to which they constrain the flexible use of monitoring and blunting.
5.7 Mechanisms of Monitoring and Blunting Coping
There is some speculation as to why people display a particular coping style. Miller has 
not provided an explicative basis for the coping styles, leaving other theorists to propose 
potential mechanisms of monitoring and blunting but little empirical research has been 
conducted to investigate these propositions. The most coherent approach is outlined by 
Krohne (1989), who states that people experience arousal in response to stressful 
situations for two reasons: the presence of ambiguity and aversive stimuli. Ambiguity 
triggers arousal because it signals uncertainty as to what the situation involves and how 
best to cope with it. Aversive stimuli trigger emotional arousal because they signal the 
unpleasant effects of the stressful situation (Hock et al., 1996; Krohne, 1989; Krohne, 
1993).
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The experience of uncertainty can prompt concerns about the nature, severity, 
predictability, controllability, and duration of the stressful situation, a response that may 
be called a ‘fear of danger’. Alternatively, the experience of arousal might lead to 
concerns about further unbearable increases in arousal, a response called a ‘fear of fear’. 
Krohne believes that people differ dispositionally in the extent to which they are 
tolerant of uncertainty and emotional arousal. Although these are separate dimensions of 
tolerance, intolerances of uncertainty and emotional arousal are difficult to regulate 
simultaneously. That is, monitoring may reduce uncertainty but also increase in 
emotional arousal while blunting may reduce emotional arousal but also increase 
uncertainty. People with a low tolerance of uncertainty will be motivated to employ a 
monitoring coping style while people with a low tolerance of emotional arousal will be 
motivated to employ a blunting style. Given that people are thought to dispositionally 
vary in their intolerance of uncertainty and arousal, they are also presumed to 
dispositionally vary in monitoring and blunting coping styles (Hock et al., 1996;
Krohne, 1989; Krohne, 1993; Wilson, 1984).
People with neither a monitoring nor blunting style are tolerant of both uncertainty and 
emotional arousal. They are thought to be able to flexibly apply monitoring or blunting 
according to the situation demands and therefore, are considered to be the most effective 
copers (Hock et al., 1996; Krohne, 1989; Krohne, 1993). Alternatively, people who 
display both a monitoring and blunting style are intolerant of both uncertainty and 
emotional arousal. They experience negative consequences when employing either 
monitoring or blunting which leads to the erratic deployment of the coping styles and 
for short durations. Adhering to one style becomes intolerable, so they are motivated to 
switch styles before discovering if the coping style is effective for the given situation.
Aside from Krohne’s (1989; 1993) theory, numerous and diverse propositions have 
been made that attribute the effects of monitoring and blunting to differences in 
perception and cognition. First, it has been said that monitoring is associated with 
greater sensitivity in the perception of physiological arousal. That is, they can detect 
changes in somatic arousal more quickly. This suggestion was prompted by evidence 
suggesting that monitors seek medical advice earlier in illness than blunters (Miller, 
1988).
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Two studies have investigated this assertion. Women completing stressful arithmetic, 
drawing and cold-presser tasks were asked to indicate the level and change in somatic 
arousal. The results indicated that monitors were no more accurate in their estimations 
than people who did not prefer to monitor, although questions regarding the accuracy of 
the measures of somatic arousal were raised (Steptoe & Voegele, 1992). In a similar 
study of participants completing stressful tasks, the results showed there was no 
relationship between monitoring and blunting and the accuracy of somatic arousal 
perception (Steptoe & Noll, 1997).
It has also been suggested that monitoring is associated with an increased attentional 
bias towards threat. That is, monitors attend more to threat-relevant information in the 
environment. Attentional bias was examined in a sample of female undergraduate 
students completing a series of Stroop tasks: a colour-naming, neutral word, and dental 
treatment-word tasks. After accounting for trait and dental anxiety, there was no effect 
of coping style on performance (Muris, Merckelbach, & de Jongh, 1995d).
The effects of monitoring, some suggest, are due to a greater capacity for imagining or 
elaborating on threat-relevant information. A sample of women was presented with a 
list of written stressful situations. They were instructed to indicate the extent to which 
they were able to imagine and elaborate on the situations described. There existed no 
association between monitoring and blunting and the capacity to imagine or elaborate 
on stressful situations (Muris et al., 1995a). Further research is needed to determine 
whether this finding is replicated when experiencing stressful situations rather than just 
reading about them.
In a similar vein, it has also been proposed that monitoring is associated with a reduced 
capacity for controlling thoughts. Interestingly, in a study of people with dental phobia, 
results indicated that monitoring was associated with less ability to control thoughts 
(Muris, De Jongh, van Zuuren, & ter Horst, 1994b). An extension of this study 
compared people with dental phobia and controls. Results indicated that monitoring was 
positively associated with the frequency and believability of negative thoughts about 
dental treatment and negatively with the ability to control these thoughts. On the other 
hand, blunting was negatively associated with frequency and believability of thoughts
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but positively with cognitive control (Muris, De Jongh, Van Zuuren, & Schoenmakers,
1996) .
Others have suggested that monitoring is not a unique construct but rather taps into 
existing constructs that are associated with increased somatic perception, such as trait 
anxiety, hypochondriasis, or medical fears (Muris & Van Zuuren, 1992; Muris et al., 
1994c; Muris, van Zuuren, & de Vries, 1994d; Steptoe & Voegele, 1992). Research has 
shown that people with high levels of trait anxiety attend more to body symptoms. To 
date, evidence exists that monitoring and trait anxiety are unrelated (Muris et al., 1994c; 
Steptoe & Voegele, 1992) although significant but small associations have been 
reported on occasion (Kohlmann, 1993; van Zuuren et al., 1999). This idea also 
contradicts evidence suggesting that monitors and blunters experience equivalent levels 
of arousal in situations of low threat (Miller, 1979b). If high monitoring merely 
reflected high trait anxiety, differences in anxiety levels would be evident in both high 
and low threat situations.
Similarly, it has been shown that people with hypochondriasis amplify existing body 
symptoms (Steptoe & Voegele, 1992). There is only one study to date which has 
investigated the relationship between perception of somatic arousal, hypochondriasis 
and monitoring and blunting coping styles. In a small sample of people instructed to 
assess their somatic arousal during periods of relaxation and stressful cognitive tasks, 
results indicated there was no relationship between the three constructs (Steptoe & Noll,
1997) . Further research is needed to investigate this idea using a clinical sample.
Given that much of the research on monitoring and blunting has been carried out 
regarding stressful medical situations, it has been argued that monitors’ heightened 
arousal levels can simply be explained by monitors’ fear of medical situations. There is 
evidence that supports this assertion. In studies of undergraduate students, monitoring 
has been associated with more fears of medical events (Muris et al., 1994d) and blood 
injury (Muris & Van Zuuren, 1992). However, it may be that monitors are conditioned 
to fear medical situations as their coping style means they typically experience these 
situations with great distress and it is this conditioned response that accounts for the 
association (Muris et al., 1994d).
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In all of the research conducted to assess whether the effects of monitoring and blunting 
can be accounted for by related constructs, there are significant methodological issues. 
The most common are the use of small, undergraduate samples, the use of either written 
hypothetical or laboratory-based situations, and the relationships between monitoring 
and the related constructs are investigated cross-sectionally. Further research is needed 
to overcome these shortcomings and hence, clarify the relationship between the 
constructs.
5.8 Measures of Monitoring and Blunting Coping
Several measures of monitoring and blunting have been developed that are similar in 
format and content. The first measure developed was the Miller Behavioral Style Scale 
(MBSS: Miller, 1987). It consists of descriptions of four stressful situations that are 
thought to vary in controllability and predictability. Each situation is followed by three 
monitoring and three blunting responses. Participants are asked to indicate the extent to 
which they believe they would employ each option on a five-point Likert scale. The 
scale yields two subscale scores of monitoring and blunting with higher scores 
indicating more use of the coping style. Mean split procedures are used to determine 
those with high/low monitoring and high/low blunting coping styles or scores are 
utilised as continuous variables.
Originally, the MBSS utilised a dichotomous true/false response format and subscale 
scores were collapsed across styles to provide an overall continuum with monitoring 
and blunting at either ends. The response format was criticised as offering little scope 
for variations in responses. The revised Likert scale version of the MBSS has 
demonstrated superior internal consistency to the dichotomous version (Muris et al., 
1994e; van Zuuren & Wolfs, 1991).
Several versions of the MBSS have been developed. The MBSS has been translated into 
Spanish with some success (Miro, 1997). At times, researchers have utilised only a 
selection of stressful situations in a measure in order to create a short-form version 
(Miro, 1997). This contradicts the purpose of providing a range of stressful situations 
that differ on important dimension (van Zuuren, 1994; van Zuuren et al., 1996) and 
perhaps unsurprisingly has received limited empirical support (Miro, 1997). A version 
for children, known as the Monitoring and Blunting Scale for Children (MBSC), has
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also been developed and its limited use to date indicates adequate psychometric 
properties (Miller et al., 1995; Muris, Merckelbach, Gadet, & Meesters, 2000).
The Threatening Medical Situations Inventory (TMSI: van Zuuren et al., 1996) was 
developed for use in populations facing stressful health situations. The MBSS was 
developed in response to feedback from respondents who reported frustration at the 
scale’s focus on what they considered to be irrelevant situations given the seriousness of 
their issues (Steptoe, 1989). Similar to the MBSS, the TMSI involves the description of 
four hypothetical stressful situations that differ in degree of threat, controllability and 
predictability. There are both Dutch and English versions of the TMSI. Much less 
utilised are the Mainz Coping Inventory (MCI) (Krohne, 1989), the Monitoring- 
Blunting Questionnaire (MBQ: Muris et al., 1994c), and the Frankfurt Monitoring 
Blunting Scale (Voss et al., 2006), all of which were developed as alternatives to the 
MBSS in measuring monitoring and blunting coping styles across general stressful 
situations, although little is known about their psychometric properties as they have not 
been widely utilised in empirical research.
Most scales demonstrate adequate internal reliability of .60-.87 (Miro, 1997; van 
Zuuren et al., 1996) and test-retest reliability of .71-.83 with a two to five week period 
(Miro, 1997; Rees & Bath, 2000; van Zuuren et al., 1996). Poor internal reliabilities for 
the blunting subscales have been reported (Bijttebier et al., 2001; Muris et al., 1994c; 
Rees & Bath, 2000). Several people have suggested that blunting consists of more and 
varied coping responses than monitoring and that this complexity may not be 
adequately represented in the scales (Bijttebier et al., 2001; Muris & Schouten, 1994; 
van Zuuren, 1994). Exploratory factor analysis has revealed two-factor solutions 
equivalent to the monitoring and blunting scales for some of the scales (Muris & 
Schouten, 1994; Ong et al., 1999; van Zuuren et al., 1996), although sample sizes have 
been mostly small. Confirmatory factor analysis has yet to be conducted.
As illustrated, empirical research has shown fairly consistent relationships between 
monitoring and blunting coping styles and chosen monitoring and blunting options in 
response to a stressful situation. For example, monitors have been shown to listen to an 
audio channel presenting information on the possible imminent electric shocks, seek 
feedback on performance on a cognitive task, and ask more questions during invasive
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dental procedures whereas blunters are more likely to listen to an audio channel of 
music and to avoid feedback on their performance on cognitive tasks, and remain quiet 
during dental procedures (Miller, 1987; Miller et al., 1995; Muris et ah, 1994e).
Construct validity has been demonstrated in several ways. Convergent validity has been 
demonstrated between the monitoring and blunting scores on the scales outlined above, 
although not consistently across scales (Bijttebier et al., 2001). Consistent associations 
have been reported between monitoring and blunting and information seeking 
behaviours. Participants in laboratory studies with a preference for monitoring 
consistently seek out information about the task and performance compared to blunters 
(Miller, 1987). Patients undergoing a series of medical and dental procedures report that 
they desire more information on the procedure when they are monitors compared to 
blunters (Miller et al., 1995; Steptoe & O'Sullivan, 1986; van Zuuren et al., 1999). This 
desire remained even when monitors demonstrated a higher level of existing knowledge 
(Steptoe & O'Sullivan, 1986). Correspondingly, reported satisfaction with the level of 
information corresponded with coping style such that monitors and blunters reported 
greater satisfaction and adjustment when receiving voluminous and minimal 
information respectively (Agre et al., 2003; Miller & Mangan, 1983; van der Zee, 
Gallandat Huet, Cazemier, & Evers, 2002; van Zuuren, 1998).
In addition, monitoring and blunting have been associated with relevant coping 
strategies. For example, monitoring has been significantly and positively associated 
with information seeking, question-proneness and seeking social support while blunting 
has been associated with avoidance strategies and negatively with information-seeking 
(Ben-Zur, 2002; Brown & Bedi, 2001; Miller et al., 1995; van Zuuren et al., 1996), 
although little or no association between the styles and these strategies has also been 
reported (Ben-Zur, 2002; Miller et al., 1996a; van Zuuren & Wolfs, 1991). Importantly, 
no research has investigated the stability of the construct. This is necessary in future 
research given the strong emphasis on coping styles as a dispositional characteristic.
Discriminant validity has been illustrated by the lack of association between monitoring 
and blunting themselves (Muris et al., 1994c; van Zuuren et al., 1996), as well as the 
related concepts of trait anxiety (Muris et al., 1994c; Steptoe & Voegele, 1992), 
hypochondriasis (Steptoe & Voegele, 1992), and repression (Myers & Derakshan,
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2000). As mentioned, some correspondence between coping styles and trait anxiety has 
been reported (Kohlmann, 1993; van Zuuren et al., 1999).
5.9 Conclusions
Monitoring and blunting coping styles are clearly important concepts for investigation. 
Research concerning the coping styles demonstrates that they are able to account, in 
part, for the variation in short- and medium-term experience of a range of largely 
uncontrollable stressful medical situations. The theory and past research suggest that it 
is in these situations that those with a tendency to monitor are more likely to experience 
poorer health outcomes, more anxiety and depressive symptoms, more intrusive and 
avoidant ideation, possess more external locus of control beliefs, and a heightened risk 
perception compared to those with a tendency not to monitor or a tendency to blunt.
Although the research has gone some way to explaining variations in the experience of 
stressful situations, further research is needed to clarify a number of issues. Given that 
the research has been conducted on small, mainly undergraduate samples, research is 
neeced to replicate the results in larger clinical samples undergoing stressful situations. 
Investigation of the interaction between the monitoring and blunting and its effect on 
outcomes is necessary. Although theory and empirical evidence has confirmed that 
moritoring and blunting are mutually exclusive dimensions of coping, there has been 
few attempts to determine the way in which these coping styles may interact and 
inflience outcomes. It would be valuable to investigate the psychometric properties of 
the coping style measures employed to ensure they possess adequate reliability and 
validity.
Restarch is needed to investigate the influence of monitoring and blunting on both 
phyiical and psychological wellbeing. It is also necessary to clarify the theorised 
relaionships between monitoring and blunting coping and related constructs of locus of 
contol beliefs and risk perception. Despite continual reference to such relationships in 
Milbr’s (1996; 1993) theory, little empirical evidence has been conducted to date. The 
resej-ch needs to be extended to include stressful situations and follow-up periods of 
longr duration to determine whether the experience of a protracted situation is 
cormarable to those of a shorter duration. Research including longer periods of follow­
up i needed to determine whether the experience over time remains similar.
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5.10 Aims
The present study provides an original and vital extension of the past literature to 
understand the role of monitoring and blunting coping styles in the physical and 
psychological experience of adjuvant chemotherapy in women with EBC. A thorough 
understanding of the experience of adjuvant chemotherapy is long overdue. 
Chemotherapy is one of the most difficult challenges facing women diagnosed with 
EBC. It consists of an intense, rigid and prolonged treatment schedule and its significant 
short- and long-term physical and psychological wellbeing. Patients’ experience of this 
treatment varies greatly, with some women experiencing severe and serious physical 
and psychological side effects. Despite this, research has yet to address this issue and 
identify the reasons why some women experience more side effects and to a lesser 
extent, distress, than others.
Investigation of coping in experience of breast cancer can be described as extensive in 
number yet narrow in scope. Research has focused solely on the use of coping strategies 
at diagnosis and its effect on outcomes several months following diagnosis. The 
advance of a new area of coping research on monitoring and blunting coping styles 
provides some hope of better understanding the experience of specific stressful medical 
experiences. Monitoring and blunting have been investigated in a range of clinical 
samples undergoing stressful medical procedures and treatments and have been shown 
to influence the physical and psychological wellbeing experienced in response to such 
procedures and treatments. It is likely that monitoring and blunting will be able to 
explain the physical and psychological wellbeing of women with EBC undergoing 
chemotherapy.
The study will involve determining whether monitoring and blunting coping styles are 
associated with;
1) . The levels of anxiety and depressive symptoms experienced before, during and six 
months following chemotherapy;
2) . The presence and severity of side effects experienced before, during and six months 
following chemotherapy;
3) . The levels of intrusive and avoidant ideation experienced;
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4) . The levels of internal, chance and powerful others locus of control beliefs before, 
during and six months following chemotherapy; and
5) . Risk perceptions of future recurrence of cancer six months following chemotherapy 
in women diagnosed with EBC.
This will be investigated while accounting for differences in women’s disease, physical 
health, and treatment while undergoing adjuvant chemotherapy for EBC.
5.11 Research Questions
The intensive and prospective nature of the study allows the investigation of several 
research questions:
1) . The levels of monitoring and blunting experienced; It is predicted that participants 
will report a wide range of use of monitoring and blunting coping styles.
2) . The relationship between monitoring and blunting: It is predicted that monitoring 
and blunting scores will be unrelated to each other, indicating that they are mutually 
exclusive dimensions of coping.
3) . The stability of monitoring and blunting over time: It is expected that use of 
monitoring and blunting coping will be constant over time, indicating that they are 
stable, dispositional factors.
4) . The relationship between scores on two widely used measures of monitoring and 
blunting; It is predicted that monitoring scores and blunting scores on two measures will 
be highly and positively related, indicating that they are measuring the same coping 
constructs.
5) . The levels of anxiety and depression experienced; It is predicted that participants 
will report a wide range of anxiety and depression throughout and following 
chemotherapy treatment, reflecting the variation in experience of chemotherapy 
reported by women undergoing chemotherapy for EBC. It is predicted that levels of 
anxiety and depression reported will increase prior to and on commencement of 
chemotherapy treatment and will decrease on completion of chemotherapy treatment 
and at follow up, indicating the challenging nature of the treatment and as reflected in
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the past research. The experience of higher levels of depression than anxiety is 
expected. Depression is reported more often than anxiety by women post-diagnosis.
6) . The levels of side effects experienced; It is predicted that levels of side effects 
reported will increase prior to and on commencement of chemotherapy treatment and 
will decrease on completion of chemotherapy treatment and at follow up. Participants 
are expected to report a wide range of side effects throughout chemotherapy treatment. 
Again, this is line with the variation in experience reported by women undergoing 
chemotherapy. It is predicted that levels of side effects will be affected in part by 
treatment factors, including the chemotherapeutic drugs administered, the anti-emetic 
medication and GCSF support provided, dose reductions in chemotherapeutic drugs (if 
any) and treatment delays (if any). It is also expected that side effects will be affected in 
part by participants’ ability to metabolise the chemotherapy drugs. This ability is 
reflected in the levels of bone marrow, hepatic, and renal functioning. Lastly, it is 
expected that the side effects reported at follow-up will be affected in part by the 
administration of radiation and/or endocrine therapy post-chemotherapy completion.
7) . The association between monitoring and blunting and the levels of anxiety and 
depression reported; It is predicted that participants who report the greater use of 
monitoring or the greater use of both monitoring and blunting will report higher levels 
of anxiety and depression throughout chemotherapy treatment and at follow-up 
compared to those who report greater use of blunting. As predicted by Miller’s 
monitoring and blunting hypothesis, it has been consistently found that those who use 
monitoring or both monitoring and blunting coping styles experience greater levels of 
psychological distress during and following a stressful situation compared to those 
using a blunting coping style or neither a monitoring nor blunting coping style.
8) . The association between monitoring and blunting and the level of side effects 
reported; It is predicted that participants who report the greater use of monitoring or the 
greater use of both monitoring and blunting will report higher levels of side effects 
throughout chemotherapy treatment compared to those who report greater use of 
blunting. Again, this reflects Miller’s theory and the finding that those who use a 
monitoring or both monitoring and blunting coping style experience greater levels of
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physical distress during and following a stressful situation compared to those using a 
blunting coping style or neither a monitoring nor blunting coping style.
9) . The association between monitoring and blunting and intrusive and avoidant 
ideation; It is predicted that greater use of monitoring or the greater use of both 
monitoring and blunting will be associated with higher levels of intrusive and avoidant 
ideation compared to those who report greater use of blunting, as predicted by Miller’s 
theory and demonstrated by past research.
10) . Whether intrusive and avoidant ideation mediate the relationship between 
monitoring and blunting and anxiety, depression, and side effects; It is predicted that 
intrusive and avoidance ideation will mediate the relationship between monitoring and 
blunting and the experience of anxiety, depression and side effects. That is, monitoring 
and blunting will be indirectly (via intrusive and avoidant ideation) associated with 
levels of anxiety, depression and side effects experienced throughout and following 
chemotherapy treatment. Horowitz’s (1993) and Miller’s (1996; 1993) theories state 
that intrusive and avoidant ideation are elicited in stressful situations in order to 
facilitate adjustment to the situation. Miller’s theory further adds and research supports 
(Miller, 1996; 1993) the idea that intrusive and avoidant ideation mediate the 
relationship between monitoring and blunting and psychological and physical 
wellbeing.
11) . The association between monitoring and blunting and locus of control beliefs; It is 
predicted that greater monitoring will be associated with more internal and powerful 
others locus of control but less chance locus of control beliefs. It is predicted that 
blunting is associated with more chance and powerful others locus of control and less 
internal locus of control beliefs. This pattern of beliefs has long been proposed by 
Miller but has been largely unexamined in research. As previously outlined, locus of 
control beliefs have been implicated in desired role in health care decision-making and 
engagement in health promotion and disease prevention behaviours.
12) . The association between monitoring and blunting and levels of risk perception; It is 
predicted that monitoring is associated with increased levels of risk perception while 
blunting is associated with decreased levels of risk perception, as proposed by Miller’s
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theory and illustrated in limited past research. Risk perceptions have been implicated in 
poor psychological wellbeing during survivorship.
5.72 Theoretical and Clinical Implications
The intensive and prospective nature of the investigation is one of the first of its kind in 
the area of chemotherapy for EBC and will provide a number of crucial theoretical and 
practical implications. In terms of the theoretical benefits, the study will reveal 
fundamental information about the monitoring and blunting coping styles. Monitoring 
and blunting will be examined in a moderately large clinical sample undergoing a long­
term, uncontrollable and highly stressful situation with a long-term follow-up. The 
hypothesised relationships between monitoring, blunting and their interaction, and 
physical and psychological wellbeing, intrusive and avoidant ideation, locus of control 
orientation, and perceived risk will be explored. This will in turn serve to enhance our 
understanding of monitoring and blunting coping styles and the nature of the theory of 
monitoring and blunting coping styles. It will also provide much needed information 
regarding the reliability and validity of widely used monitoring and blunting measures 
and the nature of the coping styles.
In terms of the clinical implications, the study will delineate some of the factors that 
influence women’s experience of chemotherapy. The consequence of which are superior 
medical and psychosocial care. Medical professionals will be able to identify those 
women at risk of poorer physical and psychological wellbeing due to their chosen 
coping styles. Once identified, medical professionals will be able to provide additional 
support to those women at risk of poorer physical wellbeing. For example, they may 
provide greater supportive medication (such as anti-emetic medication, GCSF support) 
to those using coping styles that are implicated in increased side effects. An 
understanding of locus of control beliefs can provide medical professionals with 
important information about patients’ desired role in decision-making and engagement 
in health promotion and disease prevention behaviours, both of which are critical to 
survival.
Psychologists will be able develop psychosocial interventions aimed at enhancing 
effective coping and therefore improving women’s physical and psychological 
wellbeing. The interventions may aim to either reduce the use of coping styles
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implicated in poorer outcomes or enhancing those implicated in superior outcomes. 
Examining the way in which women effectively deal with their chemotherapy treatment 
in terms of both physical and psychological wellbeing will constitute a major advance in 
our understanding and improvement of cancer services.
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CHAPTER SIX 
Method
6.1 Participants
Participants included women undergoing adjuvant chemotherapy treatment for EBC.
The inclusion criteria specified that participants had histologically confirmed EBC, had 
proficient English language skills (to ensure they could provide informed consent and 
were able to accurately understand and complete questionnaires), were over the age of 
18 years, had no prior history of adjuvant chemotherapy treatment, had no current 
psychiatric disorder(s) that could impede the accurate completion of questionnaires and 
were receiving adjuvant chemotherapy treatment in the ACT.
Participants were recruited from four hospitals in the ACT region catering to public and 
private patients. Most women attended The Canberra Hospital (34.0%), Caivary 
Hospital (28.3%) and The National Capital Hospital (28.3%). The remaining few 
participants attended John James Memorial Hospital (9.4%). The Canberra Hospital 
accommodates public patients, Calvary Hospital accommodates both public and private 
patients, and National Capital Private Hospital and John James Memorial Hospital 
accommodate only private patients. Participants were approached by their oncologist, 
chemotherapy nursing staff or breast care nurse regarding participation in the study. Of 
the 65 patients referred, 12 (5.4%) were unable to participate; 5 did not have time 
available to complete the first questionnaire prior to commencing treatment, 4 could not 
be contacted prior to commencing treatment, 2 reported being too distressed to handle 
the requirements of participation and 1 declined to undergo treatment.
All participants underwent a selection of diagnostic tests to establish the presence of 
EBC, as recommended by the NHMRC Guidelines for Clinicians (NHMRC & NBCC, 
2001). These tests may have included mammography with or without ultrasound, fine 
needle aspiration, core biopsy, full blood count and serum biochemistry, chest X-ray, 
bone scan, liver ultrasound, and chest computed tomography. All participants received a 
selection of adjuvant treatments to remove the tumour(s) from the breast and any 
remaining cancer cells in the body, as suggested by the NHMRC Guidelines (NHMRC 
& NBCC, 2001). Participants underwent surgical intervention, adjuvant chemotherapy, 
and radiation therapy and/or endocrine therapy. One (1.9%) participant refused to
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complete chemotherapy and no reason for non-compliance was provided. One 
participant (1.9%) died during the course of participation.
Of the 53 participants initially recruited, all completed the initial interview, 46 (86.8%) 
completed the questionnaire following the first infusion, 47 (88.7%) following the 
middle infusion, 44 (83.0%) following the final infusion, and 35 (66.0%) at 6-month 
follow-up. The reasons for failing to complete the questionnaire included poor health 
and lack of time due to work and family commitments. The initial interview was 
conducted a mean of 36.19 (16.13) days post-diagnosis, with a range of 14-99 days, and 
was a mean of 30.17 (12.80) days since final surgery, with a range of 9-64 days. The 
initial interview was conducted close to the time of first chemotherapy infusion, with a 
mean of 6.17 (7.62) days and a range of 0-33 days.
6.2 Design
The study was a prospective design. The dependent variables were levels of anxiety, 
depression, intrusive and avoidant ideation, side effects experienced, locus of control 
orientations and perceived risk of a breast cancer recurrence. The independent variables 
were demographic characteristics, health and disease variables, treatment variables and 
bone marrow, renal and hepatic functioning variables. Demographic variables included 
age, marital status, level of education, employment status, employment intensity, and 
occupation. Health variables included referral source, patient health care status, use of 
anxiolytic medication, use of antidepressant medication, and menopausal status.
Disease variables included method of detection, number of tumours, tumour size, 
tumour grade, number of affected lymph nodes and oestrogen receptor, progesterone 
receptor and HER2 statuses. Treatment variables included number of surgeries, type of 
surgery, performance of axillary dissection, type of chemotherapy regimen, 
chemotherapeutic drugs, anti-emetic medication and GCSF support received, dose 
reduction, treatment delay, and hospitalisation. Bone marrow, renal and hepatic 
functioning variables included neutrophils, bilirubin, alanine aminotransferase, alkaline 
phosphatise, gamma glutamyl transferase, albumin, urea and creatinine.
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6.3 Materials
6.3.1 Demographie Characteristics
Demographie characteristics were collected in the first questionnaire completed prior to 
commencement of adjuvant chemotherapy treatment. These included marital status, 
state of residence, level of education, employment status, employment intensity and 
occupation. Marital status and state of residence were defined and coded according to 
the National Health Data Dictionary (National Health Data Committee, 2003). 
Occupation was coded according to the Australian Standard Classifications of 
Occupations (Australian Bureau of Statistics, 1997).
Marital status consisted of five categories; single/never married, married or de facto, 
separated or divorced, and widowed. State of residence consisted of two categories; the 
ACT or NSW (NSW). Level of education indicated the highest level of education 
attained. Education consisted of five categories; primary school, year 10, secondary 
school, undergraduate degree, and postgraduate degree. Employment status described 
whether the participant was currently employed with three categories; employed, 
unemployed, and retired. Employment intensity described the amount of hours spent in 
employment and consisted of two categories; full-time or part-time. Occupation 
consisted of nine categories; managers and administrators, professionals, associate 
professionals, tradespersons and related workers, advanced clerical and service workers, 
intermediate clerical, sales and service workers, intermediate production and transport 
workers, elementary clerical, sales and service workers, and labourers and related 
workers.
6.3.2 Health and Disease Characteristics
Health characteristics were collected from participants’ medical files with the exception 
of referral source which was noted at the time of referral. Referral source described the 
source that referred the participants to the project and consisted of three categories; 
treating medical oncologist, breast care nurse, and chemotherapy clinic nurse. Patient 
health care status reflected the source of health care funding utilised by the participants 
and consisted of two categories; public or private health care. The use of anxiolytic and 
antidepressant medication described whether the participant was regularly taking this 
medication on throughout chemotherapy treatment and consisted of two categories; yes 
and no. Menopausal status described the participants’ menopausal status on
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commencement of chemotherapy treatment and consisted of two categories; pre­
menopausal and post-menopausal.
Disease characteristics were collected from participants’ medical files. The exception 
was the method of detection, which was collected in the first questionnaire. Disease 
characteristics include method of detection, date at diagnosis, tumour type, tumour size, 
number of affected axillary lymph nodes, histologic grade, oestrogen receptor (ER), 
progesterone receptor (PR), and HER2 statuses. Method of detection described the way 
in which participants came to discover the disease for the first time and consists of four 
categories; self-examination (accidental), breast self-examination, clinical examination 
by a health professional and routine mammography.
Date of diagnosis was taken to be the date of first surgery. The reason for this is that 
although a number of diagnostic tests are conducted, the final diagnostic information is 
obtained at the first surgery. Also, patients may differ slightly in the diagnostic tests 
completed whereas all received surgery so using the date of first surgery ensures 
consistency. Tumour type describes the form of breast cancer diagnosed and was 
recorded according to the Australian Institute of Health and Welfare Breast Cancer in 
Australia report (AIHW & NBCC, 2006).
Tumour size described the size of the tumour’s diameter or in the case of several 
tumours, the largest tumour’s diameter in millimetres. Number of affected axillary 
lymph node was recorded in numbers starting from zero. Histological grade described 
the extent to which the tumour is differentiated and consisted of three categories; 1, 2 
and 3. One signifies a low grade in which tumours are well differentiated while three is 
a high grade in which tumours are poorly differentiated. ER, PR and HER2 statuses 
described the nature of oestrogen, progesterone and HER2 receptor expression and was 
recorded using two categories; positive or negative.
6.3.3 Treatment Characteristics - Surgery 
Information on the surgical intervention(s) received was recorded from participants’ 
medical files. The surgical information collected included the number of surgeries, 
type(s) of surgery performed, whether axillary dissection was performed, and the date of 
the first and final surgeries performed. The number of surgeries reflected the number of
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surgical interventions performed (excluding axillary dissection). While many patients 
will undergo one form of surgical intervention, some will undergo more than one. The 
most common example is when patients undergo breast conserving surgery (BCS) but 
due to the extent of the disease uncovered during BCS, the patient goes on to receive a 
unilateral total mastectomy (TM). The type of surgery performed describes form of 
surgical intervention performed. The types of surgery consisted of four categories; BCS, 
BCS plus TM, TM, or bilateral TM. The performance of axillary dissection refers to 
whether the participants underwent surgery to remove the nearby lymph nodes and 
consisted of two categories; yes or no.
6.3.4 Adjuvant Chemotherapy
Chemotherapy treatment variables were collected from the participants’ medical files. 
The chemotherapy information collected included the chemotherapy regimen prescribed 
and the chemotherapeutic drugs, anti-emetic medication and GCSF support 
administered, dose reductions, treatment delays and hospitalisations for the first, middle 
and final chemotherapy cycles.
Five standard chemotherapy regimens were prescribed and consisted of:
1) . FEC (5-fluorouracil 600mg/m2, epirubicin 100mg/m2, and cyclophosphamide
9 . •600mg/rrr given intravenously on day 1) every three weeks for six cycles;
2) . Oral CMF (cyclophosphamide 100mg/m2, orally on days 1-14, methotrexate 
40mg/m2 and 5-fluorouracil 600mg/m2 both given intravenously) on days 1 and 8 every 
four weeks for six cycles;
3) . AC (adrimyacin 60mg/m2, and cyclophosphamide 600mg/m2 both given 
intravenously on day 1) every two weeks for four cycles;
4) . AC/Taxol (adrimyacin 60mg/m2, and cyclophosphamide 600mg/m2 both given 
intravenously on day 1 for four cycles, and Taxol 175mg/m2 given intravenously on day 
1 for four cycles) every four weeks for eight cycles; and
5) . EC/Taxol (epirubicin 60mg/m”, and cyclophosphamide 600mg/m both given 
intravenously on day 1 for four cycles, and Taxol 175mg/m2 given intravenously on day 
1 for four cycles) every four weeks for eight cycles (Chap, Barsky, Bassett, & Haskell, 
2001a).
Correspondingly, the chemotherapeutic drugs administered at an infusion were recorded 
and consisted of five categories; FEC, Oral CMF, AC, EC and Taxol.
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The anti-emetic drugs describe the level of anti-emetic medication provided to 
participants after each treatment in either intravenous or oral form or both. The anti­
emetic medication consisted of 4 levels:
1) . Level 0 - None;
2) . Level 1 - Single anti-emetic (for example, a 5-HT} antagonist, corticosteroid, 
dopamine receptor agonists, or apprepitant);
3) . Level 2 - Combination of a 5-HT  ^antagonist and a corticosteroid; and
4) . Level 3 - Combination of a 5 -HT3 antagonist and a corticosteroid plus an apprepitant 
and/or anxiolytic.
Typically, levels 0 and 1 are prescribed for patients receiving IV CMF, Oral CMF, and 
Taxol and levels 3 and 4 are prescribed for AC, EC, and FEC (Grunberg, 2001).
Treatment delay describes the need to postpone the scheduled chemotherapy treatment 
and consisted of two categories; yes or no. The length of delay (if any) was recorded in 
days. Dose reduction describes the need to decrease the quantities of drugs administered 
and consists of two categories; yes or no. The amount of dose reduction (if any) was 
recorded as a percentage by which the quantity of drugs was decreased. Hospitalisation 
describes the need for patients to be admitted to hospital for medical treatment 
following chemotherapy treatment and consisted of two categories; yes or no. The 
length of hospitalisation (if any) was recorded in days. Delays in treatment, dose 
reductions and hospitalisations are all indicators of excessive toxicity experienced from 
the previous chemotherapy treatments.
6.3.5 Bone Marrow, Hepatic and Renal Functioning 
To assess the level of bone marrow, hepatic and renal functioning, the date and results 
of pathology tests of bone marrow, hepatic (liver), and renal (kidney) functioning 
conducted prior to the first, middle and final chemotherapy cycles were recorded from 
the ACT Pathology database. Bone marrow, hepatic, and renal functioning are all 
indicators of the extent to which the body metabolises the chemotherapy drugs. 
Increases in the functioning of these indicators means that the body is working hard to 
deal with the effects of the drugs on the body. Participants whose bone marrow, hepatic 
and renal functioning is compromised may in turn experience greater side effects.
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Bone marrow functioning was indicated by a measure of neutrophils. Neutrophils are 
one of several types of white blood cell. Neutrophils are made in the bone marrow and 
move out of the bloodstream into the body’s tissue to fight infections. When the body is 
fighting off infection, neutrophil count increases and very low levels of neutrophils 
places the body at risk of infections. Renal functioning was assessed by the levels of 
urea and creatinine. Urea and creatinine are waste substances that are normally cleared 
from the blood by the kidneys into the urine. When the kidneys’ functioning is 
compromised, the levels of urea and creatinine increase (IDG Books Worldwide, 2000).
Hepatic functioning by measures of bilirubin, albumin, alanine aminotransferase (ALT), 
alkaline phosphatise (AlkP) and gamma glutamyl transferase (GGT). Bilirubin is a 
compound that is produced by the breakdown from red blood cells. Bilirubin is used by 
the liver to make bile for processing substances. Albumin is a protein in the blood that 
helps regulate the osmotic pressure of blood. Albumin transports substances to the liver 
for processing. ALT, AlkP and GGT are different types of enzyme that is normally 
present in the liver and are released into the bloodstream when the liver is damaged. 
Increased levels of any of these indices indicate the liver may be seriously compromised 
(IDG Books Worldwide, 2000).
6.3.6 Radiation Therapy
Information recorded on radiation therapy was obtained from participants’ medical files. 
The variables recorded included the receipt of radiation therapy was completed, dates of 
first and final treatment, length of treatment, and length of time between final treatment 
and six-month follow-up questionnaire. The receipt of radiation therapy was completed 
consisted of two categories; yes or no. The length of treatment and the length of time 
between the final treatment and six-month follow-up were recorded in days.
6.3.7 Endocrine Therapy
Information was also recorded regarding endocrine therapy and included the receipt of 
endocrine therapy and the type of endocrine therapy prescribed. The receipt of 
endocrine therapy consisted of two categories; yes or no. The type of endocrine therapy 
prescribed included three categories; Tamoxifen (a non-steroidal anti-estrogen), 
Arimidex (an aromatase-inhibitor), and Zoladex (a pituitary downregulator), all 
prescribed in standard doses for five years.
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6.3.8 Monitoring and Blunting Coping Styles 
The Threatening Medical Situations Inventory (TMSI) (van Zuuren et ah, 1996) was 
used to assess monitoring and blunting coping styles (Appendix A). Participants 
completed the TMSI as part of the first and final questionnaires, completed prior to and 
six months following chemotherapy respectively. The TMSI presents participants with 
four stressful medical situations that differ in the extent to which they are stressful, 
controllable, and predictable. Participants are asked to indicate the extent to which they 
would engage in three monitoring and three blunting responses described at the end of 
each scenario. Responses to the 24-item scale are made on a five-point Likert scale, 
ranging from one (not at all) to five (very much so).
The TMSI yields two subscale scores of monitoring and blunting, with higher scores 
indicating a greater use of coping style. Internal consistency is adequate with estimates 
of 0.66-0.85 for monitoring and 0.78-0.88 for blunting (Brown & Bedi, 2001; Pieterse 
et al., 2005; van der Zee et al., 2002; van Zuuren et ah, 1999). Test-retest reliability is 
adequate with an estimate of 0.71 for a two week period (van Zuuren et ah, 1996). 
Exploratory factor analysis has confirmed the two-factor structure originally proposed 
(Ong et ah, 1999).
Convergent and discriminant validity is indicated by the pattern of associations between 
monitoring and blunting scores on the TMSI and corresponding scores of other 
measures of monitoring and blunting, including the MBSS (Miller, 1987) and MCI 
(Krohne, 1989). TMSI monitoring scores have been shown to be positively and 
moderately associated with the MBSS and MCI monitoring scores and the TMSI 
blunting scores was positively and moderately associated with MBSS and MCI blunting 
scores (Bijttebier et ah, 2001; van Zuuren & Muris, 1993). Predictive validity evident in 
the association between TMSI-B and observed blunting behaviour such as increased 
time taken to switch from distracting music to information (Muris et ah, 1994d).
The TMSI was considered to be the most appropriate and valid measure of monitoring 
and blunting in the present sample. Past research indicates that participants with serious 
health problems find it frustrating to complete measures of general stressful situations 
which they consider to be irrelevant to their current circumstances. Therefore, it was
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expected that the TMSI’s inclusion of only stressful medical situations would have 
increased face validity for the present sample (Steptoe, 1989; van Zuuren et al., 1996). It 
also avoids the need to create a new scale that addresses the cancer experience 
specifically as this would be costly and time consuming (van Zuuren et ah, 1996). By 
closely reflecting their current circumstances, it was expected that participants’ 
responses would more accurately reflect what they actually did in their situation, thus 
improving predictive validity.
The TMSI has been used successfully in a wide range of populations experiencing 
health concerns, including cardiac patients (Brown & Bedi, 2001; van der Zee et ah, 
2002), dental surgery patients (van Zuuren et ah, 1999), those at high risk of cancer 
(Lerman et ah, 1990; Pieterse et ah, 2005; Tercyak et ah, 2001), and breast cancer 
patients (McKinnon, 2001) cancer patients with varying diagnoses and prognoses (Ong 
etah, 1999).
The Miller Behavioral Style Scale (MBSS) (Miller, 1987) was also used to assess 
monitoring and blunting scores (Appendix B). The MBSS was completed as part of the 
final six-month follow-up questionnaire. As previously outlined, the MBSS was 
included as a comparison of monitoring and blunting use in general stressful situations 
as opposed to the stressful medical situation included in the TMSI. Given that the past 
research has suggested the MBSS lacks face validity in medical patients and the need to 
keep the questionnaires brief during treatment, a decision was made to include the 
MBSS only at the follow-up.
Like the TMSI, the MBSS presents participants with four stressful but general situations 
that differ in the extent to which they are stressful, controllable, and predictable. 
Participants are asked to indicate the extent to which they would engage in the four 
monitoring and four blunting responses described at the end of each scenario.
Responses to the 32-item scale are made on a five-point Likert scale, ranging from one 
(not at all) to five (very much so).
The MBSS yields two subscale scores of monitoring and blunting, with higher scores 
indicating a greater use of coping style. The estimates of internal consistency range 
from .65-.79 for monitoring and .41-.76 for blunting (Miller, Shoda, & Hurley, 1996b;
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Muris et al., 1995a; Muris & Schouten, 1994; Muris et al., 1994c; Rees & Bath, 2000; 
Schwartz et al., 1995; van Zuuren & Wolfs, 1991). Concern exists at the number of low 
internal reliability estimates reported for the blunting subscale. A test-retest reliability 
estimate was .71 for five weeks for the monitoring subscale (Rees & Bath, 2000). The 
two-factor structure has been confirmed using exploratory factor analysis in several 
studies (Muris & Schouten, 1994).
As previously outlined in the discussion of the TMSI, convergent and divergent validity 
have been demonstrated in the expected pattern of relationships between monitoring and 
blunting scores on a range of measures, including the TMSI and MBSS (Bijttebier et al., 
2001; Muris et al., 1994c; van Zuuren et al., 1996). Predictive validity has been 
demonstrated in studies in which monitoring is associated with monitoring behaviours 
in real-life stressful situations. For example, high monitors looked at a light signalling 
performance level during a test more often than low monitors (Miller, 1987; Muris et 
al., 1994e). The MBSS has been used in a range of cancer samples including women at 
risk of breast or ovarian cancer (Andrykowski et al., 2002; Cull et al., 2001; Miller et 
al., 1999a; Miller et al., 1994; Rees & Bath, 2000), breast cancer patients (Gard, 
Edwards, Harris, & McCormack, 1988) and cancer patients with varying diagnoses and 
prognoses (Petersson et al., 2002).
6.3.9 Intrusive and Avoidant Ideation
The Impact of Events Scale (IES) (Horowitz et al., 1993) was used to measure intrusive 
and avoidant ideation (Appendix C). The IES was completed as part of all 
questionnaires provided, before, during and six months following chemotherapy 
treatment. The IES is a 15-item scale which yields two subscale scores of intrusive 
ideation and avoidant ideation. Participants are asked to indicate the extent to which 
they are experiencing intrusive and avoidant ideation described on a four-point Likert 
scale. Higher scores indicate greater levels of intrusive and avoidant ideation. The 
measure is brief, is easy and efficient to administer, has good face validity, and is the 
most widely accepted and utilised measure of intrusive thoughts and avoidance 
(Thewes, Meiser, & Hickie, 2001).
The IES was originally used in populations of war veterans who were at risk of post- 
traumatic stress disorder. However, the realisation that populations experiencing
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stressful situations also experience intrusive and avoidant ideation coupled with the 
items’ lack of reference to a specific situation has meant the IES’s use has been 
extended to populations experiencing a range of stressful situations. The measure has 
been used widely in breast cancer patients (Bleiker, Pouwer, van der Ploeg, Leer, & 
Ader, 2000; Cordova et al., 1995; Hampton & Frombach, 2000; Johnson Vickberg,
2001; Nordin et al., 2001), although it should be noted that IES scores can vary 
according to severity of cancer, age at diagnosis, and treatment received (McBride, 
Clipp, Peterson, Lipkus, & Demark-Wahnefried, 2000).
Exploratory factor analysis has confirmed the two-factor structure which discriminates 
intrusive and avoidance items (Thewes et al., 2001). Internal consistency is adequate 
with estimates ranging from .86-.89 for intrusive ideation and .11-.90 for avoidant 
ideation and test-retest over a 14-day period of .75-.80 (Andrykowski et al., 2002; 
Baider, Ever-Hadani, & De-Nour, 1999; Devine, Parker, Fouladi, & Cohen, 2003; 
Thewes et al., 2001). Concurrent validity has been demonstrated by moderate positive 
associations between the subscales (Epping-Jordan, Compas, & Howell, 1994) as well 
as with similar constructs such as psychological distress (Baider & De-Nour, 1997; 
Thewes et al., 2001; Vickberg, Bovbjerg, DuHamel, Currie, & Redd, 2000), anxiety and 
depression (Bleiker et al., 2000; Nordin et al., 2001), health status and complaints 
(Bleiker et al., 2000; McBride et al., 2000), problems with health care (Hampton & 
Frombach, 2000), family history of breast cancer (Andrykowski et al., 2002; Baider et 
al., 1999), and over-performance of breast self-examination (Erblich, Bovbjerg, & 
Valdimarsdottir, 2000). Discriminant validity has been demonstrated with negative and 
moderate associations with engagement in health behaviours (McBride et al., 2000).
6.3.10 Locus of Control Beliefs
The Multidimensional Health Locus of Control Scale Form C (MHLOC-C) (Wallston et 
al., 1976; Wallston et al., 1994) was used to assess the extent to which a person believes 
their current illness is determined by their own behaviour (internal locus of control), 
chance, fate, or luck (chance locus of control) and other powerful people such as health 
professionals or friends and family (powerful others locus of control) (Appendix D).
The MHLOC scale was completed as part of all questionnaires provided, before, during 
and six months following chemotherapy treatment. There are several forms of the 
MHLOC scale. The original forms, Forms A (MHLOC-A) and B (MHLOC-B), were
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designed to address locus of control beliefs about general health (Wallston et al., 1976). 
These scales were increasingly utilised in samples of patients with chronic illness which 
led to the development of the illness-specific MHLOC-C scale. Given that health locus 
of control beliefs are thought to differ according to experience, it is thought that a 
measure specific to an illness would be more appropriate and valid. The MHLOC-C 
was used to measure locus of control beliefs in the present study (Wallston et ah, 1994).
The MHLOC-C scale is an 18-item scale that yields three subscale scores of internal, 
chance, and powerful other locus of control. Participants are asked to indicate the extent 
to which they agree with statements regarding locus of control orientation and to 
consider the items according to their cancer disease. Higher scores indicate a greater 
level of orientation (Wallston, 1989). The measure is brief, easy and efficient to 
administer, and is the most widely accepted and utilised measure of health locus of 
control beliefs in breast cancer patients (Bourjolly, 1999; Bremer, Moore, Bourbon, 
Hess, & Bremer, 1997; Grassi & Rosti, 1996; Watson, Pruyn, Greer, & van den Borne, 
1990).
The MHLOC-C subscales have adequate internal reliabilities with estimates ranging 
from .63-.80 (Chen, Deng, & Chang, 2001; Dahnke, Garlick, & Kazoleas, 1994; Holm, 
Frank, & Curtin, 1999). Exploratory and confirmatory factor analysis indicates a three- 
factor solution distinguishing the three forms of locus of control orientation is most 
commonly obtained (Dahnke et al., 1994; Malcarne, Fernandez, & Flores, 2005). The 
MHLOC-C has demonstrated excellent disciminant and convergent validity. As 
expected, medical patients with chronic disease report less internal and more chance and 
powerful others locus of control beliefs compared to those with less severe and short 
term disease (Dahnke et al., 1994). Evidence for discriminative validity has been 
demonstrated in the lack of association between the subscales of the MHLOC-C 
(Dahnke et al., 1994; Wallston, 2005b).
Convergent validity is illustrated in the positive and moderate to strong associations 
between subscale scores and the corresponding subscales of locus of control scales, 
including the MHLOC-A and MHLOC-B (Wallston, 2005a). Further convergent 
validity is evident in the positive associations with constructs to which the subscales are 
expected to be related. Internal LOC is associated with the performance of health-
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promoting behaviours (Schultheis, Peterson, & Selby, 1987) and lower perceived risk of 
disease (Rowe et al., 2005). Chance LOC is associated with the God Locus of Control 
scale (Wallston et al., 1999), and powerful others LOC is associated with medical 
professional-dependent cancer screening procedures such as pap smears and clinical 
breast examinations (Bundek et al., 1993). Patients with illnesses that are less amenable 
to personal control, such as cancer and aplastic anaemia, report more chance LOC 
beliefs whereas those with illness that are in part controllable, such as diabetes, report 
more internal LOC beliefs (Dahnke et al., 1994; Wallston, 2005b).
6.3.11 Risk Perception
To date, risk perceptions of the recurrence of breast cancer, indeed any type of cancer, 
has been identified as an important construct in qualitative (Vickberg et al., 2000) but 
rarely quantitative research (Mullens, McCaul, Erickson, & Sandgren, 2004). As a 
result, there exists no widely accepted and utilised measure of risk perceptions of 
recurrence. A similar construct, risk perceptions of developing breast cancer for the first 
time, has received considerable attention in more recent research investigating the 
effects of genetic counselling (Culver, Burke, Yasui, Durfy, & Press, 2001; Hurley, 
Miller, Costalas, Gillespie, & Daly, 2001). The present study therefore modified a 
commonly used method of measuring the risk perceptions of developing breast cancer 
in order to investigate perceived risk of recurrence, the Risk Perception Scale (RPS: 
Appendix E). The RPS was completed as part of the final six months follow-up 
questionnaire.
Measures of perceived risk of developing breast cancer have instructed participants to 
estimate their personal risk using numbers (Bottorff et al., 2004; Cunningham et al., 
1998; Gil et al., 2003; Weinstein et al., 2004), verbal descriptors (Absetz, Aro, &
Sutton, 2002; Andrykowski et al., 2002; Bowen et al., 2003; Culver et al., 2001; 
Diefenbach et al., 1999; Facione, 2002; Kent et al., 2000), or both (Absetz, Aro, 
Rehnberg, & Sutton, 2000; Lipkus, Green, & Marcus, 2003; Lipkus, Klein, Skinner, & 
Rimer, 2005; Rowe et al., 2005). Numerical estimates often involve either providing a 
percentage estimate (Bottorff et al., 2004; Gil et al., 2003; Lipkus et al., 2003; Lipkus et 
al., 2005; Rowe et al., 2005), or choosing one of a selection of numerical estimates 
(Cunningham et al., 1998; Weinstein et al., 2004). Verbal estimates involve providing 
an estimate response to a single (Absetz et al., 2000; Andrykowski et al., 2002; Bowen
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et al., 2003; Diefenbach et al., 1999; Kent et al., 2000; Lipkus et al., 2005) or several 
(Absetz et al., 2002) questions according to verbal descriptors on a Likert scale.
Research indicates a lack of correspondence between numerical and verbal estimates 
(Absetz et al., 2000; Lipkus et al., 2003; Lipkus et al., 2005; Rowe et al., 2005). It is 
thought that the discrepancy is due to a lack of understanding of the meaning of 
numerical risk estimates (Absetz et al., 2000). Also, perceived risk may be based on 
different factors compared to actual risk. Research has shown little or no 
correspondence between objective and subjective risk of cancer (Kent et al., 2000; 
Weinstein et al., 2004). Furthermore, providing information on personal objective risk 
estimates does not appear to change personal perceived risk (Weinstein et al., 2004). 
This may explain why some research reports significant overestimations of risk but little 
psychological distress (Absetz et al., 2000).
To qualify the estimates of personal risk, some researchers have obtained a measure of 
comparative risk. That is, the extent to which personal risk is thought to be greater or 
lesser than that of peer risk. Comparative risk is thought to give an indication of how 
vulnerable people feel to developing cancer. Comparative risk estimates have been 
calculated in four ways: by subtracting numerical or verbal estimates of peer risks from 
personal risk (Bottorff et al., 2004; Cunningham et al., 1998) and by asking participants 
directly to indicate whether their risk is greater or lesser than peers’ risk in numerical or 
verbal terms (Culver et al., 2001; Facione, 2002; Lipkus et al., 2005; Rowe et al., 2005; 
Weinstein et al., 2004).
The construct validity of perceived risk of developing cancer has been demonstrated 
repeatedly with scores correlating with other constructs in theoretically expected ways. 
For example, greater levels of perceived risk is associated with increased distress, 
worry, and thoughts about breast cancer (Cunningham et al., 1998; Kent et al., 2000), 
increased acceptance of genetic counselling (Culver et al., 2001), increased adherence 
screening behaviour (Bowen et al., 2003; Gil et al., 2003) but less benefit from 
screening adherence (Gil et al., 2003).
The present study asked participants to consider “What do you think is the likelihood 
you will develop breast cancer in the future?” as a measure of personal risk perception
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and “What do you think is the likelihood that a woman the same age and who has had 
the same diagnosis and treatment will develop breast cancer in the future?” as a measure 
of peer risk perception. Responses were indicated on a seven-point Likert scale ranging 
from one (none) to seven (very likely). A measure of comparative risk perception was 
calculated by subtracting the score of peer risk from personal risk.
6.3.12 Anxiety and Depressive Symptoms
The Hospital Anxiety and Depression Scale (HADS: (Zigmond & Snaith, 1983) was 
used to measure the number and severity of anxiety and depressive symptoms 
(Appendix F). The HADS was completed as part of all questionnaires provided, before, 
during and six months following chemotherapy treatment. The HADS yields two 
subscale scores of anxiety and depressive symptoms. Higher scores indicate higher 
levels of anxiety and depression symptoms. The subscales have demonstrated adequate 
internal consistency, with estimates ranging from .68-.93 for anxiety and .67-.90 for 
depression (Bjelland, Dahl, Haug, & Neckelmann, 2002).
Both exploratory and confirmatory factor analyses have consistently reported a two- 
factor solution that distinguishes anxiety and depression items (Bjelland et al., 2002; 
Osborne, Elsworth, Sprangers, Oort, & Hopper, 2004). Alternative solutions of one 
(Johnston, Pollard, & Hennessey, 2000) and three (Rodgers et al., 2005) factors have 
also been reported but these analyses have been hampered by small sample sizes and 
diverse samples of patients (Bjelland et al., 2002; Rodgers et al., 2005).
Concurrent validity has been demonstrated with comparisons to other widely used and 
accepted measures of anxiety and depressive symptoms, such as the Spielberger State- 
Trait Anxiety Inventory (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983), Beck 
Depression Inventory (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961), Symptom 
Check List 90 Scale (Derogatis & et al., 1974). Correlations with these scales ranged 
between .49 and .83 (for a review, see (Bjelland et al., 2002). Scores on the HADS have 
also been shown to correlate with other constructs in theoretically expected ways. For 
example, scores are significantly and positively correlated with side effect burden and 
negatively correlated with quality of life (Dausch et al., 2004).
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Discriminant validity is evident in research showing that factor analysis of items from 
measures of both psychological and somatic symptoms showed all items of the H ADS 
loaded onto the psychological factor, demonstrating that the HADS measures 
psychological, rather than somatic, symptoms of anxiety and depression (Johnston et al., 
2000). It is the ability of the HADS to measure anxiety and depression without 
contamination of somatic symptoms, also manifest in heath conditions, that has led to 
its use in samples of medical patents, including those with breast cancer (Groenvold et 
ah, 1999; Montazeri et ah, 2000; Osborne et ah, 2004; Osborne et ah, 2003; Turner et 
ah, 2005). Although some concerns about its narrow focus on the depression symptoms 
of anhedonia exists (Hall et ah, 1999; Love et ah, 2002).
6.3.13 Chemotherapy Side Effects Scale
There is no widely used and accepted self-report measure of adjuvant chemotherapy 
side effects with demonstrated reliability and validity. The chemotherapy regimens 
prescribed to patients with breast cancer have changed continually over the years. These 
changes have been in response to research demonstrating the improved effectiveness of 
certain regimens over others. The continual change has made it difficult to develop a 
reliable and valid measure for use over an extended period of time. As a result, much 
research has utilised general measures of negative physical symptoms although concern 
exists regarding the specificity and sensitivity of the measures in breast cancer patients.
For the purposes of the present study, a self-report measure was created to assess the 
most commonly experienced side effects in patients undergoing adjuvant chemotherapy 
for EBC. A list of side effects was generated in response to the literature and in 
consultation with the Director of Clinical Cancer Services in the ACT. The aim was to 
develop a scale that was brief but covered the most common side effects. The 
Chemotherapy Side Effects Scale was a 12-item scale that yielded one overall score of 
side effects (CSES) (Appendix G). The side effects included lack of appetite, fatigue, 
sore muscles, pain, constipation, nausea, vomiting, difficulty sleeping, and memory 
problems.
The response scale was based on the Common Toxicity Criteria for Adverse Events 
(National Cancer Institute, 1999, 2003). The Criteria are widely used and accepted 
manual for rating the level of impairment caused by physical symptoms. Responses
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were made on a five-point Likert scale that lists the levels of impairment according the 
Criteria. Generally, the five-point scale ranges from zero (no impairment) to four 
(severe impairment) (National Cancer Institute, 1999, 2003). The CSES was completed 
as part of all questionnaires provided, before, during and six months following 
chemotherapy treatment. The assessment prior to chemotherapy was to determine a 
baseline as it was possible some participants would be experiencing the symptoms listed 
in the scale as a result of recent breast surgery.
6.4 Procedure
Prior to commencement of the study, approval was sought and granted from the relevant 
ethics committees (Appendix H). To recruit participants, suitable patients were asked 
whether they would be interested in participating in a study on coping and 
chemotherapy by their oncologist, breast care nurse or chemotherapy clinic nurse during 
a routine consultation. Those interested provided oncologists, breast care nurses or 
nursing staff with permission to pass on their contact details to the investigator. The 
patient was subsequently contacted by telephone by the investigator to discuss the aim 
and nature of the study and participation. If the patient chose to participate, an 
appointment time was made to meet the investigator.
All appointments were conducted in a convenient and private space. Participants were 
provided with an information sheet and two consent forms, one each for the participant 
and investigator to keep on file. Two versions of the information sheet (Appendices I 
and J) and consent form (Appendices K and L) were produced. The first version was 
given to participants attending The Canberra Hospital, The National Capital Hospital, 
and the John James Memorial Hospital, and the second version for those attending the 
Calvary Hospital, as specified by the relevant ethics committees. Following this, the 
first questionnaire was conducted as a semi-structured interview. This enabled the 
investigator to build rapport with the participant and show them how to complete the 
questionnaire. Any questions that arose during this process were addressed.
Given that most appointments were conducted within several days of the first 
chemotherapy infusion, the participant was provided with the questionnaire to be 
completed after the first treatment cycle and a replied paid envelope. Participants were 
instructed to complete the questionnaire one-week following the first treatment cycle
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before returning it to the investigator. A telephone call was made in order for the 
investigator to determine the performance status rating of the participants.
Following the participants’ first treatment, the investigator obtained the date and time of 
their middle treatment cycle appointment from the oncology reception or nursing staff. 
The investigator met with patients prior to their treatment appointment to provide them 
with the next questionnaire package. This process was repeated for the final 
chemotherapy treatment cycle. When the questionnaire was not received within 2 weeks 
following the first, middle or final treatments, a second questionnaire and replied paid 
envelope were sent to participants with a letter reminding them to complete and return 
the questionnaire (Appendix M).
Once chemotherapy was completed, medical data concerning patients’ diagnosis and 
treatment were collected from patients’ medical files and results of pathology tests of 
hepatic and renal functioning were collected from the relevant pathology database by 
the investigator or participants’ oncologist. Six months following the completion of 
chemotherapy, the follow-up questionnaire and reply-paid envelope were sent to the 
participants to complete and return to the investigator. Again, when the follow-up 
questionnaire was not received within 2 weeks, a second questionnaire and replied paid 
envelope were sent to participants with a letter reminding them to complete and return 
the questionnaire. (A time-line of the assessment points and contents of the 
questionnaires is illustrated in Figure 1.)
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CHAPTER SEVEN
Results
7.1 Data Analysis
7.1.1 Analysis Plan
The statistical analysis plan aimed to provide insight into the research questions posed. 
In order to do so, the main aims of the analyses were to investigate:
1) the demographic, health, disease and treatment characteristics of the sample (please 
refer to Chapter 7);
2) the extent to which monitoring and blunting coping styles were employed 
(Chapter 7);
3) the reliability and validity of the monitoring and blunting coping styles measure, the 
Threatening Medical Situations Inventory (Chapter 7);
4) the relationships between monitoring and blunting and the levels of anxiety, 
depression, and side effects (Chapters 8 and 9);
5) the relationships between monitoring and blunting and intrusive and avoidant 
ideation (Chapters 8 and 9);
6) the mediating role of intrusive and avoidant ideation in the relationships between 
monitoring and blunting and the levels of anxiety, depression, and side effects 
(Chapters 8 and 9);
7) the relationships between monitoring and blunting and the locus of control beliefs, 
internal-, chance-, and powerful others-locus of control beliefs (Chapter 10); and
8) the relationships between monitoring and blunting and perceived risks estimated 
(Chapter 11).
7.1.2 Data Preparation and Screening
All scores were entered and analysed using the Statistical Package for the Social 
Sciences (SPSS) (SPSS Inc., 2004). Given the small numbers of missing values (less 
than 5% of values on each variable), the mean substitution method was used for 
replacement purposes. Scores on the relevant items of the Hospital Anxiety and 
Depression Scale (HADS; (Zigmond & Snaith, 1983) were reversed. Item scores were 
summed to calculate the relevant overall and/or subscale scores on the TMSI (van 
Zuuren & Muris, 1993), MBSS (Miller, 1987), IES (Horowitz et al., 1979); MHLOC 
(Wallston et ah, 1994), HADS (Zigmond & Snaith, 1983), CSES and PRS.
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Internal reliabilities were calculated for all of the scales at each time-point measured. 
Internal reliabilities are presented in Table 1 and most range from adequate to excellent 
for each of the subscales. Of concern are the lower reliabilities reported for the MHLOC 
powerful others locus of control subscale and the HADS depression subscale. The low 
reliabilities were reported at baseline for both subscales and at follow-up for the 
powerful others locus of control subscale. Item deletion did not improve the reliabilities 
of any of the subscales.
Table 1
Internal reliabilities of the subscale scores (N=53)
Subscale Cronbach’s a
TMSI
Monitoring .84 - .87
Blunting .70 - .78
MBSS
Monitoring .79
Blunting .73
IES
Intrusive ideation .77 - .93
Avoidance ideation .70 - .89
MHLOC
Internal .73 - .86
Chance .80 - .84
Powerful others .51 - .79
HADS
Anxiety .82 - .90
Depression .52 - .87
CSES
Overall .68 - .79
Inspection of the scale distributions revealed that all subscales were normally 
distributed. The distributions for anxiety and depression illustrated a slight positive 
skew and kurtosis at baseline, indicating that most participants reported lower levels of
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experience of these constructs. This is not surprising given that participants have not yet 
started chemotherapy treatment and are therefore unlikely to be highly distressed. For 
this reason, a decision was made not to transform the variables. A small number of 
univariate outliers were identified. The univariate outliers were included in the analyses 
for two reasons: they were deemed to be within the acceptable limits of inclusion (they 
were around 3 decimal places from the mean) and they were necessary to maintain the 
moderate size of the sample thus ensuring adequate power of analyses (Tabachnik & 
Fidell, 2001).
In order to minimise Type I error, Bonferroni adjustments were made when a large 
number of analyses were conducted on a set of variables. Furthermore, in order to 
maximise the power of analyses, the number of categories of most of the demographic 
variables were collapsed into two categories. These variables and their revised 
categories included marital status (single or partnered), level of education (primary or 
secondary or tertiary level), employment status (employed or retired) and occupation 
(non-professionals or professionals). The two marital status categories were formed by 
combining the single, separated or divorced and widowed categories into one single 
category and keeping the married/de facto category. The level of education categories 
were formed by combining the primary school, year 10 and secondary school categories 
into one primary or secondary category and combining the undergraduate and 
postgraduate degree categories into one tertiary category.
The employment status categories were formed by deleting the one participant who was 
unemployed and maintaining those employed and retired participants in separate 
categories. The occupation categories were formed by combining professionals, 
associate professionals, and managers and administrators in one professional category 
and combining tradespersons and related workers, advanced clerical and service 
workers, intermediate clerical, sales and service workers, intermediate production and 
transport workers, elementary clerical, sales and service workers, and labourers and 
related workers into one non-professional category.
Backward elimination regression analyses were conducted to investigate whether 
monitoring and blunting were significant predictors of anxiety, depression and side 
effects while accounting for demographic, health, disease and treatment variables. The
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benefits of backward elimination regression analysis are two-fold: the method allows 
easy examination of general trends over time and increased degrees of freedom so a 
greater number of predictor variables can be included (allowing for more complex 
explanatory model to be employed). This was important given the exploratory nature of 
this research. This approach starts with the full model and eliminates the least 
significant predictors, resulting in a final model that contains only significant predictors. 
The advantage of this approach is that non-significant predictors do not detract variance 
away from the significant ones.
The data for each variable from every time-point were pooled into a single variable to 
create a repeated-measures data set (N=226). The regression analyses were conducted 
using a standard inclusion and exclusion criteria (inclusion criteria p < .05, exclusion 
criteria p > .051). Dummy coding was utilised to derive time-point dummy variables to 
distinguish the between observations made at different time-points. This resulted in five 
dummy variables which consisted of 0 or 1 (when the observation corresponded to the 
relevant time-point). Dummy coding was also used to derive a linear trend dummy 
variable to distinguish the effect of time on the variables investigated. This resulted in 
one dummy variable which consisted of 0, 1, 2, 3 or 4 (depending on the time-point at 
which the observation was made). For each backwards elimination regression analysis, 
time-point variables for Tl, T2, T3 and T4 were entered so that the changes in side 
effects at each time-point were considered according to the baseline levels at TO 
(Tabachnik & Fidell, 2001).
For those variables which were consistent across time-points (for example, demographic 
characteristics), the observations were entered at each time-point. Predictor variables 
were entered and consisted of two levels. For example, marital status was entered as 
single (1) or partnered (2). For those variables with more than two levels, each level 
became a single variable with dummy codes of two levels. For example, method of 
detection included four levels of self-examination by accident, breast self-examination, 
clinical examination and routine mammogram. Each method formed a single dependent 
variable and dummy codes were entered and consisted of no (0) or yes (1). Inspection of 
the pooled scale distributions for monitoring, blunting, intrusive and avoidant ideation, 
anxiety, depression and side effects revealed that all scales and subscales were normally 
distributed (Tabachnik & Fidell, 2001).
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Hierarchical regression analyses were conducted to investigate whether monitoring and 
blunting were significant predictors of perceived risks. Multivariate outlier analysis was 
conducted. A small number of multivariate outliers were identified. Given the 
sensitivity of the regression analyses to outliers, they were excluded from the analyses 
with the use of a p < .001 criterion for Mahalanobis distance. Occasions when outliers 
were excluded from analysis are indicated when relevant (Tabachnik & Fidell, 2001).
7.2 Sample Characteristics
7.2.1 Demographic Characteristics
Descriptive statistics were conducted to investigate the demographic characteristics of 
participants. Participants’ mean age was 52.65 (SD = 9.33) years, with a range from 
30.16 - 71.26 years. The marital status and state of residence are presented in Table 2. 
The majority of participants were married or de facto and equivalent amounts were 
single or separated and/or divorced. Participants resided mainly in the ACT, while the 
remaining participants lived in the surrounding NSW region.
Table 2
Marital Status, and State of Residence of Participants (N=53)
Variable /(% ) (n)
Marital status
Married/de facto 66.0 (35)
Separated/divorced 15.1 (8)
Single 15.1 (8)
Widowed 3.8 (2)
State of residence
ACT 79.2 (41)
NSW 20.8 ( ID
The education and occupational characteristics of participants are presented in Table 3. 
The majority of participants were highly educated, almost a quarter had completed 
secondary school and two-thirds had completed a tertiary qualification. Most 
participants were in full-time employment or retired. Of those employed, the majority 
were employed full-time. The occupations reflected the high level of education achieved
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with the majority working in professional appointments, followed almost equally by 
associate professional, managerial or administration, and clerical, sales or service 
positions.
Table 3
Education and Occupation Characteristics o f Participants (N=53)
Variable /(% ) (N)
Education level
Primary school 3.8 (2)
Year 10 9.4 (5)
Secondary school 24.5 (13)
Undergraduate degree 45.3 (24)
Postgraduate degree 17.0 (9)
Employment status
Employed 69.8 (37)
Retired 28.3 (15)
Unemployed 1.9 (1)
Employment intensity
Full-time 81.1 (30)
Part-time 18.9 (7)
Occupation
Professional 39.6 (21)
Managerial/administration 9.4 (5)
Associate professional 7.5 (4)
Advanced clerical/sales/service 5.7 (3)
Intermediate clerical/sales/service 7.5 (4)
7.2.2 Health Characteristics
The methods of detection and referral sources of participants are reported in Table 4. 
When considering the method of disease detection, over half of participants detected a 
lump by themselves accidentally. Almost one-fifth of women detected the disease via 
breast self-examination (BSE) and routine mammogram and only a small number via 
clinical examination by a general practitioner or other medical professional. The 
majority of participants were referred to the project by their treating medical oncologist,
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with the remaining by either their breast care nurse or chemotherapy nursing staff. All 
of the 6 medical oncologists approached to act as a referral source to the project agreed. 
Oncologists referred a mean of 8.83 (SD=9.50) participants to the study, with a range of 
1 to 27 participants.
Table 4
Methods of Detection and Referral Sources of Participants (N=53)
Variable /(% ) (n)
Method of detection
Self examination (accident) 58.5 (31)
Self examination (BSE) 18.9 (10)
Mammogram 17.0 (9)
Clinical examination 5.7 (3)
Referral source
Oncologist 77.4 (41)
Breast care nurse 13.2 (7)
Hospital nurse 9.4 (5)
Almost two-thirds of participants were public patients (62.3%) and over one-third 
private (37.7%). Most women attended The Canberra Hospital (34.0%), Calvary 
Hospital (28.3%) and The National Capital Hospital (28.3%). The remaining few 
participants attended John James Memorial Hospital (9.4%).
7.2.3 Disease Characteristics
Descriptive statistics were again conducted to investigate the disease characteristics of 
participants. Participants’ number of tumours, tumour grade, number of affected axillary 
nodes are reported in Table 5. All participants were diagnosed with early breast 
carcinoma. The overwhelming majority of participants (92.5% or 42 participants) were 
diagnosed with infiltrating duct carcinoma. Of the remaining forms of EBC diagnosed, 
infiltrating lobular carcinoma, infiltrating duct and lobular carcinoma, infiltrating 
pleomorphic carcinoma, and infiltrating micropapillary carcinoma, were each diagnosed 
in one participant (1.9%). This distribution roughly reflects the histology subtypes of 
breast cancer cases diagnosed nationally in Australia (AIHW & NBCC, 2006). There 
was a greater number of participants diagnosed with infiltrating ductal carcinoma
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compared to the national rates but this may be due to the inclusion of all cases of breast 
cancer, early and advanced, in the national rates.
Most participants had one tumour, with a range of 1 to 8 tumours. The mean tumour 
size was calculated by considering only the largest tumour for those with several 
tumours, as is usual practice by oncologists (AIHW & NBCC, 2006; Chap et al., 
2001a). The mean tumour size was 29.51mm (SD= 16.09). Most participants were 
diagnosed with a histological grade of 3. Over two-thirds of participants had evidence 
of lymph node metastases. The mean number of affected lymph nodes was 6.64 
(SD=7.42), with a range of 1 to 29. The majority of participants had oestrogen receptor 
(OR) positive status (64.2%), progesterone receptor (PR) positive status (56.6%) and 
HER2 receptor negative status (75.5%). Most women were post-menopausal at 
diagnosis (60.4%) and the remainder were pre-menopausal (39.6%).
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Table 5
Tumour characteristics o f Participants (N=53)
Variables /(% ) (n)
Number of tumours
1 84.9 (45)
2-3 11.4 (6)
>3 3.8 (2)
Tumour grade
1 1.9 (1)
2 24.5 (13)
3 73.9 (39)
DCIS
Positive 71.7 (38)
Negative 28.3 (15)
LCIS
Positive 7.5 (4)
Negative 92.5 (49)
Affected axillary nodes involved
0 32.1 (17)
1-3 30.2 (15)
4-9 20.8 ( I D
>9 17.0 (9)
7.2.4 Surgical Treatment
Descriptive statistics were conducted to determine the characteristics of surgical 
intervention. All participants received surgical intervention. The majority of participants 
underwent one surgery (73.6%), although over one-quarter underwent two surgeries 
(26.4%). The type of surgical intervention received is presented in Table 6. Most 
participants underwent a unilateral total mastectomy (TM) or breast conserving surgery 
(BCS). For those undergoing two surgeries, the mean amount of time between 
procedures was 22.79 (SD =9.67) days with a range from 13 to 45 days.
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Table 6
Type of Surgical Intervention Received (N=53)
Surgery type /(% ) (n)
TM 47.2 (25)
BCS 34.0 (18)
BCS plus TM 11.3 (6)
Bilateral TM 7.5 (4)
Note. TM (Total mastectomy), BCS (Breast conserving surgery), BCS plus TM (Breast 
conserving surgery followed by total mastectomy), Bilateral TM (Bilateral total 
mastectomy).
7.2.5 Adjuvant Chemotherapy Treatment
On average, chemotherapy commenced with the first infusion 36.34 (SD =14.66) days 
after the final surgery, with a range of 14-92 days. As evident in Table 7, participants 
were prescribed a range of chemotherapeutic regimens. The most common regimen was 
FEC which just under half of all participants were prescribed, followed by AC plus 
Taxol, which around one-quarter were prescribed. Correspondingly, this meant that 
most participants underwent six treatment cycles (64.2% or 34 participants) while the 
remaining participants underwent 8 cycles (30.2% or 16 participants) and 4 cycles 
(5.7% or 3 participants). The majority underwent treatment cycles of 21 days’ duration 
(73.6% or 39 participants) and equal numbers underwent cycles of 28 days’ (15.1% or 8 
participants) and 14 days’ (11.3% or 6 participants) duration. The overwhelming 
majority of participants were not taking either antidepressants (98.1%) or anxiolytic 
(96.2%) at diagnosis and throughout chemotherapy.
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Table 7
Participants’ Prescribed Adjuvant Chemotherapy Treatment Regimens (N=53)
Variables /(% ) (n)
Chemotherapy Regimen 
FEC 49.1 (26)
Oral CMF 11.3 (6)
AC 7.5 (4)
AC plus Taxol 24.5 (13)
EC plus Taxol 5.7 (3)
Note. FEC (5-fluorouracil, epirubicin, and cyclophosphamide), Oral CMF 
(cyclophosphamide, methotrexate and 5-fluorouracil), AC (adrimyacin and 
cyclophosphamide), AC plus Taxol (adrimyacin and cyclophosphamide followed by 
Taxol), EC plus Taxol (epirubicin and cyclophosphamide followed by Taxol).
The chemotherapeutic drugs received at TI, T2 and T3 are presented in Table 8 and are 
in line with the regimens prescribed prior to treatment. In line with the prescribed 
regimens, the majority of participants received FEC followed by AC plus Taxol. T2 was 
most commonly the third or fourth treatment and T3 was the sixth or eighth treatment 
received. Small changes in the number of participants receiving the chemotherapeutic 
drugs at each cycle assessed is due to participants’ experience of excessive side effects 
and therefore the subsequent change to less toxic regimens.
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Table 8
Chemotherapeutic Drugs Received at the First, Middle, and Final Chemotherapy 
Treatments (N=53)
Chemotherapeutic drugs T1
/(% ) in)
T2
/(% ) in)
T3
/(% ) (n)
FEC 49.1 (26) 50.9 (27) 45.3 (24)
AC 32.1 (17) 32.1 (17) 11.3 (6)
EC 5.7 (3) 5.7 (3)
Oral CMF 11.3 (6) 11.3 (6) 13.2 (7)
Taxol 30.2 (16)
Note. FEC (5-fluorouracil, epirubicin, and cyclophosphamide), AC (adrimyacin and 
cyclophosphamide), EC (epirubicin and cyclophosphamide), Oral CMF 
(cyclophosphamide, methotrexate and 5-fluorouracil), and Taxol.
The levels of anti-emetic medication prescribed at TI, T2 and T3 are presented in Table 
9. The majority of participants received the combination of 5 HT3 agonist and 
corticosteroid. The numbers of those receiving this ievel of anti-emetic medication 
declined over time. A small number of participants switched to the more intensive anti­
emetic medication of the combination of 5 HT3 agonist and corticosteroid plus an 
apprepitant and/or anxiolytic. Others switched to less intensive anti-emetic medication 
of the single anti-emetic and most likely included those who were prescribed the AC or 
EC plus Taxol regimen. These participants received AC or EC for T1 and T2, and Taxol 
for T3. Taxol is considered a less emetogenic chemotherapeutic drug than AC or EC 
and therefore participants required a less intensive anti-emetic medication at T3.
Table 9
Anti-emetic Medication at the First, Middle, and Final Chemotherapy Treatments 
(N=53)
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Anti-emetic medication T1 T2 T3
/(% ) (n) /(% ) (n) /(% ) in)
Level 0 9.4 (5)
Level 1 7.5 (4) 7.5 (4) 18.9 (10)
Level 2 84.5 (45) 66.0 (35) 43.4 (23)
Level 3 7.5 (4) 26.4 (14) 28.3 (15)
Participants received additional support during their treatment via the prescription of 
GCSF support, reduction of chemotherapeutic drug dose, delay of treatment cycle and 
hospitalisation. GCSF support, dose reductions and treatment delays occurred only at 
T2 and T3. At T2, almost half of the participants received GCSF support (43.4%) but 
this declined to around one-third at T3 (34.0%).
A dose reduction was carried out for over one-quarter of participants (26.4%) at T2. The 
mean reduction from standard dosage was 18.65% (SD=9.28), ranging from 5% to 40%. 
The number receiving a dose reduction increased slightly to almost one-third of 
participants (32.1%) at T3. The mean dose reduction from standard dosage was 24.17% 
(SD= 14.63), ranging from 10% to 55%. At T2, almost one-quarter of participants 
(18.9%) delayed their treatment a mean of 4.90 (579=2.77) days and a range from 2 to 9 
days. After the final treatment, the number declined to just two participants (3.8%) with 
a mean of 3 days and a range from 1 to 6 days. Treatment delays were all carried out 
due to excessive side effects from chemotherapy.
A small but considerable number of 6 participants (11.3%) were hospitalised at T1 for 
neutropenia, fever, dehydration, and cellulitis associated with the surgery wound. Only 
2 participants (3.8%) were hospitalised at T2 for fever and haematoemesis due to a 
Mallory-Weiss tear. An increased number of 6 participants (11.3%) were hospitalised at 
T3 for neutropenia, tachycardia, dehydration, and thrombosis. It is possible that the 
number of participants requiring hospitalisation decreased at T2 due to adjustments to 
the regimens (for example, changes to chemotherapy regimen, dose reductions, and 
treatment delays) and increases in the anti-emetic and GCSF support provided. The
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increase at T3 may be due to an accumulation of toxicity across the treatments, despite 
the alterations to the treatment provided (Tucker, Chap, & Haskell, 2001).
7.2.6 Radiation Therapy Characteristics
Participants were followed up approximately 6 months post-completion of 
chemotherapy treatment, with a mean of 194.78 (SD=33.71) days post-chemotherapy 
and a range of 128-272 days. Upon completion of adjuvant chemotherapy, the majority 
of participants (84.5%) received radiation therapy. On average, participants started 
radiation therapy 36.14 (SD=12.27) days following the final chemotherapy infusion, 
with a range from 13-76 days. The treatment lasted a mean of 40.44 (SD=5.94) days 
with a range from 21-51 days. On average, participants completed radiation therapy 
163.57 (SD=35.29) days before the six-month follow-up questionnaire, with a range 
from 105-259 days.
7.2.7 Endocrine Therapy Characteristics
Following completion of chemotherapy and radiation therapy, the majority of 
participants (63.2%) commenced endocrine therapy. Of these participants, five years of 
Tamoxifen was prescribed for almost two-thirds of participants (63.6%), Arimidex for 
over one-quarter of participants (27.3%), and Zoladex was rarely prescribed (3.0%).
The endocrine therapy prescribed was unknown for 2 (6.1%) participants.
7.3 Analysis of Drop-Outs
7.3.1 Demographic Characteristics
Analyses were conducted to determine whether there was a difference in demographic, 
medical, disease, and treatment characteristics of those participants who completed 
questionnaires at all time-points and those who failed to complete at least one 
questionnaire at any of the time-points. A Bonferroni adjustment of a  = .007 was 
applied to the results of the analyses of demographic variables. The completers and 
drop-outs reported similar ages. Completers had a mean age of 53.81 (SD = 7.82) years 
while drop-outs had a mean age of 51.05 {SD = 11.12) years. The marital status and 
state of residence of completers and drop-outs are presented in Table 10. An 
independent-samples t-test revealed no significant difference in age between completers 
and drop-outs (t (51)= 1.08, p > .007). Chi-square tests revealed no significant
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difference between the two groups in marital status (Xn (1) = .08, p > .007) and state of 
residence (X 2 (1) = .09, p > .007).
Table 10
Demographic Characteristics o f Completers (32) and Drop-outs (21)
Variable Completers Drop-outs
/(% ) in ) /(% ) in )
Marital status
Married/de facto 64.5 (20) 68.2 (15)
Separated/Divorced 12.9 (4) 18.2 (4)
Single 16.1 (5) 13.6 (3)
Widowed 6.5 (2)
State of residence
ACT 80.6 (25) 77.3 (17)
NSW 19.4 (6) 22.7 (5)
The educational and occupational characteristics of the completers and drop-outs are 
presented in Table 11. A series of independent-samples t-tests revealed that there were 
no significant differences between the two groups in terms of education level (t (51) = 
.03, p > .007), employment status (t (51) = .35, p > .007), and employment intensity (t 
(37) = .31, p  > .007). A chi-square test of the two groups and occupation type revealed 
no significant differences for the two groups (X~ (4) = 4.86, p > .007).
Table 11
Education and Occupation Characteristics o f Completers (N=32) and Drop-outs 
(N=21)
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Variable Completers 
/(% ) (n)
Drop-outs 
/(% ) (*)
Education level
Primary school 6.5 (2)
Year 10 12.9 (4) 4.5 (1)
High School 19.4 (6) 31.8 (7)
University Degree 38.7 (12) 54.5 (12)
Postgraduate Degree 22.6 (7) 9.1 (2)
Employment status
Employed 74.2 (23) 63.6 (14)
Unemployed 4.5 (1)
Retired 25.8 (8) 31.8 (7)
Employment Intensity
Full-time 78.3 (18) 85.7 (12)
Part-time 21.7 (5) 14.3 (2)
Occupational
Professional 21.7 (5)
Managerial/administration 52.2 (12) 64.3 (9)
Associate professional 13.0 (3) 7.1 (1)
Advanced clerical/sales/service 4.3 (1) 14.3 (2)
Intermediate clerical/sales/service 8.7 (2) 14.3 (2)
7.3.2. Health Characteristics
The health characteristics of completers and drop-outs are presented in Table 12. Chi- 
square analyses were conducted using a Bonferroni adjustment of a  = .017. The results 
revealed that there were no significant differences between the two groups on method of 
detection (X2 (3) = .92, p > .017), referral source (X2 (2) = 3.95, p > .017) and patient 
health care status (X2 (1) = .56, p > .017).
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Table 12
Methods o f Detection and Referral Sources o f Completers (N=32) and Non-Completers
(N=21)
Variable Completers 
f ( %)  (n)
Drop-outs 
f ( %)  (n)
Method of Detection
Self Examination (accidental) 61.3 (19) 54.5 (12)
Self Examination (BSE) 19.4 (6) 18.2 (4)
Clinical Examination 3.2 (1) 9.1 (2)
Routine Mammography 16.1 (5) 18.2 (4)
Referral Source
Oncologist 71.0 (22) 86.4 (19)
Breast care nurse 12.9 (4) 13.6 (3)
Hospital nurse 16.1 (5)
Patient Health Care Status
Public 58.1 (18) 68.2 (15)
Private 41.9 (13) 31.8 (7)
7.3.3 Disease Characteristics
The disease characteristics of completers and drop-outs are presented in Table 13. A 
series of independent-samples t-test were conducted using a Bonferroni adjustment of 
a=.007. Completers and drop-outs had similar tumour sizes. Completers had a mean 
tumour size of 1.23mm (SD = 0.56) while drop-outs had a mean of 1.59mm (SD =
1.71). Menopausal status was somewhat similar, 29.0% of completers were pre­
menopausal (9 participants) and 71.0% were post-menopausal While to 54.5% of drop­
outs were pre-menopausal and 45.5% were post-menopausal. The results indicated there 
were no significant differences between the two groups on number of tumours (r (51) = 
-1.11, p > .007), tumour size (t (51) = -1.36, p > .007), and the number of affected 
axillary nodes (t (51) = -.07, p > .007). Chi-square analyses revealed no significant 
differences between the groups on tumour grade (X2 (2) = .83, p > .007), DCIS (X2 (1) = 
.27, p > .007), LCIS (X2(l) = .67, p > .007), and menopausal status (X2(l)  = 3.50, p > 
.007).
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Table 13
Tumour characteristics o f Completers (N=32) and Drop-outs (N=21)
Variables Completers 
/(% ) (n)
Drop-outs 
/(% ) (n)
Number of tumours
1 83.9 (26) 86.4 (19)
2-3 16.1 (5) 4.5 (1)
>3 9.0 (2)
Tumour grade
1 3.2 (1)
2 22.6 (7) 27.3 (6)
3 74.2 (23) 72.7 (16)
DCIS
Positive 74.2 (23) 68.2 (15)
Negative 25.8 (8) 31.8 (7)
LCIS
Positive 9.7 (3) 95.5 (21)
Negative 90.3 (28) 4.5 (1)
Number of affected axillary nodes
0 38.7 (12) 22.7 (5)
1-3 22.4 (7) 40.5 (9)
4-9 22.4 (7) 18.0 (4)
>9 16.0 (5) 18.0 (4)
7.3.4 Treatment Characteristics
The surgical treatment characteristics of completers and drop-outs are presented in 
Table 14. A Bonferroni adjustment of a  = .025 was applied to the analyses of surgical 
characteristics. Chi-square tests revealed no significant differences in the number of 
surgeries (X2 (1) = .26, p > .025) and the type of surgery performed (X2 (3) = 7.54, p > 
.025).
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Table 14
Type of Surgical Intervention Received by Completers (N=32) and Drop-outs (N-21) 
Variable Completers Drop-outs
_____________________________ /(% ) (n)_________/(% ) (n)____________
Number of surgeries
1 71.0 (22) 77.3 (17)
2 29.0 (9) 22.7 (5)
Surgery type
TM 51.6 (16) 40.9 (9)
BCS 32.3 (10) 36.4 (8)
BCS plus TM 16.1 (5) 4.5 (1)
Bilateral TM 18.2 (4)
Note. TM (Total mastectomy), BCS (Breast conserving surgery), BCS plus TM (Breast 
conserving surgery followed by total mastectomy), Bilateral TM (Bilateral total 
mastectomy).
The chemotherapy treatment regimen of completers and drop-outs are presented in 
Table 15. Chi-square tests revealed no significant differences in the type of 
chemotherapy regimen (X2 (4) = 2.87, p > .05).
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Table 15
Prescribed Adjuvant Chemotherapy Treatment Regimens for Completers (N=32) and 
Drop-outs (N=21)
Variables Completers Drop-outs
/(% ) (n) /(% ) (n)
Chemotherapy Regimen
FEC 46.9 (15) 57.1 (12)
Oral CMF 15.6 (5) 4.8 (1)
AC 9.4 (3) 4.8 (1)
AC plus Taxol 25.0 (8) 23.8 (5)
EC plus Taxol 3.1 (1) 9.5 (2)
Note. FEC (5-fluorouracil, epirubicin, and cyclophosphamide), Oral CMF 
(cyclophosphamide, methotrexate and 5-fluorouracil), AC (adrimyacin and 
cyclophosphamide), AC plus Taxol (adrimyacin and cyclophosphamide followed by 
Taxol), EC plus Taxol (epirubicin and cyclophosphamide followed by Taxol).
7.3.5 Clinical Characteristics
The baseline psychological variables for completers and drop-outs are presented in 
Table 16. A series of independent-samples t-tests were conducted to determine whether 
there were any differences in the completers and drop-outs on baseline measures of 
these psychological variables. A Bonferroni adjustment of a  = .004 was applied to the 
results of the analyses of psychological variables. As illustrated in Table 16, there were 
no significant differences between the two groups on anxiety (r (51) = .04, p > .004), 
depression (r (51) =-1.34, p > .004), side effects (t (51) = -1.84, p > .004), intrusive 
ideation (r (51) = -.63, p > .004), avoidant ideation (t (51) = -.91, p > .004), internal (t 
(51) = -1.31,p> .004), chance (t (51) = -.08, p > .004), and powerful others (t (51) = - 
1.37, p > .004) locus of control beliefs and personal (t (34) = .60, p > .004), peer (t (34) 
= -.24, p > .004) and comparative (t (34) = 1.69, p > .004) perceived risk of recurrence.
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Table 16
Baseline Psychological Variables for Completers (N=32) and Drop-outs (N -21)
Variables Completers Drop-outs
M SD M SD
Anxiety 4.13 2.70 4.09 4.65
Depression 2.39 1.71 3.45 3.43
Side effects 4.35 2.90 6.27 4.66
Intrusive Ideation 2.84 3.88 13.64 5.36
Avoidant Ideation 10.84 3.68 11.86 4.51
Internal LOC 17.77 5.65 19.82 5.54
Chance LOC 17.56 6.61 17.72 7.34
Powerful Others LOC 26.32 5.37 28.00 3.52
Personal Perceived Risk 4.64 2.21 4.00 2.24
Peer Perceived Risk 4.77 2.00 5.00 1.58
Comparative Perceived Risk -.13 .95 -1.00 1.73
7.4 Monitoring and Blunting Coping Styles
7.4.1 Monitoring and Blunting Interaction Term 
Before investigating the distribution of monitoring and blunting coping style scores 
reported, an interaction term was calculated. While high scores on monitoring and 
blunting indicate the independent use of monitoring and blunting coping styles, an 
interaction term indicates use of both coping styles. That is, a high score on the 
interaction term indicates a greater use of both monitoring and blunting and a low score 
indicates little use of either monitoring or blunting. Middle scores indicate either a 
moderate use of both monitoring and blunting or greater use of one but not the other. To 
calculate the interaction term, monitoring and blunting scores were centred by using the 
following formula; (Xm-Xm) x (Xb-Xb), where Xm represents the raw monitoring score, 
Xm the mean monitoring score, Xb the raw blunting score and Xb the mean blunting 
score.
7.4.2 Monitoring and Blunting Coping
To investigate participants’ use of monitoring and blunting coping styles, descriptive 
statistics were calculated for monitoring, blunting and the interaction term scores at TO 
and the results are reported in Table 17. At TO, it appears that participants reported
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blunting more than monitoring and this was confirmed by a paired-samples t-test (t (52) 
= -2.31, p < .025). Investigation as to whether monitoring and blunting coping were 
separate dimensions of coping revealed that there was a small, positive but non­
significant association between monitoring and blunting scores at TO (r = .20, p > .05).
Table 17
Descriptive Statistics of Monitoring, Blunting and the Interaction Term Scores on the 
TMSI at TO (N=53)
Variable M SD Range Skewness Kurtosis
Monitoring 40.09 10.68 17-60 -.61 -.21
Blunting 44.11 9.30 24-59 -.44 -.38
Monitoring-Blunting 19.74 89.60 -238.86 - 255.52 -.16 2.55
Monitoring and blunting were again assessed at T4. The interaction term for these 
scores was calculated and the descriptive statistics of monitoring, blunting, and the 
interaction term scores at T4. The results are presented in Table 18 and suggest that 
participants reported similar levels of monitoring and blunting and this was confirmed 
by a paired samples t-test (t (35) = 1.21, p > .05). Investigation as to whether 
monitoring and blunting coping at T4 were separate dimensions of coping again 
revealed that there was little association between monitoring and blunting scores at T4 
(r = .05, p > .05).
Table 18
Descriptive Statistics of Monitoring, Blunting and the Interaction Term Scores on the 
TMSI at T4 (N=35)
Variable M SD Range Skewness Kurtosis
Monitoring 42.54 8.28 18-55 -.85 .96
Blunting 44.54 5.93 32-60 .30 .54
Monitoring-Blunting 2.46 34.44 -93.55 - 81.07 -.47 1.53
To investigate the stability of monitoring and blunting coping, Pearson product-moment 
correlations and paired-samples t-tests were conducted on monitoring, blunting, and the 
interaction term scores at TO and T4. Test-retest reliability estimates were moderate for 
monitoring (r = .61, p < .05) and low for blunting (r = .25, p > .05) and the interaction
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term (r = .38, p < .05). Paired-samples t-tests revealed that there was a significant 
increase in monitoring scores from TO to T4 (t (35) = 2.58, p < .05), but no significant 
difference in blunting scores (t (35) = -.78, p > .05) and the interaction term scores (t 
(35) = .76, p > .05).
Monitoring and blunting were also assessed using the Miller Behavioral Style Scale 
(MBSS) at T4. The interaction term was again calculated and the descriptive statistics 
for the monitoring, blunting, and interaction term scores are presented in Table 19. 
Participants appeared to report the use of more monitoring than blunting on the MBSS 
and this was confirmed by a paired-samples t-test (t (19) = 2.70, p < .05). To investigate 
whether monitoring and blunting were separate dimensions of coping as measured by 
the MBSS, a Pearson product-moment correlation showed that there was a small, 
positive but non-significant association between monitoring and blunting (r = .27, p > 
.05).
Table 19
Descriptive Statistics of Monitoring, Blunting and the Interaction Term Scores on the 
MBSS at T4 (N=35)
Variable M SD Range Skewness Kurtosis
Monitoring 52.90 8.79 31 -68 -.86 .89
Blunting 46.60 8.45 34-60 .94 .31
Monitoring-Blunting 19.26 47.96 -75.50- 131.40 .59 1.05
To investigate the concurrent validity of the TMSI, the relationships between 
monitoring and blunting assessed by the TMSI and MBSS were investigated. Pearson 
product-moment correlations revealed a positive, moderate to strong and significant 
association between monitoring scores on the TMSI and MBSS at T4 (r = .75, p < .05), 
and positive, small to moderate but non-significant associations between the blunting 
scores (r = .40, p > .05) and interaction scores (r = .23, p > .05).
7.4.3 Monitoring and Blunting Coping and Demographic Characteristics 
To determine whether monitoring and blunting coping are associated with demographic, 
health, disease and treatment characteristics, a series of analyses were conducted. To 
investigate the relationships between monitoring and blunting coping and the
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demographic characteristics, a Bonferroni adjustment of a  = .007 was applied to the 
results of the analyses. Pearson product-moment correlations revealed negative, small 
and non-significant associations between age and monitoring (r = -.12, p > .007), 
blunting (r = -.20, p > .007), and the interaction term (r = -.05, p > .007).
Independent-samples t-tests revealed no difference in marital status for monitoring (t 
(51) = -1.79, p > .007), blunting (t (51) = .71, p > .007) and the interaction term (r (51)
= -1.17,/? > .007). There was no difference in state of residence for monitoring (t (51) = 
2.72, p .007), blunting (t (51)= 1.85, p > .007) and the interaction term (t (51)= 1.26, 
p > .007). There was no difference in education level for monitoring (t (51) = -.15 p > 
.007), blunting (t (51) = .81, p > .007) and the interaction term (t (51)= 1.77, p > .007).
There was no difference in employment status for monitoring (t (50) = -.07, p > .007), 
blunting (t (50) = .30, p > .007) and the interaction term (t (50) = -.20, p > .007). There 
was no difference in employment intensity for monitoring (t (35) = -.22, p > .007), 
blunting (t (35) = -.86, p > .007) and the interaction term (t (35) = -2.62, p > .007). 
There was no difference in occupational status for monitoring (t (35) = -.17, p > .007), 
blunting (t (35) = -2.37, p > .007) and the interaction term (t (35) = -1.31, p > .007).
7.4.4 Monitoring and Blunting Coping and Health Characteristics 
Analyses were also conducted to investigate the relationships between monitoring, 
blunting and the interaction term and health variables using a Bonferroni adjustment of 
a  = .012. Independent-samples t-tests revealed no significant differences in monitoring 
(f (50.96) = .23, p > .012), blunting (t (51) = 1.45, p > .012) and the interaction term (t 
(44.16) = .88, p > .012) according to patient health care status. Levene’s test of equality 
of variances were significant for the t-tests of patient status and monitoring (F = 5.34, p 
< .05) and the interaction term (F = 6.74, p < .05) so the t-tests with variance not 
assumed were considered (Pallant, 2001).
There were no significant differences in monitoring (t (51) = 1.03, p > .012), blunting (f 
(51) = .95, p > .012) and interaction term (t (51) = -.24,p  > .012) scores according to 
menopausal status. One-way ANOVAs also revealed no significant differences in 
monitoring (F(3, 49) = .47, p > .012 and F( 2, 50) = .35, p > .012 respectively), 
blunting (F (3, 49) = 1.89, p > .012 and F (2, 50) = .46, p > .012) and the interaction
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term (F (3, 49) = 1.63, p > .012 and F (2, 50) = . 18, p > .012) according to the method 
of detection and referral source.
7.4.5 Monitoring and Blunting Coping and Disease Characteristics 
Investigation of the differences in disease characteristics according to monitoring, 
blunting and the interaction term were conducted using a Bonferroni adjustment of a  = 
.008. Pearson product-moment correlations revealed no significant differences between 
number of tumours and tumour size and monitoring (r = .08, p > .008 and r = .05, p > 
.008), blunting (r = -.06, p > .008 and r = .29, p > .008) and the interaction term (r = 
.13, p > .008 and r = .09, p > .008). One-way ANOVAs showed no significant 
differences in monitoring (F (2, 50) = 1.75, p > .008), blunting (F (2, 50) = .87, p >
.008) and the interaction term (F (2, 50) = 2.00, p > .008) according to tumour grade.
Independent-samples t-tests revealed no significant differences in the presence of DCIS 
and LCIS on monitoring (7 (51) = -.66, p > .008 and t (51) = -1.11, p > .008 
respectively), blunting (f (51) = .11, p > .008 and t (51) = .52, p > .008) and the 
interaction term (t (51) = -.66, p > .008 and t (51) = .45, p > .008). Pearson product- 
moment correlations revealed no significant associations between the number of 
affected axillary lymph nodes and monitoring (r = .19, p > .008), blunting (r = .06, p > 
.008) and the interaction term (r = .04, p > .008).
7.4.6 Monitoring and Blunting Coping and Treatment Characteristics 
Analyses of the differences in treatment characteristics according to monitoring, 
blunting and the interaction term were conducted using a Bonferroni adjustment of a  = 
.025. Independent-samples t-tests revealed no significant differences in monitoring (t 
(17.67) = .25, p > .025), blunting (t (51) = -.81, p > .025) and the interaction term (t 
(51) =1.06, p > .025) according to the number of surgeries undergone. Levene’s test of 
equality of variance was significant for the t-test of the number of surgeries and 
monitoring (F = 4.86, p < .05) so the t-test of equality of variances not assumed was 
considered (Pallant, 2001). One-way ANOVAs revealed no significant differences in 
type of surgery and monitoring (F (3, 49) = 1.41, p > .025), blunting (F (3, 49) = 1.25, p 
> .025) and the interaction term (F (3, 49) = 1.16, p > .025) scores.
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7.5 Discussion
The demographic, health, disease, treatment and clinical characteristics of the sample 
were investigated in order to provide an overall description of the nature of the sample 
recruited. The results revealed several advantages of the present study compared to 
those previously conducted. The sample size is similar to those reported in other 
published prospective studies of women with EBC undergoing treatment (Bishop & 
Warr, 2003; Jacobsen & Butler, 1996; Lerman et al., 1990; Manne et al., 1994; Shapiro 
et al., 1997). However, when considering the number of assessment points and the 
period over which they occur in the present study in comparison to those in the 
literature, the sample size is considerable.
The present sample was homogenous in terms of demographic, health, disease, 
treatment and baseline clinical characteristics. The homogeneity in health, disease, 
treatment and clinical characteristics was no doubt due to the strict inclusion criteria. 
Most prospective studies include samples that differ significantly in terms of disease, 
treatment, and to a lesser extent, demographic characteristics (Culver et al., 2002; 
Epping-Jordan et al., 1999; Hack & Degner, 1999, 2004; McCaul et al., 1999;
Osowiecki & Compas, 1999). There was some variation in the sample on specific 
characteristics but this variation was representative of women diagnosed with EBC in 
Australia.
Of the demographic and health characteristics, participants reported a wide range of 
ages, indicative of the full range of ages at which breast cancer is diagnosed in 
Australian women (AIHW & AACR, 2004, 2006). A number of women in the study 
lived outside of the ACT, in the surrounding region of NSW, which is indicative of the 
breast cancer patients treated in the ACT (AIHW & AACR, 2004). Participants reported 
high levels of education and professional employment, which is in line with the 
available data of ACT residents (AIHW, 2003).
Participants detected their disease using a range of methods. Fewer participants reported 
detecting the disease via routine mammogram than the national statistics but this is due 
to the number of women under the age of 50 years who are not targeted by BreastScreen 
Australia program (AIHW, 2005). Most participants were referred to the project by their 
treating oncologist. Oncologists were in the most advantageous position to discuss
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research participation because consultations occur immediately prior to chemotherapy 
treatment and involve discussion of the treatment.
All participants reported similar diagnoses in terms of tumour type, size, grade, axillary 
node involvement, and presence of DCIS and LCIS, typical of EBC (AIHW, 2006). All 
treatment was in line with the recommendations for women diagnosed with EBC 
(NHMRC & NBCC, 2001). The only variation was the time between surgical treatment 
and the commencement of chemotherapy treatment varied widely. This is perhaps 
expected given that the interim period involves recovery from surgery, receipt of full 
diagnosis, and decision-making regrading treatment options, all of which may require 
significant time (NHMRC & NBCC, 2001).
Interestingly, there were no significant differences between those participants who 
completed all questionnaires and those who failed to complete at least one questionnaire 
on any of the demographic, health, disease, surgical treatment, chemotherapy regimen, 
and baseline clinical characteristics. It might be expected that participants who were 
more distressed at baseline were less likely to complete all questionnaires. The reason 
for this is likely due to the homogeneity of the overall sample on these characteristics. 
This enabled all cases to be included in the analyses.
Of interest was participants’ use of monitoring and blunting coping styles. Monitoring 
and blunting scores were investigated to determine the psychometric properties of the 
TMSI, participants’ use of monitoring and blunting coping styles and the nature of 
monitoring and blunting coping styles. It was expected that participants used a wide 
range of monitoring and blunting coping styles, that the TMSI is an acceptable measure 
of monitoring and blunting coping styles and that monitoring and blunting are mutually 
exclusive, stable constructs that were unrelated to demographic, health, disease and 
treatment characteristics.
Participants reported a wide range of use of coping styles on both the TMSI and MBSS 
scales, although distribution was more restricted on the MBSS scales. The monitoring 
and blunting coping scores were similar to those reported in other samples, including 
those at risk of breast, ovarian or cervical cancer (Miller et al., 1999a; Miller, Fang, 
Manne, Engstrom, & Daly, 1999b; Rees & Bath, 2000; Tercyak et al., 2001) and those
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with cancer (Gard et al., 1988; Lerman et al., 1990; Ong et al., 1999; Petersson et ah,
2002) .
The TMSI appears to be an acceptable measure of monitoring and to a lesser extent, 
blunting coping. The internal consistencies were excellent for the monitoring subscale 
and adequate for the blunting subscale. This pattern of internal consistencies is in line 
with those reported in the literature (van Zuuren et ah, 1996; van Zuuren et ah, 1999). It 
has been speculated that the blunting coping style is a more heterogeneous construct 
than the monitoring coping style (Muris & Schouten, 1994). Therefore, it is possible 
that the number of blunting coping behaviours included in the TMSI fails to fully 
capture the construct and results in the low internal consistency.
The test-retest reliabilities of the TMSI coping style scores were moderate for 
monitoring and low for blunting. The low test-retest reliability of blunting does not fully 
support the theoretical conceptualisation of blunting as a stable, dispositional attribute 
(Miller, 1987, 1996; Miller et ah, 1993). However, blunting may be a relatively stable 
attribute but that attribute is not fully captured by the TMSI due to the blunting 
construct’s heterogeneity (Muris & Schouten, 1994), thus test-retest reliability is low. 
The TMSI and MBSS monitoring and blunting scores were unrelated at baseline and 
six-month follow-up. This confers with the theoretical conceptualisation of monitoring 
and blunting as mutually exclusive coping constructs. A lack of association between the 
coping styles has been consistently reported in the literature (Muris & Schouten, 1994).
The blunting scores were similar at baseline and six-month follow-up, but the 
monitoring scores were increased at follow-up. Participants were encouraged by 
medical professionals to monitor their physical wellbeing. Some physical symptoms 
experienced during chemotherapy indicate conditions that require medical attention. For 
example, participants are asked to contact the hospital if they develop a fever. A fever 
during chemotherapy may indicate the body’s immune system is compromised, leaving 
the participant vulnerable to infection (NHMRC & NBCC, 2001). Some participants 
were even asked to keep a diary of their experience for medical professionals. 
Participants may have been frequently asked how they are coping with their treatment 
by family and friends. This may force them to continually reflect on their wellbeing and 
therefore lead to the increased use of monitoring coping over time.
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Monitoring and blunting coping were not associated with any of the demographic, 
health, disease and treatment characteristics. This confirms the theory that monitoring 
and blunting coping styles are attributions that are largely independent of personal and 
situational factors. This is in line with the previous research that suggests the coping 
styles are unrelated to the situational factors (for example, type of stressful situation -  
stressful physical or psychological task) (Miller, 1987) and person factors (for example, 
trait anxiety, hypochondriasis, or medical fears) (Muris et al., 1994d; Steptoe & Noll, 
1997; Steptoe & Voegele, 1992).
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CHAPTER EIGHT
Monitoring and Blunting Coping Styles and the Experience o f Anxiety and Depression
8.1 Anxiety and Depression
8.1.1 Anxiety and Depression Scores
Participants’ experience of anxiety and depression scores were calculated by summary 
scores of the HADS (Zigmond & Snaith, 1983) subscales. The experiences of anxiety 
and depression across TO to T4 were explored. The aim was to determine whether 
anxiety and depression levels were affected by the monitoring and blunting coping 
styles. To determine whether monitoring and blunting influenced the experience of 
anxiety and depression, further analyses were conducted. Descriptive statistics were 
calculated for anxiety and depression at TO to T4. The results are presented in Tables 20 
and 21 respectively. Consideration of the descriptive statistics shows that anxiety levels 
fluctuated across time-points while depression levels appear to increase at the start of 
chemotherapy and decrease following chemotherapy.
Table 20
Descriptive Statistics o f Anxiety Scores Across T0-T4
Time-point N M SD Range Skewness Kurtosis
TO 53 4.11 3.60 0-12 1.84 6.10
T1 46 6.09 4.46 0-20 1.29 1.43
T2 47 4.81 3.44 0-13 .62 -.30
T3 44 5.16 4.32 0-20 1.45 2.24
T4 35 3.64 3.51 0-16 1.55 3.27
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Table 21
Descriptive Statistics of Depression Scores Across T0-T4
Time-point N M SD Range Skewness Kurtosis
TO 53 2.83 2.59 0-12 1.58 3.37
Tl 46 4.50 3.18 0-14 .93 .28
T2 47 5.53 3.59 1-15 .52 -.60
T3 44 5.79 4.24 1-16 .60 -.74
T4 35 2.36 2.67 0-11 1.46 1.82
A series of Pearson product-moment correlations were conducted to investigate the 
relationships between anxiety scores and depression scores at adjacent time-points. The 
results for anxiety are presented in Table 22 and show that there were significant, 
positive, and moderate to strong associations between anxiety scores across TO to Tl. 
The results for depression are presented in Table 23 and show that there were 
significant, positive, and moderate to strong associations between depression scores at 
Tl to T4 but no significant association between scores at TO and Tl.
Table 22
Intercorrelations Between Anxiety Scores Across T0-T4
Time-point TO Tl T2 T3 T4
N 53 46 47 44 35
TO 1 .67* .46* .52* .25
Tl 1 .74* .68* .45
T2 1 .78* .59*
T3 1 .62*
T4 1
*p < .05
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Table 23
Intercorrelations Between Depression Scores Across T0-T4
Time-point TO T1 T2 T3 T4
N 53 47 46 44 35
TO 1 .20 .22 .23 .20
T1 1 .71* .68* .32*
T2 1 .64* .43*
T3 1 .43*
T4 1
*p < .05
Comparison of the levels of anxiety and depression at each time-point suggested that 
more anxiety than depression was reported at TO, T1 and T4. Paired-samples t-tests 
revealed that there were significantly more anxiety than depression reported at TO (t 
(52) = 2.83, p < .05), at T1 (f (52) = 2.74, p < .05) and at T4 (t (35) = 3.06, p < .05) but 
similar levels of anxiety and depression at T2 (t (46) = -1.65, p > .05) and at T3 (t (43) 
= -1.17,/? > .05).
Figure 2 presents the mean anxiety scores across TO to T4 and illustrates that anxiety 
scores were comparable across TO to T4. This was confirmed by a non-significant 
repeated-measures ANOVA (F (4, 27) = 2.16, p > .05).
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Figure 2. Mean anxiety scores across T0-T4
166
Consideration of the mean depression scores presented in Figure 3 illustrates that there 
appears to be an increase in scores from TO to T1, and a decrease from T3 to T4. Given 
the lack of association between TO and Tl, an independent-samples t-test was 
conducted to determine if there was a difference in the scores while a repeated-measures 
ANOVA was conducted to determine if there were differences in scores across Tl to 
T4. The independent-samples t-test revealed a significant increase in scores from TO (M 
= 2.83, SD = 2.59) to Tl (M = 4.50, SD = 3.18) (t (86.85) = -2.83, p < .05). Levene’s 
test of equality of variance was significant (F = 4.80, p < .05) for the t-test with equality 
of variances not assumed was considered (Pallant, 2001).
The repeated-measures ANOVA revealed significant differences in scores across Tl to 
T4 (F (3, 28) = 8.50, p < .05, partial eta squared = .22). A series of paired-samples t- 
tests revealed a significant increase in scores from Tl (M = 4.63, SD = 3.24) to T2 (M = 
5.58, SD = 3.55) (t (42) = 2.41, p < .05) and a significant decrease from T3 (M = 4.97, 
SD = 3.86) to T4 (M = 2.29, SD = 2.60) (t (33) = 4.32, p < .05). To determine if there 
was a significant difference in depression scores at TO and T4, an independent-samples 
t-test was conducted and revealed no significant differences (t (87) = .83, p > .05).
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Figure 3. Mean depression scores across T0-T4
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To examine the levels of anxiety and depression reported more closely, the frequencies 
with which the anxiety and depression items were endorsed across TO to T4 were 
conducted. The results are presented in Tables 24 and 25 respectively.
Table 24
Frequency (%) of Anxiety Symptoms Reported by Participants Across T0-T4
Symptoms
TO T1
/(% )
T2 T3 T4
N 53 46 47 44 35
Butterflies in stomach 98.1 97.8 100 97.7 27.8
Tension 69.8 80.4 72.3 72.7 63.9
Worrying thoughts 69.8 69.6 59.6 70.5 47.2
Uneasy/not relaxed 30.2 71.7 68.1 70.5 50.0
Restlessness 41.5 71.7 59.6 63.6 52.8
Frightened 41.5 60.9 42.6 36.4 27.8
Panic 24.5 32.6 29.8 36.4 30.6
Table 25
Frequency (%) of Depressive Symptoms Reported by Participants Across T0-T4
Symptoms
TO T1
/(% )
T2 T3 T4
N 53 46 47 44 35
Not cheerful 94.3 100 100 100 16.7
Slowed down 26.4 97.8 100 100 75.0
Not enjoy things used to enjoy 15.1 63.0 78.7 72.7 19.4
Not look forward to things 13.2 39.1 48.9 47.7 19.4
Unable to enjoy TV/radio/book 18.9 30.4 40.4 38.6 19.4
Unable to laugh and see funny side 11.3 26.1 44.7 40.9 13.9
Lost interest in appearance 3.8 28.3 36.2 34.1 13.9
8.1.2 Anxiety and Depression and Demographic Characteristics 
A series of analyses were conducted to determine any differences in anxiety and 
depression according to demographic variables. A Bonferroni adjustment of a  = .008 
was applied to the results of analyses. A Pearson product-moment correlation revealed
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there was no significant association between age and anxiety and depression (r = .04, p 
> .008 and r = .01, p > .008 respectively). Independent-samples t-tests revealed no 
significant differences in anxiety and depression according to marital status (t (51) = - 
2.26, p > .008 and t (51) = -1.23, p > .008), education level (t (51) = .68, p > .008 and t 
(51) = .48, p > .008), employment status (t (50) = .83, p > .008 and t (50) = . 12, p > 
.008), and employment intensity (t (35) = . 13, p > .008 and t (35) = .83, p > .008) and 
occupational status (t (35) = 1.54, p > .008 and t (35) = -1.32, p > .008).
8.1.3 Anxiety and Depression and Health Characteristics
Analyses were also conducted to determine the differences in anxiety and depression 
according to patient health care status, menopausal status, method of detection and 
referral source. A Bonferroni adjustment of a  = .025 was applied to the results of the 
analyses. Independent-samples t-tests revealed no significant differences in anxiety and 
depression according to menopausal status (t (51) = -.65, p > .025 and t (51) = .27, p > 
.025). One-way ANOVAs indicated no significant differences in anxiety according to 
method of detection (F (3, 49) = 1.77, p > .025 and F (3, 49) = .65, p > .025).
8.1.4 Anxiety and Depression and Disease Characteristics 
Analyses of the differences in anxiety and depression according to disease 
characteristics were conducted using a Bonferroni adjustment of a  = .008. Pearson 
product-moment correlations revealed no significant associations between anxiety and 
depression and the number of tumours (r = -. 15, p > .008 and r = -.08, p > .008, 
respectively), tumour size (r = .03, p > .008 and r = .27, p > .008) and number of 
axillary nodes affected (r = -.13, p > .008 and r = .02, p > .008). A one-way ANOVA 
revealed no significant differences in anxiety and depression according to tumour grade 
(F (2, 50) = 3.10, p > .008 and t (50) = .88, p > .008). Independent-samples t-tests 
revealed no significant differences in anxiety and depression according to the presence 
of DCIS (t (51) = .11, p > .008 and t (51) = -.64, p > .008) and LCIS (f (51) = -.63, p > 
.008 and f (51) = .66, p > .008).
8.1.5 Anxiety and Depression and Treatment Characteristics 
Investigation of the differences in monitoring, blunting and the interaction term 
according to treatment variables were conducted using a Bonferroni adjustment of a  = 
.012. Pearson product-moment correlations revealed there were no significant
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associations between anxiety and depression and the length of time since diagnosis (r = 
.03, p > .012 and r = .04, p > .012 respectively) and length of time since final surgery 
(r = -.02, p > .012 and r = .00, p > .012). An independent-samples t-test revealed no 
significant difference in anxiety and depression for the number of surgeries endured (t 
(51) = -.29, p > .012 and t (51) = -.40, p > .012). A one-way ANOVA revealed no 
significant difference in anxiety and depression and type of surgery (F (3, 49) = 1.15, p 
> .012 and F (3, 49) = .55, p > .012).
8.2 Intrusive and Avoidant Ideation and Monitoring and Blunting 
8.2.1 Intrusive and Avoidance Ideation Scores 
Participants’ experience of intrusive and avoidant ideation were calculated by summary 
scores of the IES subscales (Horowitz et al., 1979). In order to investigate the mediating 
role of intrusive and avoidant ideation in the relationships between monitoring and 
blunting and anxiety, depression and side effects, a series of analyses were conducted. 
First, participants’ experiences of intrusive and avoidant ideation were examined. 
Descriptive statistics of intrusive and avoidant ideation were conducted and are 
presented in Tables 26 and 27.
Table 26
Descriptive Statistics for Intrusive Ideation Across T0-T4
Time-point N M SD Range Skewness Kurtosis
TO 53 7.77 6.71 0-26 .95 .46
T1 46 10.00 7.52 0-32 1.14 1.20
T2 47 9.21 9.08 0-32 .85 -.25
T3 44 10.52 9.81 0-34 .82 -.10
T4 35 7.31 8.55 0-32 1.21 .77
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Table 27
Descriptive Statistics fo r  Avoidant Ideation Across T0-T4
Time-point N M SD Range Skewness Kurtosis
TO 53 6.00 5.92 0-28 1.49 2.78
T1 47 9.04 6.89 0-27 .85 .16
T2 46 7.49 6.85 0-27 .68 -.14
T3 44 7.82 7.38 0-27 .75 -.16
T4 35 5.69 5.48 0-19 .70 -.32
Pearson product-moment correlations were conducted to determine the relationships 
between intrusive and avoidant ideation across TO to T4. The results reveal that both 
intrusive and avoidant ideation are significantly, positively, and moderately to strongly 
associated at TO (r = .73, p < .05 at TO), T1 (r = .77, p < .05), T2 (r = .89, p < .05), T3 
(r = .89, p < .05), and T4 (r = .64, p < .05).
Pearson product-moment correlations were conducted to determine the association 
between intrusive and avoidant ideation at each adjacent time-point. The results are 
presented in Tables 28 and 29, and reveal that intrusive and avoidant ideation are 
positive, moderately to strongly and significantly associated at TO to T4.
Table 28
Intercorrelations Between Intrusive Ideation Across T0-T4
TO T1 T2 T3 T4
N 53 46 47 44 35
TO 1 .69* .58* .72* .45*
T1 1 .61* .65* .54*
T2 1 .67* .71*
T3 1 .72*
T4 1
*p < .05
171
Table 29
Intercorrelations Between Avoidant Ideation Across T0-T4
TO T1 T2 T3 T4
N 53 46 47 44 35
TO 1 .60* .47* .59* .34*
T1 1 .71* .81* .52*
T2 1 .67* .56*
T3 1 .59*
T4 1
*p < .05
Repeated-measures ANOVAs were conducted to determine whether intrusive and 
avoidant ideation changed significantly across TO to T4. The results revealed that there 
was a significant change in scores over time for avoidant ideation (F (4, 27) = 3.32, p < 
.05, partial eta squared = .10), but not intrusive ideation (F (4, 27) = 1.68, p > .05). 
Paired-samples t-tests revealed that there were significant increases in avoidant ideation 
from TO to T1 (t (45) = -3.40, p < .05) and from T1 to T2 (t (42) = 2.09, p < .05). 
Means plots of intrusive and avoidant ideation across the time-points are presented in 
Figures 4 and 5, respectively.
TO T1 T2 T3 T4
Time-points
Figure 4. Mean intrusive ideation scores across T0-T4
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Figure 5. Mean avoidant ideation scores across T0-T4
8.2.2 Intrusive and Avoidant Ideation and Anxiety, Depression and Side Effects 
Pearson product-moment correlations between intrusive and avoidant ideation and 
anxiety, depression and side effects across TO to T4 are presented in Table 30. A 
Bonferroni adjustment of a  = .017 were applied to the results of the analyses. The 
results suggest that there are positive, moderate to large and significant associations 
between intrusive and avoidant ideation and anxiety, depression and side effects.
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Table 30
Intercorrelations Between Intrusive and Avoidant Ideation and Anxiety, Depression and 
Side Effects Across T0-T4
Variables N Anxiety Depression Side Effects
TO
Intrusive Ideation 53 .57* .40* .26
Avoidant Ideation 53 .55* .07 .23
T1
Intrusive Ideation 46 .65* .30 .31
Avoidant Ideation 46 .67* .22 .23
T2
Intrusive Ideation 47 .61* .47* .58*
Avoidant Ideation 47 .67* .47* .61*
T3
Intrusive Ideation 44 .78* .62* .68*
Avoidant Ideation 44 .77* .58* .69*
T4
Intrusive Ideation 35 .59* .59* .74*
Avoidant Ideation 35 .55* .50* .66*
*p < .017
8.2.3 Intrusive and Avoidant Ideation and Monitoring and Blunting Coping 
Next, the relationships between monitoring and blunting coping and intrusive and 
avoidant ideation were investigated. Pearson product-moment correlations between 
monitoring, blunting, the interaction term and intrusive and avoidant ideation were 
conducted using a Bonferroni adjustment of a  = .01. The results are presented in Table 
31 and indicate mainly positive, small to moderate but non-significant associations 
between the variables.
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Table 31
Intercorrelations Between Monitoring, Blunting, the Interaction Term and Intrusive 
Ideation Across T0-T4
Variables
TO
Intrusive Ideation 
T1 T2 T3 T4
N 53 46 47 44 35
Monitoring .29 .25 .33 .33 .36
Blunting -.01 .33 .25 .20 .34
Monitoring-Blunting -.02 .08 .12 .02 .24
*p < .01
Similarly, in order to investigate whether monitoring, blunting, and the interaction term 
were associated with avoidant ideation, a series of Pearson product-moment correlations 
were conducted using a Bonferroni adjustment of a  = .01. The results are presented in 
Table 32 and indicate mainly positive, small to moderate but non-significant 
associations between the variables. A positive, moderate and significant association was 
found between blunting and avoidant ideation at T2.
Table 32
Intercorrelations Between Monitoring, Blunting, the Interaction Term, and Avoidant 
Ideation Across T0-T4
Variables
TO T1
Avoidant Ideation 
T2 T3 T4
N 53 46 47 44 35
Monitoring .29 .30 .39* .30 .36
Blunting -.01 .14 .32 .14 .20
Monitoring-Blunting -.02 .03 .23 -.03 .03
*p < .01
8.2.4 Intrusive and Avoidant Ideation and Monitoring and Blunting and Anxiety 
and Depression
Backwards elimination regression analysis was conducted to determine whether 
monitoring, blunting, the interaction term, anxiety, depression and side effects were 
significant predictors of intrusive and avoidant ideation. Intrusive ideation was
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investigated in the first regression analysis and was entered as the dependent variable. 
Monitoring, blunting, the interaction term, avoidant ideation, depression and side effects 
were entered as predictors. Additionally, demographic, health, and disease and 
treatment characteristics were included so they were accounted for. The time-line 
variable and time-point variables for Tl, T2, T3 and T4 were entered into the model.
Demographic characteristics included marital status (single or partnered), state of 
residence (ACT or NSW), level of education (high school or tertiary), employment 
status (employed or retired), employment intensity (full-time or part-time) and 
occupation (professional or non-professional). Health characteristics included method of 
detection (self-examination -  accident, self-examination -  BSE, clinical examination, or 
routine mammography), patient status (private or public), and menopausal status (pre­
menopausal or post-menopausal).
Disease characteristics included number of tumours, tumour size, tumour grade (1, 2 or 
3), number of affected axillary nodes, and presence of DCIS (present or absent) and 
LCIS (present or absent). Treatment characteristics included number of surgeries, type 
of surgery (BCS, BCS plus TM, TM, or bilateral TM), performance of axillary lymph 
node clearance (performed or not performed), radiation therapy (received or not 
received) and endocrine therapy (received or not received).
The unstandardised regression coefficients (B), the standard error of the regression 
coefficient (s.e.), standardised regression coefficients (ß), and the T test results are 
presented in Table 33. By design of backward elimination procedures, the overall model 
is significant ( F  (9, 216) = 81.00,/? < .001) and accounts for 76% of variance in 
intrusive ideation. Of the variables of interest, blunting, avoidant ideation and 
depression positively predicted intrusive ideation. Participants who reported using more 
blunting coping and experiencing more avoidant ideation and depression also reported 
experiencing more intrusive ideation.
Of the demographic and health variables, levels of education negatively predicted 
intrusive ideation such that participants that were less well educated reported 
experiencing more intrusive ideation than those who were better educated. Patient 
health care status and detection of disease via routine mammography positively
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predicted intrusive ideation. Participants who had private health care status and detected 
their disease via routine mammography reported experiencing more intrusive ideation 
than participants who had public health care status and detected their disease via self- 
examination (accidental or BSE) and clinical examination.
Of the disease variables, tumour size, tumour grade and the presence of LCIS positively 
predicted intrusive ideation. Participants who had larger tumours, higher grade tumours 
and the presence of LCIS compared to those who had smaller tumours, lower grade 
tumours and the absence of LCIS. Detection of disease via routine mammography and 
the experience of more avoidant ideation were clearly the two strongest predictors of 
intrusive ideation.
Table 33
Summary of Backward Elimination Regression Analysis for Variables Predicting 
Intrusive Ideation (N=226)
Variables B s.e. p T
Blunting .12 .03 .14 4.00**
Avoidant ideation .84 .05 .66 17.40**
Depression .48 .09 .20 5.50**
Education -2.43 .60 -.14 -4.02**
Routine mammography 1.79 .75 .82 2.37*
Patient status 1.89 .60 .11 3.12**
Tumour size .06 .02 .11 3.20**
Tumour grade 1.26 .57 .07 2.20*
LCIS 2.86 1.09 .09 2.63**
Note. R2=.77, AR2=.76 
*p < .05, **p < .05
Avoidant ideation was entered as the dependent variable. Monitoring, blunting, the 
interaction term, avoidant ideation, anxiety, depression and side effects were entered as 
predictors. The demographic, medical, disease and treatment characteristics were also 
entered. The time-line variables and the time-point variables Tl, T2, T3 and T4 were 
entered into the model.
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The results of the regression are presented in Table 34. The model was significant (F (9, 
216) = 70.22, p < .001) and accounted for 61% of variance in avoidant ideation. The 
intrusive ideation, anxiety and side effects positively predicted avoidant ideation. The 
interaction term and depression negatively predicted avoidant ideation. Participants who 
reported experiencing more intrusive ideation, anxiety and side effects also experienced 
more avoidant ideation. On the other hand, participants who reported using more of 
both monitoring and blunting coping and experienced more depression reported 
experiencing less avoidant ideation.
Of the health variables, detection of the disease via accidental self-examination 
positively predicted and patient status negatively predicted avoidant ideation. 
Participants who detected the disease via accidental self-examination and those who had 
public health care status reported more avoidant ideation. Of the disease and treatment 
variables, the number of tumours positively predicted and having undergone bilateral 
TM negatively predicted avoidant ideation. Participants with more tumours and who 
underwent surgeries other than bilateral TM (BCS, BCS plus TM and TM) reported 
experiencing more avoidant ideation. Intrusive ideation and anxiety were the strongest 
predictors of avoidant ideation.
Table 34
Summary of Backward Elimination Regression Analysis for Variables Predicting 
Avoidant Ideation (N-226)
Variables B s.e. p T
Monitoring-Blunting -.01 .00 -.09 -2.43*
Intrusive ideation .51 .04 .64 13.45**
Anxiety .52 .08 .31 6.15**
Depression -.37 .09 -.20 -3.88**
Side effects .16 .06 .13 2.61**
Self-exam (accidental) 1.29 .48 .10 2.71**
Patient status -1.39 .49 -.10 -2.85**
Number of tumours .69 .24 .11 2.86**
Bilateral TM -2.55 1.18 -.08 -2.17*
Note. R2=.74, AR2=.73 
*p < .05, **p < .01
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8.3. Anxiety and Monitoring and Blunting
To investigate the relationships between monitoring and blunting coping and anxiety, a 
series of analyses were conducted. Pearson product-moment correlations using a 
Bonferroni adjustment of a  = .01 were conducted to determine the relationships 
between anxiety and monitoring, blunting and the interaction term. The results are 
presented in Table 35 and revealed mainly positive, small to moderate but non­
significant associations between anxiety and the coping styles.
Table 35
Intercorrelations Between Monitoring, Blunting, the Interaction Term and Anxiety
Across T0-T4
Variables
TO
Anxiety
Tl T2 T3 T4
N  53 46 47 44 35
Monitoring .12 .23 .36 .34 .41
Blunting -.01 .22 .34 .23 .41
Monitoring-Blunting -.02 .10 .20 .16 .39
*p < .01
Next, backward elimination regression analyses were conducted to determine whether 
monitoring, blunting, the interaction term and intrusive and avoidant ideation 
significantly predict anxiety and depression. For the first analysis, anxiety was entered 
as the dependent variable. Monitoring, blunting, the interaction term, intrusive and 
avoidant ideation, depression and side effects were entered as predictors. Demographic, 
health, disease and treatment characteristics were included. The time-line variable and 
time-point variables for T l, T2, T3 and T4 were entered into the model.
The unstandardised regression coefficients (B), the standard error of the regression 
coefficient (s.e.), standardised regression coefficients (ß), and the T test results are 
presented in Table 36. The model was significant ( F ( l  1, 214) = 36.85,/? < .001) and 
accounted for 64% of variance in anxiety. Of interest, blunting coping, avoidant 
ideation and depression positively predicted anxiety. Participants who use more 
blunting coping and those who experienced more avoidant ideation and depression also
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reported experiencing more anxiety. In fact, avoidant ideation and depression were 
clearly the strongest predictors of anxiety. Of the demographic variables, marital status 
positively predicted and employment status and occupation negatively predicted 
anxiety. Participants who were married, were employed and were in professional 
occupations reported experiencing more anxiety.
Of the treatment variables, the number of surgeries and having undergone axillary 
clearance negatively predicted anxiety. Having undergone BCS plus TM positively 
predicted anxiety. Those having undergone one surgery, BCS plus TM surgeries and not 
undergone axillary clearance reported more anxiety. T2 and T3 positively predicted 
anxiety such that levels of anxiety at T2 and T3 were higher than expected from the 
general trend in anxiety.
Table 36
Summary of Backward Elimination Regression Analysis for Variables Predicting 
Anxiety (N=226)
Variables B s.e. ß T
Blunting .05 .02 .13 2.92**
Avoidant ideation .27 .03 .46 10.24**
Depression .51 .54 .46 9.52**
Marital status 1.76 .36 .21 4.82**
Employment status -.76 .36 -.09 -2.11*
Occupation -1.67 .44 -.16 -3.82**
Number of surgeries -1.21 .49 -.14 -2.46*
BCS plus TM 1.85 .67 .15 2.77**
Axillary clearance -1.21 .53 -.10 -2.27*
T2 1.12 .42 -.12 -2.68**
T3 -.97 .43 -.10 -2.24*
Note. R2=.65, AR2=.64 
*p < .05, **p < .01
The results of the above regression analyses provide information about the way in 
which monitoring and blunting coping styles predict intrusive and avoidant ideation. It 
is now possible to integrate the findings from all of the regression analyses to determine
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the way in which monitoring and blunting and intrusive and avoidant ideation affect the 
experience of anxiety, depression and side effects across TO to T4. The model of anxiety 
is illustrated in Figure 6. The figure shows that the blunting coping style both direct and 
indirectly via intrusive and avoidant ideation increased anxiety. Only avoidant and not 
intrusive ideation increased anxiety. As previously mentioned, depression was a 
significant predictor of anxiety.
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8.4. Depression and Monitoring and Blunting
Next, the relationships between depression and monitoring and blunting coping were 
conducted. Pearson product-moment correlations using a Bonferroni adjustment of a  = 
.01 were conducted to determine the relationships between depression and monitoring, 
blunting and the interaction term. The results are presented in Table 37 and revealed 
mainly positive, small to moderate but non-significant associations between depression 
and the coping styles.
Table 37
Intercorrelations Between Monitoring, Blunting, the Interaction Term and Depression
Across T0-T4
Variables
TO Tl
Depression
T2 T3 T4
N 53 46 47 44 35
Monitoring .06 .08 .21 .05 .34
Blunting .10 .06 .13 .17 .40
Monitoring-Blunting -.02 .19 .10 .08 .35
*p < .01
Further analysis was conducted using a backward elimination regression analysis. 
Depression was entered as the dependent variable. Monitoring, blunting, the interaction 
term, intrusive and avoidant ideation, anxiety and side effects were entered as 
predictors. Again, demographic, health, disease and treatment characteristics, the time­
line variable and the time-point variables for Tl, T2, T3 and T4 were included. The 
results of the analysis are presented in Table 38. By design of backward elimination 
regression analysis, the model of depression was significant (F (13, 212) = 28.92, p < 
.001) and accounted for 62% of variance. Intrusive and avoidant ideation, anxiety and 
side effects positively predicted depression. Participants who reported experiencing 
more intrusive and avoidant ideation, anxiety and side effects also reported experiencing 
more depression.
Of the demographic and health variables, age and state of residence positively predicted 
depression while marital status and patient health care status negatively predicted 
depression. Participants who were older, single, lived in the ACT and had public health 
care status reported more depression than those who were younger, married, lived in
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surrounding NSW and had private health care status. Of the disease and treatment 
predictors, tumour grade, presence of DCIS and number of surgeries negatively 
predicted depression. Participants who had a low grade of tumour, no evidence of DCIS 
and underwent two surgeries reported more depression than those who had a high grade 
of tumour, presence of DCIS and underwent one surgery. T2 and T3 positively 
predicted depression such that levels of depression were higher at T2 and T3 compared 
to the general trend in depression.
Table 38
Summary o f Backward Elimination Regression Analysis for Variables Predicting 
Depression (N=226)
Variables B s.e. p T
Intrusive ideation .09 .03 .22 2.85**
Avoidant ideation -.16 .04 -.30 -3.94**
Anxiety .37 .06 .41 6.61**
Side effects .27 .04 .42 7.28**
Age .05 .02 .14 3.19**
State of residence 1.02 .39 .12 2.61**
Marital status -.76 .34 -.10 -2.21*
Patient status -1.38 .31 -.19 -4.38**
Tumour grade -.71 .33 -.10 -2.19*
DCIS -1.19 .38 -.15 -3.17**
Number of surgeries .90 .37 .11 2.45*
T2 1.22 .39 .14 3.13**
T3 1.82 .40 .13 2.92**
Note. R2=.64, AR2=.62 
*p < .05, **p < .01
Figure 7 illustrates the model of depression. Depression was indirectly influenced by the 
use of blunting and the use of neither monitoring nor blunting via intrusive and avoidant 
ideation. Intrusive ideation increased depression but avoidant ideation reduced 
depression. An inspection of the beta weights suggested that the strength of the 
associations between intrusive ideation and depression, and avoidant ideation and 
depression, were similar. Both side effects and anxiety increased depression.
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8.5 Discussion
The experience of anxiety and depression before, during and following chemotherapy 
treatment was investigated. Participants reported a broad range of anxiety and 
depression experienced at baseline, during treatment and at follow-up. The mean levels 
of anxiety and depression reported are equivalent to that reported in other samples of 
women undergoing treatment for breast cancer (Alder & Bitzer, 2003; Groenvold et al., 
1999; Mathews, Ridgeway, Warren, & Britton, 2002; Montazeri et al., 2000; Morasso et 
al., 2001; Osborne et al., 2004; Osborne et al., 2003; Payne et al., 1999; Rodgers et ah, 
2005).
Mean anxiety levels remained relatively stable over time with decreases after the middle 
and final chemotherapy treatments. Few studies have investigated levels of anxiety 
across chemotherapy treatments, instead investigating general distress during a limited 
period of time. These studies suggest distress remains relatively stable (McKinnon,
2001; (Lerman et al., 1990; Manne et al., 1994; Shapiro et al., 1997) although patients 
experience some significant concerns at the beginning of treatment. Patients report that 
they have significant concerns about the challenging nature of chemotherapy prior to 
commencement and are eager to start chemotherapy to see what it involves (Moyer & 
Salovey, 1996). These concerns were reflected in the remarks from participants at the 
baseline interview. Many participants made comments similar to the following, “I just 
want to get the first one over so I know what I’m in for” and ‘T il feel better after the 
first one”. Therefore it is understandable that anxiety would be elevated prior to and 
during the first treatment but would decline as participants became familiar with the 
treatment and its effects.
On the other hand, depression levels increased during treatment and in particular, after 
the middle and final treatments. Again, past research has typically investigated general 
distress during a limited period of chemotherapy treatment and has suggested distress 
levels were stable (Lerman et al., 1990; Manne et al., 1994; McKinnon, 2001; Shapiro 
et al., 1997). No research has indicated that levels of distress increase during treatment, 
although this pattern of depression is perhaps understandable. Once participants are 
aware of what chemotherapy and its effects involve, they then have to adjust to dealing 
with the treatment for the remainder of the treatment. Patients may find this period long, 
difficult and exhausting, resulting in the experience of depression. As one participant 
succinctly said, “It got to be quite a grind.” Another explained, “I started off my chemo
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ride full of hope for a speedy and problem free experience. As I proceeded through my 
treatment my resolve started to wain.”
At six-month follow-up, anxiety and depression levels were similar to those reported at 
baseline. That is, anxiety levels were maintained whereas depression levels declined 
from those experienced during chemotherapy. This is understandable when considering 
that the six-month follow-up coincided with the first few months of survival. Perhaps 
when participants finish their treatments and are able to return to the routine of their 
daily lives, their depression levels decline. Participants commented, “I feel like my old 
self again”, “I am feeling better and back to normal” and “I am enjoying life, 
relationships, friends etc. as much as I ever did before my diagnosis”.
Alternatively, their anxiety levels may be maintained due to the significant concerns 
reported during early survivorship. Past research has shown that when patients are no 
longer undergoing active treatment, they feel a loss of support from medical 
professionals, family and friends. In the present study, participants did report that they 
felt disconnected after completion of treatment. One participant went as far to say that 
she was “disappointed with post-care” while another felt that “some follow-up 
counselling would be in order -  not just physical checks about recurrence”. This is 
compounded by concerns about recurrence, especially given that active treatment is 
completed and there is little to do but anticipate the next check-up. One participant said 
that although they felt positive, “from time to time I worry about it coming back”. 
Another commented on occasionally experiencing the “‘patient’ feeling of the last years 
and the uncertainty of good health”.
The patterns of anxiety and depression symptoms reported were similar across all time- 
points. The overwhelming majority of participants reported experiencing the anxiety of 
butterflies in the stomach, tension and worrying thoughts and the depression symptoms 
of not feeling cheerful and having slowed down. The least experienced anxiety 
symptom was panic while the least experienced depressive symptoms were unable to 
laugh and see the funny side of things and having lost interest in one’s appearance. The 
fact that a loss of interest in appearance was one of the least common symptoms is 
surprising. Body image problems have been widely reported by patients following 
breast surgery (Abend & Williamson, 2002; Al-Ghazal et al., 2000; Arora et al., 2001;
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Curran et al., 1998; Hartl et al., 2003; Hopwood et al., 2001). Perhaps body image 
concerns are better reflected as concern about appearance rather than a lack of interest 
in it. Nevertheless, the least experienced symptoms were still experienced by significant 
number of participants.
There is the possibility that the levels of depression reported are an underestimation of 
participants’ actual experience of depression. Concern exists regarding the validity of 
the HADS in assessing depressive symptoms. The HADS depression items appear to 
overwhelming focus on symptoms indicative of anhedonia. This is to the exclusion of 
other symptoms of depression such as indecisiveness, guilt, helplessness, worthlessness 
and suicidality (Love et al., 2002; Osborne et al., 2004). Evidence supporting these 
concerns comes from research showing that the HADS underestimates depression levels 
in breast cancer patients compared to other, more comprehensive, depression scales 
(Hall et al., 1999; Love et al., 2002).
In addition, it is concerning that one of the most common depression symptoms 
reported was having slowed down. Most participants commented that they had slowed 
down due to the side effects experienced from chemotherapy treatment, rather than as a 
reflection of their mental wellbeing. The item of feeling slowed down may therefore be 
an inappropriate indicator of depression in breast cancer patients undergoing 
chemotherapy treatment. A reliable and valid measure of anxiety and depression in 
cancer patients is vital for future research in the field and according to some, is long 
overdue (Hall et al., 1999).
Monitoring and blunting coping styles played significant roles in the experience of 
anxiety and depression, although not in the ways expected. Miller’s (1996; 1993) theory 
states that the use of monitoring coping is associated with increased levels of anxiety 
and depression while the use of blunting coping is associated with reduced levels of 
distress. This has been supported by empirical research indicating that monitoring is 
associated with greater levels of distress than blunting coping (Lerman et al., 1990; 
Miller, 1979b; Miller et al., 1996a; Miller et al., 1995; Muris & de Jong, 1993; Schwartz 
et al., 1995; Tercyak et al., 2001; van Zuuren, 1993).
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Miller’s (1996; 1993) theory also states that the influence of coping styles is mediated 
by the experience of increased levels of intrusive and avoidant ideation, which in turn, 
increase levels of anxiety and depression. This too has been supported in the past 
research (Devine et ah, 2003; Manne et ah, 2001). Finally, Miller’s theory suggests that 
anxiety and depression in turn increase levels of intrusive and avoidant ideation 
although this has not been investigated in studies of coping, intrusive and avoidant 
ideation and psychological and physical wellbeing.
The findings partially support Miller’s (1996; 1993) theory and the past research. The 
use of blunting and the use of both monitoring and blunting increased levels of anxiety 
indirectly via the experience of increased intrusive and avoidant ideation. Intrusive and 
avoidant ideation appeared to have a reciprocal relationship in which each served to 
increase levels of the other. Avoidant ideation then increased levels of anxiety and in 
turn, anxiety was found to increase avoidant ideation. Anxiety levels were also directly 
increased by the use of blunting coping.
Similar results were reported for depression whereby the use of blunting increased 
depression indirectly, via the experience of intrusive and avoidant ideation. The use of 
blunting increased intrusive ideation while the use of both monitoring and blunting 
reduced the levels of avoidant ideation. As stated, intrusive and avoidant ideation both 
increased levels of each other. Intrusive ideation then increased depression and in turn, 
depression increased intrusive ideation. On the other hand, avoidant ideation reduced 
levels of depression and depression reduced levels of avoidant ideation. That is, the 
coping styles were able to increase depression via intrusive ideation and reduce 
depression via avoidant ideation. Inspection of the beta weights in both paths revealed 
that the strength of the relationships between coping styles and intrusive and avoidant 
ideation, and intrusive and avoidant ideation and depression were similar. This suggests 
that overall changes in levels of depression via coping styles were minimal.
Although the finding is contrary to Miller’s (1996; 1993) theory, Horowitz’s (1993; 
1979) and Miller’s theories may provide a possible reason why participants’ use of 
blunting increased intrusive ideation. According to the theories, failure to engage with 
the information about a stressful situation means the situation is not processed or 
adjusted to. Intrusive and avoidant ideation occur in order to facilitate engagement with
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the stressful situation and therefore encourage the processing of and adjustment to the 
situation. When using blunting coping, people avoid or escape information regarding 
the stressful situation. That is, they do not engage with the information and therefore are 
unable to process and adjust to the situation. Intrusive ideation may then occur to help 
facilitate this process of adjustment.
Miller’s (1996; 1993) theory also provides a reason why participants’ use of blunting 
directly increased anxiety levels. It is also possible that participants using blunting 
coping knew less about treatment. Therefore, they may have experienced more anxiety 
because they were uncertain about what to expect of the treatment and/or they were ill- 
prepared to deal with the treatment. As one participant commented, “being given 
information about my diagnosis and treatment...made it easier to understand what to 
expect.” Although the results do not confirm past research of monitoring and blunting 
coping styles, research investigating the related construct of avoidance coping strategies 
has suggested these strategies are associated with more psychological distress in breast 
cancer patients (Carver et al., 1993; Culver et al., 2002; Epping-Jordan et al., 1999; 
Friedman et al., 1988; Hack & Degner, 1999, 2004).
The reasons why participants’ use of both monitoring and blunting were associated with 
reduced levels of avoidant ideation. Miller’s (1996; 1993) theory provides no 
description of the nature and effects of this form of coping, although attempts have been 
made by Krohne (Krohne, 1993). According to Krohne, people using both monitoring 
and blunting coping are intolerant of both the uncertainty and emotional arousal elicited 
by stressful situations. They employ monitoring because it serves to reduce uncertainty 
and they employ blunting because it serves to reduce emotional arousal. The intolerance 
of both uncertainty and emotional arousal experienced means that distress is high in 
stressful situations. In an effort to reduce distress, they continually switch between the 
coping styles in order to reduce distress. Unfortunately, this allows insufficient time for 
either coping style to be effective, resulting in high levels of distress. As a result,
Krohne has labelled these people as ‘ineffective copers’. It is possible that this continual 
switching provides little opportunity for people to engage in avoidant ideation.
The results then show that avoidant ideation decreases depression and depression in turn 
reduces avoidant ideation. Although this is contrary to Miller’s (1996; 1993) theory,
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Horowitz’s (1993; 1979) and Miller’s theories do provide possible explanations for the 
results. Avoidant ideation involves avoidance of intrusive ideation about stressful 
situations, in order to reduce distress. Therefore, it is likely that avoiding intrusive 
ideation would reduce depression levels.
When considering the finding that depression reduces avoidant ideation, it may be 
hypothesised that depression inhibits people’s ability to engage in avoidant ideation. 
Depression symptoms involve reduced concentration and increased helplessness and 
hopelessness (American Psychiatric Association, 1994), all of which make it less likely 
that participants are able to actively engage in strategies to reduce distress, such as 
avoidant ideation. Clearly, further investigation is needed to delineate the mechanisms 
underlying the pattern of results obtained.
Anxiety and depression were found to be significant predictors of each other. This 
confirms a large body of empirical evidence demonstrating a strong relationship 
between anxiety and depression (Barlow & et al., 1986). Indeed, there is suggestion that 
anxiety and depression represent the same response at a biological level (Middeldorp, 
Cath, Van Dyck, & Boomsma, 2005). Side effects also increased depression levels but 
not anxiety levels. Anxiety results from concerns about future negative events 
(American Psychiatric Association, 1994). While participants may experience anxiety in 
anticipation of side effects, they would be unlikely to do so once they have developed 
the side effects. Instead, the experience of side effects might make participants feel 
depressed because they weren’t able to prevent the side effects and the side effects 
negatively affect quality of life.
Aside from the influence of monitoring and blunting coping styles, marital status and 
employment was shown to be the only background characteristics to consistently affect 
levels of anxiety and/or depression. Single participants reported significantly less 
anxiety than partnered participants. This is contrary to past research which has 
suggested that being partnered acts as a protective factor against elevated levels of 
psychological distress in patients with breast cancer (Compas et al., 1999; Epping- 
Jordan et al., 1999; Osborne et al., 2003; Turner et al., 2005). Although, it should be 
noted that having a partner does not necessarily mean that people experienced enhanced 
support.
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Nonetheless, it is possible that partnered participants not only have a partner but also 
may be more likely to have children and therefore greater family responsibilities. 
Partnered participants may be worried about their ability to cope with these 
responsibilities when undergoing treatment and about how these responsibilities will be 
met if they do not survive the disease. Being surrounded by family may also lead to 
frequent enquiries about participants’ wellbeing, which may serve to highlight 
participants’ declines in wellbeing and therefore raise anxiety.
It has been suggested that there may also be secondary gains for partnered women 
experiencing distress. Secondary gain has not previously been discussed in the cancer 
research but is evident in the research on patients with chronic pain (Fishbain,
Rosomoff, Cutler, & Rosomoff, 1995). That is, partnered women may receive a number 
of benefits in their relationships with their partners when they are unwell. Alternatively, 
single women do not experience such benefits and may be unlikely to dwell on worries. 
One participant reported that going through the experience as a “single woman living 
alone...has made me a stronger person.”
In contrast, single participants reported more depression than partnered participants.
This result confirms past research that suggests single women experience more 
psychological distress than partnered women when receiving and undergoing treatment 
for breast cancer (Compas et al., 1999; Epping-Jordan et al., 1999; Osborne et al., 2003; 
Turner et ah, 2005). It is thought that partners offer support that buffers the woman 
from stress and therefore may serve to lower the likelihood of experiencing depression 
(de Groot, 2002). It is also possible that partnered participants have more family 
responsibilities than single participants. While these responsibilities may cause 
significant anxiety, they may form as a distraction which prevents women from 
reflecting on their disease and treatment and developing depression.
Participants who were employed or employed in professional occupations reported 
more anxiety than those who were retired or employed in non-professional occupations. 
It is possible that participants who have the responsibility of work, particularly 
professional work, might find it difficult to take time off work for treatment and 
recovery and/or to cope with work while undergoing treatment. As one participant 
explained, “I pushed myself to work normally”. Taking time off work may also result in
192
a loss of income that significantly affects participants’ abilities to meet financial 
responsibilities. It may also be that participants in professional occupations may be used 
to feeling in control and successful in their work and when faced with a new and largely 
uncontrollable situation, they experience greater anxiety.
To a lesser extent, disease and treatment characteristics affected levels of anxiety and 
depression although the individual characteristics did not consistently affect anxiety and 
depression in the same manner. When considering the characteristics as a whole, it may 
be said that participants who underwent less extensive the surgical intervention (one 
surgery compared to two and no axillary clearance) reported more anxiety than those 
undergoing more extensive surgical intervention (two surgeries and axillary clearance).
It is possible that participants receiving less extensive treatment are concerned that not 
all cancer cells have been removed and therefore, the disease will return. Indeed, it has 
been suggested that participants’ perceptions of risk regarding cancer is unrelated to 
objective indices of disease and are instead based on psychological factors (Kent et al., 
2000).
Alternatively, participants diagnosed with less extensive disease (low tumour grade and 
no evidence of DCIS) and those participants who underwent more treatment (two rather 
than one surgery) reported more depression. Participants with less extensive disease 
may have had fewer symptoms upon diagnosis than those with more extensive disease 
and therefore may have been unprepared for the diagnosis of cancer. This may lead to 
the experience of depression as participants struggle to adjust to the diagnosis. 
Participants who underwent more treatment may be more resigned to the disease and its 
treatment and therefore feel more depressed than those who underwent less extensive 
surgery.
Overall, the results of the levels of anxiety and depression has provided an intensive 
examination of psychological distress experienced before, during and following 
chemotherapy treatment for EBC. The results indicate that the patterns of anxiety and 
depression levels over time differed considerably. As expected, monitoring and blunting 
coping styles accounted for a significant amount of the variation in anxiety and 
depression scores reported, although not in the ways predicted by Miller’s (1996; 1993) 
theory and past research.
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CHAPTER NINE
Monitoring and Blunting Coping Styles and the Experience o f Side Effects
9.1. Side Effects
9.1.1. Side Effect Scores
Participants’ experience of overall side effects was calculated from the summary score 
of the Chemotherapy Side Effects Scale, developed for use in the present study. The 
experience of side effects across TO to T4 were investigated with the aim of determining 
whether the experience of side effects are affected by the monitoring and blunting 
coping styles. To investigate the relationships between monitoring and blunting and side 
effects, a series of analyses were conducted. Descriptive statistics for side effects scores 
across TO to T4 were calculated and are presented in Table 39. The descriptive statistics 
indicate that participants reported a wide range of overall side effects but generally, 
mean side effects increased during chemotherapy treatment.
Table 39
Descriptive Statistics o f Side Effects Scores Across T0-T4
Time-point N M SD Range Skewness Kurtosis
TO 53 5.15 3.81 0-16 1.12 1.19
T1 46 10.22 4.66 2-24 .80 1.13
T2 47 10.34 4.99 3-22 .62 -.58
T3 44 10.77 5.84 3-33 1.58 4.14
T4 35 5.34 4.69 0-22 1.70 3.69
The frequency with which side effects were reported across TO to T4 are reported in 
Table 40. Many participants reported experiencing a number of side effects prior to the 
beginning of chemotherapy treatment. The most common side effects experienced at TO 
were pain, difficulty sleeping, fatigue and sore muscles. Most of the side effects 
increased at the beginning of treatment and declined after the completion of treatment. 
Several of these side effects did not return to similar levels as thought at TO but instead 
remained elevated. These side effects included fatigue, memory problems, shortness of 
breath and coughing.
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Table 40
Frequency (%) of Side Effects Reported by Participants Across T0-T4
Side Effects
TO Tl
/(% )
T2 T3 T4
N 53 46 47 44 35
Fatigue 50.9 100 100 97.7 65.7
Difficulty Sleeping 52.8 73.9 78.7 75.0 57.1
Nausea 24.5 82.6 72.3 56.8 14.3
Lack of Appetite 30.2 77.8 68.1 63.6 17.1
Pain 62.3 43.5 63.8 56.8 45.7
Sore Muscles 50.9 42.2 58.7 65.9 45.7
Memory Problems 22.6 40.0 67.4 72.7 54.3
Constipation 26.4 69.6 57.4 47.7 8.6
Coughing 20.8 15.6 34.8 34.1 31.4
Dizziness 18.9 37.8 32.6 34.1 5.7
Shortness of Breath 5.7 21.7 19.6 29.5 22.9
Vomiting 1.9 32.6 17.4 18.2 2.9
Pearson product-moment correlations indicated that there were significant, positive and 
moderate to strong associations between side effects scores across T1 to T4, but not 
between TO and T l. The results are presented in Table 41.
Table 41
Intercorrelations Between Side Effects Across T0-T4
Time-point TO Tl T2 T3 T4
N 53 46 47 44 35
TO 1 .28 .28 .29 .17
Tl 1 .50* .60* .42*
T2 1 .71* .36*
T3 1 .58*
T4 1
*p < .05
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Examination of the mean side effects scores across TO to T4 in Figure 8 suggests an 
increase in side effects from TO to T1 and a decrease from T3 to T4. Again, given the 
lack of association between scores at TO and Tl, an independent-samples t-test was 
conducted to determine whether there was a difference in scores between TO and Tl and 
a repeated-measures ANOVA was conducted on scores from Tl to T4. The 
independent-samples t-test indicated that there was a significant increase from TO (M = 
5.15, SD = 3.81) to Tl (M = 10.22, SD = 4.66) (t (95) = 5.82, p < .05). The repeated- 
measures ANOVA showed that there were significant differences in scores across Tl to 
T4 (F (4, 27) = 17.75, p < .05, partial eta squared = .37). A series of paired-samples t- 
tests revealed a significant decrease from T3 (M = 9.65, SD = 4.47) to T4 (M = 4.92, SD 
= 3.82) (t (33) = 7.17, p < .05). An independent-samples t-test of side effects at TO and 
T4 revealed no significant differences (/ (87) = -.21, p > .05).
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Figure 8. Mean side effects scores across T0-T4
9.1.2 Side Effects and Demographic Characteristics 
Analyses of differences in side effects according to demographic characteristics were 
conducted using a Bonferroni adjustment of a  = .008. A Pearson product-moment 
correlation showed no association between age and overall side effects (r = -.22, p > 
.008). Independent samples t-tests revealed there were significant differences in overall 
side effects and marital status (t (51) = -2.90, p < .008), with partnered participants
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experiencing significantly greater overall side effects (M = 6.17, SD = 3.88) than single 
participants (M = 3.17, SD = 2.85). There were no significant differences in side effects 
in terms of education level (r (51)= 1.15, p > .008), employment status (t (50) = .51,/? 
> .008), employment intensity (t (35) = .60, p > .008) and occupation (t (35) = .60, p > 
.008).
9.1.3 Side Effects and Health Characteristics
Analyses were conducted to determine the differences in side effects according to health 
variables using a Bonferroni adjustment of a  = .025. An independent-samples t-test 
revealed no significant difference in side effects according to menopausal status (/ (51)
= 1.09, p > .025). A one-way ANOVA also revealed no significant difference in side 
effects according to method of detection (F (2, 50) = 1.45, p > .025).
9.1.4 Side Effects and Disease Characteristics
Investigation of the differences in side effects according to disease characteristics were 
conducted using a Bonferroni adjustment of a  = .007. Pearson product-moment 
correlations indicated no significant associations between the number of tumours (r = - 
.06, p > .007), tumour size (r = .18, p > .007) and number of axillary nodes involved (r 
= -.11, p > .007). Independent samples t-tests showed no significant differences in 
overall side effects in terms of the presence of DCIS (t (51) = .94, p > .007) and LCIS (t 
(51) = -.87,/? > .007). A one-way ANOVA showed no significant difference in side 
effects according to tumour grade (F (2, 50) = 1.21,/? > .007).
9.1.5 Side Effects and Treatment Characteristics
Investigation of the differences in side effects in terms of treatment characteristics were 
conducted. Bonferroni adjustments (range of a  = .007 to .012) were applied to the 
results of analyses at each time-point. At TO, Pearson product-moment correlations 
revealed no significant association between side effects and the time since diagnosis (r 
= -.01,/? > .012) and final surgery (r = -.18,/? > .012). An independent samples t-test 
revealed no significant differences in side effects and number of surgeries (/ (51) = - 
1.14,/? > .012). A one-way ANOVA revealed no significant differences in side effects 
in terms of the type of surgery (F (3, 49) = 1.59,/? > .012).
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At Tl, a two-way ANOVA revealed no significant main effect of chemotherapeutic 
drugs (F (3, 46) = 2.28, p > .01) and anti-emetic medication administered (F (2, 46) = 
.65, p > .01) on side effects. No interaction effects were calculated because of the 
limited number of cases in each cell. Independent-samples t-tests revealed no significant 
difference in side effects in terms of the treatment reduction (7 (44) = 1.83, p > .01) and 
hospitalisation (r (44) = .72, p > .01).
At T2, a two-way ANOVA indicated there were no significant main effects of 
chemotherapeutic drugs (F (2, 47) = .32, p > .007) and anti-emetic medication (F (2,
47) = .34, p > .007) or an interaction between the two (F (1, 47) = 2.99, p > .007) on 
side effects experienced. Independent-samples t-tests revealed no significant difference 
in side effects in terms of the use of GCSF support (t (45) = -1.39, p > .007), treatment 
reduction (t (45) = 1.21, p > .007), treatment delay (t (45) = .81,/? > .007) and 
hospitalisation (t (45) = -.77, p > .007).
At T3, a two-way ANOVA indicated there were no main effects of chemotherapeutic 
drugs (F (3, 44) = 4.04, p > .008) and anti-emetic medication (F (3, 44) = .86, p > .008) 
and no interaction effect (F (4, 44) = 1.28, p > .008) on side effects experienced. 
Participants receiving IV CMF as chemotherapeutic drugs and those receiving level 1 
anti-emetic medication were excluded from analysis as there was only one case in each 
group. Independent-samples t-tests revealed no significant difference in side effects in 
terms of the use of GCSF support (t (42) = -.95, p > .008), treatment reduction (t (42) = 
-.01, p > .008) and hospitalisation (t (42) = -.17,/? > .008). An independent-samples t- 
test for treatment delay could not be calculated as only two participants were delayed 
and one of these failed to report side effects experienced.
At T4, independent-samples t-tests revealed that there is no difference in side effects at 
T4 between those who underwent radiation (t (34) = -.29, p > .012) and those that are 
undergoing endocrine therapy (t (34) = -.54, p > .012). Pearson product-moment 
correlations revealed no significant associations between side effects at T4 and time 
since chemotherapy (r = .02, p > .012) and radiation therapy completion (r = -.02, p > 
.012).
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9.1.6 Side Effects and Bone Marrow, Hepatic, and Renal Functioning 
To investigate the relationships between bone marrow, hepatic, and renal functioning 
and side effects reported at TI, T2 and T3, Pearson product-moment correlations were 
conducted using a Bonferroni adjustment of a  = .006. The results are presented in Table 
42 and reveal there to be no significant associations between bone marrow, renal and 
hepatic functioning and side effects at TI, T2 and T3. The only exception was a 
significant, positive and moderate relationship between side effects and the GGT index 
of hepatic functioning at T1.
Table 42
Intercorrelations Between Bone Marrow, Renal and Hepatic Functioning Indices and 
Side Effects at TI, T2 and T3 (N=53)
Variable T1 T2 T3
N 46 47 44
Bone Marrow
Neutrophils .12 .04 .09
Renal
Urea -.20 -.28 -.19
Creatinine .03 .07 .01
Hepatic
Bilirubin .22 .02 .29
ALT .31 -.18 .02
AlkP .06 -.28 -.34
GGT .60* -.12 .11
Albumin -.08 -.19 -.19
*p < .006
9.1.7 Side Effects and Anxiety and Depression 
Pearson product-moment correlations using a Bonferroni adjustment of a  = .025 were 
conducted to investigate the relationships between side effects, anxiety and depression 
at each time-point. The results are presented in Table 43 and suggest that there are 
largely significant, moderate to strong, positive associations between anxiety, 
depression and side effects at TO to T4.
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Table 43
Intercorrelations Between Anxiety, Depression and Side Effects Across T0-T4
Variables TO T1 T2 T3 T4
N 53 46 47 44 35
Anxiety-Depression .47* .51* .64* .65* .70*
Anxiety-Side Effects .20 .46* .65* .78* .52*
Depression-Side Effects .22 .54* .71* .70* .71*
*p < .025
9.2 Side Effects and Monitoring and Blunting Coping
Lastly, the associations between monitoring, blunting, and the interaction term and side 
effects were investigated. Pearson product-moment correlations were conducted using a 
Bonferroni adjustment of a = .01. The results are presented in Table 44 and revealed 
largely positive, small to moderate associations between the variables. These 
associations were positive, moderate and significant for the interaction term and side 
effects at T1 and monitoring and side effects at T2.
Table 44
Intercorrelations Between Monitoring, Blunting, the Interaction Term, and Side Effects
Across T0-T4
Variables
TO
Side Effects 
TI T2 T3 T4
N 53 46 47 44 35
Monitoring .33 .28 .40* .31 .33
Blunting -.02 .24 .18 .13 .38
Monitoring-Blunting -.04 .48* .30 .35 .34
*p < .01
A backward elimination regression analysis was conducted to determine whether the 
monitoring and blunting coping styles predict the experience of side effects. Side effects 
was entered as the dependent variable. Monitoring, blunting, the interaction term, 
intrusive and avoidant ideation, anxiety and depression were entered as predictors. The 
same demographic, medical, disease and treatment characteristics were included as in 
the previous regression analyses for anxiety and depression. Chemotherapy treatment
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characteristics were also included and consisted of the type of chemotherapeutic drugs 
administered, anti-emetic medication received, GSCF support received, dose reduction 
received, treatment delay received, and hospitalisation. The time-line variable and time- 
point variables for Tl, T2, T3 and T4 were entered into the model.
The unstandardised regression coefficients (B), the standard error of the regression 
coefficient (s.e.), standardised regression coefficients (ß), and the T test results are 
presented in Table 45. The model was significant (Z7 (13, 212) = 35.29, p < .001) and 
accounted for 66% of variance. The interaction term, intrusive and avoidant ideation 
and depression positively predicted side effects. Participants who used both monitoring 
and blunting coping and reported experiencing intrusive and avoidant ideation and 
depression also reported experiencing side effects.
Of the demographic and treatment variables, employment status and having undergone 
BCS plus TM negatively predicted side effects while the number of surgeries and 
having undergone BCS positively predicted side effects. Participants who were 
employed, underwent two surgeries, underwent BCS, and underwent surgeries other 
than BCS plus TM reported experiencing more side effects compared to those who were 
retired, underwent one surgery, underwent BCS and underwent surgeries other than 
BCS plus TM.
Of the treatment variables, receiving Taxol and levels two or three of anti-emetic 
support positively predicted side effects. Participants who received Taxol and level 2 or 
3 of anti-emetic support reported more side effects than those who received 
chemotherapeutic drugs other than Taxol and level one of anti-emetic support. Of the 
indices of renal functioning, urea negatively predicted and creatinine positively 
predicted side effects. Participants with low levels of urea and high levels of creatinine 
experienced more side effects.
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Table 45
Summary o f Backward Elimination Regression Analysis fo r  Variables Predicting Side 
Effects (N=226)
Variables B s.e. p T
Monitoring-Blunting .01 .00 .20 4.72**
Intrusive ideation .10 .05 .16 2.13*
Avoidant ideation .15 .06 .18 2.57*
Depression .49 .08 .32 6.35**
Employment status -1.28 .49 -.11 -2.62**
Number of surgeries 1.82 .65 .15 2.81**
BCS 1.69 .51 .15 3.29**
BCS plus TM -2.65 .81 -.16 -2.97**
Taxol 2.8 1.03 .12 2.60**
Anti-emetic level 2 2.55 .86 .23 2.95**
Anti-emetic level 3 2.53 .95 .16 2.67**
Urea -.54 .20 -.25 -2.70**
Creatinine .05 .02 .32 3.00**
Note. R2=.68, AR2- 66 
*p < .05, **p < .01
Figure 9 illustrates the model of side effects. The use of blunting indirectly increased 
side effects via intrusive and avoidant ideation. The use of neither monitoring nor 
blunting increased side effects both directly and indirectly, via intrusive and avoidant 
ideation. Like the anxiety model, side effects were increased by intrusive ideation but 
also avoidant ideation. Depression also increased side effects.
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9.3 Discussion
Participants’ experience of side effects before, during and following chemotherapy 
treatment was investigated. The results revealed that participants reported a broad range 
of side effects before, during and six months following chemotherapy treatment, 
although levels of side effects were elevated during chemotherapy. Given that there are 
no currently utilised measures of side effects experienced in response to adjuvant 
chemotherapy and the measure utilised in the present study was specifically created, it is 
not possible to compare the levels of side effects with other samples.
Nonetheless, investigation of the levels of side effects experienced revealed some 
interesting results. Many participants reported that they were experiencing side effects 
at baseline. Closer inspection revealed that the side effects experienced were those 
commonly associated with recovery from breast surgery, including pain, sore muscles, 
fatigue and difficulty sleeping. Pain and sore muscles were likely due to breast surgery 
and both of which may contribute to the significant fatigue and difficulty sleeping 
reported via little or poor sleep. Fatigue may also be due to the effects of a general 
anaesthetic. Past research has indicated that all of these symptoms are common 
following breast surgery (NHMRC & NBCC, 2001).
Alternatively, side effects reported after the first, middle and final treatments appeared 
to be more closely associated with the effects of the chemotherapeutic drugs 
administered. When considering the pattern of side effects experienced during 
chemotherapy, there are some differences in the side effects reported after the first and 
middle chemotherapy treatment compared to the final treatment. Memory problems and 
sore muscles were more common and nausea was less common after the final treatment 
compared to the first and middle treatments. This corresponds with changes in the types 
of chemotherapeutic drugs administered.
A significant number of participants were prescribed AC or EC plus Taxol, with AC or 
EC received at the first and middle treatments and Taxol at the final treatment. AC and 
EC often elicit nausea while Taxol elicits muscle soreness (Chap & Haskell, 2001), thus 
accounting for the increases in sore muscles and decreases in nausea across the 
treatments. Declines in nausea and vomiting may also be due to the addition of anti­
emetic treatments. The failure to reduce nausea and vomiting altogether confers with the 
past research stating that despite the wide spread use of anti-emetic medication, a
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significant number of participants still experience nausea and vomiting (Dibble et al., 
2004; Kris et al., 1998; Lee et al., 2005). The fact that the side effects reported before 
chemotherapy reflected recovery from breast surgery and the side effects after the first 
treatment reflected those experienced as a result of chemotherapy might explain the lack 
of association between scores of side effects at baseline and after the first treatment.
As expected, side effects declined on completion of treatment such that the levels of 
side effects reported at six-month follow-up were equivalent to those reported at 
baseline. Even so, several of the side effects did not return to baseline levels but instead 
remained elevated. These side effects included fatigue, memory problems, shortness of 
breath and coughing. Fatigue is commonly reported in the months following 
chemotherapy treatment although few explanations are provided for the prolonged 
experience of fatigue (Beisecker et al., 1997; Bower et al., 2000; de Jong et al., 2002b; 
Frost et al., 2000; Sadler & Jacobsen, 2001). It is possible that both fatigue and 
shortness of breath may be explained by a lack of fitness following cancer treatment.
The declines in functioning experienced as a result of surgery, chemotherapy, radiation 
and/or endocrine therapy may have led to decrements in fitness that participants have 
not yet recovered by follow-up.
Increases in self-reported memory problems in the period following treatment reflect the 
trends reported in past research but as yet, the nature and reason for such memory 
problems is unknown (Castellon et al., 2005; Failed et al., 2005; Jansen et al., 2005; 
NHMRC & NBCC, 2001; Schagen et al., 1999). The reason for continued elevations in 
coughing is more difficult to explain. Several participants reported coughing prior to 
chemotherapy treatment due to regular cigarette smoking. It is possible that the presence 
of coughing at follow-up is simply the result of those regularly smoking rather than a 
result of cancer treatment, although it is unlikely that these levels would increase over 
time. The present study is the first of its kind in assessing chemotherapy side effects 
following chemotherapy. Clearly further research is needed to confirm the findings and 
investigate the reasons for elevated levels of certain side effects six-month following 
chemotherapy compared to baseline.
Similar to the results for anxiety and depression, monitoring and blunting coping styles 
appeared to play significant roles in the experience of side effects. Again, the coping
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styles affected side effects in ways contrary to those expected. As in the models of 
anxiety and depression, the use of blunting coping increased the levels of intrusive 
ideation experienced while the use of both monitoring and blunting reduced the levels 
of avoidant ideation experienced.
Miller’s (1996; 1993) theory states that the use of the monitoring coping is associated 
with increased side effects while blunting coping is associated with reduced side effects. 
This has been supported in research investigating patients undergoing a several medical 
procedures and treatments (Miller et al., 1988; Miller & Mangan, 1983; Steptoe & 
O'Sullivan, 1986), including cancer patients undergoing chemotherapy treatment 
(Lerman et al., 1990). No research has reported that the use of blunting results in 
increased levels of side effects.
Intrusive and avoidant ideation each served to increase levels of the other. Consistent 
with the model of depression, both intrusive and avoidant ideation were then shown to 
increase levels of side effects. Consistent with both the models of anxiety and 
depression, side effects were associated with increased avoidant ideation but not 
intrusive ideation. The ability of intrusive and avoidant ideation to increase side effects 
has been demonstrated in samples of late stage cancer patients (Manne et al., 2001) and 
cancer survivors (Lewis et al., 2001). Research has also demonstrated that side effects 
may increase levels of avoidant ideation (Manne et al., 2001).
In the model of side effects the use of monitoring and blunting was also directly 
associated with increased side effects. As previously outlined in the discussion of the 
anxiety and depression models, Krohne (Krohne, 1993) describes people using both 
monitoring and blunting coping as ineffective copers. He theorises that they are 
intolerant of both the uncertainty and emotional arousal elicited by stressful situations, 
intolerances that are relived by monitoring and blunting coping, respectively. They 
continually switch between coping styles which provides little opportunity for either 
forms of coping to be effective, resulting in increased side effects. Alternatively, 
Krohne (Krohne, 1993) states that people who employ neither monitoring nor blunting 
coping are the most effective copers. They are tolerant of both uncertainty and 
emotional arousal and are therefore able to strategically employ the use of either
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monitoring or blunting as the situation requires. This ensures they effectively deal with 
the stressful situation and consequently experience fewer side effects.
Similar to the experience of anxiety and depression, side effects appear to be predicted 
by some demographic, health and treatment characteristics. A relationship was found 
between marital status and side effects although this relationship was not reported in the 
regression analyses. Partnered participants reported more side effects than single 
participants. As discussed, this finding is contrary to the result of past research (de 
Groot, 2002). Again, it is possible that partnered women’s greater spousal and family 
responsibilities meant that any side effects that might affect physical functioning were 
noticed. Family’s concern about participants’ wellbeing prompted frequent questions, 
which in turn, prompted reflection and awareness of side effects. Secondary gains in the 
marital relationship may have accounted for increased reporting of side effects 
(Fishbain et al., 1995).
The only demographic characteristic shown to predict side effects in the regression 
analysis was employment status. Participants who were employed reported more side 
effects than those who were retired. It is possible that participants who were employed 
were more active and therefore noticed any side effects that might affect their physical 
functioning more than those who were retired and therefore perhaps less active. Many 
participants who were employed during treatment reported great difficulty physically 
dealing with work days. As one participant explained, “I pushed myself to work 
normally.”
A number of surgical treatment characteristics significantly predicted side effects, but 
the nature of the influence of these characteristics appears contradictory. Participants 
who underwent two surgeries reported more side effects than those who underwent one. 
Two surgeries involve increased interference to the operated area as well as a second 
general anaesthetic, all of which may result in significant side effects. On the other 
hand, participants who underwent BCS reported more side effects than those who 
underwent other surgeries. Participants who underwent BCS and TM reported fewer 
side effects. These two findings appear to suggest that few and less invasive surgical 
treatment is associated with more side effects. The reason for this pattern of results is 
unknown and requires further investigation.
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In terms of the chemotherapy treatment characteristics, the receipt of Taxol and levels 2 
and 3 of anti-emetic medication were associated with increased side effects. Taxol does 
attract significant side effects, although it is unknown why receipt of the other 
chemotherapeutic drugs did not also result in increased side effects. It is possible that 
the measure of side effects does not comprehensively capture the full range of side 
effects experienced in response to adjuvant chemotherapy for breast cancer. The 
measure might include side effects common to Taxol but uncommon to the other 
chemotherapeutic drugs. For example, FEC, CMF, AC and EC all have the potential to 
elicit significant fatigue, nausea, vomiting and loss of appetite whereas Taxol may elicit 
pain and sore muscles (Chap & Haskell, 2001).
It must be acknowledged that the measure of side effects utilised was by no means a 
comprehensive measure of the possible side effects experienced. The scale included the 
most common side effects reported during adjuvant chemotherapy for breast cancer.
The scale used may have underestimated the side effects experienced. Participants 
reported that some side effects encountered were not included in the measure and this 
has been confirmed by recent literature suggesting several additional side effects that 
are commonly experienced during chemotherapy. For example, some of these side 
effects include declines in sexual functioning, peripheral neuropathy and weight gain 
(Arora et al., 2001; Chap & Haskell, 2001; Young-McCaughn, 1996).
Furthermore, the frequency and functional impairment ratings are combined in the 
ECOG rating scales. Although the scale is familiar to medical professionals, it may 
confound information regarding the nature of side effects experienced. Existing 
measures of negative physical symptoms have typically focused on one dimension of 
ratings, for example, frequency, functional impairment and distress elicited by 
symptoms. As a result, the measures have provided different estimations of physical 
symptoms in the one person (Barresi et ah, 2003). One participant felt that the 
confounding of frequency and impairment meant that, “I often felt that some of the 
answers I chose were not reflective of my experience.” The development of a more 
comprehensive and accurate measure of side effects is essential for future research. A 
measure that provides several dimensions of ratings might be more appropriate, 
although brevity in clinical samples is also critical.
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Participants receiving levels 2 and 3 of anti-emetic support reported increased side 
effects. Anti-emetic support has its own side effects, several of which are included in 
the measure of side effects. For example, constipation, fatigue, appetite loss and sore 
muscles are all possible side effects of these levels of support (Grunberg, 2001). 
Conversely, it may be that those experiencing more side effects overall were more likely 
to receive anti-emetic medication. This is possible as the side effects assessed are 
interdependent such that the presence of one might increase the likelihood of another. 
For example, it would be expected that nausea would result in a loss of appetite, 
difficulty sleeping and/or fatigue.
In addition to these variables, several indices of hepatic and renal functioning were 
associated with increased side effects. Participants reporting more side effects also 
demonstrated higher levels of GGT and creatinine but lower levels of urea. Elevated 
levels of GGT, creatinine and urea indicate the liver and kidneys are working hard to 
metabolise the chemotherapeutic drugs. Although urea is increased when the kidneys 
are taxed, it is efficiently expelled from the body via urine and therefore may account 
for the negative association with side effects (IDG Books Worldwide, 2000).
In summary, participants reported a wide range of side effects before, during and 
following chemotherapy treatment for EBC. The pattern of side effects reported 
indicated that participants experienced more side effects during chemotherapy 
treatment. Similar to the experience of anxiety and depression, monitoring and blunting 
coping styles appeared to play significant roles in the experience of side effects but not 
in the ways expected by Miller’s (1996; 1993) theory and past research.
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CHAPTER TEN
Monitoring and Blunting Coping Styles and Locus of Control Beliefs
10.1 Locus of Control Beliefs
10.1.1. Locus of Control Beliefs Scores
Next, the relationships between monitoring and blunting coping styles and cancer- 
specific internal, chance and powerful others locus of control were investigated. 
Participants’ locus of control beliefs were calculated by summary scores of the MHLOC 
subscales (Wallston et al., 1994). First, the descriptive statistics for internal locus of 
control (ILOC), chance locus of control (CLOC) and powerful others locus of control 
(PLOC) across TO to T4 were investigated. The results are presented in Tables TO to T4 
and are presented in Tables 46, 47 and 48.
Table 46
Descriptive Statistics for Internal Locus of Control Beliefs AcrossT0-T4
Time-point N M SD Range Skewness Kurtosis
TO 53 18.62 5.64 6-30 -.11 .57
T1 46 17.42 6.34 6-30 .01 -.89
T2 47 17.46 6.36 6-32 .08 -.38
T3 44 18.37 6.40 6-29 -.41 -.72
T4 35 19.08 6.23 6-34 -.02 .29
Table 47
Descriptive Statistics for Chance Locus of Control Beliefs AcrossT0-T4
Time-point N M SD Range Skewness Kurtosis
TO 53 17.63 6.85 6-36 .85 .59
T1 46 18.05 6.71 6-36 .50 .19
T2 47 17.79 5.84 6-30 -.09 -.42
T3 44 18.78 6.38 6-35 .33 .15
T4 35 19.33 6.31 6-30 .33 -.46
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Table 48
Descriptive Statistics fo r  Powerful Others Locus o f Control Beliefs AcrossT0-T4
Time-point N M SD Range Skewness Kurtosis
TO 53 27.02 4.72 16-36 -.23 -.67
T1 46 26.23 5.35 11-35 -.90 .63
T2 47 26.40 3.79 18-34 -.16 -.39
T3 44 26.36 4.63 16-36 -.44 -.01
T4 35 27.25 4.18 19-36 .34 -.37
Pearson product-moment correlations were calculated to investigate the associations 
between ILOC, CLOC, and PLOC at adjacent time-points. The results are presented in 
Tables 49, 50 and 51. There were mostly significant, positive, and moderate to very 
strong associations between ILOC, CLOC and PLOC scores across T0-T4.
Table 49
Intercorrelations Between Internal Locus o f Control Beliefs Across T0-T4
TO T1 T2 T3 T4
N 53 46 47 44 35
TO 1 .54* .58* .55* .63*
T1 1 .74* .75* .66*
T2 1 .73* .65*
T3 1 .77*
T4 1
*p < .05
Table 50
Intercorrelations Between Chance Locus o f Control Beliefs Across T0-T4
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TO T1 T2 T3 T4
N 53 46 47 44 35
TO 1 .66* .46* .37* .49*
T1 1 .52* .57* .49*
T2 1 .79* .47*
T3 1 .55*
T4 1
*p < .05
Table 51
Intercorrelations Between Powerful Others Locus o f Control Beliefs Across T0-T4
TO T1 T2 T3 T4
N 53 47 46 44 35
TO 1 .55* .50* .43* .53*
T1 1 .69* .71* .53*
T2 1 .75* .46*
T3 1 .56*
T4 1
*p < .05
To investigate the changes in ILOC, CLOC and PLOC across TO to T4, a series of 
repeated-measures ANOVAs were conducted. The results revealed that there were 
significant differences in ILOC scores across TO to T4 (F (4, 27) = 2.97, p < .05, partial 
eta squared = .09). However, post-hoc paired-samples t-tests revealed no significant 
differences in ILOC scores at any of the adjacent time-points. Inspection of the means 
plot presented in Figure 10 indicates that there was a slight decrease in ILOC from TO 
(M = 18.62,57) = 5.64) t o Tl  (M = 17.42, SD = 6.34) (t (45) = .99, p > .05), and 
increases from T2 (M = 17.46, SD = 6.36) to T3 (M = 18.37, SD = 6.40) (t (42) = -1.29, 
p > .05). There were no significant differences in CLOC scores (F (4, 27) = 1.27, p > 
.05) and PLOC scores (F (4, 27) = .59, p > .05) across TO to T4. Figures 11 and 12 
illustrate mean CLOC and PLOC scores across the time-points.
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Figure 10. Mean internal locus of control beliefs scores across T0-T4
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Figure 11. Mean chance locus of control beliefs scores across T0-T4
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Figure 12. Mean powerful others locus o f control beliefs scores across T0-T4
Participants appeared to report more PLOC and equivalent ILOC and CLOC across TO 
to T4. Paired-samples t-tests were conducted to determine whether the differences were 
significant, with a Bonferroni adjustment of a  = .017. The results are presented in Table 
52 and reveal that participants reported significantly more PLOC than ILOC and CLOC 
at all time-points.
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Table 52
Paired-samples T-tests Between Internal, Chance, and Powerful Others Locus o f 
Control Beliefs AcrossT0-T4
Time-points Variables N t d f
TO PLOC - ILOC 53 52 8.14*
PLOC - CLOC 53 52 9.28*
T1 PLOC - ILOC 46 45 7.38*
PLOC - CLOC 46 45 6.73*
T2 PLOC - ILOC 47 46 7.71*
PLOC - CLOC 47 46 8.81*
T3 PLOC - ILOC 44 43 6.90*
PLOC - CLOC 44 43 6.90*
T4 PLOC - ILOC 36 35 6.90*
PLOC - CLOC 36 35 6.61*
*p < .017
Pearson product-moment correlations were calculated between the locus of control 
beliefs across TO to T4. The results are presented in Table 53. Using a Bonferroni 
adjustment of a  = .025, there were small but non-significant associations between 
ILOC, CLOC and PLOC at all time-points. As expected, ILOC was mainly negatively 
associated with CLOC and to a lesser extent, PLOC. There were little associations 
between CLOC and PLOC.
Table 53
Intercorrelations Between Internal, Chance, and Powerful Others Locus o f Control 
Beliefs Across T0-T4
Variables TO T1 T2 T3 T4
N 53 46 47 44 35
ILOC - CLOC -.17 -.32 -.19 -.20 .03
ILOC - PLOC -.04 .05 -.17 .06 .11
CLOC - PLOC .22 .08 .08 .15 .11
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10.1.2 Locus of Control Beliefs and Demographic Characteristics
A series of analyses were conducted to determine any relationships between locus of 
control beliefs and demographic variables using a Bonferroni adjustment of a=.007. 
Pearson product-moment correlations revealed no significant association between age 
and internal (r = -.21, p > .007), chance (r = .03, p > .007), and powerful others (r =
.02, p > .007) locus of control beliefs. Independent-samples t-tests were conducted to 
determine whether there were differences in locus of control beliefs in terms of 
demographic characteristics. There was a significant difference in education for chance 
locus of control beliefs (t (51) = 3.79, p < .007) with those who were well educated 
reporting less chance locus of control beliefs (M = 15.15, SD = 5.27) compared to those 
who were less well educated (M = 21.72, SD = 7.32). There were no differences in 
education for internal (t (51) = -2.32, p > .007) and powerful others (t (51) = 1.18,p > 
.007) locus of control beliefs.
The results indicated that there were no differences in marital status for internal (t (51) = 
-.32, p > .007), chance {t (51) = -.38, p > .007) and powerful others (f (51) = .90, p > 
.007) locus of control beliefs and no differences in state of residence for internal (/ (51)
= 1.47, p > .007), chance (7 (51) = .74, p > .007), and powerful others it (51) =.77, p > 
.007) locus of control beliefs. There were no significant differences in employment 
status for internal (t (51) = 1.47, p > .007), chance {t (51) = -1.03, p > .007) and 
powerful others (t (51) = -1.63, p > .007) locus of control. There were no significant 
differences in employment intensity for internal (t (35) = -.02, p > .007), chance (t (35) 
= -. 14, p > .007) and powerful others (t (35) = .24, p > .007) locus of control beliefs. 
Lastly, the same was true for occupation with no significant differences between 
occupation and internal (t (35) = .08, p > .007), chance (t (35) = -.43, p > .007) and 
powerful others (t (35) = 1.32, p > .007) locus of control beliefs.
10.1.3 Locus of Control Beliefs and Health Characteristics
The relationships between health variables and locus of control beliefs were conducted 
using a Bonferroni adjustment of a  = .012. Independent-samples t-tests revealed no 
significant differences in internal (t (51) = .32, p > .012), chance (t (51) =.88, p > .012) 
and powerful others (t (32.61) = .30, p > .012) locus of control beliefs according to 
patients’ health care status. Levene’s test of equality of assumed variance was 
significant (F = 5.23, p < .05) so the t-test with equality of variance not assumed was
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considered (Pallant, 2001). Independent-samples t-tests revealed no significant 
differences in internal (r (51)= 1.56, p > .012), chance (t (51) = -.01, p > .012) and 
powerful others (t (51) = .69, p > .012) locus of control beliefs according to menopausal 
status. One-way ANOVAs revealed no difference in internal (F (3, 49) = 1.47,/? > .012 
and F (2, 50) = .78, p > .012 respectively), chance (F (3, 49) = .56, p > .012 and F  (2,
50) = .38, p > .012) and powerful others (F (3, 49) = .58, p > .012 and F  (2, 50) = .10, p 
> .012) locus of control beliefs for the method of detection and referral source.
10.1.4 Locus o f Control Beliefs and Disease Characteristics
Analyses were conducted to determine the relationships between locus of control beliefs 
and disease variables using a Bonferroni adjustment of a  = .008. Pearson product- 
moment correlations revealed no significant association between number of tumours 
and internal (r = -.01, p > .008), chance (r = .01, p > .008) and powerful others (r =
.17, p > .008) locus of control beliefs. Pearson product-moment correlations did reveal a 
significant association between tumour size and internal locus of control beliefs (r =
.36, p < .008) but not between tumour size and chance (r = . 16, p > .008) and powerful 
others (r = .13, p > .008) locus of control beliefs. One-way ANOVAs indicated there 
were no significant differences in tumour grade and internal (F (2, 50) = 1.01, p > .008), 
chance (F (2, 50) = .32, p > .008) and powerful others (F (2, 50) = .26, p > .008) locus 
of control beliefs.
Pearson product-moment correlations revealed no significant associations between the 
number of affected axillary nodes and internal (r = .21, p > .008), chance (r = .04, p > 
.008) and powerful others (r = .20, p > .008) locus of control beliefs. Independent- 
samples t-tests revealed no significant differences in the presence of DCIS and LCIS 
and internal (7 (51) = -.104,/? > .008 and t (51) = 1.34,/? > .008 respectively), chance (t 
(51)= 1.42, p > .008 and t (51) = .41, p  > .008) and powerful others (t (51)= 1.01, p > 
.008 and t (51) =.44, p > .008) locus of control beliefs.
10.1.5 Locus o f Control Beliefs and Treatment Characteristics
The relationships between locus of control beliefs and treatment variables were 
conducted using a Bonferroni adjustment of a  = .017. Independent-samples t-tests 
indicated that there were no significant differences in the number of surgeries and 
internal (t (51) = -.40, p > .017), chance (t (51) = -.46, p > .017) and powerful others (t
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(51) = 1.14,/? > .017) locus of control beliefs. One-way ANOVAs showed no 
differences in surgery type and internal (F (3, 49) = 1.63,/? > .017), chance (F(3, 49) = 
.12,/? > .017) and powerful others (F (3, 49) = .54,/? > .017) locus of control beliefs. 
Independent-samples t-tests revealed no difference in the receipt of axillary clearance 
and internal (r (51) = 2.00, p > .017), chance (t (51) = -1.54, p > .017) and powerful 
others (t (51) = -1.11, p > .017) locus of control beliefs.
10.1.6 Locus of Control Beliefs and Anxiety, Depression and Side Effects 
Pearson product-moment correlations were conducted between locus of control beliefs 
and anxiety, depression and side effects. A Bonferroni adjustment of a  = .017 was 
applied to the results of the analyses. The results are presented in Table 54 and revealed 
no associations between locus of control beliefs and anxiety, depression and side 
effects, although there was a small, positive but non-significant association between 
chance locus of control beliefs and anxiety.
Table 54
Intercorrelations Between Locus of Control Beliefs and Anxiety, Depression and Side 
Effects (N=53)
Variables Anxiety Depression Side Effects
ILOC -.06 .09 -.07
CLOC .32 .17 .14
PLOC .02 .02 .07
*p < .017
10.2. Locus of Control Beliefs and Monitoring and Blunting Coping 
Pearson product-moment correlations were calculated between monitoring, blunting and 
the interaction term and ILOC, CLOC and PLOC at each time point using a Bonferroni 
adjustment of a  = .01. The results are presented in Tables 55, 56 and 57, respectively. 
There were small to moderate, positive but non-significant associations between 
monitoring, blunting and the interaction term scores and locus of control beliefs at TO to 
T4. Exceptions include a moderate, positive and significant association between the 
interaction term and CLOC at T4 and some small, negative and non-significant 
associations between blunting and the interaction term, and PLOC.
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Table 55
Intercorrelations Between Internal Locus o f Control Beliefs and Monitoring, Blunting 
and the Interaction Term Across T0-T4
Variables ILOC
TO T1 T2 T3 T4
N 53 46 47 44 35
Monitoring .32 .21 .11 .21 .10
Blunting .23 .07 .15 .30 .35
Monitoring-Blunting .10 -.11 .07 .02 .14
*p < .01
Table 56
Intercorrelations Between Chance Locus o f Control Beliefs and Monitoring, Blunting
and the Interaction Term Across T0-T4
Variables CLOC
TO T1 T2 T3 T4
N 53 46 47 44 35
Monitoring .04 .21 .28 .20 .00
Blunting .14 .22 .22 .22 .18
Monitoring-Blunting .22 .32 .19 .22 .44*
*p < . 01
Table 57
Intercorrelations Between Monitoring, Blunting, the Interaction Term and PLOC 
Across T0-T4
Variables PLOC
TO T1 T2 T3 T4
N  53 46 47 44 35
Monitoring .21 .11 .30 .05 -.20
Blunting .25 -.04 .09 -.05 .10
Monitoring-Blunting -.03 -.05 -.02 .01 .04
*p < .01
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Next, backward elimination regression analyses were conducted to determine whether 
monitoring, blunting and the interaction term significantly predict locus of control 
beliefs across TO to T4. For the first analysis, internal locus of control beliefs was 
entered as the dependent variable. The predictors entered into the model included the 
remaining locus of beliefs (chance and powerful others locus of control), monitoring, 
blunting, the interaction term, anxiety, depression, side effects, and demographic, 
health, disease and treatment characteristics. The time-line variable and the time-point 
variables for Tl, T2, T3 and T4 were entered into the model.
The unstandardised regression coefficients (B), the standard error of the regression 
coefficient (s.e.), standardised regression coefficients (ß), and the T test results of the 
analysis are presented in Table 58. By design of backward elimination regression 
analysis, the model was significant (Z7 (17, 208) = 12.08,/? < .001) and accounted for 
56% of the variance in internal locus of control. Chance locus of control and depression 
negatively predicted internal locus of control while monitoring coping positively 
predicted internal locus of control. Participants who reported experiencing fewer chance 
locus of control beliefs, less depression and greater use of monitoring coping reported 
stronger internal locus of control beliefs.
Of the demographic and health variables, state of residence, marital status and 
menopausal status negatively predicted internal locus of control. Participants who lived 
in NSW, were single and pre-menopausal reported more internal locus of control beliefs 
than those who were living in the ACT, were partnered and post-menopausal. Patient 
status positively predicted internal locus of control such that participants who had 
private health care status reported stronger internal locus of control beliefs than those 
with public health care status. All methods of detecting the disease negatively predicted 
internal locus of control beliefs which suggest that whichever method of detecting 
disease participants used, they reported more anxiety than those using other methods.
Of the disease and treatment variables, the number of tumours, LCIS and axillary 
clearance negatively predicted internal locus of control beliefs. The number of 
surgeries, undergoing TM and bilateral TM positively predicted internal locus of control 
beliefs. Participants with fewer tumours, no LCIS, did not undergo axillary clearance,
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underwent two surgeries, TM and bilateral TM reported more internal locus of control 
beliefs.
Table 58
Summary of Backward Elimination Regression Analysis for Variables Predicting 
Internal Locus o f Control Beliefs (N=226)
Variables B s.e. p T
CLOC -.12 .05 -.13 -2.28*
Monitoring .11 .04 .19 3.02**
Depression -.34 .09 -.19 -3.69**
State of residence -7.05 .92 -.46 -7.68**
Marital status -1.70 .77 -.13 -2.20*
Self-exam (accidental) -10.38 4.61 -.84 -2.25*
Self-exam (BSE) -10.15 4.67 -.66 -2.17*
Clinical exam -12.18 4.90 -.46 -2.49*
Routine mammography -10.79 4.67 -.67 -2.31*
Patient status 3.80 .73 .30 5.22**
Menopausal status -2.70 .71 -.21 -3.80**
Number of tumours -.98 .37 -.17 -2.69**
LCIS -6.86 1.42 -.31 -4.83**
Number of surgeries 2.98 1.01 .22 2.96**
TM 2.79 .81 .23 3.46**
Bilateral TM 5.59 1.78 .20 3.13**
Axillary clearance -5.66 1.10 -.29 -5.12**
Note. R2=.50, A R2= 56 
*p < .05, **p < .01
For the next regression analysis, chance locus of control beliefs was entered as the 
dependent variable. The same variables entered as predictors in the previous analysis 
were included in this model. The results of the analysis are presented in Table 59. The 
model was significant (F (14, 211) = 10.74, p < .001) and accounted for 38% of 
variance. The use of monitoring and the use of both monitoring and blunting coping 
positively predicted chance locus of control beliefs. Participants who used more 
monitoring coping or both monitoring and blunting coping reported more chance locus
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of control beliefs. Anxiety positively predicted and depression and internal locus of 
control negatively predicted chance locus of control. Participants who reported 
experiencing more anxiety and less depression and internal locus of control beliefs 
negatively predicted chance locus of control beliefs.
Education level and patient status positively predicted and employment status 
negatively predicted chance locus of control. Participants who were less well educated, 
had public health insurance and were retired reported more chance locus of control than 
those who were better educated, had private health status and were employed. Tumour 
size, the numbers of surgeries, undergoing TM and axillary clearance positively 
predicted and LOS negatively predicted chance locus of control. Participants with 
larger tumours, no evidence of LOS and who underwent two surgeries, TM and axillary 
clearance reported more chance locus of control than those with smaller tumours, 
evidence of LOS and who underwent one surgery, BCS, BCS plus TM and bilateral 
TM and no axillary clearance.
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Table 59
Summary of Backward Elimination Regression Analysis for Variables Predicting 
Chance Locus of Control Beliefs (N-226)
Variables B s.e. ß T
Monitoring .11 .04 .18 2.74**
Monitoring-Blunting .01 .00 .20 3.53**
ILOC -.15 .07 -.14 -2.23*
Anxiety .62 .12 .38 5.25**
Depression -.29 .13 -.16 -2.30*
Education -2.03 .83 -.15 -2.45*
Employment status 2.26 .82 .16 2.75*
Patient status -2.00 .80 -.15 -2.48*
Tumour size .08 .02 .20 3.37**
Number of surgeries 3.84 .86 .24 3.55**
TM 3.07 .86 .24 3.55**
Axillary clearance 2.63 1.20 .13 2.20*
LCIS -4.86 1.57 -.21 -3.09**
T0-T4 .63 .24 .14 2.60*
Note. R2= 42, A R2= 38 
*p < .05, **p < .01
In the final backward elimination regression analysis, powerful others locus of control 
beliefs were entered as the dependent variable and the same variables entered as 
predictors. The results of the analysis are presented in Table 60. The model was 
significant (F (10, 215) = 7.11, p < .001) and accounted for 21% of variance. Chance 
locus of control, the use of monitoring coping and the use of blunting coping positively 
predicted powerful other locus of control and depression negatively predicted powerful 
other locus of control. Participants who reported more chance locus of control, used 
more monitoring or blunting coping, reported less depression and more powerful other 
locus of control beliefs than those who reported less chance locus of control beliefs, less 
monitoring or blunting coping and more depression.
Of the demographic variables, age and state of residence positively predicted and 
education level and occupation negatively predicted powerful other locus of control.
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Participants who were older, lived in the ACT, were better educated and were employed 
in professional work reported more powerful others locus of control. Detection of 
disease via clinical examination and the number of tumours positively predicted 
powerful others locus of control beliefs. Participants who detected the disease via 
clinical examination and had more tumours reported more powerful others locus of 
control. Chance locus of control beliefs positively predicted powerful others locus of 
control beliefs such that those participants reporting more chance locus of control 
beliefs also reported more powerful others locus of control beliefs.
Table 60
Summary of Backward Elimination Regression Analysis for Variables Predicting 
Powerful Others Locus of Control Beliefs (N=226)
Variables B s.e. p T
CLOC .09 .05 .13 2.08*
Monitoring .07 .03 .16 2.34*
Blunting .10 .03 .20 3.09**
Depression -.27 .08 -.21 -3.35**
Age .13 .03 .26 4.25**
State 1.60 .79 .14 2.03*
Education -1.61 .62 -.17 -2.59**
Occupation -2.45 .75 -.20 -3.25**
Clinical exam 2.87 1.25 .15 2.30*
Number of tumours .97 .26 .22 3.69**
Note. R2=.25, A R2=.21 
*p < .05, **p < .01
10.3. Discussion
The roles of monitoring and blunting coping styles in locus of control beliefs reported 
before chemotherapy treatment, after the first, middle and final chemotherapy 
treatments and six months following chemotherapy were investigated. Overall, 
participants reported moderate internal and chance locus of control beliefs and strong 
powerful others locus of control beliefs. Patients diagnosed with breast cancer tend to 
report stronger powerful others locus of control beliefs compared to internal locus of
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control beliefs (Bourjolly, 1999; Bremer et al., 1997; Marks, Richardson, Graham, & 
Levine, 1986).
The importance of medical professionals, family and friends to participants’ experiences 
of chemotherapy was evident in the comments during and following chemotherapy. 
Participants overwhelmingly agreed that medical professionals’ expertise and support 
“substantially assisted my recovery” and that “they were people I cold turn to who 
would help willingly” and “they were doing the absolute best they could for me in a 
thoroughly competent way”. Participants also emphasised the importance of family and 
friends. Many participants felt that they “could not have gotten through it if it weren’t 
for (my husband)” and “friends and family, who all pitched in their support throughout 
the process”.
There appeared to be little change in locus of control beliefs across the time-points. It is 
thought that health locus of control beliefs change over time with stressful experiences 
(Wallston et al., 1976; Wallston, 2005b; Wallston et al., 1994) and that the treatment of 
breast cancer would be one such experience. There were some changes in internal locus 
of control beliefs, from baseline to after the first treatment cycle and from the middle to 
final cycles. It is possible that prior to starting chemotherapy, participants were 
concerned about their ability to cope with the treatment but that with experience, 
participants became more confident in their ability to cope. Thus, their internal locus of 
control beliefs increased.
Alternatively, there were no changes in chance and powerful other locus of control 
beliefs across the time-points. It might be expected that as participants become more 
accustomed to coping with chemotherapy treatment, they might report less chance locus 
of control beliefs. However, it is evident that participants required supportive treatment 
throughout chemotherapy (for example, receiving anti-emetic medication, GCSF 
support, dose reduction and so on). Perhaps receipt of supportive treatment made 
participants aware that they were not able to control the effects of chemotherapy and 
therefore chance locus of control beliefs remained consistent. Indeed, some participants 
frequently reported frustration at not being able to control their experience of 
chemotherapy. For example, a common frustration was the inability to avoid the
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development of neutropenia, despite doing everything possible to ensure enhanced 
physical wellbeing.
It might be expected that powerful others locus of control beliefs would also increase 
across chemotherapy. Chemotherapy treatment often provides opportunities for 
observing the expertise of medical professionals and receiving support from family and 
friends, leading to an increase in powerful others locus of control beliefs. Having 
already received a diagnosis and undergone surgical intervention, participants may have 
had ample opportunities to receive care and support from medical professionals, family 
and friends. That is, it is likely that any changes in locus of control beliefs may have 
already occurred prior to the start of the study. Powerful others locus of control beliefs 
were already high at baseline so it might be unlikely that these beliefs could increase 
further. Past research has shown that previous experience with medical professionals 
significantly determines powerful others locus of control beliefs in patients with renal 
disease (Christensen, Turner, Smith, Holman, & et al., 1991) and cancer (Andrykowski 
& Brady, 1994).
Of central importance were the roles of monitoring and blunting in the locus of control 
beliefs. Participants using the monitoring coping style reported more internal locus of 
control beliefs. This finding was contrary to expectations. Miller’s (Miller, 1996; Miller 
et al., 1993) theory proposes that in an uncontrollable stressful medical situation, like 
the diagnosis and treatment of breast cancer, monitoring coping would make 
participants aware of their limited ability to control the situation. Therefore monitoring 
would be associated with a less internal locus of control beliefs. Empirical research has 
reported the same relationship between monitoring and internal locus of control beliefs 
(Hack & Degner, 1999; Muris et al., 1995b; van Zuuren & Wolfs, 1991).
It is possible that although breast cancer is highly threatening and uncontrollable, it does 
provide opportunities for participants to perform behaviours that reduce the 
stressfulness of the situation. Therefore, monitoring behaviour enabled participants to 
identify these opportunities and feel an increased sense of control and thus more internal 
locus of control beliefs. In line with the idea, some participants reported that receiving 
information on their diagnosis and treatment “made it easier to know what to expect” 
and therefore do things to prepare for the treatment. For example, organising time off
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work, making child care arrangements and completing effortful household chores before 
treatment.
As expected, participants using a monitoring coping style reported more chance locus of 
control belief. This supports Miller’s (Miller, 1996; Miller et al., 1993) theory that 
monitoring is associated with more chance locus of control beliefs in an uncontrollable 
stressful situation because monitoring serves to make participants acutely aware of the 
limits of their ability to control the situation. This relationship has not been 
demonstrated in the empirical research. Participants using both a monitoring and 
blunting coping style also reported more chance locus of control. It is thought that 
people using both monitoring and blunting coping are thought to alternate between both 
forms of coping without allowing sufficient time to determine if the coping is successful 
(Krohne, 1993). As a result, participants employing this coping style might feel that 
there is little that they can do to affect the situation and therefore their beliefs in chance 
locus of control are strengthened. Again, no research has demonstrated this relationship.
Participants using a monitoring coping style also reported more powerful others locus of 
control beliefs. This supports Miller’s (Miller, 1996; Miller et al., 1993) theory that 
monitors believe that medical professionals are able to control their medical conditions. 
As stated, information seeking about a stressful situation may make monitors aware of 
the limits of their control as well as identifying other people who are able to exert 
control over the situation. In the medical setting, this would be medical professionals. It 
has even been suggested that one purpose of monitoring behaviour is to develop 
relationships with these people. Past research has supported the association between 
monitoring and powerful others locus of control beliefs (Miller et al., 1988).
Participants using a blunting coping style also reported more powerful others locus of 
control beliefs. This finding is in contrast to Miller’s (Miller, 1996; Miller et al., 1993) 
theory that blunting is associated with more internal locus of control beliefs. Perhaps 
participants who blunt or avoid information are not aware of actions they can perform to 
control the situation and instead hold beliefs that others are able to do something to 
control the situation. It is also possible that participants with a blunting coping style are 
aware of actions they can perform to reduce the stressfulness of the situation but have 
less information about how to implement these actions and are therefore less confident
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about performing them. As a result, they prefer to rely on others to do something about 
stressful situations. No research has demonstrated a link between blunting and locus of 
control beliefs.
Although the monitoring and blunting coping styles were consistent predictors of locus 
of control beliefs, there were several other demographic, health, disease and clinical 
characteristics that were consistent predictors of locus of control beliefs. Indeed, 
investigation of the beta weights shows these characteristics accounted for similar 
amounts of variance in locus of control beliefs as the coping styles. The most consistent 
of these was depression. Participants experiencing more depression reported less 
internal, chance and powerful other locus of control beliefs.
People who are experiencing significant depressive symptoms often report feelings of 
helplessness and hopelessness (American Psychiatric Association, 1994). It might be 
reasoned that participants feeling hopeless and/or helpless are less likely to believe that 
all situations, including stressful situations, are controllable by either internal or external 
factors. People experiencing depressive symptoms also often report a lack confidence in 
their own abilities, and this might extend to stressful situations (American Psychiatric 
Association, 1994). They might therefore hold fewer internal, chance and powerful 
others locus of control beliefs. Previous research has demonstrated participants 
experiencing high levels of distress also report fewer locus of control beliefs (Cull et al., 
2001) .
The consistent demographic characteristics predicting locus of control beliefs included 
the state of residence and education level. Participants living in NSW reported more 
internal and less powerful others locus of control beliefs compared to those living in the 
ACT. When encountering concerns or problems with chemotherapy treatment and its 
side effects, participants living in the ACT were more able to access medical 
professionals and services than those in NSW, who had to rely more on their personal 
resources. This might have the effect of enhancing powerful others locus of control 
beliefs in ACT residents while enhancing internal locus of control beliefs in NSW 
residents.
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Participants who were better educated reported less chance and powerful others locus of 
control beliefs compared to those who were less well educated. This is in line with past 
research that shows that people with higher levels of education report more internal and 
less chance and powerful others locus of control beliefs. People who are better educated 
may be more aware of ways in which they can affect their health care. This association 
has been found in women at risk of and diagnosed with breast cancer (Barroso et al., 
2000; Helmes et al., 2002), although it has not been consistent (Tittle, Chiarelli, 
McGough, McGee, & McMillan, 2002).
Participants with private health care status reported more internal and less chance locus 
of control beliefs. This is not surprising as those people who believe they are able to 
control their health would be more likely to engage in disease prevention activities of 
which acquiring private health cover might be considered one such activity. Past 
research has shown that people with greater internal locus of control beliefs engage in a 
range of health prevention activities. For example, women with internal locus of control 
beliefs are more likely to engage in breast cancer screening or those with breast cancer 
are more likely to take nutritional supplements than those with external locus of control 
beliefs (Aro et al., 1999; Borrayo & Guarnaccia, 2000; Bundek et al., 1993; Fajardo et 
al., 1992; Franco et al., 2000; Glenn & Moore, 1990; Murray & McMillan, 1993; 
Patterson et al., 2003).
A range of disease and surgical treatment characteristics predicted locus of control 
beliefs. However, none of these characteristics were consistent predictors of beliefs as 
different disease and treatment characteristics predicted different beliefs. When the 
characteristics are considered as a whole, it appears that participants with less extensive 
disease reported more internal locus of control beliefs while participants with more 
extensive surgical treatment reported more internal and chance locus of control beliefs. 
Participants with less extensive disease but more extensive treatment might feel less 
vulnerable to the disease and perhaps more in control of outcomes and therefore 
enhanced internal locus of control beliefs. As previously stated, research has confirmed 
that patients with more acute and chronic illnesses reported more chance and less 
internal locus of control beliefs (Andrykowski & Brady, 1994; Christensen et al., 1991). 
Alternatively, participants undergoing more extensive surgery may have had less choice 
in the type of surgery required and therefore reported enhance chance locus of control
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beliefs. It is also possible that participants with more chance locus of control beliefs felt 
compelled to do everything within their control to affect outcomes and therefore opted 
for more extensive surgery.
In summary, participants’ locus of control beliefs were remarkably consistent before, 
during and following chemotherapy treatment. Participants reported significantly more 
powerful others locus of control beliefs compared to internal and chance locus of 
control beliefs. Monitoring and blunting coping styles played a significant role in 
participants’ locus of control beliefs. The roles of monitoring and blunting coping were 
not entirely consistent with Miller’s (Miller, 1996; Miller et al., 1993) theory, although 
it should be noted that little past research has been conducted and confirmed the 
theorised relationships.
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CHAPTER ELEVEN
Monitoring and Blunting Coping Styles and Risk Perception
11.1 Risk Perception
11.1.1 Comparative Risk Perception Calculation
To investigate whether monitoring, blunting and the interaction term were associated 
with levels of perceived risk of developing breast cancer, a series of analyses were 
conducted. First, while participants reported their levels of personal risk perception 
(Personal RP) and peer risk perception (Peer RP), a third score was calculated to 
estimate the extent to which personal risk perception differed from peer risk perception 
This score was referred to as comparative risk perception (Comparative RP) and was 
calculated using the following formula; Xprp -  Xpro = Xprc, where Xprp is the 
personal risk perception score and Xpro is the peer risk perception score.
11.1.2 Risk Perception Estimates
Descriptive statistics were conducted and are presented in Table 61. The results indicate 
that participants reported a broad range of personal, peer and comparative perceived 
risks. It appeared that participants reported similar estimates of personal and peer risk 
perception. This was confirmed by a significant, positive and strong Pearson product- 
moment correlation between personal and peer risk perception (r = .87, p < .05) and a 
non-significant paired-samples t-test indicated that participants reported similar levels 
of personal and peer risk perception (t (35) = -1.36, p > .05).
Table 61
Descriptive Statistics of Personal, Peer and Comparative Risk Perception (N=35)
Variables M SD Range Skewness Kurtosis
Personal RP 4.56 2.20 Ö i © .40 -.37
Peer RP 4.81 1.93 2.0-9.0 .49 -.03
Comparative RP -.25 1.10 -4.0 - 2.5 -1.13 4.89
Frequencies were calculated to determine the percentages of participants who estimated 
their risk to be equivalent, greater or lesser than others. The results are presented in
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Table 62 and indicate that the majority of participants reported their personal risk to be 
equivalent to their peers.
Table 62
Frequencies (%) of Participants Reporting Equivalent, Greater or Lesser Comparative 
Perceived Risks (N=35)
Comparative RP /(% ) (n)
Lesser 20.0 (7)
Equivalent 74.3 (26)
Greater 5.7 (2)
11.1.3 Risk Perception and Demographic Characteristics 
Analyses were conducted to assess any differences in risk perception according to 
demographic variables. A Bonferroni adjustment of a  = .008 was applied to the results 
of the analyses of demographic characteristics. Pearson product-moment correlations 
revealed no significant associations between age and personal (r = .06, p > .008), peer 
(r = -.06, p > .008) and comparative (r = -.02, p > .008) risk perception. Independent- 
samples t-tests showed no significant differences in personal (t (34) = -1.26, p > .008), 
peer (t (34) = -1.92, p > .008) and comparative (t (34) = .74, p > .008) risk perception 
for marital status and no significant differences in personal (t (34) = 1.08, p > .008), 
peer (r (7.03) = 1.02, p > .008) and comparative (t (34) = -.28, p > .008) risk perception 
for state of residence. Levene’s test of equality of variance was significant (F = 5.53, p 
< .05) for the test of marital status and peer risk perception so the t-test with equality of 
variance not assumed was considered (Pallant, 2001).
There were no significant differences in personal (t (34) = .75, p > .008), peer (t (34) = 
.54, p > .008) and comparative (t (34) = .55, p > .008) risk perception by education 
level. There were no significant differences in personal (t (34) = .26, p > .008), peer (t 
(34) = .01, p > .008) and comparative (t (34) = .50, p > .008) risk perception by 
employment status and in personal {t (24) = .66, p > .008), peer (t (24) =.83, p > .008) 
and comparative (t (24) = -.14, p > .008) risk perception by employment intensity. 
Lastly, there were no significant differences in personal (t (24) = .27, p > .008), peer (t 
(9.07) = -.27, p > .008) and comparative (t (24) = 1.21, p > .008) risk perception by 
occupation. Levene’s test of equality of variance was significant (F = 5.55, p < .05) for
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the test of occupation and peer risk perception so the t-test with equality of variance not 
assumed was considered (Pallant, 2001).
11.1.4 Risk Perception and Health Characteristics
Analyses of the differences in risk perception according to health variables were 
conducted using a Bonferroni adjustment of a  = .012. Independent-samples t-tests show 
that there were no differences in personal (t (34) = -.48,/? > .012), peer (t (34) =.19,/? > 
.012) and comparative (t (34) = -1.32, p > .012) risk perception by patient health care 
status and in personal (t (34) = 1.05, p > .012), peer (t (34) = 1.06, p > .012) and 
comparative (t (34) = .24, p > .012) risk perception by menopausal status. One-way 
ANOVAs revealed no significant differences in personal (.F (3, 32) = 1.96, p > .012 and 
F (2, 33) = .81,/? > .012 respectively), peer (F (3, 32) = 1.79, p > .012 and F {2,33) = 
.72, p > .012) and comparative (F (3, 32) = 2.30, p > .012 and F (2, 33) = .35, p > .012) 
risk perception in terms of the method of detection and referral source.
11.1.5 Risk Perception and Disease Characteristics
Analyses were also conducted to determine differences in risk perception and disease 
characteristics using a Bonferroni adjustment of a  = .008. Pearson product-moment 
correlations revealed no significant associations between the number of tumours and 
personal (r = .30, p > .008), peer (r = .18, p > .008) and comparative (r = .28, p >
.008) risk perception, tumour size and personal (r = -. 14, p > .008), peer {r = .05, p > 
.008) and comparative (r = -.37, p > .008) risk perception and number of affected 
axillary nodes and personal (r = .20, p > .008), peer (r = .24, p > .008) and comparative 
risk perception (r = -.01, p > .008).
One-way ANOVAs showed no difference in tumour grade and personal (F (2, 33) = .27, 
p > .008), peer (F (2, 33) = .44, p > .008) and comparative risk perception (F (2, 33) = 
.18,/? > .008). Independent-samples t-tests revealed no significant differences in 
personal (t (34) = .01,/? > .008 and t (34) = -3.25, p < .008 respectively), peer (f (34) = - 
.09,/? > .008 and t (34) = 1.79,/? > .008) and comparative risk perception (t (34) = .18, 
p > .008 and t (34) = -.33, p > .008) in terms of the presence of DCIS and LCIS.
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11.1.6 Risk Perception and Treatment Characteristics
Analyses were conducted to determine differences in risk perception according to the 
receipt of radiation and endocrine therapy. A Bonferroni adjustment of a = .012 was 
applied to the results of the analyses. Independent-samples t-tests revealed no 
differences in personal (t (34) = -1.19, p > .012 and t (34) = -1.72,/? > .012 
respectively), peer (t (34) = -.77,/? > .012 and t (34) = -1.59,/? > .012) and comparative 
risk perception (t (34) = -1.02,/? > .012 and t (34) = -.62, p > .012) and the receipt of 
radiation therapy and endocrine therapy, respectively. Pearson product-moment 
correlations showed no significant association between receipt of radiation and 
endocrine therapy and personal (r = .19,/? < .012 and r = .08,/? < .012), peer (r = .21, 
p < .012 and r = -.05,/? < .012) and comparative risk perception (r = .00,/? < .012 and 
r = .25, p < .012).
11.1.7 Risk Perception and Anxiety, Depression and Side Effects
Pearson product-moment correlations using a Bonferroni adjustment of a  = .017 were 
conducted to determine whether there were associations between risk perception and 
anxiety, depression and side effects at T4. As shown in Table 63, there are some mainly 
negative, small but non-significant associations between risk perception and anxiety, 
depression and side effects.
Table 63
Intercorrelations of Personal, Peer, and Comparative Risk Perception and Anxiety, 
Depression and Side Effects at T4 (N=35)
Variables Personal RP Peer RP Comparative RP
Anxiety -.15 -.13 -.06
Depression -.04 -.09 .06
Side Effects -.23 -.10 -.23
11.2 Risk Perception and Monitoring and Blunting
A series of Pearson product-moment correlations using a Bonferroni adjustment of a  = 
.017 were conducted to determine the associations between risk perception and 
monitoring, blunting and the interaction term. As shown in Table 64, there appear to be 
positive, small and non-significant associations between monitoring and personal risk
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perception and negative, small and non-significant associations between blunting and 
the interaction term and peer and comparative risk perception.
Table 64
Intercorrelations of Personal, Peer and Comparative Risk Perception and Monitoring, 
Blunting, and the Interaction Term (N=35)
Variables Personal RP Peer RP Comparative RP
Monitoring .29 .29 .07
Blunting -.31 -.18 -.30
Monitoring-Blunting -.22 -.12 -.23
To investigate these findings further, a series of hierarchical multiple regression 
analyses were conducted to determine the extent to which monitoring, blunting, and the 
interaction term predicted personal, peer, and comparative risk perception. Given the 
modest sample available for the regression analyses, a selection of background variables 
was included. These variables consisted of education level, number of tumours, type of 
surgery and receipt of endocrine therapy. Education level was chosen as past research 
suggests it may be linked with risk perceptions (Culver et al., 2001; Lerman et ah,
1996). The number of tumours was selected as an indicator of the extensiveness of the 
disease while the type of surgery received was an indicator of the extensiveness of 
surgical intervention, both of which might affect participants’ feelings of vulnerability 
to the disease and therefore risk perception estimates. The receipt of endocrine therapy 
indicates whether participants were receiving active treatment at the time of estimating 
perceived risks.
To determine the amount of variance in personal risk perception accounted for by 
monitoring, blunting and their interaction, risk perception was entered into the 
hierarchical regression equation as the dependent variable. Peer risk perception was 
entered in the first step, education level, number of tumours, type of surgery and receipt 
of endocrine therapy were entered in the second step, monitoring and blunting were 
entered in the third step, and the interaction term was entered in the fourth step. 
Investigations of the assumptions of regression analyses were conducted. With the use 
of a p < .001 criterion for Mahalanobis distance, no outliers were identified.
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The unstandardised regression coefficients (B), the standard error of the regression 
coefficient (s.e.), standardised regression coefficients (ß), and the T test results are 
presented in Table 65. The overall model with all variables included was significant (F 
(8, 27) = 21.05, p < .05) and accounted for 82% of variance in personal risk perception. 
Peer risk perception, the use of blunting coping and the number of tumours all made 
significant unique contributions to personal risk perception. Participants who reported 
more peer risk perception and had more tumours reported greater personal risk 
perception. Participants who reported the use of blunting reported lower personal risk 
perception.
Table 65
Summary of Hierarchical Multiple Regression Analysis for Variables Predicting 
Personal Risk Perception (N=35)
Variables B s.e. p T
Step 1 Peer RP .77 .10 .68 7.73**
Step 2 Number of tumours .41 .15 .22 2.76**
Education
0
0
<
N .17 -.13 -1.65
Surgery type -.32 .31 -.09 -1.04
Endocrine therapy .73 .37 .16 1.96
Step 3 Monitoring .03 .02 .12 1.44
Blunting -.05 .02 -.23 -2.74*
Step 4 Monitoring-Blunting -.00 .00 -.17 -1.96
Note. Step 1 R2=.75, AR2=.74, Step 2 R2=.80, AR2=.77, Step 3 R2=.84, AR2=.80, Step 4 
R2=.86, AR2=.82 
*p < .05, **p < .01
To investigate this finding further, scatterplots of blunting on personal risk perception 
were generated. The results indicate a negative association between blunting and 
personal risk perception and are presented in Figure 13.
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Figure 13. Distribution of Personal Perceived Risks by Blunting Scores
Participants’ blunting scores were divided into tertiles such that group 1 reported the 
lowest scores on blunting, group 2 the middle scores and group 3 the highest scores. A 
one-way ANOVA was conducted to determine whether there were significant 
differences in personal risk perception for the blunting tertile groups. The results of 
indicated no significant differences in personal risk perception for the blunting groups 
(F (2, 33) = 1.28, p > .05, eta squared = .07). Inspection of the means indicate that 
group 1 scores lower (Af= 3.86, SD=2.24) than group 2 (M=4.42, SD=2.28), which in 
turn scored lower than group 3 (M=5.54, SD= 1.85) on personal risk perception. That is, 
high blunting scores were associated with lower personal risk perception. A means plot 
is presented in Figure 14.
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Blunting Tertile Groups
Figure 14. Mean Personal Perceived Risk of Blunting Tertile Groups
The same process was repeated for peer risk perception. Peer risk perception was 
entered as the dependent variable. Personal risk perception was entered in the first step, 
education level, number of tumours, type of surgery and receipt of endocrine therapy 
were entered in the second step, monitoring and blunting coping were entered in the 
third step and the interaction term was entered in the fourth step. The results of the 
regression analysis of peer risk perception are presented in Table 66. With the use of a p 
< .001 criterion for Mahalanobis distance, no outliers were identified.
The overall model was not significant (F (8, 27) = 12.83,/? < .05). Only personal risk 
perception made a significant unique contribution to peer perceived risk. Participants 
who reported higher peer risk perception estimates also reported higher personal risk 
perception. Monitoring, blunting and the interaction term did not make a significant 
contribution.
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Table 66
Summary o f Hierarchical Multiple Regression Analysis for Variables Predicting Peer 
Risk Perception (N=35)
Variables B s.e. ß T
Step 1 Personal RP .90 .12 1.02 7.73**
Step 2 Number of tumours .12 .19 .06 .61
Education -.30 .17 -.18 -1.74
Surgery type .41 .33 .13 1.26
Endocrine therapy -.32 .42 -.08 -.76
Step 3 Monitoring -.00 .02 -.01 -.09
Blunting .03 .02 .13 1.13
Step 4 Monitoring-Blunting .00 .00 .10 .92
Note. Step 1 R2=.75, AR2=.74, Step 2 R2=.77, AR2=.73, Step 3 R2=.78, AR2=.73, Step 4 
R2=.79, AR2=.73 
*p < .05, **p < .01
For the analysis of comparative risk perception, comparative risk perception was 
entered as the dependent variable. Background variables were entered in the first step, 
monitoring and blunting coping were entered in the second step and the interaction term 
was entered in the third step. With the use of a p < .001 criterion for Mahalanobis 
distance, no outliers were identified.
The results of the analysis are presented in Table 67 and reveals that the overall model 
was not significant (F (7, 28) = 2.03, p > .05). Only the number of tumours made a 
significant unique contribution to comparative risk perception. Monitoring, blunting and 
the interaction term did not make significant unique contributions to comparative risk 
perception.
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Table 67
Summary of Hierarchical Multiple Regression Analysis for Variables Predicting 
Comparative Risk Perception (N=35)
Variables B s.e. ß T
Step 1 Number of tumours .36 .16 .39 2.28*
Education -.18 .18 -.17 -1.02
Surgery type .48 .38 .21 1.26
Endocrine therapy -.41 .33 -.22 -1.26
Step 3 Monitoring .01 .02 .10 .56
Blunting -.04 .02 -.32 -1.90
Step 4 Monitoring-Blunting -.00 .00 -.24 -1.36
Note. Step 1 R2=.18, AR2=.08, Step 2 R:=.29, AR2=.15, Step 3 R2=.34, AR2=.17 
*p < .05, **p < .01
11.3. Discussion
Perceived risks of recurrence six months following completion of chemotherapy 
treatment were investigated. At this point, all participants have completed active 
treatment with the exception of the 63% of participants receiving endocrine therapy. 
Inspection of the risk perception estimates revealed that participants reported a wide 
range of personal and peer risk perception. The mean personal and peer risk perception 
estimates were similar, indicting that participants perceived their own level of risk as 
being comparable to peers’ level of risk. Indeed, three-quartes of participants reported 
that personal and peer risks were the equivalent, one-fifth reported that their risk was 
lower and the remaining few participants felt their risk was higher than peers. That is, 
participants were slightly optimistic about their risk of recurrence compared to their 
peers.
It is difficult to compare the levels of personal perceived risk to other samples. Little 
empirical research of perceived risk of recurrence has been conducted and instead, 
research has focused on the perceived risk of developing cancer for the first time. This 
research has also tended to utilise diverse measures of risk perception, typically 
designed specifically for the study (Absetz et al., 2000; Bottorff et al., 2004; Bowen et 
ah, 2003; Culver et ah, 2001; Cunningham et ah, 1998; Diefenbach, Schnoll, Miller, & 
Brower, 2000; Gil et ah, 2003; Kent et ah, 2000; Lipkus et ah, 2005; Weinstein et ah,
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2004). Given the growing interest in risk perceptions regarding future cancer 
recurrence, it would be prudent for future research to investigate the construct further 
and determine the best way in which to assess risk perceptions. This would enable an 
accurate estimation of perceived risks reported and comparisons to be made across 
samples.
The relationship between the monitoring and blunting coping styles and perceived risk 
estimates indicate that the coping styles play a limited yet significant role in 
participants’ personal perceived risks. Participants who prefer the blunting coping style 
reported lower personal risk perception. This finding confirms Miller’s (1996; 1993) 
theory that blunting is associated with reduced perceived risk of developing a serious 
medical condition but does not support the theory that monitoring coping is associated 
with increased risk perception. Of the few studies conducted regarding coping styles 
and risk perception, the results have supported the association between monitoring and 
increased risk perception (Schwartz et al., 1995; Zakowski et al., 1997).
According to Miller (1996; 1993), the blunting coping style results in lowered estimates 
for two reasons. First, participants using blunting coping avoid all information about the 
stressful situation, including the risks incurred. Second, blunting coping is also thought 
to elicit lower levels of psychological distress which in turn, might make patients feel 
less vulnerable in stressful situations. Thus, blunting results in low levels of risk 
perception. However, the second assertion appears to be implausible in the current 
study. The results reported previously state that participants using blunting coping 
report greater levels of distress than those not using blunting coping.
The strongest predictor of personal risk perception was peer risk perception while the 
strongest predictor of peer risk perception was personal risk perception. This finding is 
not surprising given the strong association between the two risk estimates. The 
background variables played little role in participants’ risk estimates. Only the number 
of tumours was significantly associated with personal risk perception. It is 
understandable that participants with more extensive disease would feel more 
vulnerable to developing breast cancer again in the future. The number of tumours is 
just one possible indicator of the extent of disease. Future research is needed to 
investigate other disease characteristics and their effect on perceived risks.
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In summary, participants reported a broad range of risk perception estimates. 
Monitoring and blunting appeared to have a significant yet limited influence on the 
experience of perceived risk of recurrence. However, it should be noted that the 
regression analyses conducted involved a small sample of participants in comparison to 
the number of predictor variables entered in the analyses. Indeed, the assumption that at 
least 8 cases are required per predictor variable was violated in the analyses (Tabachnik 
& Fidell, 2001). Consequently, the results and conclusiosn drawn from the analyses 
should be considered tentative. Further research is required due to the small number of 
participants who completed the six-month follow-up questionnaire and the cross- 
sectional nature of the investigation of risk perception.
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CHAPTER TWELVE 
Conclusions
The present study signifies one of the first and most comprehensive attempts to examine 
women’s experience of adjuvant chemotherapy for EBC. Women’s physical and 
psychological wellbeing before, during and six months following treatment was 
intensively examined. The results highlighted the importance of understanding the role 
of coping styles in the experience of chemotherapy and as such, offer numerous and 
significant theoretical and clinical implications.
In terms of the theoretical implications, the study has significantly extended the existing 
knowledge of coping and its role in the experience of stressful medical situations. The 
study is one of few to investigate the theoretical conceptualisation and empirical 
measurement of monitoring and blunting coping styles. The results suggest that the 
coping styles are likely to be mutually exclusive coping constructs but raised doubts 
regarding the stability of monitoring and blunting coping. It is thought that monitoring 
and blunting are fairly independent of situational and personal factors (Krohne, 1993; 
Miller, 1996; Miller et al., 1993) however participants reported use of the coping styles 
changed after the experience of chemotherapy. It appears then that the coping styles are 
more vulnerable to change in the face of significant experiences than previously 
thought. The results also demonstrated the adequate reliability of the coping measures 
but highlighted concerns about their construct validity. It appears that blunting coping is 
a more heterogeneous construct than that represented in existing measures. The results 
indicate that a more accurate conceptualisation and measurement of the coping styles is 
a priority for future research.
The present study considered both monitoring and blunting coping styles as continuous 
variables. This ensured that an accurate understanding of the roles of monitoring, 
blunting and their interaction in physical and psychological wellbeing was achieved. 
Past research has tended to consider either the role of monitoring only (Miller et al., 
1996a; Schwartz et al., 1995; Tercyak et al., 2001) or has divided people into groups of 
particular coping styles according to median split procedure or cluster analysis (Hack & 
Degner, 1999; McKinnon, 2001; Shapiro et al., 1997; Voss et al., 2006). Past research
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has focused on monitoring as initial research revealed no influence of blunting on 
outcomes. However, the scales utilised in much of the research have since been shown 
to be poor measures of blunting. The decision to disregard the role of blunting coping in 
physical and psychological wellbeing may have been premature. The tendency to 
combine the scores on coping scales into groups also results in a loss of information 
regarding the full range of variation in monitoring and blunting use and reduces sample 
sizes on which analyses are conducted.
It is therefore likely that the results of past research are misleading due to the limited 
and/or inappropriate examination of coping styles. Indeed, the results of the present 
study demonstrate that the use of blunting coping and both monitoring and blunting 
coping may have significant roles to play in physical and psychological wellbeing. It is 
crucial that future research considers the use of monitoring, blunting and the interaction 
between the two coping styles in order to better understand the nature of the coping 
styles and their effects on wellbeing. The present study investigated the interaction 
between the coping styles via the creation of an interaction term. It is possible that this 
may be a simple and effective method of investigating the interaction between 
monitoring and blunting coping syles in future research.
The study extended the research on coping styles to consider a clinical sample 
undergoing a highly stressful and prolonged medical treatment. Past research has 
focused on non-clinical samples of mainly undergraduate students (Miller, 1987; Muris 
& de Jong, 1993; Muris & Schouten, 1994; Muris & Van Zuuren, 1992; Muris et al., 
1994c; Muris et ah, 1994d; Muris et ah, 1994e; van Zuuren & Muris, 1993; van Zuuren 
& Wolfs, 1991), and small clinical samples (Miller et ah, 1988; Miller & Mangan,
1983; Miller et ah, 1994; Muris et ah, 1993a; Muris et ah, 1994b; Muris et ah, 1995c; 
van Zuuren, 1993, 1994). They have also tended to involve mildly to moderately 
stressful laboratory tasks (Miller, 1987; Muris et ah, 1994d; Muris, Van Zuuren, & 
Merckelbach, 1993b) and single-session medical or dental procedures or treatments of 
limited duration (Andrykowski et ah, 2002; Miller et ah, 1988; Miller & Mangan, 1983; 
Miller et ah, 1994).
Past research investigating the experience of chemotherapy treatment has assessed 
outcomes before treatment and after the first few treatments (Gard et ah, 1988; Lerman
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et al., 1990; McKinnon, 2001; Shapiro et al., 1997). Typically, the research has reported 
declines in physical and psychological wellbeing at the beginning (McKinnon, 2001; 
Shapiro et al., 1997) or at a arbitrary time during chemotherapy treatment (Gard et al., 
1988). The research has not investigated outcomes throughout treatment and/or included 
a substantial follow-up period. The present study enabled an understanding of the 
medium- to long-term effects of monitoring and blunting coping in the experience of a 
significantly large sample of women undergoing chemotherapy. The intensive 
assessment of wellbeing in the present study suggests that the previous estimates of 
physical and psychological wellbeing during chemotherapy treatment do not capture the 
variations in wellbeing experience. It is essential that future research employs a 
similarly intensive and long-term assessment of wellbeing during and following 
chemotherapy in order to continue to advance understanding of this challenging 
treatment.
The research provided considerable information regarding the nature of the relationships 
between monitoring and blunting coping and the experience of anxiety, depression and 
side effects in response to chemotherapy. It is one of few studies that has investigated 
both physical and psychological wellbeing experienced in response to a stressful 
medical procedure or treatment (Lerman et al., 1990; Manne et al., 2001; McKinnon, 
2001; Shapiro et al., 1997). Other studies have focused on either physical wellbeing 
(Gard et al., 1988; Muris & Van Zuuren, 1992; Steptoe & Noll, 1997) or psychological 
wellbeing (Andrykowski et al., 2002; Miller et al., 1994; Miller et al., 1995; Schwartz et 
al., 1995).
Furthermore, the study investigated the relationships between monitoring and blunting 
coping and locus of control beliefs and risk perceptions of a future recurrence. These 
constructs have been consistently linked with coping styles in the theory but to date 
only limited research has been conducted on coping styles and locus of control beliefs 
(Hack & Degner, 1999; Muris et al., 1995b; van Zuuren & Wolfs, 1991) and risk 
perception (Fang et al., 2002; Schwartz et al., 1995). Clarification of the role of coping 
styles in locus of control beliefs and risk perception is important as locus of control 
beliefs and risk perception significantly determine people’s desired role in health care 
decision-making (Helmes et al., 2002), performance of health promotion and disease 
prevention behaviours (Aro et al., 1999; Borrayo & Guarnaccia, 2000; Bundek et al.,
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1993; Fajardo et al., 1992; Franco et al., 2000; Glenn & Moore, 1990; Murray & 
McMillan, 1993; Patterson et al., 2003) and psychological wellbeing in survivorship 
(Curran et al., 1998; Dow et al., 1996; Johnson Vickberg, 2001; Kissane et al., 1997; 
Tomich & Helgeson, 2002; Wenzel et al., 1999), all of which are important in ensuring 
physical and psychological wellbeing during and following treatment.
The study is the first of its kind in accounting for a wide range of demographic, health, 
disease and treatment characteristics in the experience of chemotherapy treatment. 
Inclusion of these characteristics in the analyses ensured that the variance accounted for 
by coping styles in physical and psychological wellbeing and locus of control beliefs 
and risk perceptions was accurately detected. In so doing, the statistically significant 
and sizeable roles of coping styles in the levels of anxiety, depression, side effects, 
locus of control beliefs and, to a lesser extent, risk perception reported were made 
apparent. Further research is needed to replicate these findings.
The importance of considering demographic, health, disease and treatment 
characteristics in the analyses was also evident in that the characteristics had significant 
and small roles in the levels of anxiety, depression, side effects, locus of control beliefs 
and risk perception. The failure of past research to consider these variables in assessing 
physical and psychological wellbeing may mean the findings reported are misleading 
(Gard et al., 1988; McKinnon, 2001; Shapiro et al., 1997). The significant roles of 
monitoring and blunting coping in regards to physical and wellbeing reported in the 
present study may signal that the past research has underestimated the importance of 
coping styles in wellbeing in patients facing stressful medical procedures or treatments. 
Future research investigating the role of the coping styles in cancer patients must 
therefore ensure that these variables are included.
The presented study also offered a range of clinical implications, the first of which 
concern doctor-patient decision-making and relationships during treatment. The study 
confirmed the theory that coping styles are associated with locus of control beliefs 
(Miller, 1996; Miller et al., 1993). Past research has suggested that these beliefs have an 
important influence over the desired role of patients in health care decision-making. For 
example, patients with stronger internal locus of control beliefs desire a more active role
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in decision-making than those with stronger chance and powerful others locus of control 
beliefs (Helmes et al., 2002).
Ensuring that patients experience good relationships with medical professionals and are 
satisfied with their role in decision-making are crucial. Patients who experience good 
relationships with their medical professionals and are satisfied with their role in 
decision-making have been shown to report less distress several months post-diagnosis 
(Breaden, 1997; Ganz et al., 2004; Lethborg et ah, 2000; Ong et al., 2000; Vivar & 
McQueen, 2005; Wyatt et al., 1993). Understanding the relationships between coping 
styles and locus of control beliefs may enable doctors to more effectively tailor their 
consultations to suit the desired role of patients and thus strengthen their relationships 
with patients. This will preserve patients’ psychological wellbeing in the long-term.
The information regarding the variation in experience of anxiety, depression and side 
effects before, during and six months following chemotherapy treatment also has the 
potential to affect decision-making and doctor-patient relationships. The study provides 
important information regarding the levels of anxiety, depression and side effects 
experienced during and following chemotherapy as well as the way in which 
demographic, disease and surgical and chemotherapy treatment characteristics affect the 
levels of anxiety, depression and side effects. Providing medical professionals with this 
knowledge ensures that they are better able to provide patients with accurate and 
detailed expectations about the effect of chemotherapy on physical and psychological 
wellbeing. This enables patients make an informed choice regarding cancer treatment 
options and in cases where patients do chose to undergo chemotherapy treatment, 
medical professionals are better able to prepare them for what to expect. The benefits of 
which are good relationships between medical professionals and patients, a high degree 
of patient satisfaction with decision-making role and future psychological wellbeing.
Of great interest was the finding that coping styles were implicated in the experience of 
anxiety, depression and side effects experienced before, during and six months 
following chemotherapy treatment. An understanding of the way in which coping styles 
affect physical and psychological wellbeing means that medical professionals and 
psychologists may be able to screen patients to identify those at risk of poorer physical 
and psychological wellbeing. In the case of medical professionals, this is of particular
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importance as they have demonstrated difficulty identifying patients experiencing 
elevated levels of anxiety and depression (Badger et al., 2004; Berard et ah, 1998; 
Nordin et al., 2001; Payne et al., 1999).
Once at-risk patients are identified, medical professionals and psychologists may offer 
appropriate support to prevent or ameliorate declines in physical and psychological 
wellbeing. This might involve regular check-ups regarding patients’ levels of 
psychological distress and the provision of support to reduce distress. This may serve to 
prevent the likelihood of developing or continued experience of poor physical and 
psychological wellbeing after treatment. Research has demonstrated that women with 
breast cancer who report experiencing anxiety and/or depression at diagnosis are 
significantly more likely to experience anxiety and depression six to twelve months 
later (Nordin et al., 2001; Schou et al., 2004).
For medical professionals, this may involve finely tuning the chemotherapy regimen 
and supportive treatment offered to patients to ensure patients’ physical wellbeing is 
preserved. For example, it was found that Taxol was associated with increased side 
effects. It may be that Taxol is an inappropriate regimen for patients employing a 
coping style that places them at risk of developing significant side effects. Instead, 
medical professionals may be able to offer an equally effective yet less toxic regimen. 
Medical professionals may also be able to offer more or stronger supportive 
medications to reduce the severity and impact of side effects. For example, patients at 
risk of experiencing elevated side effects may be prescribed stronger anti-emetic 
medication or offered GCSF support.
The benefits of effectively controlling side effects are considerable. Patients with fewer 
side effects may report greater levels of physical functioning and psychological 
wellbeing. They may also be less likely to experience medical complications requiring 
intensive and expensive medical treatment. For example, patients experiencing 
significant side effects are frequently at risk of developing neutropenia, a condition 
which often requires increased use of anti-emetic, the addition of GCSF to future 
chemotherapy treatments and hospitalisation. Such medical complications are 
distressing to patients and greatly increase the economic cost of cancer treatment
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(AIHW & AACR, 2004; NHMRC & NBCC, 2001; Rhew, Young, & Goetz, 2001; 
Tucker et al., 2001).
In regards to the role of psychologists, interventions aimed at reducing the use of coping 
styles associated with poorer physical and psychological wellbeing may be designed 
and implemented in the future. Research has demonstrated that it is possible to alter 
people’s coping styles. The present study showed that participants’ reported use of 
coping styles changed over time and past research has shown that people can be 
successfully instructed to utilise coping styles different from their preferred style (Muris 
et al., 1994a; Muris et al., 1995b). Such interventions may reduce the likelihood of 
experiencing elevated levels of anxiety, depression and side effects in the period 
following chemotherapy. Research has demonstrated that the likelihood of poor 
physical and psychological wellbeing during survivorship is increased when poor 
wellbeing is experienced during diagnosis and treatment (Beisecker et al., 1997; Bower 
et al., 2000; Castellon et al., 2005; de Jong et al., 2002b; Failed et al., 2005; Frost et al., 
2000; Jansen et al., 2005; NHMRC & NBCC, 2001; Nordin et al., 2001; Sadler & 
Jacobsen, 2001; Schagen et al., 1999; Schou et al., 2004). Maintaining good physical 
and psychological wellbeing may ensure the continued compliance of patients with 
treatment.
The few interventions carried out to date have reported limited success in improving 
psychological wellbeing in the short and medium term. Many of the interventions 
consist of the provision of components of cognitive-behavioural therapy (Burish et al., 
1991; Edelman et al., 1999; Lerman et al., 1990; Morgenstern et al., 1984), a 
psychotherapy that has been shown to be effective at treating mood disorders but not 
necessarily in cancer patients (Nathan & Gorman, 2002). The limited success of these 
interventions is no doubt due to the fact that they have not been strongly based on the 
empirical literature regarding cancer patients. The present study signals an attempt to 
develop an empirical base that outlines the way in which coping styles may affect 
physical and psychological wellbeing, with the view to designing interventions aimed at 
improving physical and psychological wellbeing in cancer patients in the short- and 
medium-term. In fact, some research has already demonstrated that interventions aimed 
at altering coping styles in order to affect wellbeing are successful, although these have 
not yet been conducted on cancer patients (Muris et al., 1994a; Muris et al., 1995b).
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The study also provided new evidence regarding risk perception of breast cancer 
recurrence. Recent research has indicated that risk of recurrence is the greatest concern 
of breast cancer survivors and the perception of high risk is strongly associated with 
psychological distress (Curran et al., 1998; Dow et al., 1996; Johnson Vickberg, 2001; 
Kissane et al., 1997; Tomich & Helgeson, 2002; Wenzel et al., 1999). Again, coping 
styles were implicated in participants’ perceived risk estimates with those using the 
blunting coping style reporting lower estimates of personal perceived risk. Future 
research may be able to verify these results and if so, knowledge of the way in which 
coping styles affect perceived risk may enable psycholgists to develop and implement 
interventions designed to improve the accuracy of perceived risks via the use of 
particular coping styles.
This is a worihy avenue of future reseaerch and practice, given that recent interventions 
aimed at altering perceived risks via education about actual risks have not been 
effective. Indeed, it has been suggested that risk perception is influenced by 
psychological factors (Kent et al., 2000; Weinstein et al., 2004), of which coping styles 
may be one. The importance of holding accurate risk estimates and dealing with the 
associated distress is clear. Recent research has shown that perceived risk estimates are 
significantly associated with elevated levels of distress (Cunningham et al., 1998; Kent 
et al., 2000) and engagement in appropriate health promotion and disease preventive 
behaviours, which are important to survival (Bowen et al., 2003; Gil et al., 2003).
Similarly, coping styles were implicated in cancer-specific locus of control beliefs. Past 
research has also shown that locus of control beliefs affect engagement in health 
promotion and disease prevention behaviours. Patients with more internal locus of 
control beliefs are more likely to engage in breast cancer screening and healthy lifestyle 
behaviours than those with more chance and powerful others locus of control beliefs 
(Aro et al., 1999; Borrayo & Guarnaccia, 2000; Bundek et al., 1993; Fajardo et al.,
1992; Franco et al., 2000; Glenn & Moore, 1990; Murray & McMillan, 1993; Patterson 
et al., 2003; van Zuuren & Dooper, 1999). For women recently completing active 
treatment for breast cancer, successful survival involves participation in regular check­
ups and screening and for some, taking endocrine therapy each day (ATACTG, 2002, 
2003; NHMRC & NBCC, 2001). Women’s coping styles may serve to identify those at
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risk of not complying with the follow-up screening and treatment and may provide 
psychologists with opportunities for intervention.
The coping styles of monitoring and blunting appear to play a key role in the experience 
of adjuvant chemotherapy in women diagnosed with EBC. The exploratory nature of the 
present study has highlighted the potential for coping styles to affect all stages of 
chemotherapy treatment, from treatment decision-making to preparation, from receipt of 
chemotherapy to recovery. With the assistance of further research, understanding the 
nature and broad influence of monitoring and blunting coping styles may indicate the 
possibilities for improving women’s physical and psychological wellbeing throughout 
and following chemotherapy treatment. The ability to intervene and improve medical 
and psychosocial outcomes during and following chemotherapy treatment may have 
profound effects on the physical and psychological wellbeing of the many women 
diagnosed with breast cancer each year in Australia.
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Threatening Medical Situations Inventory (van Zuuren et al., 1996)
Below are descriptions of situations you might have found yourself in or can imagine 
finding yourself in. Each situation is followed by several statements of the things you 
might think or do in that situation. Please indicate for each statement the degree to 
which it applies to you.
1. Imagine you have been suffering from headaches and dizziness for some time. When 
you visit your doctor, he/she tells you things don't look too good and refers you to a 
specialist for a rather difficult medical examination.
Please indicate for each statement below to what degree it is applicable to you, by 
circling your answer.
1 = not at all applicable to me
2 = not very much applicable to me
3 = a bit applicable to me
4 = rather applicable to me
5 = strongly applicable to me
la) I plan to ask the specialist as many questions as possible.
1 2  3 4
b) I think things will turn out to be alright. 1 2  3 4
c) I am determined to get more information from other health centres.
1 2  3 4
d) I plan to start reading about headaches and dizziness.
1 2  3 4
e) For the time being I try not to think of unpleasant outcomes.
1 2  3 4
f) I am not going to worry: such an examination is not as bad as suffering from
headaches all the time. 1 2  3 4
5
5
5
5
5
5
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2. Imagine you work very hard and you are overweight. Your doctor has explained to 
you that this is unwise. During a check-up, he/she tells you that you have high blood 
pressure.
2a) I look at the blood pressure monitor in order to ensure he is not mistaken.
1 2 3 4 5
b) I try to take things easy. 1 2 3 4 5
c) I decide to live on normally. 1 2 3 4 5
d) I ask him extensively about the risks and consequences involved.
1 2 3 4 5
e) I tell myself some medical problems are worse than this one.
1 2  3 4 5
f) I plan to start reading a lot about high blood pressure.
1 2 3 4 5
3. Imagine you have heart problems. Your specialist advises you to have an operation. 
He/she tells you that you will have to wait four months for it and that he/she is not 
certain whether the operation will be effective.
3a) I take the line that, in my case, the operation will be effective.
1 2 3 4 5
b) I decide to go deeply into all that is known about heart surgery.
1 2 3 4 5
c) I decide to undertake as many pleasant and useful activities as possible for the next
few months. 1 2 3 4 5
d) I decide to find out whether there is a chance that the operation will make things
worse. 1 2 3 4 5
e) I decide to contact other patients with the same medical problem, for information.
1 2 3 4 5
f) I tell myself‘things will turn out to be alright’. 1 2 3 4 5
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4. Imagine, you visit your doctor because you are having some bowel problems. He/she 
diagnoses you with acute appendicitis and tells you that you have to have an operation 
in the hospital as soon as possible.
4a) I tell him I want to know precisely what they are going to do with me.
1 2  3 4
b) I decide to relax now in the face of what is coming over me.
1 2  3 4
c) I ask myself whatever can go wrong. 1 2  3 4
d) I take things easy. 1 2  3 4
e) I tell myself ‘things will turn out to be alright’. 1 2  3 4
f) I immediately try to call somebody who may inform me about this operation.
1 2  3 4
5
5
5
5
5
5
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Miller Behavioural Style Scale (Miller, 1987)
Below are descriptions of situations you might have found yourself in or can imagine 
finding yourself in. Each situation is followed by several statements of the things you 
might think or do in that situation. Please indicate for each statement below to what 
degree it is applicable to you, by circling your answer:
1 = not at all applicable to me
2 = not very much applicable to me
3 = a bit applicable to me
4 = rather applicable to me
5 = strongly applicable to me
1. Vividly imagine that you are afraid of the dentist and have to get some dental work 
done.
a) I would plan to ask the dentist exactly what he was going to do.
1 2  3 4 5
b) I would take a tranquilliser or have a drink before going.
1 2 3
c) I would try to think about pleasant memories. 1 2 3
d) I would want the dentist to tell me when I would feel pain.
1 2 3
e) I would try to sleep or switch off from what was happening.
1 2 3
4 5
4 5
4 5
4 5
f) I would watch all the dentist’s movements and listen for the sound of the drill.
1 2 3 4 5
g) I would watch the flow of the water from my mouth to see if it contained blood.
1 2 3 4 5
h) I would do mental puzzles in my mind or think of other things.
1 2 3 4 5
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2. Vividly imagine that, due to a large drop in sales, it is rumoured that several people in 
your department at work will be laid off. Your supervisor has turned in an evaluation of 
your work for the past year. The decision about lay-offs has been made and will be 
announced in several days.
a) I would talk to my fellow workers to see if they knew anything about what the
supervisor’s evaluation of me said. 1 2  3 4 5
b) I would review the list of duties for my present job and try to figure out if I had
fulfilled them all. 1 2 3 4 5
c) I would go to the movies to take my mind off things.
1 2 3 4 5
d) I would try to remember any arguments or disagreements I might have had with my 
supervisor that would have lowered his/her opinion of me.
1 2 3 4 5
e) I would push all thoughts of being laid off out of my mind.
1 2 3 4 5
f) I would tell my spouse that I’d rather not discuss my chances of being laid off.
1 2 3 4 5
g) I would try to think of which employees in my department the supervisor might have
thought had done the worst job. 1 2 3 4 5
h) I would continue doing my work as if nothing special was happening.
1 2 3 4 5
3. Vividly imagine that you are on an aeroplane, 30 minutes from your destination, 
when the plane unexpectedly goes into a deep dive and then suddenly levels off. After a 
short time, the pilot announces that nothing is wrong, although the rest of the ride may 
be tough. You, however, are not convinced that all is well.
a) I would carefully read the information provided about safety in the plane and make
sure I knew where the emergency exists were. 1 2 3 4 5
b) I would make small talk with the passenger beside me.
1 2 3 4 5
c) I would watch the end of the movie, even if I had seen it before.
1 2 3 4 5
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d) I would call for the steward/stewardess and ask him/her exactly what the problem
was. 1 2  3 4 5
e) I would order a drink from the steward/stewardess.
1 2 3 4 5
f) I would listen carefully to the engines for unusual noises and would watch the crew to
see if their behaviour was out of the ordinary. 1 2 3 4 5
g) I would talk to the passenger beside me about what might be wrong.
1 2  3 4 5
h) I would settle down and read a book or magazine, or write a letter.
1 2 3 4 5
4. Vividly imagine that you are being held hostage by a group of armed terrorists in a 
public building.
a) I would sit by myself and think about other things as much as I could.
1 2 3 4 5
b) I would stay alert and try to keep myself from falling asleep.
1 2 3 4 5
c) 1 would exchange life stories with other hostages. 1 2 3 4 5
d) If there was a radio present, I would stay near it and listen to the bulletins about what
the police were doing. 1 2 3 4 5
e) I would watch every move of my captors and keep an eye on their weapons.
1 2 3 4 5
f) I would try to sleep or relax as much as possible. 1 2 3 4 5
g) I would think about how nice it’s going to be when I get home.
1 2  3 4 5
h) I would make sure I knew where every possible exit was.
1 2 3 4 5
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Impact of Events Scale (Horowitz et al., 1979)
Below is a list of comments made by people after stressful life events such as 
chemotherapy treatment for cancer. Please circle the response indicating how frequently 
these comments were true during the past seven days. If they did not occur at all, 
please mark 1 (Not at all).
1 = Not at all
2 = Rarely
3 = Sometimes
4 = Often
I thought about it when I did not mean to. 1 2  3 4
I avoided letting myself get upset when I thought about it or was reminded of it.
1 2  3 4
I tried to remove it from my memory. 1 2  3 4
I had trouble falling asleep or staying asleep because of pictures or thoughts about it that
came to mind.
I had waves of strong feelings about it.
I had dreams about it.
I stayed away from reminders about it.
I felt as if it hadn’t happened or it wasn’t real. 
I tried not to talk about it.
Pictures of it popped into my mind.
Other things kept making me think about it.
2
2
2
2
2
2
2
2
4
4
4
4
4
4
4
4
I was aware that I still had a lot of feelings about it, but I didn’t deal with them.
1 2  3 4
I tried not to think about it. 1 2  3 4
Any reminder brought back feelings about it. 1 2  3 4
My feelings about it were kind of numb. 1 2  3 4
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Multidimensional Health Locus of Control Scale (Wallston et al., 1994)
For each statement please indicate whether you agree or not by circling the 
appropriate number. The numbers represent these attitudes:
1 strongly disagree 4 slightly agree
2 somewhat disagree 5 somewhat agree
3 slightly disagree 6 strongly agree
Circle only one number, the one which is closest to your feeling. Please answer 
every question.
1. If my health worsens, it is my own behaviour which determines how soon I will be
better again. 1 2 3 4 5 6
2. I am directly responsible for my health getting better or worse.
1 2  3 4 5 6
3. Whatever goes wrong with my health is my fault.
1 2 3 4 5 6
4. The main thing which affects my health is what I myself do.
1 2 3 4 5 6
5. If my health takes a turn for the worse, it is because I have not been taking proper
care of myself. 1 2 3 4 5 6
6. I deserve the credit when my health improves and the blame when it gets worse.
1 2  3 4 5 6
7. Most things that affect my health happen to me by chance.
1 2  3 4 5 6
8. Luck plays a big part in determining how my health improves.
1 2  3 4 5 6
9. Whatever improvement occurs with my health is largely a matter of good fortune.
1 2 3 4 5 6
10. If my health worsens, it’s a matter of fate.
1
11. If I am lucky, my health will get better. 1
12. As to my health, what will be will be. 1
2 3 4 5 6 
2 3 4 5 6 
2 3 4 5 6
263
13. If I see my doctor regularly, I am less likely to have problems with my health.
1 2  3 4 5 6
14. Following doctor’s orders to the letter is the best way to keep my health from
getting worse. 1 2 3 4 5 6
15. Whenever my health worsens, I should consult a medically trained professional.
1 2 3 4 5 6
16. Other people play a big role in whether my health improves, stays the same, or gets
worse. 1 2 3 4 5 6
17. The type of help I receive from other people determines how soon my health
improves. 1 2 3 4 5 6
18. In order for my health to improve, it is up to other people to see that the right thing
happen. 1 2 3 4 5 6
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Risk Perception Scale
In this final part of the questionnaire, we are interested in your estimates of cancer risk 
for yourself and the average woman your age. Please indicate your response by placing 
a line on the scale from 1 (not at all likely) to 9 (extremely likely).
What do you think the chances are that you will develop cancer again one day?
Not at all 
likely
Moderate
chance
Extremely
likely
1 2 3 4 5 6 7 8 S
2. What are the chances that the average woman who is your age and has received the 
same diagnosis and treatment will develop cancer one day?
Not at all 
likely
Moderate
chance
Extremely
likely
1 2 3 4 5 6 7 8 <
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Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983)
Below are some statements about how you have been feeling over the past week. Please 
choose one response from the four given by placing a tick next to the response. Try not 
to think too long about your answers and just give your immediate response.
I feel tense or wound up
_____  Most of the time
_____  A lot of the time
_____  From time to time, occasionally
_____  Not at all
I still enjoy the things I used to enjoy
_____  Definitely as much
_____  Not quite so much
_____  Only a little
_____  Hardly at all
I get a sort of frightened feeling as if something awful is about to happen
_____  Very definitely and quite badly
_____  Yes, but not too badly
_____  A little, but it doesn’t worry me
_____  Not at all
I can laugh and see the funny side of things
_____  As much as I always could
_____  Not quite so much now
_____  Definitely not so much now
_____  Not at all
Worrying thoughts go through my mind
_____  A great deal of the time
_____  A lot of the time
_____  From time to time, occasionally
_____  Only occasionally
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I feel cheerful
______  Not at all
______  Not often
______  Sometimes
______  Most of the time
I can sit at ease and feel relaxed
______  Definitely
______  Usually
______  Not often
______  Not at all
I feel as if i have slowed down
______  Nearly all the time
______  Very often
______  Sometimes
______  Not at all
I get a sort of frightened feeling like “butterflies” in the stomach
______  Not at all
______  Occasionally
______  Quite often
______  Very often
I have lost interest in my appearance 
______  Definitely
______  I don’t take as much care as I should
______  I may not take quite as much care
______  I take just as much care as ever
I feel restless as I have to be on the move
Very much indeed 
Quite a lot
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Not very much 
Not at all
I look forward with enjoyment to things
_____  As much as I ever did
_____  Rather less than I used to
_____  Definitely less than I used to
_____  Hardly at all
I get sudden feelings of panic
_____  Very often
_____  Quite often
_____  Not very often
_____  Not at all
I can enjoy a good book or radio or TV program
_____  Often
_____  Sometimes
_____  Not often
_____  Seldom
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Chemotherapy Side Effects Scale
Many people undergoing similar treatment to you have had some of the following 
symptoms or concerns at different times, and to varying degrees of severity. We would 
like you to tell us whether you have experienced any of the following symptoms in the 
last 7 days. Please indicate how severe those symptoms have been during that time by 
placing a tick next to the response that best describes your symptoms.
1. Lack of Energy
____  I did not feel any more tired than usual
____  I felt a little tired
____  I felt moderately tired
____  I felt very tired and found it difficult to do everyday activities/tasks
____  I felt so tired that I could not look after myself
2. Lack of Appetite
____  My appetite was the same as usual
____  I felt less hungry than usual
____  I felt less hungry than usual and was eating less than normal
____  I did not feel hungry and lost weight
____  I could not eat anything
3. Pain
____  I had no pain at all
____  I was in some pain
____  I was in moderate pain
____  I was in a lot of pain and found it difficult to do everyday activities/tasks
____  I was in so much pain that I could not look after myself
4. Constipation
____  I was not constipated
____  I have been constipated at times
____  I have been constipated most days
____  I was so constipated that I found it difficult to do everyday activities/tasks
____  I was so constipated that I could not do anything
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5. Nausea
_____ I did not feel nauseous
____  I felt nauseous but I managed to eat normally
____  I felt nauseous and I was eating less than usual
____  I felt so nauseous that I was eating less than usual and have lost some weight
____  I felt so nauseous that I could not eat at all and have lost weight
6. Vomiting
____  I did not vomit
____  I vomited about once on one or more days
____  I vomited 2-5 times on one or more days
____  I vomited 6 or more times on one or more days
____  I could not stop vomiting and needed medical assistance
7. Difficulty Sleeping
____  I have had no problems sleeping
____  I found it difficult to sleep at times
____  I found it difficult to sleep most nights
____  I cannot sleep and am finding it difficult to do everyday activities/tasks
____  I cannot sleep and cannot look after myself
8. Shortness of Breath
____  I did not have difficulty breathing
____  I found it difficult to breath when I tried to do something
____  I found it so difficult to breath when I did something that I needed to take a
break
____  I found it so difficult to breath that I could not look after myself
____  I found it difficult to breath even when I was not doing anything
9. Dizziness
____  I did not feel dizzy
____  I felt dizzy when I moved my head
____  I felt dizzy and found it difficult to do some things
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____  I felt so dizzy I could not do everyday activities/tasks
____  I felt so dizzy I could not do anything for myself
10. Sore Muscles
____  My muscles did not feel sore
____  My muscles felt a little sore
____  My muscles felt moderately sore
____  My muscles felt very sore
____  My muscles felt so sore I could not do anything
11. Problems Remembering Things / Memory Problems
____  I have not noticed any problems with my memory
____  I have had some problems remembering things
____  I have had moderate problems remembering things
____  My memory problems made it difficult to do everyday activities/tasks
____  I have difficulty remembering anything
12. Coughing
____  I have not been coughing any more than usual
____  I have been coughing at times
____  I have coughed so much that I needed some medication
____  I have been coughing so much that I find it difficult to sleep or do everyday
activities/tasks
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Information Sheet for Participants Attending The Canberra Hospital, The National 
Capital Hospital, and John James Memorial Hospital
Coping Styles and the Experience of Chemotherapy 
Patient Information Sheet
Each year, many people are diagnosed with cancer and for many of them, chemotherapy 
is recommended. Chemotherapy can produce a number of side effects. Research has 
shown that in order to deal with this treatment, patients use many varied ways of 
coping. The purpose of this project is to investigate how people cope with 
chemotherapy and whether a particular way of coping with chemotherapy is associated 
with enhanced emotional and physical well-being.
As you are undergoing chemotherapy for breast or colo/rectal cancer we invite you to 
participate in this project. Participation involves filling out a number of questionnaire 
packages. These will be filled out before starting chemotherapy, after the first 3-4 
chemotherapy treatments, on completion, and six months and one year after the 
completion of chemotherapy treatment. The questionnaires will ask you to consider the 
way in which you deal with stressful situations and your emotional wellbeing. You may 
complete the questionnaires in your own time and return them to the research group in 
the stamped, self-addressed envelopes provided. Alternatively, we can assist with the 
completion of the questionnaire if this is preferable. Each questionnaire will take 30-60 
minutes to complete.
In addition, we will require information about your medical history before starting 
chemotherapy, during chemotherapy and, six months and one year following the 
completion of chemotherapy. The information we are interested in includes the standard 
tests and information your Oncologist will collect as part of routine medical procedure. 
We ask that we can look at your medical records to collect this information. We will 
record any information from your medical records using your code number, not your 
name. No medical tests will be done that would not be routinely done as part of your 
medical care.
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Your participation in this study is voluntary. You can decline to participate in this study 
at any time, without reason. You decision to participate or not in this study will not 
affect your medical care in any way. If you choose to withdraw from the study, any 
previously completed documents will be destroyed.
Your participation is also confidential. All questionnaires and medical information we 
collect will be kept in a locked cabinet which can only be accessed by the research 
group. Moreover, none of the questionnaires and medical information will have your 
name written on them. You will be given a code number that will be used to identify 
your questionnaires and medical information. A sheet which matches your name and 
code number will be kept in a separate locked cabinet which again, only the research 
group can access. On completion of the study, forms containing contact details will be 
destroyed. The project has been approved both by the ACT Health Human Research 
Ethics Committee and the Australian National University Human Research Ethics 
Committee.
If you have any questions regarding any of the information covered in this sheet or 
about the research in general, please do not hesitate to contact either of the following 
researchers or the ACT Health and Community Care Human Research Ethics 
Committee:
A/Prof Robin Stuart-Harris 
Medical Oncology Unit 
The Canberra Hospital 
Yamba Drive 
Garran ACT 2605 
Ph: (02) 6244 2220
Email: Robin.Stuart-Harris@act.gov.au
Professor Don Byrne 
School of Psychology 
Building 39
The Australian National University 
Canberra ACT 0200
Ms Sarah Davenport 
School of Psychology 
Building 39
The Australian National University 
Canberra ACT 0200 
Ph: (02)6125 2147 
Email: Sarah.Davenport@anu.edu.au
The Human Ethics Officer
The Australian National University
Canberra ACT 0200
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Ph: (02)6125 3974
Email: Don.Byrne@anu.edu.au
Ph: (02)6125 7945
Emaihhuman.research. officer@anu.edu.au
ACT Community Care Human Research Ethics Committee 
Secretary
Second Floor, North Building 
London Circuit 
Canberra City ACT 2601 
Ph: (02) 6205 0846
The ACT Government Homepage is http://www.act.gov.au
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Patient Information Sheet for Participants Attending Calvary Hospital
Coping Styles and the Experience of Chemotherapy 
Patient Information Sheet
Each year, many people are diagnosed with cancer and for many of them, chemotherapy 
is recommended. Chemotherapy can produce a number of side effects. Research has 
shown that in order to deal with this treatment, patients use many varied ways of 
coping. The purpose of this project is to investigate how people cope with 
chemotherapy and whether a particular way of coping with chemotherapy is associated 
with enhanced emotional and physical well-being.
As you are undergoing chemotherapy for breast or colo/rectal cancer we invite you to 
participate in this project. Participation involves filling out a number of questionnaire 
packages. These will be filled out before starting chemotherapy, after the first 3-4 
chemotherapy treatments, on completion of chemotherapy treatment, and one year after 
the completion of chemotherapy treatment. The questionnaires will ask you to consider 
the way in which you deal with stressful situations and your emotional wellbeing. You 
may complete the questionnaires in your own time and return them to the research 
group in the stamped, self-addressed envelopes provided. Alternatively, we can assist 
with the completion of the questionnaire if this is preferable. Each questionnaire will 
take 30-60 minutes to complete.
In addition, we will require information about your medical history before starting 
chemotherapy, during chemotherapy and one year following the completion of 
chemotherapy. The information we are interested in includes the standard tests your 
Oncologist will collect as part of routine medical procedure. We will ask your 
Oncologist to pass on this information to us so the researcher will not have to look at 
your medical records. Your Oncologist will provide us with this information using your 
code number, not your name. No medical tests will be done that would not be routinely 
done as part of your medical care.
Your participation in this study is voluntary. You can decline to participate in this study 
at any time, without reason. You decision to participate or not in this study will not
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affect your medical care in any way. If you choose to withdraw from the study, any 
previously completed documents will be destroyed.
Your participation is also confidential. All questionnaires and medical information we 
collect will be kept in a locked cabinet which can only be accessed by the research 
group. Moreover, none of the questionnaires and medical information will have your 
name written on them. You will be given a code number that will be used to identify 
your questionnaires and medical information. A sheet which matches your name and 
code number will be kept in a separate locked cabinet which again, only the research 
group can access. On completion of the study, forms containing contact details will be 
destroyed. The project has been approved both by the Medico Moral, Human Research 
and Ethics Committee (MMHREC) and the Australian National University Human 
Research Ethics Committee.
If you have any questions regarding any of the information covered in this sheet or 
about the research in general, please do not hesitate to contact either of the following 
researchers or the Medico Moral, Human Research and Ethics Committee (MMHREC):
A/Prof. Robin Stuart-Harris Ms Sarah Davenport
Medical Oncology Unit School of Psychology
The Canberra Hospital Building 39
Yamba Drive The Australian National University
Garran ACT 2605 Canberra ACT 0200
Email: Robin.Stuart-Harris@act.gov.au Email: Sarah.Davenport@anu.edu.au
Ph: (02) 6244 2220 Ph: (02)6125 2147
Professor Don Byrne 
School of Psychology 
Building 39
The Australian National University
Medico Moral, Human Research 
and Ethics Committee (MMHREC) 
Ms Raeleigh Mooney 
Secretariat of the MMHREC
Canberra ACT 0200
Ph: (02)6125 3974
Email: Don.Byrne@anu.edu.au
Ph: (02) 6201 6104
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Patient Consent Form for Participants Attending The Canberra Hospital, The National 
Capital Private Hospital, and the John James Memorial Hospital
ACT Health and Community Care Consent Form
Australian Capital Territory
I ,_____________________________________ ,
(name of participant)
o f ____________________  ______________________ ___________________
(street) (suburb/town) (state & postcode)
have been asked to consent to my participation in a research project entitled:
Coping styles and the experience of chemotherapy
In relation to this project I have read the Patient Information Sheet and have been 
informed of the following points:
1. Approval has been given by the ACT Department of Health Ethics Committee and 
The Australian National University Human Ethics Committee.
2. The aim of the project is to investigate how people cope with chemotherapy and 
whether particular ways of coping are associated with better psychological and medical 
well-being.
3. The results obtained from the study may or may not be of direct benefit to my 
medical management.
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4. The procedure will involve completing a questionnaire package which will ask me to 
consider the way in which I deal with situations as well as the general state of my 
emotional wellbeing. I will be asked to complete the package prior to, following the 
first 3-4 chemotherapy infusions, on completion and 6- and 12-months following 
chemotherapy treatment. In addition, information regarding my medical progress will 
be collected by the research team from my medical files.
5. My involvement in this project may be terminated if any of the following 
circumstances develop:
I am unable to complete the tasks involved in participation
My medical condition changes according to medical staff in the Department of
Oncology, at The Canberra Hospital
6. Should I have any queries regarding participation, I am aware that I may contact:
A/Professor Robin Stuart-Harris
Department of Oncology
The Canberra Hospital
Yamba Drive
Garran ACT 2605
Ph: (02) 6244 2220
Fax: (02) 6244 4266
Email: Robin.Stuart-Harris@act.gov.au
Professor Don Byrne 
School of Psychology 
Building 39
The Australian National University
Canberra ACT 0200
Ph: (02)6125 3974
Fax: (02)6125 0499
Email: Don.Byrne@anu.edu.au
Ms Sarah Davenport 
School of Psychology 
Building 39
The Australian National University
Canberra ACT 0200
Ph: (02)6125 2147
Fax: (02) 6125 0499
Email: S arah. Davenport @ anu.edu.au
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7. Should I have any problems or queries about the way in which the study was 
conducted, and I do not feel comfortable contacting the research staff, I am aware that I 
may contact:
The Secretary
ACT Department of Health Ethics Committee 
North Building 
Second Floor 
London Circuit 
Canberra City ACT 2601 
Ph: (02) 6205 0846
8. I can refuse to take part in this project or withdraw from it at any time without 
affecting my medical care in any way.
9. Participation in this project will not result in any extra medical and hospital costs to 
me. 1 will not receive any reimbursement for my involvement in the study.
10. I understand that the results of the research will be made accessible and that my 
involvement and my identity will not be revealed.
11. In giving my consent, I acknowledge that the research team directly involved in the 
study, may receive information from my medical records only as they relate to this 
project.
After considering all these points, I accept the invitation to participate in this project.
Signature (of Participant):_________________________  D ate:_________________
Signature (of Witness):___________________________  D ate:_________________
Signature (of Investigator):________________________  D ate:__________________
The Human Ethics Officer
The Australian National University
Ph: 6125 7945
Human.Ethics.Officer @ anu.edu.au
291
APPENDIX L
292
Patient Consent Form for Participants Attending the Calvary Hospital 
The Calvary Hospital Consent Form
Calvary
Health Care 
ACT
I ,_____________________________________ ,
(name of participant)
of _____________  ________________  _________________
(street) (suburb/town) (state & postcode)
have been asked to consent to my participation in a research project entitled:
Coping styles and the experience of chemotherapy
In relation to this project I have read the Patient Information Sheet and have been 
informed of the following points:
Approval has been given by the Medico Moral, Human Research and Ethics Committee 
(MMHREC).
The aim of the project is to investigate how people cope with chemotherapy and 
whether particular ways of coping are associated with better psychological and physical 
well-being.
The results obtained from the study may or may not be of direct benefit to my medical 
management.
The procedure will involve completing a questionnaire package which will ask me to 
consider the way in which I deal with situations as well as the general state of my
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emotional wellbeing. I will be asked to complete the package prior to, following the 
first 3-4 chemotherapy infusions, on completion of chemotherapy treatment, and one- 
year following chemotherapy treatment. In addition, information regarding my medical 
progress will be gained from my medical files by one of the research team but that this 
information will be recorded using my code number, not my name.
My involvement in this project may be terminated if any of the following circumstances 
develop:
I am unable to complete the tasks involved in participation or choose not to;
My medical condition as judged by medical staff in Calvary Health Care ACT changes 
in a way they believe is inconsistent with my further participation.
Should I have any queries regarding participation, I am aware that I may contact:
A/Professor Robin Stuart-Harris
Department of Oncology
The Canberra Hospital
Yamba Drive
Garran ACT 2605
Ph: (02) 6244 2220
Fax: (02) 6244 4266
Email: Robin.Stuart-Harris @act.gov.au
Professor Don Byrne 
School of Psychology 
Building 39
The Australian National University
Canberra ACT 0200
Ph: (02)6125 3974
Fax: (02)6125 0499
Email: Don.Byrne@anu.edu.au
Ms Sarah Davenport 
School of Psychology 
Building 39
The Australian National University
Canberra ACT 0200
Ph: (02)6125 2147
Fax: (02)6125 0499
Email: Sarah.Davenport@anu.edu.au
294
Should I have any problems of queries about the way in which the study was conducted, 
and I do not feel comfortable contacting the research staff, I am aware that I may 
contact Ms Raeleigh Mooney, secretariat of the MMHREC on (02) 6201 6104 and The 
Human Ethics Officer, The Australian National University, on (02) 6125 7945 or 
Human.Ethics.Officer@anu.edu.au.
I can refuse to take part in this project or withdraw from it at any time without affecting 
my medical care in any way.
Participation in this project will not result in any extra medical and hospital costs to me. 
I will not receive any reimbursement for my involvement in the study.
I understand that the results of the research will be made accessible and that my 
involvement and my identity will not be revealed.
In giving my consent, I acknowledge that the research team directly involved in the 
study will collect information from my medical records only as they relate to this 
project.
After considering all these points, I accept the invitation to participate in this project.
Signature (of Participant):___________________ Date:_____________
Signature (of Witness):_____________________ Date:_____________
Signature (of Investigator):___________________Date:______________
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Reminder Letter to Participants
Dear Participant,
Thank you for your continued support of our project, Coping with Chemotherapy.
Recently, you were sent a questionnaire which aimed to gain an update on your progress 
since completing chemotherapy. I did not receive your completed questionnaire and am 
very keen to see your progress at this point. If you have completed the questionnaire, I 
would appreciate it if you would return it to me. If for some reason you did not receive 
the questionnaire, I have enclosed another copy for you. I would greatly appreciate it if 
you would complete the questionnaire and return it to me in the reply paid envelope 
provided.
Please remember to complete all items in the booklet as best as you can and to write the 
date you completed it on the front cover. You will receive the final questionnaire 
package in another six months’ time. We greatly appreciate your participation in this 
important study and appreciate the significant time and effort involved in participation.
If you have any questions regarding the questionnaire booklet or would like assistance 
with the completion of the questionnaire, please do not hesitate to contact me on the 
details below:
Yours sincerely,
Sarah Davenport
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